sentances,predictions
"Seven pregnancies were complicated by fetal anti-Ro-related cardiac disease (17.9%) including four cases (57.1%) of second-degree heart block, two cases of third degree heart block (28.6%) and one case (14.3%) of intense and diffuse hyperechogenicity in atrioventricular valves without heart block.","[{'Seven': 'O'}, {'pregnancies': 'O'}, {'were': 'O'}, {'complicated': 'O'}, {'by': 'O'}, {'fetal': 'O'}, {'anti-Ro-related': 'O'}, {'cardiac': 'B-Entity'}, {'disease': 'I-Entity'}, {'(17.9%)': 'O'}, {'including': 'O'}, {'four': 'O'}, {'cases': 'O'}, {'(57.1%)': 'O'}, {'of': 'O'}, {'second-degree': 'O'}, {'heart': 'B-Entity'}, {'block,': 'I-Entity'}, {'two': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'third': 'O'}, {'degree': 'O'}, {'heart': 'B-Entity'}, {'block': 'I-Entity'}, {'(28.6%)': 'O'}, {'and': 'O'}, {'one': 'O'}, {'case': 'O'}, {'(14.3%)': 'O'}, {'of': 'O'}]"
"Because pain perception has been linked to catastrophizing in other diseases, we assessed subjects with primary SS (pSS) to explore a possible link between pain, illness appraisal, and catastrophizing.","[{'Because': 'O'}, {'pain': 'I-Entity'}, {'perception': 'O'}, {'has': 'O'}, {'been': 'O'}, {'linked': 'O'}, {'to': 'O'}, {'catastrophizing': 'O'}, {'in': 'O'}, {'other': 'O'}, {'diseases,': 'O'}, {'we': 'O'}, {'assessed': 'O'}, {'subjects': 'O'}, {'with': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'(pSS)': 'O'}, {'to': 'O'}, {'explore': 'O'}, {'a': 'O'}, {'possible': 'O'}, {'link': 'O'}, {'between': 'O'}, {'pain,': 'I-Entity'}, {'illness': 'O'}, {'appraisal,': 'O'}, {'and': 'O'}, {'catastrophizing.': 'O'}]"
"However, recurrent aseptic meningitis, reported as the most uncommon initial symptom, was the presenting feature in our case.","[{'However,': 'O'}, {'recurrent': 'O'}, {'aseptic': 'B-Entity'}, {'meningitis,': 'I-Entity'}, {'reported': 'O'}, {'as': 'O'}, {'the': 'O'}, {'most': 'O'}, {'uncommon': 'O'}, {'initial': 'O'}, {'symptom,': 'O'}, {'was': 'O'}, {'the': 'O'}, {'presenting': 'O'}, {'feature': 'O'}, {'in': 'O'}, {'our': 'O'}, {'case.': 'O'}]"
Salivary glands of NOD mice displayed marked leukocyte infiltration and reduced GILZ expression in association with increased IL-17 but decreased Del-1 expression.,"[{'Salivary': 'O'}, {'glands': 'O'}, {'of': 'O'}, {'NOD': 'O'}, {'mice': 'O'}, {'displayed': 'O'}, {'marked': 'O'}, {'leukocyte': 'O'}, {'infiltration': 'O'}, {'and': 'O'}, {'reduced': 'O'}, {'GILZ': 'O'}, {'expression': 'O'}, {'in': 'O'}, {'association': 'O'}, {'with': 'O'}, {'increased': 'O'}, {'IL-17': 'O'}, {'but': 'O'}, {'decreased': 'O'}, {'Del-1': 'O'}, {'expression.': 'O'}]"
"Associated medical conditions included Hashimoto thyroiditis, Sjogren's syndrome, seronegative arthritis, food hypersensitivities, asthma, sleep apnea, and vasculitis.","[{'Associated': 'O'}, {'medical': 'O'}, {'conditions': 'O'}, {'included': 'O'}, {'Hashimoto': 'B-Entity'}, {'thyroiditis,': 'I-Entity'}, {""Sjogren's"": 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'seronegative': 'O'}, {'arthritis,': 'I-Entity'}, {'food': 'B-Entity'}, {'hypersensitivities,': 'I-Entity'}, {'asthma,': 'I-Entity'}, {'sleep': 'B-Entity'}, {'apnea,': 'I-Entity'}, {'and': 'O'}, {'vasculitis.': 'I-Entity'}]"
"These results suggest that ACA is an autoantibody reflecting impairment in the salivary and lacrimal glands and may be a useful serologic marker for SS.of Life Dentistry at Niigata, The Nippon Dental University, 1-8 Hamaura-cho, Chuo-ku, Niigata 951-8580, Japan.","[{'These': 'O'}, {'results': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'ACA': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoantibody': 'O'}, {'reflecting': 'O'}, {'impairment': 'B-Entity'}, {'in': 'I-Entity'}, {'the': 'I-Entity'}, {'salivary': 'I-Entity'}, {'and': 'I-Entity'}, {'lacrimal': 'I-Entity'}, {'glands': 'I-Entity'}, {'and': 'O'}, {'may': 'O'}, {'be': 'O'}, {'a': 'O'}, {'useful': 'O'}, {'serologic': 'O'}, {'marker': 'O'}, {'for': 'O'}, {'SS.of': 'I-Entity'}, {'Life': 'O'}, {'Dentistry': 'O'}, {'at': 'O'}, {'Niigata,': 'O'}, {'The': 'O'}, {'Nippon': 'O'}, {'Dental': 'O'}, {'University,': 'O'}, {'1-8': 'O'}, {'Hamaura-cho,': 'B-Entity'}]"
"Renal tissue samples from patients with tubulointerstitial disease secondary to primary Sjogren's disease (SS, n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢10), chronic tubulointerstitial nephritis secondary to drug (CIN, n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢8) were included in this study.","[{'Renal': 'O'}, {'tissue': 'O'}, {'samples': 'O'}, {'from': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'tubulointerstitial': 'B-Entity'}, {'disease': 'I-Entity'}, {'secondary': 'O'}, {'to': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'disease': 'I-Entity'}, {'(SS,': 'O'}, {'n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢10),': 'O'}]"
"Six women, aged 35-64, had non-length-dependent SFN, related to Crohn disease, impaired glucose tolerance and Sjogrens syndrome, or idiopathic (three cases).","[{'Six': 'O'}, {'women,': 'O'}, {'aged': 'O'}, {'35-64,': 'O'}, {'had': 'O'}, {'non-length-dependent': 'O'}, {'SFN,': 'I-Entity'}, {'related': 'O'}, {'to': 'O'}, {'Crohn': 'B-Entity'}, {'disease,': 'I-Entity'}, {'impaired': 'B-Entity'}, {'glucose': 'I-Entity'}, {'tolerance': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'or': 'O'}, {'idiopathic': 'O'}, {'(three': 'O'}, {'cases).': 'O'}]"
"Such symptoms as a hypergammaglobulinemia, positive RF without persistant arthritis, nonspecific skin lesions, recurrent parotid swelling may help to diagnosis of SS.Department.Department.Department.in Sjogrens syndrome: a systematic review and meta-analysis.","[{'Such': 'O'}, {'symptoms': 'O'}, {'as': 'O'}, {'a': 'O'}, {'hypergammaglobulinemia,': 'I-Entity'}, {'positive': 'O'}, {'RF': 'I-Entity'}, {'without': 'O'}, {'persistant': 'O'}, {'arthritis,': 'I-Entity'}, {'nonspecific': 'O'}, {'skin': 'O'}, {'lesions,': 'O'}, {'recurrent': 'O'}, {'parotid': 'B-Entity'}, {'swelling': 'I-Entity'}, {'may': 'O'}, {'help': 'O'}, {'to': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS.Department.Department.Department.in': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome:': 'I-Entity'}, {'a': 'O'}, {'systematic': 'O'}, {'review': 'O'}, {'and': 'O'}, {'meta-analysis.': 'O'}]"
"These findings therefore demonstrate that the IkappaBalpha-mediated feedback regulation of NF-kappaB has an essential role in controlling T-cell development and functions, provide mechanistic insight into the development of Sjogrens Syndrome, and suggest the potential of NF-kappaB signaling as a therapeutic target for Sjogrens Syndrome and other autoimmune diseases.Center, Houston, TX 77030, USA.Epub 2010 Aug 9.diagnosis: analysis of 10,500 patients (Sjogren Big Data Project).","[{'These': 'O'}, {'findings': 'O'}, {'therefore': 'O'}, {'demonstrate': 'O'}, {'that': 'O'}, {'the': 'O'}, {'IkappaBalpha-mediated': 'O'}, {'feedback': 'O'}, {'regulation': 'O'}, {'of': 'O'}, {'NF-kappaB': 'O'}, {'has': 'O'}, {'an': 'O'}, {'essential': 'O'}, {'role': 'O'}, {'in': 'O'}, {'controlling': 'O'}, {'T-cell': 'O'}, {'development': 'O'}, {'and': 'O'}, {'functions,': 'O'}, {'provide': 'O'}, {'mechanistic': 'O'}, {'insight': 'O'}, {'into': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome,': 'I-Entity'}, {'and': 'O'}, {'suggest': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'of': 'O'}, {'NF-kappaB': 'O'}]"
We enrolled 19 women with pSS (54 pregnancies) matched by age and BMI to 216 controls.,"[{'We': 'O'}, {'enrolled': 'O'}, {'19': 'O'}, {'women': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'(54': 'O'}, {'pregnancies)': 'O'}, {'matched': 'O'}, {'by': 'O'}, {'age': 'O'}, {'and': 'O'}, {'BMI': 'O'}, {'to': 'O'}, {'216': 'O'}, {'controls.': 'O'}]"
"Patients with positive anti-Ro/SSA and anti-Ro52 antibodies had a higher frequency of positive salivary gland biopsy, parotid enlargement and positive RF, and higher levels of serum IgG and IgA levels in comparison with patients with positive anti-Ro/SSA but negative anti-Ro52 antibodies.","[{'Patients': 'O'}, {'with': 'O'}, {'positive': 'O'}, {'anti-Ro/SSA': 'O'}, {'and': 'O'}, {'anti-Ro52': 'O'}, {'antibodies': 'O'}, {'had': 'O'}, {'a': 'O'}, {'higher': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'positive': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'biopsy,': 'O'}, {'parotid': 'B-Entity'}, {'enlargement': 'I-Entity'}, {'and': 'O'}, {'positive': 'O'}, {'RF,': 'I-Entity'}, {'and': 'O'}, {'higher': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'serum': 'O'}, {'IgG': 'O'}, {'and': 'O'}, {'IgA': 'O'}, {'levels': 'O'}, {'in': 'O'}, {'comparison': 'O'}, {'with': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'positive': 'O'}]"
Non-productive cough was detected in 30 patients (37.5%).,"[{'Non-productive': 'O'}, {'cough': 'I-Entity'}, {'was': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'30': 'O'}, {'patients': 'O'}, {'(37.5%).': 'O'}]"
"Musculoskeletal manifestations were as follows: past or present pain in the extremities (13 females and 10 males), combined in some patients with vasomotor disorders in the extremities and telangiectasia; exercise intolerance (12 females and 12 males); osteoporotic fractures (2 brothers aged 45 and 44 years, respectively); osteoporosis (3 females, aged 57, 63, and 75 years, respectively), which contributed to death in the oldest patient; osteopenia¬¨¬®‚Äö√Ñ‚Ä†(2 females aged 38 and 47 years, respectively; and 1 male aged 43 years); Charcot foot and lymphedema with serious infectious complications (4 males older than 40 years), with avascular osteonecrosis of the lower limbs in 2 cases; toe amputations (3 cases); bilateral lower-limb amputation (1 case); abnormally slender lower limbs (5 females and 8 males); acute gout (3 males with severe chronic kidney failure); and carpal tunnel syndrome (1 female and 1 male, both younger than 40 years).","[{'Musculoskeletal': 'O'}, {'manifestations': 'O'}, {'were': 'O'}, {'as': 'O'}, {'follows:': 'O'}, {'past': 'O'}, {'or': 'O'}, {'present': 'O'}, {'pain': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'extremities': 'O'}, {'(13': 'O'}, {'females': 'O'}, {'and': 'O'}, {'10': 'O'}, {'males),': 'O'}, {'combined': 'O'}, {'in': 'O'}, {'some': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'vasomotor': 'B-Entity'}, {'disorders': 'I-Entity'}, {'in': 'I-Entity'}, {'the': 'I-Entity'}, {'extremities': 'I-Entity'}, {'and': 'O'}, {'telangiectasia;': 'I-Entity'}, {'exercise': 'B-Entity'}, {'intolerance': 'I-Entity'}, {'(12': 'O'}, {'females': 'O'}, {'and': 'O'}]"
These disorders can be associated with nephrocalcinosis and renal lithiasis.,"[{'These': 'O'}, {'disorders': 'O'}, {'can': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'nephrocalcinosis': 'I-Entity'}, {'and': 'O'}, {'renal': 'B-Entity'}, {'lithiasis.': 'I-Entity'}]"
PPAR-‚âà√≠‚Äö√¢‚Ä¢ ameliorates Sjogren's syndrome on NOD mice effectively.,"[{'PPAR-‚âà√≠‚Äö√¢‚Ä¢': 'O'}, {'ameliorates': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'on': 'O'}, {'NOD': 'O'}, {'mice': 'O'}, {'effectively.': 'O'}]"
"It could be useful to investigate whether patients presenting with a ranula are also affected by Sjogrens syndrome and, conversely, investigate patients with Sjogrens syndrome longitudinally to see whether they develop ranulas.reserved.Chiba, Japan.Chiba, Japan.Chiba, Japan.Chiba, Japan.Tokyo Dental College, Chiba, Japan.Chiba, Japan.","[{'It': 'O'}, {'could': 'O'}, {'be': 'O'}, {'useful': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'whether': 'O'}, {'patients': 'O'}, {'presenting': 'O'}, {'with': 'O'}, {'a': 'O'}, {'ranula': 'I-Entity'}, {'are': 'O'}, {'also': 'O'}, {'affected': 'O'}, {'by': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and,': 'O'}, {'conversely,': 'O'}, {'investigate': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'longitudinally': 'O'}, {'to': 'O'}, {'see': 'O'}, {'whether': 'O'}, {'they': 'O'}, {'develop': 'O'}, {'ranulas.reserved.Chiba,': 'I-Entity'}, {'Japan.Chiba,': 'O'}, {'Japan.Chiba,': 'O'}]"
Lupus alopecia is usually difficult to treat.,"[{'Lupus': 'B-Entity'}, {'alopecia': 'I-Entity'}, {'is': 'O'}, {'usually': 'O'}, {'difficult': 'O'}, {'to': 'O'}, {'treat.': 'O'}]"
"The risk of pSS was significantly increased in female patients with thyroid diseases, particularly those in their mid-forties to mid-sixties.","[{'The': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'was': 'O'}, {'significantly': 'O'}, {'increased': 'O'}, {'in': 'O'}, {'female': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'thyroid': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'particularly': 'O'}, {'those': 'O'}, {'in': 'O'}, {'their': 'O'}, {'mid-forties': 'O'}, {'to': 'O'}, {'mid-sixties.': 'O'}]"
"Particularly, we observed a high prevalence of migraine without aura, subcortical frontal executive functions and verbal memory impairment and apathy/alexythimia.","[{'Particularly,': 'O'}, {'we': 'O'}, {'observed': 'O'}, {'a': 'O'}, {'high': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'migraine': 'B-Entity'}, {'without': 'I-Entity'}, {'aura,': 'I-Entity'}, {'subcortical': 'O'}, {'frontal': 'O'}, {'executive': 'O'}, {'functions': 'O'}, {'and': 'O'}, {'verbal': 'O'}, {'memory': 'B-Entity'}, {'impairment': 'I-Entity'}, {'and': 'O'}, {'apathy/alexythimia.': 'I-Entity'}]"
"Hair disorders in CTDs may manifest as various clinical patterns, such as telogen hair loss, diffuse thinning or fragility of hair, and scarring alopecia.","[{'Hair': 'B-Entity'}, {'disorders': 'I-Entity'}, {'in': 'O'}, {'CTDs': 'I-Entity'}, {'may': 'O'}, {'manifest': 'O'}, {'as': 'O'}, {'various': 'O'}, {'clinical': 'O'}, {'patterns,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'telogen': 'O'}, {'hair': 'B-Entity'}, {'loss,': 'I-Entity'}, {'diffuse': 'O'}, {'thinning': 'O'}, {'or': 'O'}, {'fragility': 'O'}, {'of': 'O'}, {'hair,': 'O'}, {'and': 'O'}, {'scarring': 'O'}, {'alopecia.': 'I-Entity'}]"
"Acute or subacute onset is observed more frequently in multiple mononeuropathy and multiple cranial neuropathies, whereas disease progression is usually chronic in other forms of neuropathies.","[{'Acute': 'O'}, {'or': 'O'}, {'subacute': 'O'}, {'onset': 'O'}, {'is': 'O'}, {'observed': 'O'}, {'more': 'O'}, {'frequently': 'O'}, {'in': 'O'}, {'multiple': 'B-Entity'}, {'mononeuropathy': 'I-Entity'}, {'and': 'O'}, {'multiple': 'B-Entity'}, {'cranial': 'I-Entity'}, {'neuropathies,': 'I-Entity'}, {'whereas': 'O'}, {'disease': 'O'}, {'progression': 'O'}, {'is': 'O'}, {'usually': 'O'}, {'chronic': 'O'}, {'in': 'O'}, {'other': 'O'}, {'forms': 'O'}, {'of': 'O'}, {'neuropathies.': 'I-Entity'}]"
"Associated with clinical features, these methods provide the basis of correct diagnosis and appropriate therapy for lacrimal gland pathology.Romania.","[{'Associated': 'O'}, {'with': 'O'}, {'clinical': 'O'}, {'features,': 'O'}, {'these': 'O'}, {'methods': 'O'}, {'provide': 'O'}, {'the': 'O'}, {'basis': 'O'}, {'of': 'O'}, {'correct': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'appropriate': 'O'}, {'therapy': 'O'}, {'for': 'O'}, {'lacrimal': 'B-Entity'}, {'gland': 'I-Entity'}, {'pathology.Romania.': 'I-Entity'}]"
Pulmonary mucosa-associated lymphoid tissue lymphoma (MALToma) was diagnosed in seven subjects (33%).,"[{'Pulmonary': 'O'}, {'mucosa-associated': 'O'}, {'lymphoid': 'B-Entity'}, {'tissue': 'I-Entity'}, {'lymphoma': 'I-Entity'}, {'(MALToma)': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'in': 'O'}, {'seven': 'O'}, {'subjects': 'O'}, {'(33%).': 'O'}]"
Comprehensive investigations for known haematological and metabolic disorders associated with subdural haematomas or effusions in infants were all normal.,"[{'Comprehensive': 'O'}, {'investigations': 'O'}, {'for': 'O'}, {'known': 'O'}, {'haematological': 'B-Entity'}, {'and': 'I-Entity'}, {'metabolic': 'I-Entity'}, {'disorders': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'subdural': 'B-Entity'}, {'haematomas': 'I-Entity'}, {'or': 'O'}, {'effusions': 'I-Entity'}, {'in': 'O'}, {'infants': 'O'}, {'were': 'O'}, {'all': 'O'}, {'normal.': 'O'}]"
Electronic address: cylin@tmu.edu.tw.9.plasma cell accumulation in immunoglobulin G4-related disease.,"[{'Electronic': 'O'}, {'address:': 'O'}, {'cylin@tmu.edu.tw.9.plasma': 'O'}, {'cell': 'O'}, {'accumulation': 'O'}, {'in': 'O'}, {'immunoglobulin': 'B-Entity'}, {'G4-related': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"It will provide a reference for early detection, early diagnosis and early treatment of atypical primary Sjogren syndrome with neurological impairment as the first symptom.","[{'It': 'O'}, {'will': 'O'}, {'provide': 'O'}, {'a': 'O'}, {'reference': 'O'}, {'for': 'O'}, {'early': 'O'}, {'detection,': 'O'}, {'early': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'early': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'atypical': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'with': 'O'}, {'neurological': 'B-Entity'}, {'impairment': 'I-Entity'}, {'as': 'O'}, {'the': 'O'}, {'first': 'O'}, {'symptom.': 'O'}]"
"The incidence of influenza or bacterial complications (bronchitis) among vaccinated patients was significantly lower, compared to the non-vaccinated group.","[{'The': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'influenza': 'I-Entity'}, {'or': 'O'}, {'bacterial': 'O'}, {'complications': 'O'}, {'(bronchitis)': 'O'}, {'among': 'O'}, {'vaccinated': 'O'}, {'patients': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'lower,': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'the': 'O'}, {'non-vaccinated': 'O'}, {'group.': 'O'}]"
"We also examine the possible utility for US to monitor patient response to therapy in both clinical research and standard clinical care.Pisa, Italy.Pisa, Italy.Pisa, Italy.Pisa, Italy.","[{'We': 'O'}, {'also': 'O'}, {'examine': 'O'}, {'the': 'O'}, {'possible': 'O'}, {'utility': 'O'}, {'for': 'O'}, {'US': 'O'}, {'to': 'O'}, {'monitor': 'O'}, {'patient': 'O'}, {'response': 'O'}, {'to': 'O'}, {'therapy': 'O'}, {'in': 'O'}, {'both': 'O'}, {'clinical': 'O'}, {'research': 'O'}, {'and': 'O'}, {'standard': 'O'}, {'clinical': 'O'}, {'care.Pisa,': 'O'}, {'Italy.Pisa,': 'O'}, {'Italy.Pisa,': 'O'}, {'Italy.Pisa,': 'O'}, {'Italy.': 'O'}]"
"Conditions associated with parotid enlargement should also be excluded, including juvenile recurrent parotitis (JRP), sialadenosis, sarcoidosis, lymphoma, infectious parotitis caused by streptococcal and staphylococcal infections, viral infections (paramyxovirus, Epstein-Barr virus, cytomegalovirus, and parvovirus), and diffuse infiltrative lymphocytosis syndrome (associated with HIV infection), and rare congenital conditions, such as polycystic parotid disease.","[{'Conditions': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'parotid': 'B-Entity'}, {'enlargement': 'I-Entity'}, {'should': 'O'}, {'also': 'O'}, {'be': 'O'}, {'excluded,': 'O'}, {'including': 'O'}, {'juvenile': 'B-Entity'}, {'recurrent': 'I-Entity'}, {'parotitis': 'I-Entity'}, {'(JRP),': 'O'}, {'sialadenosis,': 'I-Entity'}, {'sarcoidosis,': 'I-Entity'}, {'lymphoma,': 'I-Entity'}, {'infectious': 'B-Entity'}, {'parotitis': 'I-Entity'}, {'caused': 'O'}, {'by': 'O'}, {'streptococcal': 'I-Entity'}, {'and': 'O'}, {'staphylococcal': 'I-Entity'}, {'infections,': 'I-Entity'}]"
"Both neurological symptoms and MRI findings temporarily improved, and the GC dose was gradually decreased.","[{'Both': 'O'}, {'neurological': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'MRI': 'O'}, {'findings': 'O'}, {'temporarily': 'O'}, {'improved,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'GC': 'I-Entity'}, {'dose': 'O'}, {'was': 'O'}, {'gradually': 'O'}, {'decreased.': 'O'}]"
"Slight antibody effects in pregnancy, leading to PR segment prolongation, can already be seen from 18-week gestation onwards by fMCG.","[{'Slight': 'O'}, {'antibody': 'O'}, {'effects': 'O'}, {'in': 'O'}, {'pregnancy,': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'PR': 'O'}, {'segment': 'O'}, {'prolongation,': 'O'}, {'can': 'O'}, {'already': 'O'}, {'be': 'O'}, {'seen': 'O'}, {'from': 'O'}, {'18-week': 'O'}, {'gestation': 'O'}, {'onwards': 'O'}, {'by': 'O'}, {'fMCG.': 'O'}]"
"Cardiac involvement in Sjogrens syndrome can affect all parts of the heart, but valve involvement is relatively rare.","[{'Cardiac': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'can': 'O'}, {'affect': 'O'}, {'all': 'O'}, {'parts': 'O'}, {'of': 'O'}, {'the': 'O'}, {'heart,': 'O'}, {'but': 'O'}, {'valve': 'O'}, {'involvement': 'O'}, {'is': 'O'}, {'relatively': 'O'}, {'rare.': 'O'}]"
"Therefore, we aimed to investigate whether patients with primary Sjogrens syndrome (pSS) with dry mouth have more voice-related problems than controls without the disease and to determine the factors affecting voice in pSS patients.","[{'Therefore,': 'O'}, {'we': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'whether': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'have': 'O'}, {'more': 'O'}, {'voice-related': 'B-Entity'}, {'problems': 'O'}, {'than': 'O'}, {'controls': 'O'}, {'without': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'and': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'factors': 'O'}, {'affecting': 'O'}, {'voice': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
"Our objective was to evaluate the diagnosis and manifestations associated for antibodies anti-Ro52, anti-Ro60 and anti-La at a referral hospital in Spain.","[{'Our': 'O'}, {'objective': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'manifestations': 'O'}, {'associated': 'O'}, {'for': 'O'}, {'antibodies': 'O'}, {'anti-Ro52,': 'O'}, {'anti-Ro60': 'O'}, {'and': 'O'}, {'anti-La': 'O'}, {'at': 'O'}, {'a': 'O'}, {'referral': 'O'}, {'hospital': 'O'}, {'in': 'O'}, {'Spain.': 'O'}]"
"Moreover, the good results observed in the published trials after RTX treatment in pSS should represent the starting point to develop evidence-based guidelines for the use of biologic therapy in this disease.sagepub.co.uk/journalsPermissions.nav.University of L'Aquila, L'Aquila, Italy francescocarubbi@libero.it.University of L'Aquila, L'Aquila, Italy.Palermo, Italy.Palermo, Italy.University of L'Aquila, L'Aquila, Italy.","[{'Moreover,': 'O'}, {'the': 'O'}, {'good': 'O'}, {'results': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'the': 'O'}, {'published': 'O'}, {'trials': 'O'}, {'after': 'O'}, {'RTX': 'O'}, {'treatment': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'should': 'O'}, {'represent': 'O'}, {'the': 'O'}, {'starting': 'O'}, {'point': 'O'}, {'to': 'O'}, {'develop': 'O'}, {'evidence-based': 'O'}, {'guidelines': 'O'}, {'for': 'O'}, {'the': 'O'}, {'use': 'O'}, {'of': 'O'}, {'biologic': 'O'}, {'therapy': 'O'}, {'in': 'O'}, {'this': 'O'}, {'disease.sagepub.co.uk/journalsPermissions.nav.University': 'O'}, {'of': 'O'}, {""L'Aquila,"": 'O'}]"
"The causes of anemia included anemia of chronic disease (69%), autoimmune hemolytic anemia (AIHA, 18%), iron deficiency anemia (9%) and other causes (4%), of which AIHA caused the most severe anemia.","[{'The': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'anemia': 'I-Entity'}, {'included': 'O'}, {'anemia': 'B-Entity'}, {'of': 'I-Entity'}, {'chronic': 'I-Entity'}, {'disease': 'I-Entity'}, {'(69%),': 'O'}, {'autoimmune': 'B-Entity'}, {'hemolytic': 'I-Entity'}, {'anemia': 'I-Entity'}, {'(AIHA,': 'O'}, {'18%),': 'O'}, {'iron': 'B-Entity'}, {'deficiency': 'I-Entity'}, {'anemia': 'I-Entity'}, {'(9%)': 'O'}, {'and': 'O'}, {'other': 'O'}, {'causes': 'O'}, {'(4%),': 'O'}, {'of': 'O'}, {'which': 'O'}, {'AIHA': 'I-Entity'}, {'caused': 'O'}, {'the': 'O'}, {'most': 'O'}, {'severe': 'O'}, {'anemia.': 'I-Entity'}]"
"Consequently, treatment directed to patients diagnosed using the AECC might exclude a significant proportion of patients with SjS.Faculty of Dental Medicine, Hebrew University-Hadassah School of Dental Medicine, Jerusalem, Israel.","[{'Consequently,': 'O'}, {'treatment': 'O'}, {'directed': 'O'}, {'to': 'O'}, {'patients': 'O'}, {'diagnosed': 'O'}, {'using': 'O'}, {'the': 'O'}, {'AECC': 'O'}, {'might': 'O'}, {'exclude': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'proportion': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SjS.Faculty': 'I-Entity'}, {'of': 'O'}, {'Dental': 'O'}, {'Medicine,': 'O'}, {'Hebrew': 'O'}, {'University-Hadassah': 'O'}, {'School': 'O'}, {'of': 'O'}, {'Dental': 'O'}, {'Medicine,': 'O'}, {'Jerusalem,': 'O'}, {'Israel.': 'O'}]"
"Our findings suggest that a disturbed T-cell homeostasis may drive the onset of some autoimmune features.Basel, Basel, Switzerland.25.","[{'Our': 'O'}, {'findings': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'a': 'O'}, {'disturbed': 'O'}, {'T-cell': 'O'}, {'homeostasis': 'O'}, {'may': 'O'}, {'drive': 'O'}, {'the': 'O'}, {'onset': 'O'}, {'of': 'O'}, {'some': 'O'}, {'autoimmune': 'I-Entity'}, {'features.Basel,': 'O'}, {'Basel,': 'O'}, {'Switzerland.25.': 'O'}]"
"The chronic inflammation can attack lacrimal glands, salivary glands, the thyroid, lung, pancreas, kidney, and prostate.","[{'The': 'O'}, {'chronic': 'O'}, {'inflammation': 'I-Entity'}, {'can': 'O'}, {'attack': 'O'}, {'lacrimal': 'O'}, {'glands,': 'O'}, {'salivary': 'O'}, {'glands,': 'O'}, {'the': 'O'}, {'thyroid,': 'O'}, {'lung,': 'O'}, {'pancreas,': 'O'}, {'kidney,': 'O'}, {'and': 'O'}, {'prostate.': 'O'}]"
Most common neurological findings were ataxia and areflexia followed by paresthesia and pain.,"[{'Most': 'O'}, {'common': 'O'}, {'neurological': 'O'}, {'findings': 'O'}, {'were': 'O'}, {'ataxia': 'I-Entity'}, {'and': 'O'}, {'areflexia': 'I-Entity'}, {'followed': 'O'}, {'by': 'O'}, {'paresthesia': 'I-Entity'}, {'and': 'O'}, {'pain.': 'I-Entity'}]"
Primary SS patients experience significant functional disability compared to age-matched healthy controls.,"[{'Primary': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'experience': 'O'}, {'significant': 'O'}, {'functional': 'B-Entity'}, {'disability': 'I-Entity'}, {'compared': 'O'}, {'to': 'O'}, {'age-matched': 'O'}, {'healthy': 'O'}, {'controls.': 'O'}]"
An autopsy was performed and revealed DAH and interstitial pneumonia with a fibrotic nonspecific interstitial pneumonia pattern.,"[{'An': 'O'}, {'autopsy': 'O'}, {'was': 'O'}, {'performed': 'O'}, {'and': 'O'}, {'revealed': 'O'}, {'DAH': 'I-Entity'}, {'and': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'with': 'O'}, {'a': 'O'}, {'fibrotic': 'O'}, {'nonspecific': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'pattern.': 'O'}]"
"Yeast cells (Saccharomyces cerevisiae and Schizosaccharomyces pombe) genetically depleted of La grow and proliferate, whereas deletion from mice causes early embryonic lethality, raising the question of whether La is required by mammalian cells generally or only to surpass a developmental stage.","[{'Yeast': 'O'}, {'cells': 'O'}, {'(Saccharomyces': 'O'}, {'cerevisiae': 'O'}, {'and': 'O'}, {'Schizosaccharomyces': 'O'}, {'pombe)': 'O'}, {'genetically': 'O'}, {'depleted': 'O'}, {'of': 'O'}, {'La': 'I-Entity'}, {'grow': 'O'}, {'and': 'O'}, {'proliferate,': 'O'}, {'whereas': 'O'}, {'deletion': 'O'}, {'from': 'O'}, {'mice': 'O'}, {'causes': 'O'}, {'early': 'O'}, {'embryonic': 'O'}, {'lethality,': 'O'}, {'raising': 'O'}, {'the': 'O'}, {'question': 'O'}, {'of': 'O'}, {'whether': 'O'}, {'La': 'I-Entity'}, {'is': 'O'}, {'required': 'O'}, {'by': 'O'}, {'mammalian': 'O'}]"
Reduced bladder sensation is defined as bladder volume at the first sensation >300 ml.,"[{'Reduced': 'B-Entity'}, {'bladder': 'I-Entity'}, {'sensation': 'I-Entity'}, {'is': 'O'}, {'defined': 'O'}, {'as': 'O'}, {'bladder': 'O'}, {'volume': 'O'}, {'at': 'O'}, {'the': 'O'}, {'first': 'O'}, {'sensation': 'O'}, {'>300': 'O'}, {'ml.': 'O'}]"
The reduction in SFRs in NOD mice was significantly alleviated from 9 to 17 weeks of age along with the suppression of IL-21 in submandibular glands.,"[{'The': 'O'}, {'reduction': 'O'}, {'in': 'O'}, {'SFRs': 'O'}, {'in': 'O'}, {'NOD': 'O'}, {'mice': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'alleviated': 'O'}, {'from': 'O'}, {'9': 'O'}, {'to': 'O'}, {'17': 'O'}, {'weeks': 'O'}, {'of': 'O'}, {'age': 'O'}, {'along': 'O'}, {'with': 'O'}, {'the': 'O'}, {'suppression': 'O'}, {'of': 'O'}, {'IL-21': 'O'}, {'in': 'O'}, {'submandibular': 'O'}, {'glands.': 'O'}]"
"The deep learning system showed a high diagnostic performance for SjS, suggesting that it could possibly be used for diagnostic support when interpreting CT images.Japan.Japan.Japan.Japan.Japan.University, Gifu, Japan.Japan.2019 May 22.","[{'The': 'O'}, {'deep': 'O'}, {'learning': 'O'}, {'system': 'O'}, {'showed': 'O'}, {'a': 'O'}, {'high': 'O'}, {'diagnostic': 'O'}, {'performance': 'O'}, {'for': 'O'}, {'SjS,': 'I-Entity'}, {'suggesting': 'O'}, {'that': 'O'}, {'it': 'O'}, {'could': 'O'}, {'possibly': 'O'}, {'be': 'O'}, {'used': 'O'}, {'for': 'O'}, {'diagnostic': 'O'}, {'support': 'O'}, {'when': 'O'}, {'interpreting': 'O'}, {'CT': 'O'}, {'images.Japan.Japan.Japan.Japan.Japan.University,': 'O'}, {'Gifu,': 'O'}, {'Japan.Japan.2019': 'O'}, {'May': 'O'}, {'22.': 'O'}]"
"There were statistically significant differences of positive anti-dsDNA antibodies in renal damage, photosensitization, hematological abnormalities and serositis (p<0.05) and a statistically significant difference of positive AHAs in photosensitization (p<0.05).","[{'There': 'O'}, {'were': 'O'}, {'statistically': 'O'}, {'significant': 'O'}, {'differences': 'O'}, {'of': 'O'}, {'positive': 'O'}, {'anti-dsDNA': 'O'}, {'antibodies': 'O'}, {'in': 'O'}, {'renal': 'B-Entity'}, {'damage,': 'I-Entity'}, {'photosensitization,': 'O'}, {'hematological': 'B-Entity'}, {'abnormalities': 'I-Entity'}, {'and': 'O'}, {'serositis': 'I-Entity'}, {'(p<0.05)': 'O'}, {'and': 'O'}, {'a': 'O'}, {'statistically': 'O'}, {'significant': 'O'}, {'difference': 'O'}, {'of': 'O'}, {'positive': 'O'}, {'AHAs': 'O'}, {'in': 'O'}, {'photosensitization': 'O'}, {'(p<0.05).': 'O'}]"
"The underlying diseases were Stevens-Johnson syndrome (22 eyes), Sjogren's syndrome (11 eyes), graft-versus-host disease (2 eyes), dry eye after keratomileusis (2 eyes) and undifferentiated ocular surface disease (4 eyes).","[{'The': 'O'}, {'underlying': 'O'}, {'diseases': 'O'}, {'were': 'O'}, {'Stevens-Johnson': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(22': 'O'}, {'eyes),': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(11': 'O'}, {'eyes),': 'O'}, {'graft-versus-host': 'B-Entity'}, {'disease': 'I-Entity'}, {'(2': 'O'}, {'eyes),': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'after': 'O'}, {'keratomileusis': 'O'}, {'(2': 'O'}, {'eyes)': 'O'}, {'and': 'O'}, {'undifferentiated': 'B-Entity'}, {'ocular': 'B-Entity'}, {'surface': 'I-Entity'}, {'disease': 'I-Entity'}, {'(4': 'O'}, {'eyes).': 'O'}]"
"Six patients (11,5%) were positive for celiac disease serological tests although two of them were asymptomatic.","[{'Six': 'O'}, {'patients': 'O'}, {'(11,5%)': 'O'}, {'were': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'celiac': 'B-Entity'}, {'disease': 'I-Entity'}, {'serological': 'O'}, {'tests': 'O'}, {'although': 'O'}, {'two': 'O'}, {'of': 'O'}, {'them': 'O'}, {'were': 'O'}, {'asymptomatic.': 'O'}]"
"Since pregnancy complications have been described in NOD mice, we evaluated the ability of anti-tTG antibodies to affect the functions of tTG relevant to the normal course of an early pregnancy like extracellular matrix assembling and apoptotic cell phagocytosis by macrophages.","[{'Since': 'O'}, {'pregnancy': 'O'}, {'complications': 'O'}, {'have': 'O'}, {'been': 'O'}, {'described': 'O'}, {'in': 'O'}, {'NOD': 'O'}, {'mice,': 'O'}, {'we': 'O'}, {'evaluated': 'O'}, {'the': 'O'}, {'ability': 'O'}, {'of': 'O'}, {'anti-tTG': 'O'}, {'antibodies': 'O'}, {'to': 'O'}, {'affect': 'O'}, {'the': 'O'}, {'functions': 'O'}, {'of': 'O'}, {'tTG': 'O'}, {'relevant': 'O'}, {'to': 'O'}, {'the': 'O'}, {'normal': 'O'}, {'course': 'O'}, {'of': 'O'}, {'an': 'O'}, {'early': 'O'}, {'pregnancy': 'O'}, {'like': 'O'}, {'extracellular': 'O'}, {'matrix': 'O'}, {'assembling': 'O'}, {'and': 'O'}, {'apoptotic': 'O'}, {'cell': 'O'}, {'phagocytosis': 'O'}, {'by': 'O'}, {'macrophages.': 'O'}]"
"We examined the antibodies to antinuclear factor, ds-DNA, extracted nuclear antigens, rheumatoid factor, as well as antiphospholipid antibodies, in 23 primary NH patients.","[{'We': 'O'}, {'examined': 'O'}, {'the': 'O'}, {'antibodies': 'O'}, {'to': 'O'}, {'antinuclear': 'O'}, {'factor,': 'O'}, {'ds-DNA,': 'O'}, {'extracted': 'O'}, {'nuclear': 'O'}, {'antigens,': 'O'}, {'rheumatoid': 'O'}, {'factor,': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'antiphospholipid': 'O'}, {'antibodies,': 'O'}, {'in': 'O'}, {'23': 'O'}, {'primary': 'O'}, {'NH': 'I-Entity'}, {'patients.': 'O'}]"
Ongoing studies in murine models are aimed at developing more effective and targeted therapies in SS.,"[{'Ongoing': 'O'}, {'studies': 'O'}, {'in': 'O'}, {'murine': 'O'}, {'models': 'O'}, {'are': 'O'}, {'aimed': 'O'}, {'at': 'O'}, {'developing': 'O'}, {'more': 'O'}, {'effective': 'O'}, {'and': 'O'}, {'targeted': 'O'}, {'therapies': 'O'}, {'in': 'O'}, {'SS.': 'I-Entity'}]"
"Results showed that the stimulated salivary flow rate was gradually decreased and lymphocytic infiltration was found as age increased in 12- and 21-week-old NOD mice, but not 7-week-old NOD mice.","[{'Results': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'the': 'O'}, {'stimulated': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'rate': 'O'}, {'was': 'O'}, {'gradually': 'O'}, {'decreased': 'O'}, {'and': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'was': 'O'}, {'found': 'O'}, {'as': 'O'}, {'age': 'O'}, {'increased': 'O'}, {'in': 'O'}, {'12-': 'O'}, {'and': 'O'}, {'21-week-old': 'O'}, {'NOD': 'O'}, {'mice,': 'O'}, {'but': 'O'}, {'not': 'O'}, {'7-week-old': 'O'}, {'NOD': 'O'}, {'mice.': 'O'}]"
"Incomplete dRTA is common in pSS and causes mild acidaemia and higher urinary pH, which may contribute to bone demineralization and kidney stone formation.","[{'Incomplete': 'O'}, {'dRTA': 'I-Entity'}, {'is': 'O'}, {'common': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'causes': 'O'}, {'mild': 'O'}, {'acidaemia': 'I-Entity'}, {'and': 'O'}, {'higher': 'O'}, {'urinary': 'O'}, {'pH,': 'O'}, {'which': 'O'}, {'may': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'bone': 'O'}, {'demineralization': 'O'}, {'and': 'O'}, {'kidney': 'B-Entity'}, {'stone': 'I-Entity'}, {'formation.': 'O'}]"
Diagnosis and treatment of pSS led to significant improvement in systemic and renal presentations of the patient.,"[{'Diagnosis': 'O'}, {'and': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'led': 'O'}, {'to': 'O'}, {'significant': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'systemic': 'O'}, {'and': 'O'}, {'renal': 'O'}, {'presentations': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patient.': 'O'}]"
"Significantly, dry eyes can lead to corneal abrasions, infection, ulceration, chronic scarring and, in severe cases, perforation.","[{'Significantly,': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'can': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'corneal': 'B-Entity'}, {'abrasions,': 'I-Entity'}, {'infection,': 'I-Entity'}, {'ulceration,': 'I-Entity'}, {'chronic': 'O'}, {'scarring': 'I-Entity'}, {'and,': 'O'}, {'in': 'O'}, {'severe': 'O'}, {'cases,': 'O'}, {'perforation.': 'I-Entity'}]"
Dry mouth is not usually seen if low doses of (131)I are used.,"[{'Dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'is': 'O'}, {'not': 'O'}, {'usually': 'O'}, {'seen': 'O'}, {'if': 'O'}, {'low': 'O'}, {'doses': 'O'}, {'of': 'O'}, {'(131)I': 'O'}, {'are': 'O'}, {'used.': 'O'}]"
"If treatment is initiated within 2 months of symptom onset, there is a better opportunity for improvement of the patient's condition.","[{'If': 'O'}, {'treatment': 'O'}, {'is': 'O'}, {'initiated': 'O'}, {'within': 'O'}, {'2': 'O'}, {'months': 'O'}, {'of': 'O'}, {'symptom': 'O'}, {'onset,': 'O'}, {'there': 'O'}, {'is': 'O'}, {'a': 'O'}, {'better': 'O'}, {'opportunity': 'O'}, {'for': 'O'}, {'improvement': 'O'}, {'of': 'O'}, {'the': 'O'}, {""patient's"": 'O'}, {'condition.': 'O'}]"
"Here, we evaluated the levels of FURIN in the plasma and peripheral blood mononuclear cells (PBMCs) of patients with primary Sjogrens syndrome (pSS) and in healthy controls.","[{'Here,': 'O'}, {'we': 'O'}, {'evaluated': 'O'}, {'the': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'FURIN': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'plasma': 'O'}, {'and': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'mononuclear': 'O'}, {'cells': 'O'}, {'(PBMCs)': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'and': 'O'}, {'in': 'O'}, {'healthy': 'O'}, {'controls.': 'O'}]"
Pulmonary involvement was defined as typical abnormalities identified with high-resolution CT (HRCT) and/or pulmonary function tests (PFTs).,"[{'Pulmonary': 'O'}, {'involvement': 'O'}, {'was': 'O'}, {'defined': 'O'}, {'as': 'O'}, {'typical': 'O'}, {'abnormalities': 'O'}, {'identified': 'O'}, {'with': 'O'}, {'high-resolution': 'O'}, {'CT': 'O'}, {'(HRCT)': 'O'}, {'and/or': 'O'}, {'pulmonary': 'O'}, {'function': 'O'}, {'tests': 'O'}, {'(PFTs).': 'O'}]"
Our results indicate that SLE patients present with different clinical and serological manifestations according to age at disease onset.,"[{'Our': 'O'}, {'results': 'O'}, {'indicate': 'O'}, {'that': 'O'}, {'SLE': 'I-Entity'}, {'patients': 'O'}, {'present': 'O'}, {'with': 'O'}, {'different': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'serological': 'O'}, {'manifestations': 'O'}, {'according': 'O'}, {'to': 'O'}, {'age': 'O'}, {'at': 'O'}, {'disease': 'O'}, {'onset.': 'O'}]"
Lung involvement was defined based on the presence of pulmonary signs/symptoms and/or impaired pulmonary function tests along with alterations in high-resolution computerized tomography (HRCT).,"[{'Lung': 'B-Entity'}, {'involvement': 'I-Entity'}, {'was': 'O'}, {'defined': 'O'}, {'based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'pulmonary': 'O'}, {'signs/symptoms': 'O'}, {'and/or': 'O'}, {'impaired': 'B-Entity'}, {'pulmonary': 'I-Entity'}, {'function': 'I-Entity'}, {'tests': 'O'}, {'along': 'O'}, {'with': 'O'}, {'alterations': 'O'}, {'in': 'O'}, {'high-resolution': 'O'}, {'computerized': 'O'}, {'tomography': 'O'}, {'(HRCT).': 'O'}]"
"We also observed that RTX is able to reduce glandular infiltrate, interfere with B/T compartmentalization and consequently with the formation of ectopic lymphoid structures and germinal center-like structures in pSS-MSGs.","[{'We': 'O'}, {'also': 'O'}, {'observed': 'O'}, {'that': 'O'}, {'RTX': 'I-Entity'}, {'is': 'O'}, {'able': 'O'}, {'to': 'O'}, {'reduce': 'O'}, {'glandular': 'O'}, {'infiltrate,': 'O'}, {'interfere': 'O'}, {'with': 'O'}, {'B/T': 'O'}, {'compartmentalization': 'O'}, {'and': 'O'}, {'consequently': 'O'}, {'with': 'O'}, {'the': 'O'}, {'formation': 'O'}, {'of': 'O'}, {'ectopic': 'O'}, {'lymphoid': 'O'}, {'structures': 'O'}, {'and': 'O'}, {'germinal': 'O'}, {'center-like': 'O'}, {'structures': 'O'}, {'in': 'O'}, {'pSS-MSGs.': 'O'}]"
"Sex, dry eye, Saxon test, Schirmer's test, anti-SSA/Ro antibody, MSGB grading and sialography statistically contributed to the diagnosis.","[{'Sex,': 'O'}, {'dry': 'B-Entity'}, {'eye,': 'I-Entity'}, {'Saxon': 'O'}, {'test,': 'O'}, {""Schirmer's"": 'O'}, {'test,': 'O'}, {'anti-SSA/Ro': 'O'}, {'antibody,': 'O'}, {'MSGB': 'O'}, {'grading': 'O'}, {'and': 'O'}, {'sialography': 'O'}, {'statistically': 'O'}, {'contributed': 'O'}, {'to': 'O'}, {'the': 'O'}, {'diagnosis.': 'O'}]"
The efficacy of HCQ in treating pain associated with pSS was superior to that of the placebo.,"[{'The': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'HCQ': 'I-Entity'}, {'in': 'O'}, {'treating': 'O'}, {'pain': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'pSS': 'O'}, {'was': 'O'}, {'superior': 'O'}, {'to': 'O'}, {'that': 'O'}, {'of': 'O'}, {'the': 'O'}, {'placebo.': 'O'}]"
"The E-FABP concentration in tears appears to be related to ocular surface epithelial damage and tear stability and may be a promising novel biomarker in the diagnosis of SS.2728513, Japan.","[{'The': 'O'}, {'E-FABP': 'O'}, {'concentration': 'O'}, {'in': 'O'}, {'tears': 'O'}, {'appears': 'O'}, {'to': 'O'}, {'be': 'O'}, {'related': 'O'}, {'to': 'O'}, {'ocular': 'B-Entity'}, {'surface': 'I-Entity'}, {'epithelial': 'O'}, {'damage': 'O'}, {'and': 'O'}, {'tear': 'O'}, {'stability': 'O'}, {'and': 'O'}, {'may': 'O'}, {'be': 'O'}, {'a': 'O'}, {'promising': 'O'}, {'novel': 'O'}, {'biomarker': 'O'}, {'in': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS.2728513,': 'I-Entity'}, {'Japan.': 'O'}]"
Low-dose rituximab has good efficacy and safety in the treatment of hematologic abnormalities in patients with connective tissue disease.syndrome as a proof of concept.,"[{'Low-dose': 'O'}, {'rituximab': 'I-Entity'}, {'has': 'O'}, {'good': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'safety': 'O'}, {'in': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'hematologic': 'B-Entity'}, {'abnormalities': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease.syndrome': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'proof': 'O'}, {'of': 'O'}, {'concept.': 'O'}]"
"For different disease activity index cut-off values, more potentially eligible participants were found when ClinESSDAI was used than with ESSDAI.","[{'For': 'O'}, {'different': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'index': 'O'}, {'cut-off': 'O'}, {'values,': 'O'}, {'more': 'O'}, {'potentially': 'O'}, {'eligible': 'O'}, {'participants': 'O'}, {'were': 'O'}, {'found': 'O'}, {'when': 'O'}, {'ClinESSDAI': 'O'}, {'was': 'O'}, {'used': 'O'}, {'than': 'O'}, {'with': 'O'}, {'ESSDAI.': 'O'}]"
"Histopathological findings of IgG4-RD may co-exist with low malignant B-cell lymphoma in patients with initially suspected pSS and may be associated with an underlying IgG4-RD.Uppsala , Sweden.University , Uppsala , Sweden.Uppsala , Sweden.Uppsala , Sweden.Uppsala , Sweden.Epub 2016 May 19.","[{'Histopathological': 'O'}, {'findings': 'O'}, {'of': 'O'}, {'IgG4-RD': 'O'}, {'may': 'O'}, {'co-exist': 'O'}, {'with': 'O'}, {'low': 'O'}, {'malignant': 'B-Entity'}, {'B-cell': 'I-Entity'}, {'lymphoma': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'initially': 'O'}, {'suspected': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'may': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'an': 'O'}, {'underlying': 'O'}, {'IgG4-RD.Uppsala': 'O'}, {',': 'O'}, {'Sweden.University': 'O'}, {',': 'O'}, {'Uppsala': 'O'}, {',': 'O'}]"
To determine whether anti-Ro52 antibodies are associated with ILD in pSS.,"[{'To': 'O'}, {'determine': 'O'}, {'whether': 'O'}, {'anti-Ro52': 'O'}, {'antibodies': 'O'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'ILD': 'I-Entity'}, {'in': 'O'}, {'pSS.': 'I-Entity'}]"
"PATIENT'S CONCERNS: A 44-year-old Chinese female was admitted with three months history of painless abdominal distension accompanied by watery diarrhea 5-6 times daily, shortness of breath, fatigue, lower limb swelling, and 10‚Äö√Ñ√∂‚àö√ë‚àö¬ßkg weight loss.","[{""PATIENT'S"": 'O'}, {'CONCERNS:': 'O'}, {'A': 'O'}, {'44-year-old': 'O'}, {'Chinese': 'O'}, {'female': 'O'}, {'was': 'O'}, {'admitted': 'O'}, {'with': 'O'}, {'three': 'O'}, {'months': 'O'}, {'history': 'O'}, {'of': 'O'}, {'painless': 'O'}, {'abdominal': 'B-Entity'}, {'distension': 'I-Entity'}, {'accompanied': 'O'}, {'by': 'O'}, {'watery': 'O'}, {'diarrhea': 'I-Entity'}, {'5-6': 'O'}, {'times': 'O'}, {'daily,': 'O'}, {'shortness': 'B-Entity'}, {'of': 'I-Entity'}, {'breath,': 'I-Entity'}, {'fatigue,': 'I-Entity'}, {'lower': 'O'}, {'limb': 'O'}, {'swelling,': 'I-Entity'}, {'and': 'O'}, {'10‚Äö√Ñ√∂‚àö√ë‚àö¬ßkg': 'O'}]"
"In this retrospective, real-world analysis, medical claims in the first year after SS diagnosis revealed that cardiovascular (CV) events increased and all-cause healthcare costs grew by 40%.","[{'In': 'O'}, {'this': 'O'}, {'retrospective,': 'O'}, {'real-world': 'O'}, {'analysis,': 'O'}, {'medical': 'O'}, {'claims': 'O'}, {'in': 'O'}, {'the': 'O'}, {'first': 'O'}, {'year': 'O'}, {'after': 'O'}, {'SS': 'I-Entity'}, {'diagnosis': 'O'}, {'revealed': 'O'}, {'that': 'O'}, {'cardiovascular': 'O'}, {'(CV)': 'I-Entity'}, {'events': 'O'}, {'increased': 'O'}, {'and': 'O'}, {'all-cause': 'O'}, {'healthcare': 'O'}, {'costs': 'O'}, {'grew': 'O'}, {'by': 'O'}, {'40%.': 'O'}]"
"All patients reported a significant decrease in the Ocular Surface Disease Index (p < 0.01), which indicates improvement of the patient's subjective feelings after therapy.","[{'All': 'O'}, {'patients': 'O'}, {'reported': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'the': 'O'}, {'Ocular': 'B-Entity'}, {'Surface': 'I-Entity'}, {'Disease': 'I-Entity'}, {'Index': 'O'}, {'(p': 'O'}, {'<': 'O'}, {'0.01),': 'O'}, {'which': 'O'}, {'indicates': 'O'}, {'improvement': 'O'}, {'of': 'O'}, {'the': 'O'}, {""patient's"": 'O'}, {'subjective': 'O'}, {'feelings': 'O'}, {'after': 'O'}, {'therapy.': 'O'}]"
To determine whether certain rheumatic diseases will affect the fetal thymus diameter when compared to uncomplicated singleton pregnancies.,"[{'To': 'O'}, {'determine': 'O'}, {'whether': 'O'}, {'certain': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases': 'I-Entity'}, {'will': 'O'}, {'affect': 'O'}, {'the': 'O'}, {'fetal': 'O'}, {'thymus': 'O'}, {'diameter': 'O'}, {'when': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'uncomplicated': 'O'}, {'singleton': 'O'}, {'pregnancies.': 'O'}]"
Multilayer amniotic membrane transplantation is a safe and efficient technique for a long restoration of the corneal integrity after non-traumatic corneal perforations or deep corneal ulcers with descemetocele.,"[{'Multilayer': 'O'}, {'amniotic': 'O'}, {'membrane': 'O'}, {'transplantation': 'O'}, {'is': 'O'}, {'a': 'O'}, {'safe': 'O'}, {'and': 'O'}, {'efficient': 'O'}, {'technique': 'O'}, {'for': 'O'}, {'a': 'O'}, {'long': 'O'}, {'restoration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'corneal': 'O'}, {'integrity': 'O'}, {'after': 'O'}, {'non-traumatic': 'O'}, {'corneal': 'B-Entity'}, {'perforations': 'I-Entity'}, {'or': 'O'}, {'deep': 'O'}, {'corneal': 'B-Entity'}, {'ulcers': 'I-Entity'}, {'with': 'O'}, {'descemetocele.': 'I-Entity'}]"
Sjogrens syndrome is a systemic chronic autoimmune inflammatory disease that primarily targets the salivary and lacrimal glands (LGs).,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'chronic': 'O'}, {'autoimmune': 'B-Entity'}, {'inflammatory': 'I-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'primarily': 'O'}, {'targets': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands': 'O'}, {'(LGs).': 'O'}]"
Therapy with belimumab in pSS patients induced a significant reduction in transitional and naive B cell subsets to levels similar to those observed in healthy donors.,"[{'Therapy': 'O'}, {'with': 'O'}, {'belimumab': 'I-Entity'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'induced': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'reduction': 'O'}, {'in': 'O'}, {'transitional': 'O'}, {'and': 'O'}, {'naive': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'subsets': 'O'}, {'to': 'O'}, {'levels': 'O'}, {'similar': 'O'}, {'to': 'O'}, {'those': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'healthy': 'O'}, {'donors.': 'O'}]"
M2 macrophages are involved in acute tubular injury in patients with primary Sjogren's disease.,"[{'M2': 'O'}, {'macrophages': 'O'}, {'are': 'O'}, {'involved': 'O'}, {'in': 'O'}, {'acute': 'O'}, {'tubular': 'B-Entity'}, {'injury': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'disease.': 'I-Entity'}]"
The underlying cause was identified in 18 cases (85.7%).,"[{'The': 'O'}, {'underlying': 'O'}, {'cause': 'O'}, {'was': 'O'}, {'identified': 'O'}, {'in': 'O'}, {'18': 'O'}, {'cases': 'O'}, {'(85.7%).': 'O'}]"
"Of the 95 included patients, 55 (57.9%) had pSS and 40 (42.1%) had sicca without pSS.","[{'Of': 'O'}, {'the': 'O'}, {'95': 'O'}, {'included': 'O'}, {'patients,': 'O'}, {'55': 'O'}, {'(57.9%)': 'O'}, {'had': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'40': 'O'}, {'(42.1%)': 'O'}, {'had': 'O'}, {'sicca': 'I-Entity'}, {'without': 'O'}, {'pSS.': 'I-Entity'}]"
"Decreased mRNA levels for IRE1‚âà√≠¬¨¬±, XBP-1 and GRP78 can be partially explained by hypermethylation of their promoters and is consistent with chronic endoplasmic reticulum stress, which may explain the glandular dysfunction observed in LSGs of SS patients.","[{'Decreased': 'O'}, {'mRNA': 'O'}, {'levels': 'O'}, {'for': 'O'}, {'IRE1‚âà√≠¬¨¬±,': 'O'}, {'XBP-1': 'O'}, {'and': 'O'}, {'GRP78': 'O'}, {'can': 'O'}, {'be': 'O'}, {'partially': 'O'}, {'explained': 'O'}, {'by': 'O'}, {'hypermethylation': 'O'}, {'of': 'O'}, {'their': 'O'}, {'promoters': 'O'}, {'and': 'O'}, {'is': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'chronic': 'O'}, {'endoplasmic': 'O'}, {'reticulum': 'O'}, {'stress,': 'O'}, {'which': 'O'}, {'may': 'O'}, {'explain': 'O'}, {'the': 'O'}, {'glandular': 'O'}]"
"Direct and indirect B-cell blocking seems to be the most promising biological pathway in primary Sjogrens syndrome, especially for systemic involvement, although a large controlled trial has failed to demonstrate the efficacy of rituximab for nonsystemic symptomatology (dryness, fatigue and pain).","[{'Direct': 'O'}, {'and': 'O'}, {'indirect': 'O'}, {'B-cell': 'O'}, {'blocking': 'O'}, {'seems': 'O'}, {'to': 'O'}, {'be': 'O'}, {'the': 'O'}, {'most': 'O'}, {'promising': 'O'}, {'biological': 'O'}, {'pathway': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'especially': 'O'}, {'for': 'O'}, {'systemic': 'O'}, {'involvement,': 'O'}, {'although': 'O'}, {'a': 'O'}, {'large': 'O'}, {'controlled': 'O'}, {'trial': 'O'}, {'has': 'O'}, {'failed': 'O'}, {'to': 'O'}, {'demonstrate': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'rituximab': 'I-Entity'}, {'for': 'O'}, {'nonsystemic': 'O'}, {'symptomatology': 'O'}, {'(dryness,': 'O'}, {'fatigue': 'I-Entity'}, {'and': 'O'}, {'pain).': 'I-Entity'}]"
"Laboratory investigations suggested anemia, thrombocytopenia, significantly increased lactic dehydrogenase, schistocytes in peripheral blood smear, and a disintegrin-like metalloproteinase with thrombospondin motif type 1 member 13 (ADAMTS13) activity deficiency with high inhibitor titers.","[{'Laboratory': 'O'}, {'investigations': 'O'}, {'suggested': 'O'}, {'anemia,': 'I-Entity'}, {'thrombocytopenia,': 'I-Entity'}, {'significantly': 'O'}, {'increased': 'O'}, {'lactic': 'I-Entity'}, {'dehydrogenase,': 'O'}, {'schistocytes': 'I-Entity'}, {'in': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'smear,': 'O'}, {'and': 'O'}, {'a': 'O'}, {'disintegrin-like': 'O'}, {'metalloproteinase': 'O'}, {'with': 'O'}, {'thrombospondin': 'O'}, {'motif': 'O'}, {'type': 'O'}, {'1': 'O'}, {'member': 'O'}, {'13': 'O'}, {'(ADAMTS13)': 'O'}]"
"Although autoimmune thyroid disease is well known to be associated with primary Sjogrens syndrome (SjS) and with various autoimmune diseases, it is less clear whether a similar association also exists for ankylosing spondylitis (AS).","[{'Although': 'O'}, {'autoimmune': 'B-Entity'}, {'thyroid': 'I-Entity'}, {'disease': 'I-Entity'}, {'is': 'O'}, {'well': 'O'}, {'known': 'O'}, {'to': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SjS)': 'O'}, {'and': 'O'}, {'with': 'O'}, {'various': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'it': 'O'}, {'is': 'O'}, {'less': 'O'}, {'clear': 'O'}, {'whether': 'O'}, {'a': 'O'}, {'similar': 'O'}, {'association': 'O'}, {'also': 'O'}, {'exists': 'O'}, {'for': 'O'}, {'ankylosing': 'B-Entity'}, {'spondylitis': 'I-Entity'}, {'(AS).': 'O'}]"
"Considering the clinical symptoms, statistically significant differences were noted between pSS patients and the control group in frequency (p = 0.02) and severity (p = 0.042) of fatigue, lymphadenopathy, major salivary gland involvement, and photosensitivity to UV light.","[{'Considering': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'symptoms,': 'O'}, {'statistically': 'O'}, {'significant': 'O'}, {'differences': 'O'}, {'were': 'O'}, {'noted': 'O'}, {'between': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'the': 'O'}, {'control': 'O'}, {'group': 'O'}, {'in': 'O'}, {'frequency': 'O'}, {'(p': 'O'}, {'=': 'O'}, {'0.02)': 'O'}, {'and': 'O'}, {'severity': 'O'}, {'(p': 'O'}, {'=': 'O'}, {'0.042)': 'O'}, {'of': 'O'}, {'fatigue,': 'I-Entity'}, {'lymphadenopathy,': 'I-Entity'}, {'major': 'O'}, {'salivary': 'O'}, {'gland': 'I-Entity'}, {'involvement,': 'O'}, {'and': 'O'}, {'photosensitivity': 'O'}, {'to': 'O'}, {'UV': 'I-Entity'}]"
Growing evidence demonstrated that patients with autoimmune and inflammatory chronic diseases display an impairment of TREG cells or activated effector T cells unresponsive to TREG.,"[{'Growing': 'O'}, {'evidence': 'O'}, {'demonstrated': 'O'}, {'that': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'and': 'I-Entity'}, {'inflammatory': 'I-Entity'}, {'chronic': 'I-Entity'}, {'diseases': 'I-Entity'}, {'display': 'O'}, {'an': 'O'}, {'impairment': 'O'}, {'of': 'O'}, {'TREG': 'O'}, {'cells': 'O'}, {'or': 'O'}, {'activated': 'O'}, {'effector': 'O'}, {'T': 'O'}, {'cells': 'O'}, {'unresponsive': 'O'}, {'to': 'O'}, {'TREG.': 'I-Entity'}]"
Patients must be informed by their physician of the risk of having auditory damage as a complication of the disease.,"[{'Patients': 'O'}, {'must': 'O'}, {'be': 'O'}, {'informed': 'O'}, {'by': 'O'}, {'their': 'O'}, {'physician': 'O'}, {'of': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'having': 'O'}, {'auditory': 'B-Entity'}, {'damage': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
"Her symptoms gradually improved after administration of steroids including pulse therapy; however, her amnesia remained for a long time.","[{'Her': 'O'}, {'symptoms': 'O'}, {'gradually': 'O'}, {'improved': 'O'}, {'after': 'O'}, {'administration': 'O'}, {'of': 'O'}, {'steroids': 'I-Entity'}, {'including': 'O'}, {'pulse': 'O'}, {'therapy;': 'O'}, {'however,': 'O'}, {'her': 'O'}, {'amnesia': 'I-Entity'}, {'remained': 'O'}, {'for': 'O'}, {'a': 'O'}, {'long': 'O'}, {'time.': 'O'}]"
"Autoimmune thyroid disease (adjusted odd ratio [aOR], 1.32; 95% confidence interval [CI], 1.05-1.64), Sjogrens syndrome (aOR, 11.6; 95% CI, 4.36-31.0) and ankylosing spondylitis (aOR, 3.80; 95% CI, 2.42-5.97) were significantly associated with sarcoidosis.","[{'Autoimmune': 'B-Entity'}, {'thyroid': 'I-Entity'}, {'disease': 'I-Entity'}, {'(adjusted': 'O'}, {'odd': 'O'}, {'ratio': 'O'}, {'[aOR],': 'O'}, {'1.32;': 'O'}, {'95%': 'O'}, {'confidence': 'O'}, {'interval': 'O'}, {'[CI],': 'O'}, {'1.05-1.64),': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(aOR,': 'O'}, {'11.6;': 'O'}, {'95%': 'O'}, {'CI,': 'O'}, {'4.36-31.0)': 'O'}]"
"These age-related changes are, at least in part, to be the consequence of decreased androgen levels.","[{'These': 'O'}, {'age-related': 'O'}, {'changes': 'O'}, {'are,': 'O'}, {'at': 'O'}, {'least': 'O'}, {'in': 'O'}, {'part,': 'O'}, {'to': 'O'}, {'be': 'O'}, {'the': 'O'}, {'consequence': 'O'}, {'of': 'O'}, {'decreased': 'O'}, {'androgen': 'O'}, {'levels.': 'O'}]"
"In multivariate modelling, all 11 domains remained significantly associated with disease activity, with slight modifications of some domain weights.","[{'In': 'O'}, {'multivariate': 'O'}, {'modelling,': 'O'}, {'all': 'O'}, {'11': 'O'}, {'domains': 'O'}, {'remained': 'O'}, {'significantly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'with': 'O'}, {'slight': 'O'}, {'modifications': 'O'}, {'of': 'O'}, {'some': 'O'}, {'domain': 'O'}, {'weights.': 'O'}]"
"Brain magnetic resonance images (MRI) showed abnormal signaling in long corticospinal tract involving internal capsules and cerebral peduncles, middle cerebellar peduncle, and frontal subcortical white matter lesions.","[{'Brain': 'O'}, {'magnetic': 'O'}, {'resonance': 'O'}, {'images': 'O'}, {'(MRI)': 'O'}, {'showed': 'O'}, {'abnormal': 'O'}, {'signaling': 'O'}, {'in': 'O'}, {'long': 'O'}, {'corticospinal': 'O'}, {'tract': 'O'}, {'involving': 'O'}, {'internal': 'O'}, {'capsules': 'O'}, {'and': 'O'}, {'cerebral': 'O'}, {'peduncles,': 'O'}, {'middle': 'O'}, {'cerebellar': 'O'}, {'peduncle,': 'O'}, {'and': 'O'}, {'frontal': 'O'}, {'subcortical': 'O'}, {'white': 'B-Entity'}, {'matter': 'I-Entity'}, {'lesions.': 'I-Entity'}]"
"Instead, our patients could have syndromes which phenotypically resembled paraneoplastic and other inflammatory disorders which are known to be associated with antineuronal antibodies.","[{'Instead,': 'O'}, {'our': 'O'}, {'patients': 'O'}, {'could': 'O'}, {'have': 'O'}, {'syndromes': 'O'}, {'which': 'O'}, {'phenotypically': 'O'}, {'resembled': 'O'}, {'paraneoplastic': 'O'}, {'and': 'O'}, {'other': 'O'}, {'inflammatory': 'B-Entity'}, {'disorders': 'I-Entity'}, {'which': 'O'}, {'are': 'O'}, {'known': 'O'}, {'to': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'antineuronal': 'O'}, {'antibodies.': 'O'}]"
"The study indicates that because of obtaining normal suppression levels in DPOAE, the medial olivocochlear efferent system is functional in pSS.","[{'The': 'O'}, {'study': 'O'}, {'indicates': 'O'}, {'that': 'O'}, {'because': 'O'}, {'of': 'O'}, {'obtaining': 'O'}, {'normal': 'O'}, {'suppression': 'O'}, {'levels': 'O'}, {'in': 'O'}, {'DPOAE,': 'O'}, {'the': 'O'}, {'medial': 'O'}, {'olivocochlear': 'O'}, {'efferent': 'O'}, {'system': 'O'}, {'is': 'O'}, {'functional': 'O'}, {'in': 'O'}, {'pSS.': 'O'}]"
Corneal epithelium in dry eyes presents morphological changes such as areas of enlarged and irregular shaped cells.,"[{'Corneal': 'O'}, {'epithelium': 'O'}, {'in': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'presents': 'O'}, {'morphological': 'O'}, {'changes': 'O'}, {'such': 'O'}, {'as': 'O'}, {'areas': 'O'}, {'of': 'O'}, {'enlarged': 'O'}, {'and': 'O'}, {'irregular': 'O'}, {'shaped': 'O'}, {'cells.': 'O'}]"
"Clinical symptoms are concentrated in auricula, nose, larynx, upper respiratory tract, joints, heart, blood vessels, inner ear, cornea and sclera.","[{'Clinical': 'O'}, {'symptoms': 'O'}, {'are': 'O'}, {'concentrated': 'O'}, {'in': 'O'}, {'auricula,': 'O'}, {'nose,': 'O'}, {'larynx,': 'O'}, {'upper': 'O'}, {'respiratory': 'O'}, {'tract,': 'O'}, {'joints,': 'O'}, {'heart,': 'O'}, {'blood': 'O'}, {'vessels,': 'O'}, {'inner': 'O'}, {'ear,': 'O'}, {'cornea': 'O'}, {'and': 'O'}, {'sclera.': 'O'}]"
An increase of iNKT was detected ex vivo in peripheral blood of pSS patients; after ‚âà√≠¬¨¬±-GalCer stimulation this subset produce IL-17 and IFN-iNKT were undetectable in the salivary glands of pSS patients and anti-SSA specific B cells were found in target tissue.,"[{'An': 'O'}, {'increase': 'O'}, {'of': 'O'}, {'iNKT': 'O'}, {'was': 'O'}, {'detected': 'O'}, {'ex': 'O'}, {'vivo': 'O'}, {'in': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'patients;': 'O'}, {'after': 'O'}, {'‚âà√≠¬¨¬±-GalCer': 'O'}, {'stimulation': 'O'}, {'this': 'O'}, {'subset': 'O'}, {'produce': 'O'}, {'IL-17': 'O'}, {'and': 'O'}, {'IFN-iNKT': 'O'}, {'were': 'O'}, {'undetectable': 'O'}, {'in': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'of': 'O'}]"
"MID estimates for improvemenT/worsening (SD) respectively were: -7.4 (27.8) / 20.7 (20.0) for pain VAS, -6.2 (28.3) / 15.2 (21.8) for fatigue VAS, -24.0 (24.0) / 15.2 (28.0) for sleep VAS, -0.18 (0.23) / 0.14 (0.30) for HAQ and -23.1 (21.6) / 16.4 (20.9) for global VAS.","[{'MID': 'O'}, {'estimates': 'O'}, {'for': 'O'}, {'improvemenT/worsening': 'O'}, {'(SD)': 'O'}, {'respectively': 'O'}, {'were:': 'O'}, {'-7.4': 'O'}, {'(27.8)': 'O'}, {'/': 'O'}, {'20.7': 'O'}, {'(20.0)': 'O'}, {'for': 'O'}, {'pain': 'I-Entity'}, {'VAS,': 'O'}, {'-6.2': 'O'}, {'(28.3)': 'O'}, {'/': 'O'}, {'15.2': 'O'}, {'(21.8)': 'O'}, {'for': 'O'}, {'fatigue': 'I-Entity'}, {'VAS,': 'O'}]"
Both cases demonstrated marked improvement in the degree and extent of pleural thickening and rounded atelectasis following corticosteroid therapy.,"[{'Both': 'O'}, {'cases': 'O'}, {'demonstrated': 'O'}, {'marked': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'the': 'O'}, {'degree': 'O'}, {'and': 'O'}, {'extent': 'O'}, {'of': 'O'}, {'pleural': 'B-Entity'}, {'thickening': 'I-Entity'}, {'and': 'O'}, {'rounded': 'O'}, {'atelectasis': 'I-Entity'}, {'following': 'O'}, {'corticosteroid': 'O'}, {'therapy.': 'O'}]"
"Although none demonstrated erosion on x-ray, all required methotrexate or leflunomide, and 4 required a biologic agent for the treatment of their arthritis.","[{'Although': 'O'}, {'none': 'O'}, {'demonstrated': 'O'}, {'erosion': 'O'}, {'on': 'O'}, {'x-ray,': 'O'}, {'all': 'O'}, {'required': 'O'}, {'methotrexate': 'I-Entity'}, {'or': 'O'}, {'leflunomide,': 'I-Entity'}, {'and': 'O'}, {'4': 'O'}, {'required': 'O'}, {'a': 'O'}, {'biologic': 'O'}, {'agent': 'O'}, {'for': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'their': 'O'}, {'arthritis.': 'I-Entity'}]"
Systemic activity and pSS symptoms were evaluated by ESSDAI and ESSPRI.,"[{'Systemic': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'pSS': 'I-Entity'}, {'symptoms': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'by': 'O'}, {'ESSDAI': 'O'}, {'and': 'O'}, {'ESSPRI.': 'O'}]"
"Therefore, therapeutic strategies that target TLR2/IL-15 pathway might be strong candidates for preventing or treating pSS.Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Medical School, Piazza Giulio Cesare 1, 70124, Bari, Italy.","[{'Therefore,': 'O'}, {'therapeutic': 'O'}, {'strategies': 'O'}, {'that': 'O'}, {'target': 'O'}, {'TLR2/IL-15': 'O'}, {'pathway': 'O'}, {'might': 'O'}, {'be': 'O'}, {'strong': 'O'}, {'candidates': 'O'}, {'for': 'O'}, {'preventing': 'O'}, {'or': 'O'}, {'treating': 'O'}, {'pSS.Basic': 'I-Entity'}, {'Medical': 'O'}, {'Sciences,': 'O'}, {'Neurosciences': 'O'}, {'and': 'O'}, {'Sense': 'O'}, {'Organs,': 'O'}, {'University': 'O'}, {'of': 'O'}, {'Bari': 'O'}, {'Medical': 'O'}, {'School,': 'O'}, {'Piazza': 'O'}, {'Giulio': 'O'}, {'Cesare': 'O'}, {'1,': 'O'}, {'70124,': 'O'}, {'Bari,': 'O'}, {'Italy.': 'O'}]"
All patients underwent neurological clinical examination followed by nerve conduction studies (NCS) and rheumatological examination.,"[{'All': 'O'}, {'patients': 'O'}, {'underwent': 'O'}, {'neurological': 'O'}, {'clinical': 'O'}, {'examination': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'nerve': 'O'}, {'conduction': 'O'}, {'studies': 'O'}, {'(NCS)': 'O'}, {'and': 'O'}, {'rheumatological': 'O'}, {'examination.': 'O'}]"
All cases showed persistent itchy dry skin and eczematous lesions complicated by sicca symptoms including dry eyes and dry mouth with moderate joint pain.,"[{'All': 'O'}, {'cases': 'O'}, {'showed': 'O'}, {'persistent': 'O'}, {'itchy': 'O'}, {'dry': 'B-Entity'}, {'skin': 'I-Entity'}, {'and': 'O'}, {'eczematous': 'B-Entity'}, {'lesions': 'I-Entity'}, {'complicated': 'O'}, {'by': 'O'}, {'sicca': 'I-Entity'}, {'symptoms': 'O'}, {'including': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'with': 'O'}, {'moderate': 'O'}, {'joint': 'B-Entity'}, {'pain.': 'I-Entity'}]"
Both treatments improved symptoms after 1 month.,"[{'Both': 'O'}, {'treatments': 'O'}, {'improved': 'O'}, {'symptoms': 'O'}, {'after': 'O'}, {'1': 'O'}, {'month.': 'O'}]"
Systemic disease activity was measured by the EULAR SS disease activity index (ESSDAI).,"[{'Systemic': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'was': 'O'}, {'measured': 'O'}, {'by': 'O'}, {'the': 'O'}, {'EULAR': 'O'}, {'SS': 'I-Entity'}, {'disease': 'O'}, {'activity': 'O'}, {'index': 'O'}, {'(ESSDAI).': 'O'}]"
Overall efficacy according to the treating physician was observed in 47 patients (60%) after the first cycle of rituximab.,"[{'Overall': 'O'}, {'efficacy': 'O'}, {'according': 'O'}, {'to': 'O'}, {'the': 'O'}, {'treating': 'O'}, {'physician': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'47': 'O'}, {'patients': 'O'}, {'(60%)': 'O'}, {'after': 'O'}, {'the': 'O'}, {'first': 'O'}, {'cycle': 'O'}, {'of': 'O'}, {'rituximab.': 'I-Entity'}]"
"Constrictive change was the most significant determinant of physiological and imaging presentations and of changes in these factors after therapy for small airway disease associated with Sjogrens syndrome.Eiheizi-cho, Fukui 910 1193, Japan.","[{'Constrictive': 'O'}, {'change': 'O'}, {'was': 'O'}, {'the': 'O'}, {'most': 'O'}, {'significant': 'O'}, {'determinant': 'O'}, {'of': 'O'}, {'physiological': 'O'}, {'and': 'O'}, {'imaging': 'O'}, {'presentations': 'O'}, {'and': 'O'}, {'of': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'these': 'O'}, {'factors': 'O'}, {'after': 'O'}, {'therapy': 'O'}, {'for': 'O'}, {'small': 'B-Entity'}, {'airway': 'I-Entity'}, {'disease': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.Eiheizi-cho,': 'I-Entity'}, {'Fukui': 'O'}, {'910': 'O'}, {'1193,': 'O'}, {'Japan.': 'O'}]"
"Bone marrow fibrosis has been found to be associated with autoimmune disorders, and autoimmune myelofibrosis (AIMF) has been defined.","[{'Bone': 'B-Entity'}, {'marrow': 'I-Entity'}, {'fibrosis': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'found': 'O'}, {'to': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'and': 'O'}, {'autoimmune': 'B-Entity'}, {'myelofibrosis': 'I-Entity'}, {'(AIMF)': 'O'}, {'has': 'O'}, {'been': 'O'}, {'defined.': 'O'}]"
"Since these can lead to blindness in the case of insufficient therapeutic steps, diagnostic tools and therapeutic options in Sjogren-syndrome associated ocular diseases are outlined.","[{'Since': 'O'}, {'these': 'O'}, {'can': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'blindness': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'case': 'O'}, {'of': 'O'}, {'insufficient': 'O'}, {'therapeutic': 'O'}, {'steps,': 'O'}, {'diagnostic': 'O'}, {'tools': 'O'}, {'and': 'O'}, {'therapeutic': 'O'}, {'options': 'O'}, {'in': 'O'}, {'Sjogren-syndrome': 'B-Entity'}, {'associated': 'O'}, {'ocular': 'B-Entity'}, {'diseases': 'I-Entity'}, {'are': 'O'}, {'outlined.': 'O'}]"
"Histopathological evaluation of salivary gland biopsies showed implications of milder inflammation in non-SS subjects through mononuclear cell infiltration, fibrosis and fatty replacement, as compared to pSS patients.","[{'Histopathological': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'biopsies': 'O'}, {'showed': 'O'}, {'implications': 'O'}, {'of': 'O'}, {'milder': 'O'}, {'inflammation': 'I-Entity'}, {'in': 'O'}, {'non-SS': 'O'}, {'subjects': 'O'}, {'through': 'O'}, {'mononuclear': 'O'}, {'cell': 'O'}, {'infiltration,': 'O'}, {'fibrosis': 'I-Entity'}, {'and': 'O'}, {'fatty': 'B-Entity'}, {'replacement,': 'I-Entity'}, {'as': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'pSS': 'O'}, {'patients.': 'O'}]"
"In conclusion, cardiovascular autonomic and peripheral sympathetic neuropathy occurs in PsA.","[{'In': 'O'}, {'conclusion,': 'O'}, {'cardiovascular': 'O'}, {'autonomic': 'O'}, {'and': 'O'}, {'peripheral': 'O'}, {'sympathetic': 'I-Entity'}, {'neuropathy': 'I-Entity'}, {'occurs': 'O'}, {'in': 'O'}, {'PsA.': 'I-Entity'}]"
FINDINGS: In neither case did the child protection investigations raise concerns.,"[{'FINDINGS:': 'O'}, {'In': 'O'}, {'neither': 'O'}, {'case': 'O'}, {'did': 'O'}, {'the': 'O'}, {'child': 'O'}, {'protection': 'O'}, {'investigations': 'O'}, {'raise': 'O'}, {'concerns.': 'O'}]"
"Systemic sclerosis was associated with Sjogren's syndrome after adjusting for age, sex, and various autoimmune diseases (HR: 5.98, 95% CI‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢4.79-7.47, p‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.001).","[{'Systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'after': 'O'}, {'adjusting': 'O'}, {'for': 'O'}, {'age,': 'O'}, {'sex,': 'O'}, {'and': 'O'}, {'various': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'(HR:': 'O'}, {'5.98,': 'O'}, {'95%': 'O'}, {'CI‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢4.79-7.47,': 'O'}]"
"Due to its systemic involvement, it can exhibit a wide range of clinical manifestations that contribute to confusion and delay in diagnosis.","[{'Due': 'O'}, {'to': 'O'}, {'its': 'O'}, {'systemic': 'O'}, {'involvement,': 'O'}, {'it': 'O'}, {'can': 'O'}, {'exhibit': 'O'}, {'a': 'O'}, {'wide': 'O'}, {'range': 'O'}, {'of': 'O'}, {'clinical': 'O'}, {'manifestations': 'O'}, {'that': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'confusion': 'I-Entity'}, {'and': 'O'}, {'delay': 'O'}, {'in': 'O'}, {'diagnosis.': 'O'}]"
"For dry mouth and dry eyes, the effectiveness of HCQ treatment was essentially the same as placebo treatment.","[{'For': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'eyes,': 'I-Entity'}, {'the': 'O'}, {'effectiveness': 'O'}, {'of': 'O'}, {'HCQ': 'I-Entity'}, {'treatment': 'O'}, {'was': 'O'}, {'essentially': 'O'}, {'the': 'O'}, {'same': 'O'}, {'as': 'O'}, {'placebo': 'O'}, {'treatment.': 'O'}]"
Patients with primary SS are associated with an increased risk of developing asthma.,"[{'Patients': 'O'}, {'with': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'an': 'O'}, {'increased': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'developing': 'O'}, {'asthma.': 'I-Entity'}]"
"Treatment of the metabolic disease leads to symptomatic improvement.jambrus@buffalo.edu.Room 8030C, Center for Translational Research, 875 Ellicott Street, Buffalo, NY, 14203, USA.","[{'Treatment': 'O'}, {'of': 'O'}, {'the': 'O'}, {'metabolic': 'B-Entity'}, {'disease': 'I-Entity'}, {'leads': 'O'}, {'to': 'O'}, {'symptomatic': 'O'}, {'improvement.jambrus@buffalo.edu.Room': 'O'}, {'8030C,': 'O'}, {'Center': 'O'}, {'for': 'O'}, {'Translational': 'O'}, {'Research,': 'O'}, {'875': 'O'}, {'Ellicott': 'O'}, {'Street,': 'O'}, {'Buffalo,': 'O'}, {'NY,': 'O'}, {'14203,': 'O'}, {'USA.': 'O'}]"
We then examined the relationship between Candida species and oral mucosal symptoms.,"[{'We': 'O'}, {'then': 'O'}, {'examined': 'O'}, {'the': 'O'}, {'relationship': 'O'}, {'between': 'O'}, {'Candida': 'I-Entity'}, {'species': 'O'}, {'and': 'O'}, {'oral': 'O'}, {'mucosal': 'I-Entity'}, {'symptoms.': 'I-Entity'}]"
"The increased circulating BAFF levels are associated with higher immunoglobulin G (IgG) levels (P¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.0167) and anti-Ro/SS antigen A autoantibody (P¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.032), while the elevated circulating levels of IL-17A are associated with lower C3 levels (P¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.0213) and higher focus score of salivary gland tissue (P¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.002).","[{'The': 'O'}, {'increased': 'O'}, {'circulating': 'O'}, {'BAFF': 'O'}, {'levels': 'O'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'higher': 'O'}, {'immunoglobulin': 'O'}, {'G': 'O'}, {'(IgG)': 'O'}, {'levels': 'O'}, {'(P¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.0167)': 'O'}, {'and': 'O'}, {'anti-Ro/SS': 'O'}]"
Cultures treated with IFN-‚âà√≠‚Äö√¢‚Ä¢ increased expression of UPR-associated genes and proteins.,"[{'Cultures': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'IFN-‚âà√≠‚Äö√¢‚Ä¢': 'I-Entity'}, {'increased': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'UPR-associated': 'O'}, {'genes': 'O'}, {'and': 'O'}, {'proteins.': 'O'}]"
"To investigate the morphology, distribution, and density of inflammatory cells in the corneal epithelium of aqueous tear-deficient dry eye.","[{'To': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'morphology,': 'O'}, {'distribution,': 'O'}, {'and': 'O'}, {'density': 'O'}, {'of': 'O'}, {'inflammatory': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'the': 'O'}, {'corneal': 'O'}, {'epithelium': 'O'}, {'of': 'O'}, {'aqueous': 'O'}, {'tear-deficient': 'O'}, {'dry': 'B-Entity'}, {'eye.': 'I-Entity'}]"
"The average annual incidence of pSS in this population-based cohort was 5.8 per 100,000, with a progressive increase over the 40 years of the study.","[{'The': 'O'}, {'average': 'O'}, {'annual': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'in': 'O'}, {'this': 'O'}, {'population-based': 'O'}, {'cohort': 'O'}, {'was': 'O'}, {'5.8': 'O'}, {'per': 'O'}, {'100,000,': 'O'}, {'with': 'O'}, {'a': 'O'}, {'progressive': 'O'}, {'increase': 'O'}, {'over': 'O'}, {'the': 'O'}, {'40': 'O'}, {'years': 'O'}, {'of': 'O'}, {'the': 'O'}, {'study.': 'O'}]"
"LPS provoked a rapid, long-lasting inflammation, increasing gland weight (by almost 20%) and inflammatory cell infiltration at 3 and 24 h. Immunoblotting of glandular homogenates indicated that iNOS expression was increased approximately 4-fold, and immunohistochemistry of frozen tissue sections showed increased iNOS expression in acinar cells.","[{'LPS': 'I-Entity'}, {'provoked': 'O'}, {'a': 'O'}, {'rapid,': 'O'}, {'long-lasting': 'O'}, {'inflammation,': 'I-Entity'}, {'increasing': 'O'}, {'gland': 'O'}, {'weight': 'O'}, {'(by': 'O'}, {'almost': 'O'}, {'20%)': 'O'}, {'and': 'O'}, {'inflammatory': 'O'}, {'cell': 'O'}, {'infiltration': 'O'}, {'at': 'O'}, {'3': 'O'}, {'and': 'O'}, {'24': 'O'}, {'h.': 'O'}, {'Immunoblotting': 'O'}, {'of': 'O'}, {'glandular': 'O'}, {'homogenates': 'O'}, {'indicated': 'O'}, {'that': 'O'}, {'iNOS': 'O'}, {'expression': 'O'}, {'was': 'O'}, {'increased': 'O'}, {'approximately': 'O'}, {'4-fold,': 'O'}, {'and': 'O'}, {'immunohistochemistry': 'O'}]"
Autoimmune cytopenia is closely associated with severe ocular surface damage in pSS.,"[{'Autoimmune': 'B-Entity'}, {'cytopenia': 'I-Entity'}, {'is': 'O'}, {'closely': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'severe': 'O'}, {'ocular': 'B-Entity'}, {'surface': 'I-Entity'}, {'damage': 'I-Entity'}, {'in': 'O'}, {'pSS.': 'I-Entity'}]"
Human immunodeficiency virus (HIV) infection disturbs the host's immune function and often coexists with various autoimmune and/or systemic rheumatic diseases with manifestations that sometimes overlap with each other.,"[{'Human': 'B-Entity'}, {'immunodeficiency': 'I-Entity'}, {'virus': 'I-Entity'}, {'(HIV)': 'I-Entity'}, {'infection': 'I-Entity'}, {'disturbs': 'O'}, {'the': 'O'}, {""host's"": 'O'}, {'immune': 'O'}, {'function': 'O'}, {'and': 'O'}, {'often': 'O'}, {'coexists': 'O'}, {'with': 'O'}, {'various': 'O'}, {'autoimmune': 'B-Entity'}, {'and/or': 'I-Entity'}, {'systemic': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'diseases': 'I-Entity'}, {'with': 'O'}, {'manifestations': 'O'}, {'that': 'O'}, {'sometimes': 'O'}, {'overlap': 'O'}, {'with': 'O'}, {'each': 'O'}, {'other.': 'O'}]"
Mutations in caveolin-3 (CAV3) can lead to different clinical phenotypes affecting skeletal or cardiac muscles.,"[{'Mutations': 'O'}, {'in': 'O'}, {'caveolin-3': 'O'}, {'(CAV3)': 'O'}, {'can': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'different': 'O'}, {'clinical': 'O'}, {'phenotypes': 'O'}, {'affecting': 'O'}, {'skeletal': 'O'}, {'or': 'O'}, {'cardiac': 'O'}, {'muscles.': 'O'}]"
"The following information was summarized for articular, cutaneous, pulmonary and renal involvement: a clear, consensual definition of the clinical feature, a brief epidemiological description including an estimate of the prevalence reported in the main clinical series and a brief list of the key clinical and diagnostic features that could help physicians clearly identify these features.","[{'The': 'O'}, {'following': 'O'}, {'information': 'O'}, {'was': 'O'}, {'summarized': 'O'}, {'for': 'O'}, {'articular,': 'B-Entity'}, {'cutaneous,': 'I-Entity'}, {'pulmonary': 'I-Entity'}, {'and': 'I-Entity'}, {'renal': 'I-Entity'}, {'involvement:': 'I-Entity'}, {'a': 'O'}, {'clear,': 'O'}, {'consensual': 'O'}, {'definition': 'O'}, {'of': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'feature,': 'O'}, {'a': 'O'}, {'brief': 'O'}, {'epidemiological': 'O'}, {'description': 'O'}, {'including': 'O'}, {'an': 'O'}, {'estimate': 'O'}, {'of': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'reported': 'O'}, {'in': 'O'}, {'the': 'O'}, {'main': 'O'}, {'clinical': 'O'}, {'series': 'O'}, {'and': 'O'}, {'a': 'O'}, {'brief': 'O'}, {'list': 'O'}, {'of': 'O'}, {'the': 'O'}, {'key': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'diagnostic': 'O'}, {'features': 'O'}]"
"More specifically, we will focus on the heterogeneity of the disease, on the underlying pathogenetic pathways and on the possible new targeted treatments on the horizon.Pisa, Italy.Florence, Italy.Pisa, Italy.","[{'More': 'O'}, {'specifically,': 'O'}, {'we': 'O'}, {'will': 'O'}, {'focus': 'O'}, {'on': 'O'}, {'the': 'O'}, {'heterogeneity': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease,': 'O'}, {'on': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'pathogenetic': 'O'}, {'pathways': 'O'}, {'and': 'O'}, {'on': 'O'}, {'the': 'O'}, {'possible': 'O'}, {'new': 'O'}, {'targeted': 'O'}, {'treatments': 'O'}, {'on': 'O'}, {'the': 'O'}, {'horizon.Pisa,': 'O'}, {'Italy.Florence,': 'O'}, {'Italy.Pisa,': 'O'}, {'Italy.': 'O'}]"
We evaluated patients with unexplained cough for undiagnosed Sjogren's syndrome.,"[{'We': 'O'}, {'evaluated': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'unexplained': 'O'}, {'cough': 'I-Entity'}, {'for': 'O'}, {'undiagnosed': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"Although recurrent parotitis is reported to be the most common symptom of juvenile pSS, the clinical symptoms and features of the syndrome are not well understood and are poorly defined.","[{'Although': 'O'}, {'recurrent': 'O'}, {'parotitis': 'I-Entity'}, {'is': 'O'}, {'reported': 'O'}, {'to': 'O'}, {'be': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'symptom': 'O'}, {'of': 'O'}, {'juvenile': 'O'}, {'pSS,': 'I-Entity'}, {'the': 'O'}, {'clinical': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'features': 'O'}, {'of': 'O'}, {'the': 'O'}, {'syndrome': 'O'}, {'are': 'O'}, {'not': 'O'}, {'well': 'O'}, {'understood': 'O'}, {'and': 'O'}, {'are': 'O'}, {'poorly': 'O'}, {'defined.': 'O'}]"
"Other underlying diseases identified during the follow-up period include cryoglobulinaemia, angioimmunoblastic T-cell lymphoma, autoimmune hepatitis, hepatitis C infection and toxic thyroid goitre.","[{'Other': 'O'}, {'underlying': 'O'}, {'diseases': 'O'}, {'identified': 'O'}, {'during': 'O'}, {'the': 'O'}, {'follow-up': 'O'}, {'period': 'O'}, {'include': 'O'}, {'cryoglobulinaemia,': 'I-Entity'}, {'angioimmunoblastic': 'B-Entity'}, {'T-cell': 'I-Entity'}, {'lymphoma,': 'I-Entity'}, {'autoimmune': 'B-Entity'}, {'hepatitis,': 'I-Entity'}, {'hepatitis': 'B-Entity'}, {'C': 'I-Entity'}, {'infection': 'I-Entity'}, {'and': 'O'}, {'toxic': 'B-Entity'}, {'thyroid': 'I-Entity'}, {'goitre.': 'I-Entity'}]"
A monoclonal gammopathy can be observed in many patients with various rheumatic diseases.,"[{'A': 'O'}, {'monoclonal': 'B-Entity'}, {'gammopathy': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'many': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'various': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
We report a case in which infection might have triggered TAFRO syndrome.,"[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'case': 'O'}, {'in': 'O'}, {'which': 'O'}, {'infection': 'I-Entity'}, {'might': 'O'}, {'have': 'O'}, {'triggered': 'O'}, {'TAFRO': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
Gastrointestinal symptoms were often unspecific.,"[{'Gastrointestinal': 'B-Entity'}, {'symptoms': 'I-Entity'}, {'were': 'O'}, {'often': 'O'}, {'unspecific.': 'O'}]"
"At a 1‚Äö√Ñ√∂‚àö√ë‚àö¬¢:‚Äö√Ñ√∂‚àö√ë‚àö¬¢40/1‚Äö√Ñ√∂‚àö√ë‚àö¬¢:‚Äö√Ñ√∂‚àö√ë‚àö¬¢80 dilution the resulting comparison demonstrated 94.8%/92.9% positive, 97.4%/97.4% negative, and 96.5%/96.2% total agreements between manual IIF and NOVA View archived images.","[{'At': 'O'}, {'a': 'O'}, {'1‚Äö√Ñ√∂‚àö√ë‚àö¬¢:‚Äö√Ñ√∂‚àö√ë‚àö¬¢40/1‚Äö√Ñ√∂‚àö√ë‚àö¬¢:‚Äö√Ñ√∂‚àö√ë‚àö¬¢80': 'O'}]"
"other infections, connective tissue diseases, malignancies) in the absence of HCV infection.","[{'other': 'O'}, {'infections,': 'I-Entity'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases,': 'I-Entity'}, {'malignancies)': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'HCV': 'B-Entity'}, {'infection.': 'I-Entity'}]"
Our objective was to assess whether alterations in gut and oral microbiota compositions are specific for pSS and SLE.,"[{'Our': 'O'}, {'objective': 'O'}, {'was': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'whether': 'O'}, {'alterations': 'O'}, {'in': 'O'}, {'gut': 'O'}, {'and': 'O'}, {'oral': 'O'}, {'microbiota': 'O'}, {'compositions': 'O'}, {'are': 'O'}, {'specific': 'O'}, {'for': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'SLE.': 'I-Entity'}]"
The efficacy of cell engraftment and the area of inflammation were analyzed by microscopy.,"[{'The': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'cell': 'O'}, {'engraftment': 'O'}, {'and': 'O'}, {'the': 'O'}, {'area': 'O'}, {'of': 'O'}, {'inflammation': 'I-Entity'}, {'were': 'O'}, {'analyzed': 'O'}, {'by': 'O'}, {'microscopy.': 'O'}]"
"The associated conditions and related symptoms analysed were: the presence of depression, sleep disorders, headache, myofascial syndrome, irritable bowel syndrome, chronic fatigue syndrome, vertiginous syndrome, chronic cystitis, and sicca syndrome.","[{'The': 'O'}, {'associated': 'O'}, {'conditions': 'O'}, {'and': 'O'}, {'related': 'O'}, {'symptoms': 'O'}, {'analysed': 'O'}, {'were:': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'depression,': 'I-Entity'}, {'sleep': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'headache,': 'I-Entity'}, {'myofascial': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'irritable': 'B-Entity'}, {'bowel': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'chronic': 'B-Entity'}, {'fatigue': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'vertiginous': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'chronic': 'B-Entity'}, {'cystitis,': 'I-Entity'}, {'and': 'O'}, {'sicca': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"In our RA cohort, RA subjects with sSS had worse joint damage, suggesting that sSS is a marker of more aggressive disease.Society for Rheumatology.","[{'In': 'O'}, {'our': 'O'}, {'RA': 'I-Entity'}, {'cohort,': 'O'}, {'RA': 'I-Entity'}, {'subjects': 'O'}, {'with': 'O'}, {'sSS': 'O'}, {'had': 'O'}, {'worse': 'O'}, {'joint': 'B-Entity'}, {'damage,': 'I-Entity'}, {'suggesting': 'O'}, {'that': 'O'}, {'sSS': 'O'}, {'is': 'O'}, {'a': 'O'}, {'marker': 'O'}, {'of': 'O'}, {'more': 'O'}, {'aggressive': 'O'}, {'disease.Society': 'O'}, {'for': 'O'}, {'Rheumatology.': 'O'}]"
"Cystic mass in the anterior mediastinum decreased, and the conditions of CRVO in both eyes had much improved.","[{'Cystic': 'B-Entity'}, {'mass': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'anterior': 'O'}, {'mediastinum': 'O'}, {'decreased,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'conditions': 'O'}, {'of': 'O'}, {'CRVO': 'I-Entity'}, {'in': 'O'}, {'both': 'O'}, {'eyes': 'O'}, {'had': 'O'}, {'much': 'O'}, {'improved.': 'O'}]"
Neurological improvement was noted in 11 patients (65%) at 3 months.,"[{'Neurological': 'O'}, {'improvement': 'O'}, {'was': 'O'}, {'noted': 'O'}, {'in': 'O'}, {'11': 'O'}, {'patients': 'O'}, {'(65%)': 'O'}, {'at': 'O'}, {'3': 'O'}, {'months.': 'O'}]"
"The dry eye disease (DED) is a chronic multifactorial disorder of the tears that also involves the ocular surface, the lacrimal glands, and meibomian dysfunction.","[{'The': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease': 'I-Entity'}, {'(DED)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'multifactorial': 'O'}, {'disorder': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'tears': 'I-Entity'}, {'that': 'O'}, {'also': 'O'}, {'involves': 'O'}, {'the': 'O'}, {'ocular': 'O'}, {'surface,': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}, {'glands,': 'O'}, {'and': 'O'}, {'meibomian': 'B-Entity'}, {'dysfunction.': 'I-Entity'}]"
"Furthermore, deficiency in TAZ or overexpression of TEAD1 induced T(reg) cell differentiation, whereas expression of a transgene encoding TAZ or activation of TAZ directed T(H)17 cell differentiation.","[{'Furthermore,': 'O'}, {'deficiency': 'O'}, {'in': 'O'}, {'TAZ': 'I-Entity'}, {'or': 'O'}, {'overexpression': 'O'}, {'of': 'O'}, {'TEAD1': 'O'}, {'induced': 'O'}, {'T(reg)': 'O'}, {'cell': 'O'}, {'differentiation,': 'O'}, {'whereas': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'a': 'O'}, {'transgene': 'O'}, {'encoding': 'O'}, {'TAZ': 'I-Entity'}, {'or': 'O'}, {'activation': 'O'}, {'of': 'O'}, {'TAZ': 'I-Entity'}, {'directed': 'O'}, {'T(H)17': 'O'}, {'cell': 'O'}, {'differentiation.': 'O'}]"
We investigated if the tear volume in DE patients affects the results of MMP-9 immunoassay in clinical and in vitro settings.,"[{'We': 'O'}, {'investigated': 'O'}, {'if': 'O'}, {'the': 'O'}, {'tear': 'O'}, {'volume': 'O'}, {'in': 'O'}, {'DE': 'I-Entity'}, {'patients': 'O'}, {'affects': 'O'}, {'the': 'O'}, {'results': 'O'}, {'of': 'O'}, {'MMP-9': 'O'}, {'immunoassay': 'O'}, {'in': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'in': 'O'}, {'vitro': 'O'}, {'settings.': 'O'}]"
Electronic address: pers@univ-brest.fr.reveal differences in biological disease activity.,"[{'Electronic': 'O'}, {'address:': 'O'}, {'pers@univ-brest.fr.reveal': 'O'}, {'differences': 'O'}, {'in': 'O'}, {'biological': 'O'}, {'disease': 'O'}, {'activity.': 'O'}]"
All patients underwent neurological and rheumatological examination followed by nerve conduction studies (NCS) of nine peripheral nerves.,"[{'All': 'O'}, {'patients': 'O'}, {'underwent': 'O'}, {'neurological': 'O'}, {'and': 'O'}, {'rheumatological': 'O'}, {'examination': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'nerve': 'O'}, {'conduction': 'O'}, {'studies': 'O'}, {'(NCS)': 'O'}, {'of': 'O'}, {'nine': 'O'}, {'peripheral': 'O'}, {'nerves.': 'O'}]"
"This article discusses the dental professional's role in formulating a preventive oral health plan: meticulous oral hygiene instructions, dietary counseling, a complement of chemotherapeutic agents and more frequent recall care to avoid oral complications and improve quality of life.","[{'This': 'O'}, {'article': 'O'}, {'discusses': 'O'}, {'the': 'O'}, {'dental': 'O'}, {""professional's"": 'O'}, {'role': 'O'}, {'in': 'O'}, {'formulating': 'O'}, {'a': 'O'}, {'preventive': 'O'}, {'oral': 'O'}, {'health': 'O'}, {'plan:': 'O'}, {'meticulous': 'O'}, {'oral': 'O'}, {'hygiene': 'O'}, {'instructions,': 'O'}, {'dietary': 'O'}, {'counseling,': 'O'}, {'a': 'O'}, {'complement': 'O'}, {'of': 'O'}, {'chemotherapeutic': 'O'}, {'agents': 'O'}, {'and': 'O'}, {'more': 'O'}, {'frequent': 'O'}, {'recall': 'O'}, {'care': 'O'}, {'to': 'O'}, {'avoid': 'O'}, {'oral': 'O'}, {'complications': 'I-Entity'}, {'and': 'O'}, {'improve': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life.': 'O'}]"
"The causes of withdrawal were: 39% improvement, 35.2% patient's own decision, 18.1% toxicity and 11% lack of efficacy.","[{'The': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'withdrawal': 'O'}, {'were:': 'O'}, {'39%': 'O'}, {'improvement,': 'O'}, {'35.2%': 'O'}, {""patient's"": 'O'}, {'own': 'O'}, {'decision,': 'O'}, {'18.1%': 'O'}, {'toxicity': 'I-Entity'}, {'and': 'O'}, {'11%': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'efficacy.': 'O'}]"
"Sjogrens syndrome is a systemic autoimmune disease affecting approximately 3 million Americans, primarily perimenopausal women.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'affecting': 'O'}, {'approximately': 'O'}, {'3': 'O'}, {'million': 'O'}, {'Americans,': 'O'}, {'primarily': 'O'}, {'perimenopausal': 'O'}, {'women.': 'O'}]"
"Rheumatic diseases often affect pregnancy outcome, especially in case of primary APS.","[{'Rheumatic': 'B-Entity'}, {'diseases': 'I-Entity'}, {'often': 'O'}, {'affect': 'O'}, {'pregnancy': 'O'}, {'outcome,': 'O'}, {'especially': 'O'}, {'in': 'O'}, {'case': 'O'}, {'of': 'O'}, {'primary': 'O'}, {'APS.': 'I-Entity'}]"
"To enhance our understanding of the mechanisms underlying the progression of the disease and to discover potential biomarkers for the early diagnosis of pSS, we applied RNA sequencing to compare the gene expression patterns in minor salivary glands between pSS patients and non-pSS.","[{'To': 'O'}, {'enhance': 'O'}, {'our': 'O'}, {'understanding': 'O'}, {'of': 'O'}, {'the': 'O'}, {'mechanisms': 'O'}, {'underlying': 'O'}, {'the': 'O'}, {'progression': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'and': 'O'}, {'to': 'O'}, {'discover': 'O'}, {'potential': 'O'}, {'biomarkers': 'O'}, {'for': 'O'}, {'the': 'O'}, {'early': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'pSS,': 'I-Entity'}, {'we': 'O'}, {'applied': 'O'}, {'RNA': 'O'}, {'sequencing': 'O'}, {'to': 'O'}, {'compare': 'O'}, {'the': 'O'}, {'gene': 'O'}, {'expression': 'O'}, {'patterns': 'O'}, {'in': 'O'}, {'minor': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'between': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'non-pSS.': 'O'}]"
"The urinary anion gap was positive in the presence of acidemia, thus she was diagnosed with hypokalemic paralysis from a severe distal renal tubular acidosis (RTA).","[{'The': 'O'}, {'urinary': 'O'}, {'anion': 'O'}, {'gap': 'O'}, {'was': 'O'}, {'positive': 'O'}, {'in': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'acidemia,': 'I-Entity'}, {'thus': 'O'}, {'she': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'hypokalemic': 'O'}, {'paralysis': 'I-Entity'}, {'from': 'O'}, {'a': 'O'}, {'severe': 'O'}, {'distal': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'(RTA).': 'O'}]"
"Disease activity was scored per the EULAR Sjogrens syndrome disease activity index (ESSDAI) via systemic examination and laboratory evaluations, and the EULAR Sjogrens syndrome patient-reported index (ESSPRI) assessed via a survey of patient responses.","[{'Disease': 'O'}, {'activity': 'O'}, {'was': 'O'}, {'scored': 'O'}, {'per': 'O'}, {'the': 'O'}, {'EULAR': 'O'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'disease': 'O'}, {'activity': 'O'}, {'index': 'O'}, {'(ESSDAI)': 'O'}, {'via': 'O'}, {'systemic': 'O'}, {'examination': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'evaluations,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'EULAR': 'O'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'patient-reported': 'O'}, {'index': 'O'}, {'(ESSPRI)': 'O'}, {'assessed': 'O'}, {'via': 'O'}, {'a': 'O'}, {'survey': 'O'}, {'of': 'O'}, {'patient': 'O'}, {'responses.': 'O'}]"
Sjogren syndrome (SS) is an autoimmune disease characterized by the inflammatory destruction of salivary and lacrimal glands (LG).,"[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'the': 'O'}, {'inflammatory': 'O'}, {'destruction': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'and': 'I-Entity'}, {'lacrimal': 'I-Entity'}, {'glands': 'O'}, {'(LG).': 'O'}]"
"Most patients diagnosed with autoimmune pancreatitis in Japan have IgG4-related pancreatitis [Type 1 autoimmune pancreatitis (AIP), lymphoplasmacytic sclerosing pancreatitis (LPSP)], a disease distinct from some of the western type [Type 2 AIP, idiopathic duct-centric chronic pancreatitis (IDCP), autoimmune pancreatitis with granulocytic epithelial lesions (GEL)].","[{'Most': 'O'}, {'patients': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'pancreatitis': 'I-Entity'}, {'in': 'O'}, {'Japan': 'O'}, {'have': 'O'}, {'IgG4-related': 'O'}, {'pancreatitis': 'I-Entity'}, {'[Type': 'O'}, {'1': 'O'}, {'autoimmune': 'I-Entity'}, {'pancreatitis': 'I-Entity'}, {'(AIP),': 'O'}, {'lymphoplasmacytic': 'B-Entity'}, {'sclerosing': 'I-Entity'}, {'pancreatitis': 'I-Entity'}, {'(LPSP)],': 'O'}]"
"The BUT, Schirmer test values, vital staining scores and squamous metaplasia grades in impression cytology were significantly worse in dry eye patients compared to controls (p<0.0001).","[{'The': 'O'}, {'BUT,': 'O'}, {'Schirmer': 'O'}, {'test': 'O'}, {'values,': 'O'}, {'vital': 'O'}, {'staining': 'O'}, {'scores': 'O'}, {'and': 'O'}, {'squamous': 'B-Entity'}, {'metaplasia': 'I-Entity'}, {'grades': 'O'}, {'in': 'O'}, {'impression': 'O'}, {'cytology': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'worse': 'O'}, {'in': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'patients': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'controls': 'O'}, {'(p<0.0001).': 'O'}]"
"The dry eye indexes were also evaluated in 2 subgroups, which determined by the using of PPs, including the AS + PP group and AS only group.","[{'The': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'indexes': 'O'}, {'were': 'O'}, {'also': 'O'}, {'evaluated': 'O'}, {'in': 'O'}, {'2': 'O'}, {'subgroups,': 'O'}, {'which': 'O'}, {'determined': 'O'}, {'by': 'O'}, {'the': 'O'}, {'using': 'O'}, {'of': 'O'}, {'PPs,': 'O'}, {'including': 'O'}, {'the': 'O'}, {'AS': 'I-Entity'}, {'+': 'O'}, {'PP': 'I-Entity'}, {'group': 'O'}, {'and': 'O'}, {'AS': 'I-Entity'}, {'only': 'O'}, {'group.': 'O'}]"
To evaluate the therapeutic effects of TGP on SS in mice and anti-inflammatory mechanism.,"[{'To': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'therapeutic': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'TGP': 'I-Entity'}, {'on': 'O'}, {'SS': 'I-Entity'}, {'in': 'O'}, {'mice': 'O'}, {'and': 'O'}, {'anti-inflammatory': 'O'}, {'mechanism.': 'O'}]"
"We describe here a patient who presented with sensorimotor neuropathy along with hypothyroidism, renal failure and liver dysfunction.","[{'We': 'O'}, {'describe': 'O'}, {'here': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'who': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'sensorimotor': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'along': 'O'}, {'with': 'O'}, {'hypothyroidism,': 'I-Entity'}, {'renal': 'B-Entity'}, {'failure': 'I-Entity'}, {'and': 'O'}, {'liver': 'B-Entity'}, {'dysfunction.': 'I-Entity'}]"
"We performed a literature review regarding the appearance of autoantibodies that preceded the clinical onset of autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, Sjogrens syndrome, primary biliary cirrhosis, inflammatory bowel disease, and multiple sclerosis.","[{'We': 'O'}, {'performed': 'O'}, {'a': 'O'}, {'literature': 'O'}, {'review': 'O'}, {'regarding': 'O'}, {'the': 'O'}, {'appearance': 'O'}, {'of': 'O'}, {'autoantibodies': 'O'}, {'that': 'O'}, {'preceded': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'onset': 'O'}, {'of': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'including': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'primary': 'B-Entity'}, {'biliary': 'I-Entity'}, {'cirrhosis,': 'I-Entity'}, {'inflammatory': 'B-Entity'}]"
"Pulmonary hypertension (PH) can develop in connective tissue disease associated interstitial lung disease (CTD-ILD), and contributes to increased morbidity and mortality.","[{'Pulmonary': 'B-Entity'}, {'hypertension': 'I-Entity'}, {'(PH)': 'O'}, {'can': 'O'}, {'develop': 'O'}, {'in': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'associated': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(CTD-ILD),': 'O'}, {'and': 'O'}, {'contributes': 'O'}, {'to': 'O'}, {'increased': 'O'}, {'morbidity': 'O'}, {'and': 'O'}, {'mortality.': 'O'}]"
The patient's symptoms were initially suspected to be caused by severe bacterial infection with Sjogren's syndrome flare.,"[{'The': 'O'}, {""patient's"": 'O'}, {'symptoms': 'O'}, {'were': 'O'}, {'initially': 'O'}, {'suspected': 'O'}, {'to': 'O'}, {'be': 'O'}, {'caused': 'O'}, {'by': 'O'}, {'severe': 'O'}, {'bacterial': 'B-Entity'}, {'infection': 'I-Entity'}, {'with': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'flare.': 'O'}]"
"Primary SS is undeniably a systemic disease, with the joints, lungs, skin and peripheral nerves being the most frequently involved organs.","[{'Primary': 'O'}, {'SS': 'I-Entity'}, {'is': 'O'}, {'undeniably': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'disease,': 'O'}, {'with': 'O'}, {'the': 'O'}, {'joints,': 'O'}, {'lungs,': 'O'}, {'skin': 'O'}, {'and': 'O'}, {'peripheral': 'O'}, {'nerves': 'O'}, {'being': 'O'}, {'the': 'O'}, {'most': 'O'}, {'frequently': 'O'}, {'involved': 'O'}, {'organs.': 'O'}]"
The sweating latency time was significantly prolonged in eczematous skin of AD and AD/SS compared to normal controls.,"[{'The': 'O'}, {'sweating': 'O'}, {'latency': 'O'}, {'time': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'prolonged': 'O'}, {'in': 'O'}, {'eczematous': 'I-Entity'}, {'skin': 'O'}, {'of': 'O'}, {'AD': 'I-Entity'}, {'and': 'O'}, {'AD/SS': 'I-Entity'}, {'compared': 'O'}, {'to': 'O'}, {'normal': 'O'}, {'controls.': 'O'}]"
"The dysfunction of these secretory organs immediately leads to various diseases, such as diabetes or Sjogrens syndrome, by poorly understood mechanisms.","[{'The': 'O'}, {'dysfunction': 'O'}, {'of': 'O'}, {'these': 'O'}, {'secretory': 'O'}, {'organs': 'O'}, {'immediately': 'O'}, {'leads': 'O'}, {'to': 'O'}, {'various': 'O'}, {'diseases,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'diabetes': 'I-Entity'}, {'or': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'by': 'O'}, {'poorly': 'O'}, {'understood': 'O'}, {'mechanisms.': 'O'}]"
"Serum RF and ANA levels are associated with conjunctival staining scores and the total OSS according to the SICCA OSS in primary SS.of Medicine, The Catholic University of Korea, Seoul, Korea; ‚Äö√Ñ√∂‚àö√ë‚Äö√Ñ‚Ä†Catholic Institute for Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea; ‚Äö√Ñ√∂‚àö√ë¬¨‚àûDepartment of Ophthalmology, CHA Bundang Medical Center, CHA University, Seongnam, Korea; and ¬¨¬®‚àö√ºDivision of Rheumatology, Department of Internal Medicine, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.optica.","[{'Serum': 'O'}, {'RF': 'O'}, {'and': 'O'}, {'ANA': 'O'}, {'levels': 'O'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'conjunctival': 'O'}, {'staining': 'O'}, {'scores': 'O'}, {'and': 'O'}, {'the': 'O'}, {'total': 'O'}, {'OSS': 'O'}, {'according': 'O'}, {'to': 'O'}, {'the': 'O'}, {'SICCA': 'O'}, {'OSS': 'O'}, {'in': 'O'}, {'primary': 'O'}, {'SS.of': 'I-Entity'}, {'Medicine,': 'O'}, {'The': 'O'}, {'Catholic': 'O'}, {'University': 'O'}, {'of': 'O'}, {'Korea,': 'O'}, {'Seoul,': 'O'}, {'Korea;': 'O'}, {'‚Äö√Ñ√∂‚àö√ë‚Äö√Ñ‚Ä†Catholic': 'O'}]"
"The syndrome is characterized by dysfunction and destruction of exocrine glands leading to oral and ocular manifestations, xerostomia and keratitis sicca.","[{'The': 'O'}, {'syndrome': 'O'}, {'is': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'dysfunction': 'O'}, {'and': 'O'}, {'destruction': 'O'}, {'of': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'oral': 'O'}, {'and': 'O'}, {'ocular': 'I-Entity'}, {'manifestations,': 'O'}, {'xerostomia': 'I-Entity'}, {'and': 'O'}, {'keratitis': 'B-Entity'}, {'sicca.': 'I-Entity'}]"
Therapeutic vaccination with antigen-specific tolerogenic dendritic cells (tolDC) might become a future option of individualized therapy for patients with autoimmune diseases.,"[{'Therapeutic': 'O'}, {'vaccination': 'O'}, {'with': 'O'}, {'antigen-specific': 'O'}, {'tolerogenic': 'O'}, {'dendritic': 'O'}, {'cells': 'O'}, {'(tolDC)': 'O'}, {'might': 'O'}, {'become': 'O'}, {'a': 'O'}, {'future': 'O'}, {'option': 'O'}, {'of': 'O'}, {'individualized': 'O'}, {'therapy': 'O'}, {'for': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
The cystic pattern associated with Sjogren syndrome had a characteristic appearance on chest CT images.,"[{'The': 'O'}, {'cystic': 'O'}, {'pattern': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'had': 'O'}, {'a': 'O'}, {'characteristic': 'O'}, {'appearance': 'O'}, {'on': 'O'}, {'chest': 'O'}, {'CT': 'O'}, {'images.': 'O'}]"
Clonal expansions were identified in CD21(-/low) B cells isolated from the peripheral blood of 3 patients with SS.,"[{'Clonal': 'O'}, {'expansions': 'O'}, {'were': 'O'}, {'identified': 'O'}, {'in': 'O'}, {'CD21(-/low)': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'isolated': 'O'}, {'from': 'O'}, {'the': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'of': 'O'}, {'3': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS.': 'I-Entity'}]"
"Dry eye disease (DED) is one of the most frequent ophthalmological conditions, with a major impact on patients' quality of life.","[{'Dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease': 'I-Entity'}, {'(DED)': 'O'}, {'is': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'most': 'O'}, {'frequent': 'O'}, {'ophthalmological': 'O'}, {'conditions,': 'O'}, {'with': 'O'}, {'a': 'O'}, {'major': 'O'}, {'impact': 'O'}, {'on': 'O'}, {""patients'"": 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life.': 'O'}]"
Mean age was 60 years (study group) and 44 years (control).,"[{'Mean': 'O'}, {'age': 'O'}, {'was': 'O'}, {'60': 'O'}, {'years': 'O'}, {'(study': 'O'}, {'group)': 'O'}, {'and': 'O'}, {'44': 'O'}, {'years': 'O'}, {'(control).': 'O'}]"
"Thus, particularly to study these covert stages, researchers turn to studying animal models where mice provide great freedom for genetic manipulation and testing the effect of experimental intervention.","[{'Thus,': 'O'}, {'particularly': 'O'}, {'to': 'O'}, {'study': 'O'}, {'these': 'O'}, {'covert': 'O'}, {'stages,': 'O'}, {'researchers': 'O'}, {'turn': 'O'}, {'to': 'O'}, {'studying': 'O'}, {'animal': 'O'}, {'models': 'O'}, {'where': 'O'}, {'mice': 'O'}, {'provide': 'O'}, {'great': 'O'}, {'freedom': 'O'}, {'for': 'O'}, {'genetic': 'O'}, {'manipulation': 'O'}, {'and': 'O'}, {'testing': 'O'}, {'the': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'experimental': 'O'}, {'intervention.': 'O'}]"
"Oral administration of prednisolone resulted in the normalization of her transaminase levels, and the control of her serum potassium level became easier.","[{'Oral': 'O'}, {'administration': 'O'}, {'of': 'O'}, {'prednisolone': 'I-Entity'}, {'resulted': 'O'}, {'in': 'O'}, {'the': 'O'}, {'normalization': 'O'}, {'of': 'O'}, {'her': 'O'}, {'transaminase': 'O'}, {'levels,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'control': 'O'}, {'of': 'O'}, {'her': 'O'}, {'serum': 'O'}, {'potassium': 'I-Entity'}, {'level': 'O'}, {'became': 'O'}, {'easier.': 'O'}]"
"Out of 190 subjects examined, 140 subjects fulfilled the AEC for the diagnosis of pSS, whereas 50 subjects were classified as non-pSS subjects.","[{'Out': 'O'}, {'of': 'O'}, {'190': 'O'}, {'subjects': 'O'}, {'examined,': 'O'}, {'140': 'O'}, {'subjects': 'O'}, {'fulfilled': 'O'}, {'the': 'O'}, {'AEC': 'O'}, {'for': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'pSS,': 'I-Entity'}, {'whereas': 'O'}, {'50': 'O'}, {'subjects': 'O'}, {'were': 'O'}, {'classified': 'O'}, {'as': 'O'}, {'non-pSS': 'O'}, {'subjects.': 'O'}]"
"We recently demonstrated that this T-cell subset is expanded in the peripheral blood (PB) of patients with primary Sjogrens syndrome (pSS), produces IL-17 and accumulates in minor salivary glands (MSGs).","[{'We': 'O'}, {'recently': 'O'}, {'demonstrated': 'O'}, {'that': 'O'}, {'this': 'O'}, {'T-cell': 'O'}, {'subset': 'O'}, {'is': 'O'}, {'expanded': 'O'}, {'in': 'O'}, {'the': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'(PB)': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS),': 'O'}, {'produces': 'O'}, {'IL-17': 'O'}, {'and': 'O'}, {'accumulates': 'O'}, {'in': 'O'}, {'minor': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'(MSGs).': 'O'}]"
The symptom is included in proposed disease activity and outcome measures for pSS.,"[{'The': 'O'}, {'symptom': 'O'}, {'is': 'O'}, {'included': 'O'}, {'in': 'O'}, {'proposed': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'outcome': 'O'}, {'measures': 'O'}, {'for': 'O'}, {'pSS.': 'I-Entity'}]"
"Clinical conditions in which the peripheral nervous system is involved include peripheral sensory and sensorimotor polyneuropathy, mononeuropathies, cranial neuropathies, acute inflammatory demyelinating polyneuropathy (Guillian-Barr‚Äö√†√∂¬¨¬© syndrome), chronic inflammatory demyelinating polyneuropathy, plexopathy, myasthenia gravis, and dysfunctions of the autonomic nervous system.","[{'Clinical': 'O'}, {'conditions': 'O'}, {'in': 'O'}, {'which': 'O'}, {'the': 'O'}, {'peripheral': 'O'}, {'nervous': 'O'}, {'system': 'O'}, {'is': 'O'}, {'involved': 'O'}, {'include': 'O'}, {'peripheral': 'B-Entity'}, {'sensory': 'I-Entity'}, {'and': 'I-Entity'}, {'sensorimotor': 'I-Entity'}, {'polyneuropathy,': 'I-Entity'}, {'mononeuropathies,': 'I-Entity'}, {'cranial': 'B-Entity'}, {'neuropathies,': 'I-Entity'}, {'acute': 'O'}, {'inflammatory': 'O'}, {'demyelinating': 'I-Entity'}, {'polyneuropathy': 'I-Entity'}, {'(Guillian-Barr‚Äö√†√∂¬¨¬©': 'O'}]"
"By physician diagnosis, age-adjusted overall incidence and prevalence rates of primary SS among adult Manhattan residents were 3.5 and 13.1 per 100,000 person-years, respectively.","[{'By': 'O'}, {'physician': 'O'}, {'diagnosis,': 'O'}, {'age-adjusted': 'O'}, {'overall': 'O'}, {'incidence': 'O'}, {'and': 'O'}, {'prevalence': 'O'}, {'rates': 'O'}, {'of': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'among': 'O'}, {'adult': 'O'}, {'Manhattan': 'O'}, {'residents': 'O'}, {'were': 'O'}, {'3.5': 'O'}, {'and': 'O'}, {'13.1': 'O'}, {'per': 'O'}, {'100,000': 'O'}, {'person-years,': 'O'}, {'respectively.': 'O'}]"
"To evaluate tear osmolarity with the recently introduced TearLab system (TearLab Corporation, San Diego, CA) in patients with non-Sjogren syndrome dry eye (NSSDE) and Sjogren syndrome dry eye (SSDE), and in healthy subjects, and to compare the results with those from classical dry eye tests.","[{'To': 'O'}, {'evaluate': 'O'}, {'tear': 'O'}, {'osmolarity': 'O'}, {'with': 'O'}, {'the': 'O'}, {'recently': 'O'}, {'introduced': 'O'}, {'TearLab': 'O'}, {'system': 'O'}, {'(TearLab': 'O'}, {'Corporation,': 'O'}, {'San': 'O'}, {'Diego,': 'O'}, {'CA)': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'non-Sjogren': 'O'}, {'syndrome': 'I-Entity'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'(NSSDE)': 'O'}, {'and': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'dry': 'I-Entity'}, {'eye': 'I-Entity'}, {'(SSDE),': 'O'}, {'and': 'O'}, {'in': 'O'}, {'healthy': 'O'}, {'subjects,': 'O'}, {'and': 'O'}]"
"Laboratory work: blood count and ESR were normal, antinuclear antibodies (+) > 60, Ro (+) > 60 U, and rheumatoid factor concentration (+) 160 IU / ml.","[{'Laboratory': 'O'}, {'work:': 'O'}, {'blood': 'O'}, {'count': 'O'}, {'and': 'O'}, {'ESR': 'O'}, {'were': 'O'}, {'normal,': 'O'}, {'antinuclear': 'O'}, {'antibodies': 'O'}, {'(+)': 'O'}, {'>': 'O'}, {'60,': 'O'}, {'Ro': 'I-Entity'}, {'(+)': 'O'}, {'>': 'O'}, {'60': 'O'}, {'U,': 'O'}, {'and': 'O'}, {'rheumatoid': 'B-Entity'}, {'factor': 'O'}, {'concentration': 'O'}, {'(+)': 'O'}, {'160': 'O'}, {'IU': 'O'}, {'/': 'O'}, {'ml.': 'O'}]"
"Autoimmune blood tests for Sjogren syndrome were positive, and a sublabial biopsy confirmed the diagnosis.","[{'Autoimmune': 'B-Entity'}, {'blood': 'O'}, {'tests': 'O'}, {'for': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'were': 'O'}, {'positive,': 'O'}, {'and': 'O'}, {'a': 'O'}, {'sublabial': 'O'}, {'biopsy': 'O'}, {'confirmed': 'O'}, {'the': 'O'}, {'diagnosis.': 'O'}]"
"Besides poor compliance, pancreatic insufficiency, bacterial overgrowth, lactose intolerance, irritable bowel syndrome, lymphocytic colitis, and microscopic colitis are considered responsible for nonresponsive CD in adults but not in children.","[{'Besides': 'O'}, {'poor': 'O'}, {'compliance,': 'O'}, {'pancreatic': 'B-Entity'}, {'insufficiency,': 'I-Entity'}, {'bacterial': 'O'}, {'overgrowth,': 'I-Entity'}, {'lactose': 'I-Entity'}, {'intolerance,': 'I-Entity'}, {'irritable': 'B-Entity'}, {'bowel': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'lymphocytic': 'B-Entity'}, {'colitis,': 'I-Entity'}, {'and': 'O'}, {'microscopic': 'O'}, {'colitis': 'I-Entity'}, {'are': 'O'}, {'considered': 'O'}, {'responsible': 'O'}, {'for': 'O'}, {'nonresponsive': 'O'}, {'CD': 'I-Entity'}, {'in': 'O'}, {'adults': 'O'}, {'but': 'O'}, {'not': 'O'}, {'in': 'O'}, {'children.': 'O'}]"
"The incidence of additional connective tissue diseases in the whole group and in the overlap syndrome group respectively was: dermatomyositis or polymyositis 11.5% and 47.5%, Sjogren's syndrome 10.3% and 42.5%, rheumatoid arthritis 3.6% and 15.4%, and systemic lupus erythematosus 1.2% and 5.0%.","[{'The': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'additional': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'whole': 'O'}, {'group': 'O'}, {'and': 'O'}, {'in': 'O'}, {'the': 'O'}, {'overlap': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'group': 'O'}, {'respectively': 'O'}, {'was:': 'O'}, {'dermatomyositis': 'I-Entity'}, {'or': 'O'}, {'polymyositis': 'I-Entity'}, {'11.5%': 'O'}, {'and': 'O'}, {'47.5%,': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'10.3%': 'O'}, {'and': 'O'}, {'42.5%,': 'O'}, {'rheumatoid': 'B-Entity'}]"
"When patients with Sjogrens syndrome have developed persistent swelling of the salivary glands, it is necessary to rule out malignant lymphomas, especially MALT lymphoma, by combination of ultrasonography, MRI, FNA, and biopsy or open surgery depending on image findings.","[{'When': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'have': 'O'}, {'developed': 'O'}, {'persistent': 'O'}, {'swelling': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'salivary': 'I-Entity'}, {'glands,': 'I-Entity'}, {'it': 'O'}, {'is': 'O'}, {'necessary': 'O'}, {'to': 'O'}, {'rule': 'O'}, {'out': 'O'}, {'malignant': 'B-Entity'}, {'lymphomas,': 'I-Entity'}, {'especially': 'O'}, {'MALT': 'B-Entity'}, {'lymphoma,': 'I-Entity'}, {'by': 'O'}, {'combination': 'O'}, {'of': 'O'}, {'ultrasonography,': 'O'}, {'MRI,': 'O'}, {'FNA,': 'O'}, {'and': 'O'}, {'biopsy': 'O'}, {'or': 'O'}, {'open': 'O'}, {'surgery': 'O'}, {'depending': 'O'}, {'on': 'O'}, {'image': 'O'}]"
"Symptoms of dry eyes and dry mouth due to lacrimal and salivary gland dysfunction are prominent, but not pathognomonic, and an extensive diagnostic work-up including blood tests and labial salivary gland biopsy is often required to distinguish pSS from non-pSS.","[{'Symptoms': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'lacrimal': 'B-Entity'}, {'and': 'I-Entity'}, {'salivary': 'I-Entity'}, {'gland': 'I-Entity'}, {'dysfunction': 'I-Entity'}, {'are': 'O'}, {'prominent,': 'O'}, {'but': 'O'}, {'not': 'O'}, {'pathognomonic,': 'O'}, {'and': 'O'}, {'an': 'O'}, {'extensive': 'O'}, {'diagnostic': 'O'}, {'work-up': 'O'}, {'including': 'O'}, {'blood': 'O'}, {'tests': 'O'}, {'and': 'O'}, {'labial': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'biopsy': 'O'}, {'is': 'O'}, {'often': 'O'}, {'required': 'O'}, {'to': 'O'}, {'distinguish': 'O'}, {'pSS': 'I-Entity'}]"
"Topical CsA 0.05% improved clinical signs and symptoms, and increased corneal sensitivity.","[{'Topical': 'O'}, {'CsA': 'I-Entity'}, {'0.05%': 'O'}, {'improved': 'O'}, {'clinical': 'O'}, {'signs': 'O'}, {'and': 'O'}, {'symptoms,': 'O'}, {'and': 'O'}, {'increased': 'O'}, {'corneal': 'O'}, {'sensitivity.': 'O'}]"
"If the vasomotor symptoms are localized, a diagnosis of secondary Raynaud's phenomenon is highly probable and the main etiology is an arterial disease.","[{'If': 'O'}, {'the': 'O'}, {'vasomotor': 'O'}, {'symptoms': 'O'}, {'are': 'O'}, {'localized,': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'secondary': 'O'}, {""Raynaud's"": 'B-Entity'}, {'phenomenon': 'I-Entity'}, {'is': 'O'}, {'highly': 'O'}, {'probable': 'O'}, {'and': 'O'}, {'the': 'O'}, {'main': 'O'}, {'etiology': 'O'}, {'is': 'O'}, {'an': 'O'}, {'arterial': 'B-Entity'}, {'disease.': 'I-Entity'}]"
"The seizures, cognitive impairment and psychosis were attributable to neuropsychiatric SLE.","[{'The': 'O'}, {'seizures,': 'I-Entity'}, {'cognitive': 'B-Entity'}, {'impairment': 'I-Entity'}, {'and': 'O'}, {'psychosis': 'I-Entity'}, {'were': 'O'}, {'attributable': 'O'}, {'to': 'O'}, {'neuropsychiatric': 'B-Entity'}, {'SLE.': 'I-Entity'}]"
Cystic lung disease can be seen in patients with Sjogrens syndrome (SS) and is generally thought to be due to lymphocytic interstitial pneumonia.,"[{'Cystic': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'seen': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'and': 'O'}, {'is': 'O'}, {'generally': 'O'}, {'thought': 'O'}, {'to': 'O'}, {'be': 'O'}, {'due': 'O'}, {'to': 'O'}, {'lymphocytic': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia.': 'I-Entity'}]"
"Patients with systemic inflammatory rheumatic diseases (such as rheumatoid arthritis, lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathies, or Sjogrens syndrome) are at increased risk of cancer, including hematological malignancies (leukemias and lymphomas), as well as non-hematological cancers (e.g.","[{'Patients': 'O'}, {'with': 'O'}, {'systemic': 'O'}, {'inflammatory': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'diseases': 'I-Entity'}, {'(such': 'O'}, {'as': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {'lupus': 'B-Entity'}, {'erythematosus,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'sclerosis,': 'I-Entity'}, {'idiopathic': 'B-Entity'}, {'inflammatory': 'I-Entity'}, {'myopathies,': 'I-Entity'}, {'or': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome)': 'I-Entity'}, {'are': 'O'}, {'at': 'O'}, {'increased': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'cancer,': 'I-Entity'}, {'including': 'O'}, {'hematological': 'B-Entity'}]"
"Our results confirmed that the procedure is safe and effective, especially in high risk patients.","[{'Our': 'O'}, {'results': 'O'}, {'confirmed': 'O'}, {'that': 'O'}, {'the': 'O'}, {'procedure': 'O'}, {'is': 'O'}, {'safe': 'O'}, {'and': 'O'}, {'effective,': 'O'}, {'especially': 'O'}, {'in': 'O'}, {'high': 'O'}, {'risk': 'O'}, {'patients.': 'O'}]"
"Mean tear osmolarity was 296.77 ¬¨¬®¬¨¬± 16.48 mOsm/L in NSSDE (15% abnormal), 303.36 ¬¨¬®¬¨¬± 17.22 mOsm/L in SSDE (23% abnormal), and 303.52 ¬¨¬®¬¨¬± 12.92 mOsm/L in the control group (16% abnormal; P = 0.018, Kruskal-Wallis).","[{'Mean': 'O'}, {'tear': 'O'}, {'osmolarity': 'O'}, {'was': 'O'}, {'296.77': 'O'}, {'¬¨¬®¬¨¬±': 'O'}, {'16.48': 'O'}, {'mOsm/L': 'O'}, {'in': 'O'}, {'NSSDE': 'O'}, {'(15%': 'O'}, {'abnormal),': 'O'}, {'303.36': 'O'}, {'¬¨¬®¬¨¬±': 'O'}, {'17.22': 'O'}, {'mOsm/L': 'O'}, {'in': 'O'}, {'SSDE': 'I-Entity'}, {'(23%': 'O'}]"
"Current smoking rates were 4.6% for SS patients compared to 14.1% in non-SS sicca (p = 5.17x10E-09), 18% in a local lupus cohort (p = 1.13x10E-14) and 16.8% in the community (p = 4.12x10E-15).","[{'Current': 'O'}, {'smoking': 'I-Entity'}, {'rates': 'O'}, {'were': 'O'}, {'4.6%': 'O'}, {'for': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'14.1%': 'O'}, {'in': 'O'}, {'non-SS': 'O'}, {'sicca': 'I-Entity'}, {'(p': 'O'}, {'=': 'O'}, {'5.17x10E-09),': 'O'}, {'18%': 'O'}, {'in': 'O'}, {'a': 'O'}, {'local': 'O'}, {'lupus': 'I-Entity'}, {'cohort': 'O'}, {'(p': 'O'}, {'=': 'O'}, {'1.13x10E-14)': 'O'}, {'and': 'O'}, {'16.8%': 'O'}]"
"Our patients had a late pSS diagnosis, due to the absence of sicca syndrome and specific Sjogren serology in the early stages of their diseases, when the neurological symptoms prevailed.","[{'Our': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'a': 'O'}, {'late': 'O'}, {'pSS': 'I-Entity'}, {'diagnosis,': 'O'}, {'due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'sicca': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'specific': 'O'}, {'Sjogren': 'O'}, {'serology': 'O'}, {'in': 'O'}, {'the': 'O'}, {'early': 'O'}, {'stages': 'O'}, {'of': 'O'}, {'their': 'O'}, {'diseases,': 'O'}, {'when': 'O'}, {'the': 'O'}, {'neurological': 'O'}, {'symptoms': 'O'}, {'prevailed.': 'O'}]"
"Considering all patients with primary SS who were autoantibody positive after diagnosis, at least one autoantibody specificity was detected in 81% up to 20 years (median 4.3-5.1 years) before diagnosis.","[{'Considering': 'O'}, {'all': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'who': 'O'}, {'were': 'O'}, {'autoantibody': 'O'}, {'positive': 'O'}, {'after': 'O'}, {'diagnosis,': 'O'}, {'at': 'O'}, {'least': 'O'}, {'one': 'O'}, {'autoantibody': 'O'}, {'specificity': 'O'}, {'was': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'81%': 'O'}, {'up': 'O'}, {'to': 'O'}, {'20': 'O'}, {'years': 'O'}, {'(median': 'O'}, {'4.3-5.1': 'O'}, {'years)': 'O'}, {'before': 'O'}, {'diagnosis.': 'O'}]"
Central nervous system (CNS) involvement was recorded in 7 (63.7%) and peripheric nervous system (PNS) involvement in 4 cases (36.4%).,"[{'Central': 'B-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'(CNS)': 'I-Entity'}, {'involvement': 'O'}, {'was': 'O'}, {'recorded': 'O'}, {'in': 'O'}, {'7': 'O'}, {'(63.7%)': 'O'}, {'and': 'O'}, {'peripheric': 'O'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'(PNS)': 'O'}, {'involvement': 'I-Entity'}, {'in': 'O'}, {'4': 'O'}, {'cases': 'O'}, {'(36.4%).': 'O'}]"
"This study demonstrated that patients with sarcoidosis tended to have autoimmune thyroid disease, Sjogrens syndrome and ankylosing spondylitis, and the diagnosis of sarcoidosis usually preceded that of associated comorbidities.","[{'This': 'O'}, {'study': 'O'}, {'demonstrated': 'O'}, {'that': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'sarcoidosis': 'I-Entity'}, {'tended': 'O'}, {'to': 'O'}, {'have': 'O'}, {'autoimmune': 'B-Entity'}, {'thyroid': 'I-Entity'}, {'disease,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'ankylosing': 'B-Entity'}, {'spondylitis,': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'sarcoidosis': 'I-Entity'}, {'usually': 'O'}, {'preceded': 'O'}, {'that': 'O'}, {'of': 'O'}, {'associated': 'O'}, {'comorbidities.': 'O'}]"
Our findings show that severe neuropathy with limb weakness is often associated with Sjogrens syndrome.,"[{'Our': 'O'}, {'findings': 'O'}, {'show': 'O'}, {'that': 'O'}, {'severe': 'O'}, {'neuropathy': 'I-Entity'}, {'with': 'O'}, {'limb': 'B-Entity'}, {'weakness': 'I-Entity'}, {'is': 'O'}, {'often': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
The developing renal dysfunction associated with isolated hematuria is uncommon in glomerular diseases.,"[{'The': 'O'}, {'developing': 'O'}, {'renal': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'isolated': 'O'}, {'hematuria': 'I-Entity'}, {'is': 'O'}, {'uncommon': 'O'}, {'in': 'O'}, {'glomerular': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"Because calcinosis in spinal locations can be complicated by neurological involvement, patients with progressive symptoms may require surgical intervention.","[{'Because': 'O'}, {'calcinosis': 'I-Entity'}, {'in': 'O'}, {'spinal': 'O'}, {'locations': 'O'}, {'can': 'O'}, {'be': 'O'}, {'complicated': 'O'}, {'by': 'O'}, {'neurological': 'O'}, {'involvement,': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'progressive': 'O'}, {'symptoms': 'O'}, {'may': 'O'}, {'require': 'O'}, {'surgical': 'O'}, {'intervention.': 'O'}]"
To measure the tear menisci in Sjogrens syndrome dry eye (SSDE) by optical coherence tomography (OCT) and to determine its relationships with the clinical tests.,"[{'To': 'O'}, {'measure': 'O'}, {'the': 'O'}, {'tear': 'O'}, {'menisci': 'O'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'(SSDE)': 'O'}, {'by': 'O'}, {'optical': 'O'}, {'coherence': 'O'}, {'tomography': 'O'}, {'(OCT)': 'O'}, {'and': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'its': 'O'}, {'relationships': 'O'}, {'with': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'tests.': 'O'}]"
A urinary catheter was inserted in the two cases of acute obstructive renal failure.,"[{'A': 'O'}, {'urinary': 'O'}, {'catheter': 'O'}, {'was': 'O'}, {'inserted': 'O'}, {'in': 'O'}, {'the': 'O'}, {'two': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'acute': 'B-Entity'}, {'obstructive': 'I-Entity'}, {'renal': 'I-Entity'}, {'failure.': 'I-Entity'}]"
Fatigue is a common and sometimes debilitating phenomenon in primary Sjogrens syndrome (pSS) and other chronic inflammatory diseases.,"[{'Fatigue': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'common': 'O'}, {'and': 'O'}, {'sometimes': 'O'}, {'debilitating': 'O'}, {'phenomenon': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'and': 'O'}, {'other': 'O'}, {'chronic': 'O'}, {'inflammatory': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
Our study aimed to investigate whether the introduction of automated anti-nuclear antibody (ANA) indirect immunofluorescence (IIF) analysis decreases the interlaboratory variability of ANA titer results.,"[{'Our': 'O'}, {'study': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'whether': 'O'}, {'the': 'O'}, {'introduction': 'O'}, {'of': 'O'}, {'automated': 'O'}, {'anti-nuclear': 'O'}, {'antibody': 'O'}, {'(ANA)': 'O'}, {'indirect': 'O'}, {'immunofluorescence': 'O'}, {'(IIF)': 'O'}, {'analysis': 'O'}, {'decreases': 'O'}, {'the': 'O'}, {'interlaboratory': 'O'}, {'variability': 'O'}, {'of': 'O'}, {'ANA': 'O'}, {'titer': 'O'}, {'results.': 'O'}]"
"For fatigue, the effectiveness of HCQ was lower than placebo.","[{'For': 'O'}, {'fatigue,': 'I-Entity'}, {'the': 'O'}, {'effectiveness': 'O'}, {'of': 'O'}, {'HCQ': 'I-Entity'}, {'was': 'O'}, {'lower': 'O'}, {'than': 'O'}, {'placebo.': 'O'}]"
"The accuracy, sensitivity and specificity of the deep learning system for the PG were 89.5, 90.0 and 89.0%, respectively, and those for the inexperienced radiologists were 76.7, 67.0 and 86.3%, respectively.","[{'The': 'O'}, {'accuracy,': 'O'}, {'sensitivity': 'O'}, {'and': 'O'}, {'specificity': 'O'}, {'of': 'O'}, {'the': 'O'}, {'deep': 'O'}, {'learning': 'O'}, {'system': 'O'}, {'for': 'O'}, {'the': 'O'}, {'PG': 'O'}, {'were': 'O'}, {'89.5,': 'O'}, {'90.0': 'O'}, {'and': 'O'}, {'89.0%,': 'O'}, {'respectively,': 'O'}, {'and': 'O'}, {'those': 'O'}, {'for': 'O'}, {'the': 'O'}, {'inexperienced': 'O'}, {'radiologists': 'O'}, {'were': 'O'}, {'76.7,': 'O'}, {'67.0': 'O'}, {'and': 'O'}, {'86.3%,': 'O'}, {'respectively.': 'O'}]"
"MS-ON is more commonly misdiagnosed with NMO-ON and Sjogren's syndrome, when compared to optic neuropathy, tumors and ischemic optic neuropathy.","[{'MS-ON': 'I-Entity'}, {'is': 'O'}, {'more': 'O'}, {'commonly': 'O'}, {'misdiagnosed': 'O'}, {'with': 'O'}, {'NMO-ON': 'I-Entity'}, {'and': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'when': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'optic': 'B-Entity'}, {'neuropathy,': 'I-Entity'}, {'tumors': 'I-Entity'}, {'and': 'O'}, {'ischemic': 'B-Entity'}, {'optic': 'I-Entity'}, {'neuropathy.': 'I-Entity'}]"
"Screening for the clinical features of SS should be performed in patients with MS both receiving treatment with immunomodulatory drugs and without therapy.Siena, Siena, Italy.","[{'Screening': 'O'}, {'for': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'performed': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'MS': 'I-Entity'}, {'both': 'O'}, {'receiving': 'O'}, {'treatment': 'O'}, {'with': 'O'}, {'immunomodulatory': 'O'}, {'drugs': 'O'}, {'and': 'O'}, {'without': 'O'}, {'therapy.Siena,': 'O'}, {'Siena,': 'O'}, {'Italy.': 'O'}]"
"Our data highlighted the fact that in addition to managing primary SS symptoms, interventions aiming to improve patient empowerment, general wellbeing, access to health care, patient education, and social support are important to facilitate improved participation in daily living activities.on behalf of American College of Rheumatology.Foundation Trust, and Northumbria University, Newcastle upon Tyne, UK.Foundation Trust, Newcastle upon Tyne, UK.Northumbria University, Newcastle upon Tyne, UK.Foundation Trust, Newcastle upon Tyne, UK.2018 May 21.trigeminal neuralgia.","[{'Our': 'O'}, {'data': 'O'}, {'highlighted': 'O'}, {'the': 'O'}, {'fact': 'O'}, {'that': 'O'}, {'in': 'O'}, {'addition': 'O'}, {'to': 'O'}, {'managing': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'symptoms,': 'O'}, {'interventions': 'O'}, {'aiming': 'O'}, {'to': 'O'}, {'improve': 'O'}, {'patient': 'O'}, {'empowerment,': 'O'}, {'general': 'O'}, {'wellbeing,': 'O'}, {'access': 'O'}, {'to': 'O'}, {'health': 'O'}, {'care,': 'O'}, {'patient': 'O'}, {'education,': 'O'}, {'and': 'O'}, {'social': 'O'}, {'support': 'O'}, {'are': 'O'}, {'important': 'O'}, {'to': 'O'}, {'facilitate': 'O'}, {'improved': 'O'}, {'participation': 'O'}, {'in': 'O'}, {'daily': 'O'}, {'living': 'O'}, {'activities.on': 'O'}, {'behalf': 'O'}, {'of': 'O'}, {'American': 'O'}, {'College': 'O'}, {'of': 'O'}, {'Rheumatology.Foundation': 'I-Entity'}, {'Trust,': 'O'}]"
Hypokalemic paralysis and respiratory failure associated with distal renal tubular acidosis as first clinical manifestation of primary Sjogrens syndrome has been reported a few times.,"[{'Hypokalemic': 'I-Entity'}, {'paralysis': 'I-Entity'}, {'and': 'O'}, {'respiratory': 'B-Entity'}, {'failure': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'distal': 'O'}, {'renal': 'O'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'as': 'O'}, {'first': 'O'}, {'clinical': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'reported': 'O'}, {'a': 'O'}, {'few': 'O'}, {'times.': 'O'}]"
‚Äö√Ñ√∂‚àö√ë¬¨¬© Anti-inflammatory therapy is critical for the treatment of SS dry eye.,"[{'‚Äö√Ñ√∂‚àö√ë¬¨¬©': 'O'}, {'Anti-inflammatory': 'O'}, {'therapy': 'O'}, {'is': 'O'}, {'critical': 'O'}, {'for': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'SS': 'O'}, {'dry': 'B-Entity'}, {'eye.': 'I-Entity'}]"
"Our data revealed that TLR stimulation of PBC (n‚Äö√Ñ√∂‚àö√ë‚àö√≤=‚Äö√Ñ√∂‚àö√ë‚àö√≤17) and pSS monocytes (n‚Äö√Ñ√∂‚àö√ë‚àö√≤=‚Äö√Ñ√∂‚àö√ë‚àö√≤6) resulted in significant induction of IL12A mRNA (p‚Äö√Ñ√∂‚àö√ë‚àö√≤<‚Äö√Ñ√∂‚àö√ë‚àö√≤0.05, p‚Äö√Ñ√∂‚àö√ë‚àö√≤<‚Äö√Ñ√∂‚àö√ë‚àö√≤0.01, respectively) compared to PSC monocytes (n‚Äö√Ñ√∂‚àö√ë‚àö√≤=‚Äö√Ñ√∂‚àö√ë‚àö√≤13) and at similar levels to HC monocytes (n‚Äö√Ñ√∂‚àö√ë‚àö√≤=‚Äö√Ñ√∂‚àö√ë‚àö√≤8).","[{'Our': 'O'}, {'data': 'O'}, {'revealed': 'O'}, {'that': 'O'}, {'TLR': 'O'}, {'stimulation': 'O'}, {'of': 'O'}, {'PBC': 'O'}, {'(n‚Äö√Ñ√∂‚àö√ë‚àö√≤=‚Äö√Ñ√∂‚àö√ë‚àö√≤17)': 'O'}, {'and': 'O'}, {'pSS': 'O'}, {'monocytes': 'O'}, {'(n‚Äö√Ñ√∂‚àö√ë‚àö√≤=‚Äö√Ñ√∂‚àö√ë‚àö√≤6)': 'O'}]"
Hypokalemic paralysis associated with normal anion gap metabolic acidosis should prompt toward the diagnosis of SS.Taiwan.,"[{'Hypokalemic': 'I-Entity'}, {'paralysis': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'normal': 'O'}, {'anion': 'O'}, {'gap': 'O'}, {'metabolic': 'O'}, {'acidosis': 'I-Entity'}, {'should': 'O'}, {'prompt': 'O'}, {'toward': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS.Taiwan.': 'I-Entity'}]"
"Since autoimmune plasma cells have been detected in the salivary glands of SS patients, we wanted to investigate if the glandular microenvironment is suitable for plasma cell survival and if glandular residing plasma cells are the long-lived plasma cell subset.","[{'Since': 'O'}, {'autoimmune': 'B-Entity'}, {'plasma': 'O'}, {'cells': 'O'}, {'have': 'O'}, {'been': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'patients,': 'O'}, {'we': 'O'}, {'wanted': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'if': 'O'}, {'the': 'O'}, {'glandular': 'O'}, {'microenvironment': 'O'}, {'is': 'O'}, {'suitable': 'O'}, {'for': 'O'}, {'plasma': 'O'}, {'cell': 'O'}, {'survival': 'O'}, {'and': 'O'}, {'if': 'O'}, {'glandular': 'O'}, {'residing': 'O'}, {'plasma': 'O'}, {'cells': 'O'}, {'are': 'O'}, {'the': 'O'}, {'long-lived': 'O'}, {'plasma': 'O'}, {'cell': 'O'}, {'subset.': 'O'}]"
"Consequently, pancreatic exocrine dysfunction, which can be seen in patients with RA, may be thought to be caused by secondary SjS associated with RA (Tab.","[{'Consequently,': 'O'}, {'pancreatic': 'B-Entity'}, {'exocrine': 'I-Entity'}, {'dysfunction,': 'I-Entity'}, {'which': 'O'}, {'can': 'O'}, {'be': 'O'}, {'seen': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'RA,': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'thought': 'O'}, {'to': 'O'}, {'be': 'O'}, {'caused': 'O'}, {'by': 'O'}, {'secondary': 'O'}, {'SjS': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'RA': 'I-Entity'}, {'(Tab.': 'O'}]"
This disease is characterized by isolated or combined chronic cytopenias associated with autoimmune phenomena and bone-marrow fibrosis.,"[{'This': 'O'}, {'disease': 'O'}, {'is': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'isolated': 'O'}, {'or': 'O'}, {'combined': 'O'}, {'chronic': 'O'}, {'cytopenias': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'phenomena': 'O'}, {'and': 'O'}, {'bone-marrow': 'O'}, {'fibrosis.': 'I-Entity'}]"
"Among these conditions, chronic hepatitis C virus infection, associated with mixed cryoglobulinaemia and extra-hepatic manifestations, and HIV infection, particularly in the phase of diffuse interstitial lymphocytic infiltration, may mimic the clinical and histological aspects of Sjogrens syndrome.","[{'Among': 'O'}, {'these': 'O'}, {'conditions,': 'O'}, {'chronic': 'O'}, {'hepatitis': 'B-Entity'}, {'C': 'I-Entity'}, {'virus': 'I-Entity'}, {'infection,': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'mixed': 'O'}, {'cryoglobulinaemia': 'I-Entity'}, {'and': 'O'}, {'extra-hepatic': 'O'}, {'manifestations,': 'O'}, {'and': 'O'}, {'HIV': 'B-Entity'}, {'infection,': 'I-Entity'}, {'particularly': 'O'}, {'in': 'O'}, {'the': 'O'}, {'phase': 'O'}, {'of': 'O'}, {'diffuse': 'O'}, {'interstitial': 'O'}, {'lymphocytic': 'O'}, {'infiltration,': 'O'}, {'may': 'O'}, {'mimic': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'histological': 'O'}]"
"Interstitial lung disease (ILD) is the most common type of pulmonary involvement of extraglandular complication in patients with primary Sjogrens syndrome (pSS), but the diagnosis of pSS-associated ILD (pSS-ILD) is still challenging.","[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(ILD)': 'O'}, {'is': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'type': 'O'}, {'of': 'O'}, {'pulmonary': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'extraglandular': 'O'}, {'complication': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS),': 'O'}, {'but': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'pSS-associated': 'I-Entity'}, {'ILD': 'I-Entity'}, {'(pSS-ILD)': 'O'}, {'is': 'O'}, {'still': 'O'}, {'challenging.': 'O'}]"
"Anti-Ro/SSA52 antibodies have little impact on adult rheumatic autoimmune diseases or adult cardiac arrhythmias, but the course of autoimmune liver diseases is greatly worsened by their presence, and solid tumours tend to relapse.","[{'Anti-Ro/SSA52': 'O'}, {'antibodies': 'O'}, {'have': 'O'}, {'little': 'O'}, {'impact': 'O'}, {'on': 'O'}, {'adult': 'O'}, {'rheumatic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'diseases': 'I-Entity'}, {'or': 'O'}, {'adult': 'O'}, {'cardiac': 'B-Entity'}, {'arrhythmias,': 'I-Entity'}, {'but': 'O'}, {'the': 'O'}, {'course': 'O'}, {'of': 'O'}, {'autoimmune': 'B-Entity'}, {'liver': 'I-Entity'}, {'diseases': 'I-Entity'}, {'is': 'O'}, {'greatly': 'O'}, {'worsened': 'O'}, {'by': 'O'}, {'their': 'O'}, {'presence,': 'O'}, {'and': 'O'}, {'solid': 'O'}, {'tumours': 'I-Entity'}, {'tend': 'O'}, {'to': 'O'}, {'relapse.': 'O'}]"
"Recent advances in how to assess changes in disease progression and activity objectively (via repeated biopsies of salivary glands, sialometry, sialochemistry, biomarkers, secretion and composition of tears, EULAR Sjogrens Syndrome Disease Activity Index: ESSDAI) and subjectively (EULAR Sjogrens Syndrome Patient Related Index: ESSPRI) have opened new ways to reliably assess the outcome of a particular treatment.","[{'Recent': 'O'}, {'advances': 'O'}, {'in': 'O'}, {'how': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'disease': 'O'}, {'progression': 'O'}, {'and': 'O'}, {'activity': 'O'}, {'objectively': 'O'}, {'(via': 'O'}, {'repeated': 'O'}, {'biopsies': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'glands,': 'O'}, {'sialometry,': 'O'}, {'sialochemistry,': 'O'}, {'biomarkers,': 'O'}, {'secretion': 'O'}, {'and': 'O'}, {'composition': 'O'}, {'of': 'O'}, {'tears,': 'O'}, {'EULAR': 'O'}, {'Sjogrens': 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'Disease': 'O'}, {'Activity': 'O'}, {'Index:': 'O'}, {'ESSDAI)': 'O'}]"
"At baseline, 24 (86%) patients rated physical fatigue as the complaint most eligible for improvement (median importance of 10), followed by pain, dryness, and mental fatigue.","[{'At': 'O'}, {'baseline,': 'O'}, {'24': 'O'}, {'(86%)': 'O'}, {'patients': 'O'}, {'rated': 'O'}, {'physical': 'O'}, {'fatigue': 'I-Entity'}, {'as': 'O'}, {'the': 'O'}, {'complaint': 'O'}, {'most': 'O'}, {'eligible': 'O'}, {'for': 'O'}, {'improvement': 'O'}, {'(median': 'O'}, {'importance': 'O'}, {'of': 'O'}, {'10),': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'pain,': 'I-Entity'}, {'dryness,': 'I-Entity'}, {'and': 'O'}, {'mental': 'O'}, {'fatigue.': 'I-Entity'}]"
"Itch was a troubling symptom in 83% of dermatomyositis (DM), 61% of systemic lupus erythematosus (SLE), 59% of Sjogren syndrome (SJO), 22% of systemic sclerosis (SSc), and 60% of mixed connective tissue disease.","[{'Itch': 'I-Entity'}, {'was': 'O'}, {'a': 'O'}, {'troubling': 'O'}, {'symptom': 'O'}, {'in': 'O'}, {'83%': 'O'}, {'of': 'O'}, {'dermatomyositis': 'I-Entity'}, {'(DM),': 'O'}, {'61%': 'O'}, {'of': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE),': 'O'}, {'59%': 'O'}, {'of': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SJO),': 'O'}, {'22%': 'O'}, {'of': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}]"
"Most of the cases corresponded to localized amyloidosis mainly at skin and lung, whereas only three cases were systemic.","[{'Most': 'O'}, {'of': 'O'}, {'the': 'O'}, {'cases': 'O'}, {'corresponded': 'O'}, {'to': 'O'}, {'localized': 'O'}, {'amyloidosis': 'I-Entity'}, {'mainly': 'O'}, {'at': 'O'}, {'skin': 'O'}, {'and': 'O'}, {'lung,': 'O'}, {'whereas': 'O'}, {'only': 'O'}, {'three': 'O'}, {'cases': 'O'}, {'were': 'O'}, {'systemic.': 'O'}]"
"Anti-NR2 antibodies were associated with impaired visuospatial processing (odds ratio 4.9, P‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.03) and motor functioning (odds ratio 6.0, P‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.006).","[{'Anti-NR2': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'impaired': 'B-Entity'}, {'visuospatial': 'I-Entity'}, {'processing': 'I-Entity'}, {'(odds': 'O'}, {'ratio': 'O'}, {'4.9,': 'O'}, {'P‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.03)': 'O'}]"
"(2) Dry mouth (84.5%) and dry eyes (70.0%) were the most common symptoms, significantly lower than foreign patients (P = 0.000).","[{'(2)': 'O'}, {'Dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'(84.5%)': 'O'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'(70.0%)': 'O'}, {'were': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'symptoms,': 'O'}, {'significantly': 'O'}, {'lower': 'O'}, {'than': 'O'}, {'foreign': 'O'}, {'patients': 'O'}, {'(P': 'O'}, {'=': 'O'}, {'0.000).': 'O'}]"
"This study asked whether pregnancy, a risk factor for dry eye disease associated with both chronic, immune-mediated- and autoimmune etiologies, augments development of clusters of coordinately functioning cells (CCFC) that may be precursors to pathological lacrimal gland infiltrates.","[{'This': 'O'}, {'study': 'O'}, {'asked': 'O'}, {'whether': 'O'}, {'pregnancy,': 'O'}, {'a': 'O'}, {'risk': 'O'}, {'factor': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'both': 'O'}, {'chronic,': 'O'}, {'immune-mediated-': 'O'}, {'and': 'O'}, {'autoimmune': 'I-Entity'}, {'etiologies,': 'O'}, {'augments': 'O'}, {'development': 'O'}, {'of': 'O'}, {'clusters': 'O'}, {'of': 'O'}, {'coordinately': 'O'}, {'functioning': 'O'}, {'cells': 'O'}, {'(CCFC)': 'O'}, {'that': 'O'}, {'may': 'O'}, {'be': 'O'}, {'precursors': 'O'}, {'to': 'O'}, {'pathological': 'O'}, {'lacrimal': 'O'}, {'gland': 'O'}, {'infiltrates.': 'O'}]"
"Treatment was well tolerated, and adverse events were consistent with the known safety profile of CyA (e.g., hypertension, headache).","[{'Treatment': 'O'}, {'was': 'O'}, {'well': 'O'}, {'tolerated,': 'O'}, {'and': 'O'}, {'adverse': 'O'}, {'events': 'O'}, {'were': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'the': 'O'}, {'known': 'O'}, {'safety': 'O'}, {'profile': 'O'}, {'of': 'O'}, {'CyA': 'I-Entity'}, {'(e.g.,': 'O'}, {'hypertension,': 'I-Entity'}, {'headache).': 'I-Entity'}]"
"Although the proportion of circulating CD25highGITRhigh subset was similar in SS patients and NC, an expansion of the CD25-GITRhigh cell population was observed in the peripheral blood of SS patients.","[{'Although': 'O'}, {'the': 'O'}, {'proportion': 'O'}, {'of': 'O'}, {'circulating': 'O'}, {'CD25highGITRhigh': 'O'}, {'subset': 'O'}, {'was': 'O'}, {'similar': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'NC,': 'O'}, {'an': 'O'}, {'expansion': 'O'}, {'of': 'O'}, {'the': 'O'}, {'CD25-GITRhigh': 'O'}, {'cell': 'O'}, {'population': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'the': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'patients.': 'O'}]"
"Thus the magnitude and severity of headaches in SLE were evaluated in comparison with another autoimmune disease, namely primary Sjogrens syndrome (pSS).","[{'Thus': 'O'}, {'the': 'O'}, {'magnitude': 'O'}, {'and': 'O'}, {'severity': 'O'}, {'of': 'O'}, {'headaches': 'I-Entity'}, {'in': 'O'}, {'SLE': 'I-Entity'}, {'were': 'O'}, {'evaluated': 'O'}, {'in': 'O'}, {'comparison': 'O'}, {'with': 'O'}, {'another': 'O'}, {'autoimmune': 'B-Entity'}, {'disease,': 'I-Entity'}, {'namely': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
"In conclusion, the results of this study suggest that orally administered pilocarpine is safe and effective for treating xerostomia in juvenile-onset SS patients.","[{'In': 'O'}, {'conclusion,': 'O'}, {'the': 'O'}, {'results': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'orally': 'O'}, {'administered': 'O'}, {'pilocarpine': 'I-Entity'}, {'is': 'O'}, {'safe': 'O'}, {'and': 'O'}, {'effective': 'O'}, {'for': 'O'}, {'treating': 'O'}, {'xerostomia': 'I-Entity'}, {'in': 'O'}, {'juvenile-onset': 'O'}, {'SS': 'I-Entity'}, {'patients.': 'O'}]"
"The adult lacrimal gland (LG) is highly regenerative and is able to repair itself even after substantial damage; however, this ability to regenerate is lost with the development of dry eye conditions in chronically inflamed LGs.This study compares changes in the cell adhesion and cell matrix molecules and stem cell transcription factors in the LGs of healthy mice and of two mouse models of Sjogrens syndrome: nonobese diabetic (NOD) and MRL-lpr/lpr (MRL/lpr) mice during the early stage of inflammation.","[{'The': 'O'}, {'adult': 'O'}, {'lacrimal': 'O'}, {'gland': 'O'}, {'(LG)': 'O'}, {'is': 'O'}, {'highly': 'O'}, {'regenerative': 'O'}, {'and': 'O'}, {'is': 'O'}, {'able': 'O'}, {'to': 'O'}, {'repair': 'O'}, {'itself': 'O'}, {'even': 'O'}, {'after': 'O'}, {'substantial': 'O'}, {'damage;': 'O'}, {'however,': 'O'}, {'this': 'O'}, {'ability': 'O'}, {'to': 'O'}, {'regenerate': 'O'}, {'is': 'O'}, {'lost': 'O'}, {'with': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'conditions': 'O'}, {'in': 'O'}, {'chronically': 'O'}, {'inflamed': 'O'}, {'LGs.This': 'O'}, {'study': 'O'}, {'compares': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'the': 'O'}, {'cell': 'O'}, {'adhesion': 'O'}]"
"The mechanisms underlying immune dysregulation in this syndrome remain unknown, and clinically it is difficult to diagnose owing to a lack of specific biomarkers.","[{'The': 'O'}, {'mechanisms': 'O'}, {'underlying': 'O'}, {'immune': 'O'}, {'dysregulation': 'O'}, {'in': 'O'}, {'this': 'O'}, {'syndrome': 'O'}, {'remain': 'O'}, {'unknown,': 'O'}, {'and': 'O'}, {'clinically': 'O'}, {'it': 'O'}, {'is': 'O'}, {'difficult': 'O'}, {'to': 'O'}, {'diagnose': 'O'}, {'owing': 'O'}, {'to': 'O'}, {'a': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'specific': 'O'}, {'biomarkers.': 'O'}]"
Cystic lung disease (CLD) in Sjogren syndrome (SS) is a condition with unclear¬¨¬®‚Äö√Ñ‚Ä†prognostic implications.,"[{'Cystic': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(CLD)': 'O'}, {'in': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'condition': 'O'}, {'with': 'O'}, {'unclear¬¨¬®‚Äö√Ñ‚Ä†prognostic': 'O'}, {'implications.': 'O'}]"
"Proper awareness, clinical suspicion, and diagnosis of these diseases can greatly improve a patient's condition and prevent future ocular and systemic complications.MD, USA.MD, USA.MD, USA.MD, USA.MD, USA.eCollection 2020 Sep.of Sjogrens Syndrome.","[{'Proper': 'O'}, {'awareness,': 'O'}, {'clinical': 'O'}, {'suspicion,': 'O'}, {'and': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'these': 'O'}, {'diseases': 'O'}, {'can': 'O'}, {'greatly': 'O'}, {'improve': 'O'}, {'a': 'O'}, {""patient's"": 'O'}, {'condition': 'O'}, {'and': 'O'}, {'prevent': 'O'}, {'future': 'O'}, {'ocular': 'B-Entity'}, {'and': 'I-Entity'}, {'systemic': 'I-Entity'}, {'complications.MD,': 'I-Entity'}, {'USA.MD,': 'O'}, {'USA.MD,': 'O'}, {'USA.MD,': 'O'}, {'USA.MD,': 'O'}, {'USA.eCollection': 'O'}, {'2020': 'O'}, {'Sep.of': 'O'}, {'Sjogrens': 'B-Entity'}]"
"Diagnosis of IgG4-related disease is defined by both elevated serum IgG4 (> 1.35 g/l) and histopathological features, including lymphocyte and IgG4+ plasma cell infiltration (IgG4+ plasma cells/IgG+ plasma cells > 50% on a highly magnified slide checked at 5 points).","[{'Diagnosis': 'O'}, {'of': 'O'}, {'IgG4-related': 'O'}, {'disease': 'O'}, {'is': 'O'}, {'defined': 'O'}, {'by': 'O'}, {'both': 'O'}, {'elevated': 'O'}, {'serum': 'O'}, {'IgG4': 'O'}, {'(>': 'O'}, {'1.35': 'O'}, {'g/l)': 'O'}, {'and': 'O'}, {'histopathological': 'O'}, {'features,': 'O'}, {'including': 'O'}, {'lymphocyte': 'O'}, {'and': 'O'}, {'IgG4+': 'O'}, {'plasma': 'O'}, {'cell': 'O'}, {'infiltration': 'O'}, {'(IgG4+': 'O'}, {'plasma': 'O'}, {'cells/IgG+': 'O'}]"
Increased ease of taking oral medications also was reported.,"[{'Increased': 'O'}, {'ease': 'O'}, {'of': 'O'}, {'taking': 'O'}, {'oral': 'O'}, {'medications': 'O'}, {'also': 'O'}, {'was': 'O'}, {'reported.': 'O'}]"
Patients who were positive for anti-SSB antibodies presented with lower IL-35 levels and percentages of CD4¬¨¬®‚Äö√Ñ‚Ä†+¬¨¬®‚Äö√Ñ‚Ä†EBI3¬¨¬®‚Äö√Ñ‚Ä†+¬¨¬®‚Äö√Ñ‚Ä†T cells.,"[{'Patients': 'O'}, {'who': 'O'}, {'were': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'anti-SSB': 'O'}, {'antibodies': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'lower': 'O'}, {'IL-35': 'O'}, {'levels': 'O'}, {'and': 'O'}, {'percentages': 'O'}, {'of': 'O'}, {'CD4¬¨¬®‚Äö√Ñ‚Ä†+¬¨¬®‚Äö√Ñ‚Ä†EBI3¬¨¬®‚Äö√Ñ‚Ä†+¬¨¬®‚Äö√Ñ‚Ä†T': 'O'}]"
"Distal renal tubular acidosis (dRTA) is diagnosed when the urinary pH is greater than 5.3 and in the presence of hyperchloremic metabolic acidosis and hypokalemia, with one of the causes being primary Sjogrens syndrome (pSS).","[{'Distal': 'B-Entity'}, {'renal': 'I-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'(dRTA)': 'O'}, {'is': 'O'}, {'diagnosed': 'O'}, {'when': 'O'}, {'the': 'O'}, {'urinary': 'O'}, {'pH': 'O'}, {'is': 'O'}, {'greater': 'O'}, {'than': 'O'}, {'5.3': 'O'}, {'and': 'O'}, {'in': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'hyperchloremic': 'O'}, {'metabolic': 'B-Entity'}, {'acidosis': 'I-Entity'}, {'and': 'O'}, {'hypokalemia,': 'I-Entity'}, {'with': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'causes': 'O'}, {'being': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
"Cranial nerve injury is a harmful complication of SS, even if less commonly recorded compared to peripheral neuropathy.","[{'Cranial': 'B-Entity'}, {'nerve': 'I-Entity'}, {'injury': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'harmful': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'SS,': 'I-Entity'}, {'even': 'O'}, {'if': 'O'}, {'less': 'O'}, {'commonly': 'O'}, {'recorded': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy.': 'I-Entity'}]"
Studies show a high incidence of poor fetal outcomes for these patients.,"[{'Studies': 'O'}, {'show': 'O'}, {'a': 'O'}, {'high': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'poor': 'O'}, {'fetal': 'O'}, {'outcomes': 'O'}, {'for': 'O'}, {'these': 'O'}, {'patients.': 'O'}]"
"Trigeminal neuropathy is also frequently reported, whereas neuritis involving the other cranial nerves is quite rare.","[{'Trigeminal': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'is': 'O'}, {'also': 'O'}, {'frequently': 'O'}, {'reported,': 'O'}, {'whereas': 'O'}, {'neuritis': 'I-Entity'}, {'involving': 'O'}, {'the': 'O'}, {'other': 'O'}, {'cranial': 'O'}, {'nerves': 'O'}, {'is': 'O'}, {'quite': 'O'}, {'rare.': 'O'}]"
"An acute isolated neurological syndrome presents the greatest diagnostic problem, since it is common not only in MS, but can also be the only feature or first manifestation in SLE, APS, SS, and BD.","[{'An': 'O'}, {'acute': 'O'}, {'isolated': 'O'}, {'neurological': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'presents': 'O'}, {'the': 'O'}, {'greatest': 'O'}, {'diagnostic': 'O'}, {'problem,': 'O'}, {'since': 'O'}, {'it': 'O'}, {'is': 'O'}, {'common': 'O'}, {'not': 'O'}, {'only': 'O'}, {'in': 'O'}, {'MS,': 'I-Entity'}, {'but': 'O'}, {'can': 'O'}, {'also': 'O'}, {'be': 'O'}, {'the': 'O'}, {'only': 'O'}, {'feature': 'O'}, {'or': 'O'}, {'first': 'O'}, {'manifestation': 'O'}, {'in': 'O'}, {'SLE,': 'I-Entity'}, {'APS,': 'I-Entity'}, {'SS,': 'I-Entity'}, {'and': 'O'}, {'BD.': 'I-Entity'}]"
"Fetal microchimerism offers an interesting mechanism for our patient's renal failure and its apparent relationship to her pregnancies.Healthcare Trust, London, UK.Cork, Cork, Republic of Ireland.Cork, Cork, Republic of Ireland.Healthcare Trust, London, UK.","[{'Fetal': 'O'}, {'microchimerism': 'O'}, {'offers': 'O'}, {'an': 'O'}, {'interesting': 'O'}, {'mechanism': 'O'}, {'for': 'O'}, {'our': 'O'}, {""patient's"": 'O'}, {'renal': 'B-Entity'}, {'failure': 'I-Entity'}, {'and': 'O'}, {'its': 'O'}, {'apparent': 'O'}, {'relationship': 'O'}, {'to': 'O'}, {'her': 'O'}, {'pregnancies.Healthcare': 'O'}, {'Trust,': 'O'}, {'London,': 'O'}, {'UK.Cork,': 'O'}, {'Cork,': 'O'}, {'Republic': 'O'}, {'of': 'O'}, {'Ireland.Cork,': 'O'}, {'Cork,': 'O'}, {'Republic': 'O'}, {'of': 'O'}, {'Ireland.Healthcare': 'O'}, {'Trust,': 'O'}, {'London,': 'O'}, {'UK.': 'O'}]"
"The persistent presence of H. pylori in the gastric mucosa results in chronic immune system activation with ongoing cytokine signaling, infiltration of gastric mucosa by neutrophils, macrophages, lymphocytes, as well as production of antibodies and effector T-cells.","[{'The': 'O'}, {'persistent': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'H.': 'B-Entity'}, {'pylori': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'gastric': 'O'}, {'mucosa': 'O'}, {'results': 'O'}, {'in': 'O'}, {'chronic': 'O'}, {'immune': 'O'}, {'system': 'O'}, {'activation': 'O'}, {'with': 'O'}, {'ongoing': 'O'}, {'cytokine': 'O'}, {'signaling,': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'gastric': 'O'}, {'mucosa': 'O'}, {'by': 'O'}, {'neutrophils,': 'O'}, {'macrophages,': 'O'}, {'lymphocytes,': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'production': 'O'}, {'of': 'O'}, {'antibodies': 'O'}, {'and': 'O'}]"
"At 6 months after rituximab treatment, improvement in pulmonary function was observed (from 49.3¬¨¬®¬¨¬±12.6 to 56.9¬¨¬®¬¨¬±11.4% for DLCO, p=0.011; from 74.4¬¨¬®¬¨¬±15.8 to 85.6¬¨¬®¬¨¬±10.3% for DLCO/Va, p=0.021).","[{'At': 'O'}, {'6': 'O'}, {'months': 'O'}, {'after': 'O'}, {'rituximab': 'I-Entity'}, {'treatment,': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'pulmonary': 'O'}, {'function': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'(from': 'O'}, {'49.3¬¨¬®¬¨¬±12.6': 'O'}, {'to': 'O'}, {'56.9¬¨¬®¬¨¬±11.4%': 'O'}, {'for': 'O'}, {'DLCO,': 'O'}, {'p=0.011;': 'O'}, {'from': 'O'}, {'74.4¬¨¬®¬¨¬±15.8': 'O'}]"
"Superimposed infection, pulmonary fibrosis and lymphoma develop in less than 20% of cases.","[{'Superimposed': 'O'}, {'infection,': 'I-Entity'}, {'pulmonary': 'B-Entity'}, {'fibrosis': 'I-Entity'}, {'and': 'O'}, {'lymphoma': 'I-Entity'}, {'develop': 'O'}, {'in': 'O'}, {'less': 'O'}, {'than': 'O'}, {'20%': 'O'}, {'of': 'O'}, {'cases.': 'O'}]"
"The renal prognosis in patients with pSS is usually favorable, but renal failure may occur.","[{'The': 'O'}, {'renal': 'O'}, {'prognosis': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'is': 'O'}, {'usually': 'O'}, {'favorable,': 'O'}, {'but': 'O'}, {'renal': 'B-Entity'}, {'failure': 'I-Entity'}, {'may': 'O'}, {'occur.': 'O'}]"
"Anti-SSA/Ro antibodies have been rarely described in cases of pulmonary disease, and less so in pulmonary hypertension.","[{'Anti-SSA/Ro': 'O'}, {'antibodies': 'O'}, {'have': 'O'}, {'been': 'O'}, {'rarely': 'O'}, {'described': 'O'}, {'in': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'pulmonary': 'B-Entity'}, {'disease,': 'I-Entity'}, {'and': 'O'}, {'less': 'O'}, {'so': 'O'}, {'in': 'O'}, {'pulmonary': 'B-Entity'}, {'hypertension.': 'I-Entity'}]"
"The patient was admitted due to dyspnea, fever, polyarthralgia, and generalized edema.","[{'The': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'admitted': 'O'}, {'due': 'O'}, {'to': 'O'}, {'dyspnea,': 'I-Entity'}, {'fever,': 'I-Entity'}, {'polyarthralgia,': 'I-Entity'}, {'and': 'O'}, {'generalized': 'O'}, {'edema.': 'I-Entity'}]"
"To compare concentrations of tear cytokines in 3 groups composed of Sjogren syndrome (SS) dry eye, non-Sjogren syndrome (non-SS) dry eye, and normal subjects.","[{'To': 'O'}, {'compare': 'O'}, {'concentrations': 'O'}, {'of': 'O'}, {'tear': 'O'}, {'cytokines': 'O'}, {'in': 'O'}, {'3': 'O'}, {'groups': 'O'}, {'composed': 'O'}, {'of': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'dry': 'B-Entity'}, {'eye,': 'I-Entity'}, {'non-Sjogren': 'O'}, {'syndrome': 'I-Entity'}, {'(non-SS)': 'O'}, {'dry': 'B-Entity'}, {'eye,': 'I-Entity'}, {'and': 'O'}, {'normal': 'O'}, {'subjects.': 'O'}]"
"Awareness of this potential association as well as cognizance of its imaging findings can help for making a more accurate and prompt earlier diagnosis of the underlying disease changing also the therapeutic approach.72076, Tuebingen, Germany.","[{'Awareness': 'O'}, {'of': 'O'}, {'this': 'O'}, {'potential': 'O'}, {'association': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'cognizance': 'O'}, {'of': 'O'}, {'its': 'O'}, {'imaging': 'O'}, {'findings': 'O'}, {'can': 'O'}, {'help': 'O'}, {'for': 'O'}, {'making': 'O'}, {'a': 'O'}, {'more': 'O'}, {'accurate': 'O'}, {'and': 'O'}, {'prompt': 'O'}, {'earlier': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'disease': 'O'}, {'changing': 'O'}, {'also': 'O'}, {'the': 'O'}, {'therapeutic': 'O'}, {'approach.72076,': 'O'}, {'Tuebingen,': 'O'}, {'Germany.': 'O'}]"
"Using 5‚Äö√Ñ√∂‚àö√ë‚àö¬¢mm(2) ROIs significantly higher DWI SIRs were noted in participants with Sjogrens syndrome compared with either participants with dry mouth without Sjogrens syndrome or healthy volunteers (all, P <0.001).","[{'Using': 'O'}, {'5‚Äö√Ñ√∂‚àö√ë‚àö¬¢mm(2)': 'O'}, {'ROIs': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'DWI': 'O'}, {'SIRs': 'O'}, {'were': 'O'}, {'noted': 'O'}, {'in': 'O'}, {'participants': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'compared': 'O'}, {'with': 'O'}, {'either': 'O'}, {'participants': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'without': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'or': 'O'}, {'healthy': 'O'}, {'volunteers': 'O'}, {'(all,': 'O'}]"
Dry eye is a common problem in Ophthalmology and may occur for many reasons including Sjogren's syndrome (SS).,"[{'Dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'common': 'O'}, {'problem': 'O'}, {'in': 'O'}, {'Ophthalmology': 'O'}, {'and': 'O'}, {'may': 'O'}, {'occur': 'O'}, {'for': 'O'}, {'many': 'O'}, {'reasons': 'O'}, {'including': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
The median time from initial pSS symptom onset to the DLBCL diagnosis was 20.5¬¨¬®‚Äö√Ñ‚Ä†years and the median time from the pSS diagnosis until the DLBCL diagnosis was 14¬¨¬®‚Äö√Ñ‚Ä†years.,"[{'The': 'O'}, {'median': 'O'}, {'time': 'O'}, {'from': 'O'}, {'initial': 'O'}, {'pSS': 'O'}, {'symptom': 'O'}, {'onset': 'O'}, {'to': 'O'}, {'the': 'O'}, {'DLBCL': 'I-Entity'}, {'diagnosis': 'O'}, {'was': 'O'}, {'20.5¬¨¬®‚Äö√Ñ‚Ä†years': 'O'}, {'and': 'O'}, {'the': 'O'}, {'median': 'O'}, {'time': 'O'}, {'from': 'O'}, {'the': 'O'}, {'pSS': 'O'}, {'diagnosis': 'O'}, {'until': 'O'}, {'the': 'O'}, {'DLBCL': 'I-Entity'}, {'diagnosis': 'O'}, {'was': 'O'}, {'14¬¨¬®‚Äö√Ñ‚Ä†years.': 'O'}]"
"Systemic sclerosis (SSc; scleroderma) is associated with decreased saliva production and interincisal distance, more missing teeth, and periodontal disease.","[{'Systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(SSc;': 'O'}, {'scleroderma)': 'I-Entity'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'decreased': 'O'}, {'saliva': 'O'}, {'production': 'O'}, {'and': 'O'}, {'interincisal': 'O'}, {'distance,': 'O'}, {'more': 'O'}, {'missing': 'B-Entity'}, {'teeth,': 'I-Entity'}, {'and': 'O'}, {'periodontal': 'B-Entity'}, {'disease.': 'I-Entity'}]"
"Anti-Ma2/Ta antibodies are rare paraneoplastic antibodies, which are mostly associated with limbic encephalitis in male patients with testicular cancer.","[{'Anti-Ma2/Ta': 'O'}, {'antibodies': 'O'}, {'are': 'O'}, {'rare': 'O'}, {'paraneoplastic': 'O'}, {'antibodies,': 'O'}, {'which': 'O'}, {'are': 'O'}, {'mostly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'limbic': 'B-Entity'}, {'encephalitis': 'I-Entity'}, {'in': 'O'}, {'male': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'testicular': 'B-Entity'}, {'cancer.': 'I-Entity'}]"
We examined the stiffness in parotid and submandibular glands of 23 patients diagnosed with SS and 20 healthy volunteers.,"[{'We': 'O'}, {'examined': 'O'}, {'the': 'O'}, {'stiffness': 'I-Entity'}, {'in': 'O'}, {'parotid': 'O'}, {'and': 'O'}, {'submandibular': 'O'}, {'glands': 'O'}, {'of': 'O'}, {'23': 'O'}, {'patients': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'20': 'O'}, {'healthy': 'O'}, {'volunteers.': 'O'}]"
"This disease predominantly affects middle-aged women, but can also be observed in children, men and the elderly.","[{'This': 'O'}, {'disease': 'O'}, {'predominantly': 'O'}, {'affects': 'O'}, {'middle-aged': 'O'}, {'women,': 'O'}, {'but': 'O'}, {'can': 'O'}, {'also': 'O'}, {'be': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'children,': 'O'}, {'men': 'O'}, {'and': 'O'}, {'the': 'O'}, {'elderly.': 'O'}]"
"Fifty percent (n = 8) of the patients with PsA had at least two or more abnormal CAN parasympathetic dysfunction; of these, 18.75% (n = 3) of the patients had abnormal parasympathetic and sympathetic dysfunction, 68.7% (n = 11) and 25% (n = 4) of the patients had at least one abnormal parasympathetic and sympathetic parameters, respectively, and 37.5% (n = 6) of the patients had moderate sudomotor dysfunction.","[{'Fifty': 'O'}, {'percent': 'O'}, {'(n': 'O'}, {'=': 'O'}, {'8)': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'PsA': 'I-Entity'}, {'had': 'O'}, {'at': 'O'}, {'least': 'O'}, {'two': 'O'}, {'or': 'O'}, {'more': 'O'}, {'abnormal': 'O'}, {'CAN': 'O'}, {'parasympathetic': 'O'}, {'dysfunction;': 'O'}, {'of': 'O'}, {'these,': 'O'}, {'18.75%': 'O'}, {'(n': 'O'}, {'=': 'O'}, {'3)': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'abnormal': 'O'}, {'parasympathetic': 'I-Entity'}, {'and': 'I-Entity'}, {'sympathetic': 'I-Entity'}, {'dysfunction,': 'I-Entity'}, {'68.7%': 'O'}]"
Studies on animal models have reaffirmed that hCG treatment mimics the benefits of pregnancy.,"[{'Studies': 'O'}, {'on': 'O'}, {'animal': 'O'}, {'models': 'O'}, {'have': 'O'}, {'reaffirmed': 'O'}, {'that': 'O'}, {'hCG': 'O'}, {'treatment': 'O'}, {'mimics': 'O'}, {'the': 'O'}, {'benefits': 'O'}, {'of': 'O'}, {'pregnancy.': 'O'}]"
"Sjogren syndrome (SS), although commonly associated with xerostomia and xerophthalmia, can present with extraglandular manifestations that make definitive diagnosis difficult.","[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'although': 'O'}, {'commonly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'xerostomia': 'I-Entity'}, {'and': 'O'}, {'xerophthalmia,': 'I-Entity'}, {'can': 'O'}, {'present': 'O'}, {'with': 'O'}, {'extraglandular': 'O'}, {'manifestations': 'O'}, {'that': 'O'}, {'make': 'O'}, {'definitive': 'O'}, {'diagnosis': 'O'}, {'difficult.': 'O'}]"
Tests showed positive antiphospholipid antibodies and the diagnosis of secondary antiphospholipid syndrome was made.,"[{'Tests': 'O'}, {'showed': 'O'}, {'positive': 'O'}, {'antiphospholipid': 'O'}, {'antibodies': 'O'}, {'and': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'secondary': 'B-Entity'}, {'antiphospholipid': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'was': 'O'}, {'made.': 'O'}]"
A latent Sjogrens syndrome can lead to a wide variety of focal brain MRI abnormalities and should be evoked when the etiology is not clear.2009 Oct 6.calcification in the chest wall in a patient with rheumatoid overlap syndrome.,"[{'A': 'O'}, {'latent': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'can': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'a': 'O'}, {'wide': 'O'}, {'variety': 'O'}, {'of': 'O'}, {'focal': 'O'}, {'brain': 'B-Entity'}, {'MRI': 'I-Entity'}, {'abnormalities': 'I-Entity'}, {'and': 'O'}, {'should': 'O'}, {'be': 'O'}, {'evoked': 'O'}, {'when': 'O'}, {'the': 'O'}, {'etiology': 'O'}, {'is': 'O'}, {'not': 'O'}, {'clear.2009': 'O'}, {'Oct': 'O'}, {'6.calcification': 'O'}, {'in': 'O'}, {'the': 'O'}, {'chest': 'O'}, {'wall': 'O'}, {'in': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'rheumatoid': 'B-Entity'}, {'overlap': 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
Sicca symptoms and/or recurrent parotid gland swelling are often accompanied by fatigue.,"[{'Sicca': 'I-Entity'}, {'symptoms': 'O'}, {'and/or': 'O'}, {'recurrent': 'O'}, {'parotid': 'B-Entity'}, {'gland': 'I-Entity'}, {'swelling': 'I-Entity'}, {'are': 'O'}, {'often': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'fatigue.': 'I-Entity'}]"
"Primary Sjogrens syndrome can present with variable central nervous system signs, which may precede the classic sicca symptoms.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'can': 'O'}, {'present': 'O'}, {'with': 'O'}, {'variable': 'O'}, {'central': 'O'}, {'nervous': 'O'}, {'system': 'O'}, {'signs,': 'O'}, {'which': 'O'}, {'may': 'O'}, {'precede': 'O'}, {'the': 'O'}, {'classic': 'O'}, {'sicca': 'B-Entity'}, {'symptoms.': 'O'}]"
"Distal renal tubular acidosis is a rare complication of several autoimmune diseases such as systemic lupus erythematosus, Sjogrens syndrome, and Hashimoto thyroiditis.","[{'Distal': 'O'}, {'renal': 'O'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'several': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'O'}, {'such': 'O'}, {'as': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'Hashimoto': 'B-Entity'}, {'thyroiditis.': 'I-Entity'}]"
"To evaluate the efficacy and safety of a novel topical cyclosporin A 0.05% nanoemulsion in comparison with a conventional emulsion in primary Sjogrens syndrome dry eyes.Prospective, randomized, double-blinded study was conducted.Corneal and conjunctival staining score was improved in both groups, with a faster change noted in the nanoemulsion group at 12 weeks (p < 0.05).","[{'To': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'safety': 'O'}, {'of': 'O'}, {'a': 'O'}, {'novel': 'O'}, {'topical': 'O'}, {'cyclosporin': 'B-Entity'}, {'A': 'I-Entity'}, {'0.05%': 'O'}, {'nanoemulsion': 'O'}, {'in': 'O'}, {'comparison': 'O'}, {'with': 'O'}, {'a': 'O'}, {'conventional': 'O'}, {'emulsion': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'dry': 'B-Entity'}, {'eyes.Prospective,': 'I-Entity'}, {'randomized,': 'O'}, {'double-blinded': 'O'}, {'study': 'O'}, {'was': 'O'}, {'conducted.Corneal': 'O'}, {'and': 'O'}]"
Mesenteric inflammatory venoocclusive disease is an uncommon cause of intestinal ischemia.,"[{'Mesenteric': 'O'}, {'inflammatory': 'B-Entity'}, {'venoocclusive': 'I-Entity'}, {'disease': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'uncommon': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'intestinal': 'B-Entity'}, {'ischemia.': 'I-Entity'}]"
"Non-obese diabetic (NOD) mice are well-established models of independently developing spontaneous autoimmune diseases, Sjogrens syndrome (SS) and type 1 diabetes (T1D).","[{'Non-obese': 'O'}, {'diabetic': 'I-Entity'}, {'(NOD)': 'O'}, {'mice': 'O'}, {'are': 'O'}, {'well-established': 'O'}, {'models': 'O'}, {'of': 'O'}, {'independently': 'O'}, {'developing': 'O'}, {'spontaneous': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'and': 'O'}, {'type': 'B-Entity'}, {'1': 'I-Entity'}, {'diabetes': 'I-Entity'}, {'(T1D).': 'O'}]"
Distal Renal Tubular Acidosis was identified in all.,"[{'Distal': 'B-Entity'}, {'Renal': 'I-Entity'}, {'Tubular': 'I-Entity'}, {'Acidosis': 'I-Entity'}, {'was': 'O'}, {'identified': 'O'}, {'in': 'O'}, {'all.': 'O'}]"
"Mucus III has been proven to be an objective diagnostic tool for patients with serious dry mouth, such as in patients with Sjogren's syndrome.","[{'Mucus': 'O'}, {'III': 'O'}, {'has': 'O'}, {'been': 'O'}, {'proven': 'O'}, {'to': 'O'}, {'be': 'O'}, {'an': 'O'}, {'objective': 'O'}, {'diagnostic': 'O'}, {'tool': 'O'}, {'for': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'serious': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"Most cases of pulmonary amyloidosis involve multiple nodules; solitary pulmonary nodular amyloidosis, as an associated condition of Sjogrens syndrome, is very rare.In our report, we present the case of an 80-year-old female with Sjogrens syndrome who was incidentally found to have a small solitary pulmonary nodule.","[{'Most': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'pulmonary': 'B-Entity'}, {'amyloidosis': 'I-Entity'}, {'involve': 'O'}, {'multiple': 'O'}, {'nodules;': 'O'}, {'solitary': 'O'}, {'pulmonary': 'O'}, {'nodular': 'O'}, {'amyloidosis,': 'I-Entity'}, {'as': 'O'}, {'an': 'O'}, {'associated': 'O'}, {'condition': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'is': 'O'}, {'very': 'O'}, {'rare.In': 'O'}, {'our': 'O'}, {'report,': 'O'}, {'we': 'O'}, {'present': 'O'}, {'the': 'O'}, {'case': 'O'}, {'of': 'O'}, {'an': 'O'}, {'80-year-old': 'O'}, {'female': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'who': 'O'}, {'was': 'O'}, {'incidentally': 'O'}]"
"The findings from this case suggest that DAH can occur as a pulmonary manifestation of SjS as well as other connective tissue diseases or vasculitis.y-tomita@space.ocn.ne.jp1.of ""Profile of Fatigue and Discomfort - Sicca Symptoms Inventory (short form) (PROFAD-SSI-SF)"".","[{'The': 'O'}, {'findings': 'O'}, {'from': 'O'}, {'this': 'O'}, {'case': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'DAH': 'I-Entity'}, {'can': 'O'}, {'occur': 'O'}, {'as': 'O'}, {'a': 'O'}, {'pulmonary': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'SjS': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'other': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'or': 'O'}, {'vasculitis.y-tomita@space.ocn.ne.jp1.of': 'I-Entity'}, {'""Profile': 'O'}, {'of': 'O'}, {'Fatigue': 'I-Entity'}, {'and': 'O'}]"
"IPL treatment has excellent results regarding both: dry eye disease symptoms improvement and in office objective tests such as tBUT, Schirmer test and Van Bijsterveld score; IPL could be considered as an effective adjunct for dry eye disease.S.L.U.","[{'IPL': 'I-Entity'}, {'treatment': 'O'}, {'has': 'O'}, {'excellent': 'O'}, {'results': 'O'}, {'regarding': 'O'}, {'both:': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease': 'I-Entity'}, {'symptoms': 'O'}, {'improvement': 'O'}, {'and': 'O'}, {'in': 'O'}, {'office': 'O'}, {'objective': 'O'}, {'tests': 'O'}, {'such': 'O'}, {'as': 'O'}, {'tBUT,': 'O'}, {'Schirmer': 'O'}, {'test': 'O'}, {'and': 'O'}, {'Van': 'O'}, {'Bijsterveld': 'O'}, {'score;': 'O'}, {'IPL': 'I-Entity'}, {'could': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'as': 'O'}, {'an': 'O'}, {'effective': 'O'}, {'adjunct': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease.S.L.U.': 'I-Entity'}]"
An expert panel identified 52 functional limitation items.,"[{'An': 'O'}, {'expert': 'O'}, {'panel': 'O'}, {'identified': 'O'}, {'52': 'O'}, {'functional': 'B-Entity'}, {'limitation': 'I-Entity'}, {'items.': 'O'}]"
"However, laboratory inflammatory and serological features were poorly associated with PFT results in patients with pSS.","[{'However,': 'O'}, {'laboratory': 'O'}, {'inflammatory': 'O'}, {'and': 'O'}, {'serological': 'O'}, {'features': 'O'}, {'were': 'O'}, {'poorly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'PFT': 'O'}, {'results': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS.': 'I-Entity'}]"
"Moreover, in recent years a growing interest has been focused on severe organ involvement such as pulmonary arterial hypertension and interstitial lung disease which can accrue during the long-term follow-up and can still significantly influence disease prognosis.","[{'Moreover,': 'O'}, {'in': 'O'}, {'recent': 'O'}, {'years': 'O'}, {'a': 'O'}, {'growing': 'O'}, {'interest': 'O'}, {'has': 'O'}, {'been': 'O'}, {'focused': 'O'}, {'on': 'O'}, {'severe': 'O'}, {'organ': 'O'}, {'involvement': 'O'}, {'such': 'O'}, {'as': 'O'}, {'pulmonary': 'B-Entity'}, {'arterial': 'I-Entity'}, {'hypertension': 'I-Entity'}, {'and': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'which': 'O'}, {'can': 'O'}, {'accrue': 'O'}, {'during': 'O'}, {'the': 'O'}, {'long-term': 'O'}, {'follow-up': 'O'}, {'and': 'O'}, {'can': 'O'}, {'still': 'O'}, {'significantly': 'O'}, {'influence': 'O'}, {'disease': 'O'}, {'prognosis.': 'O'}]"
The disease mainly affects small and medium-sized blood vessels and causes vasculitis due to cryoglobulin-containing immune complexes.,"[{'The': 'O'}, {'disease': 'O'}, {'mainly': 'O'}, {'affects': 'O'}, {'small': 'O'}, {'and': 'O'}, {'medium-sized': 'O'}, {'blood': 'O'}, {'vessels': 'O'}, {'and': 'O'}, {'causes': 'O'}, {'vasculitis': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'cryoglobulin-containing': 'O'}, {'immune': 'O'}, {'complexes.': 'O'}]"
"Dysphagia, pain and eye discomfort may occur in both Sjogrens syndrome and DM1, and in this case, may have delayed the diagnosis of muscular dystrophy.permissions.","[{'Dysphagia,': 'I-Entity'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'eye': 'B-Entity'}, {'discomfort': 'I-Entity'}, {'may': 'O'}, {'occur': 'O'}, {'in': 'O'}, {'both': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'DM1,': 'I-Entity'}, {'and': 'O'}, {'in': 'O'}, {'this': 'O'}, {'case,': 'O'}, {'may': 'O'}, {'have': 'O'}, {'delayed': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'muscular': 'B-Entity'}, {'dystrophy.permissions.': 'I-Entity'}]"
The adequate use of anti-thrombotic agents resulted in a significant amelioration of pregnancy outcome in antiphospholipid syndrome.,"[{'The': 'O'}, {'adequate': 'O'}, {'use': 'O'}, {'of': 'O'}, {'anti-thrombotic': 'O'}, {'agents': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'amelioration': 'O'}, {'of': 'O'}, {'pregnancy': 'O'}, {'outcome': 'O'}, {'in': 'O'}, {'antiphospholipid': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"However, fewer studies have investigated whether the presence of thyroid diseases is associated with increased risk of developing pSS.","[{'However,': 'O'}, {'fewer': 'O'}, {'studies': 'O'}, {'have': 'O'}, {'investigated': 'O'}, {'whether': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'thyroid': 'B-Entity'}, {'diseases': 'I-Entity'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'increased': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'developing': 'O'}, {'pSS.': 'I-Entity'}]"
The results provide strong evidence that patients who received immunosuppressants are more likely to reach the treatment goals.,"[{'The': 'O'}, {'results': 'O'}, {'provide': 'O'}, {'strong': 'O'}, {'evidence': 'O'}, {'that': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'received': 'O'}, {'immunosuppressants': 'O'}, {'are': 'O'}, {'more': 'O'}, {'likely': 'O'}, {'to': 'O'}, {'reach': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'goals.': 'O'}]"
Current therapeutic options are mainly empiric and often translated by other autoimmune diseases.,"[{'Current': 'O'}, {'therapeutic': 'O'}, {'options': 'O'}, {'are': 'O'}, {'mainly': 'O'}, {'empiric': 'O'}, {'and': 'O'}, {'often': 'O'}, {'translated': 'O'}, {'by': 'O'}, {'other': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
Serum vitamin B(12) levels were determined using an enzyme-linked microtiter plate assay.,"[{'Serum': 'O'}, {'vitamin': 'B-Entity'}, {'B(12)': 'I-Entity'}, {'levels': 'O'}, {'were': 'O'}, {'determined': 'O'}, {'using': 'O'}, {'an': 'O'}, {'enzyme-linked': 'O'}, {'microtiter': 'O'}, {'plate': 'O'}, {'assay.': 'O'}]"
Improvements in the physical and mental component summary scores failed to correlate with improvements in the VAS scores.,"[{'Improvements': 'O'}, {'in': 'O'}, {'the': 'O'}, {'physical': 'O'}, {'and': 'O'}, {'mental': 'O'}, {'component': 'O'}, {'summary': 'O'}, {'scores': 'O'}, {'failed': 'O'}, {'to': 'O'}, {'correlate': 'O'}, {'with': 'O'}, {'improvements': 'O'}, {'in': 'O'}, {'the': 'O'}, {'VAS': 'O'}, {'scores.': 'O'}]"
"TMD symptoms (muscle pain on chewing, difficulty in mouth opening, arthralgia, headaches, tinnitus) were complained by 91.7% of SS patients and by 84.7% of controls (‚âà√¨‚àö¬∞(2)= 1,667 p= 0,196).","[{'TMD': 'I-Entity'}, {'symptoms': 'O'}, {'(muscle': 'O'}, {'pain': 'I-Entity'}, {'on': 'O'}, {'chewing,': 'O'}, {'difficulty': 'O'}, {'in': 'O'}, {'mouth': 'O'}, {'opening,': 'O'}, {'arthralgia,': 'I-Entity'}, {'headaches,': 'I-Entity'}, {'tinnitus)': 'I-Entity'}, {'were': 'O'}, {'complained': 'O'}, {'by': 'O'}, {'91.7%': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'by': 'O'}, {'84.7%': 'O'}, {'of': 'O'}, {'controls': 'O'}, {'(‚âà√¨‚àö¬∞(2)=': 'O'}, {'1,667': 'O'}]"
"This improvement can be attributed to increased attention to low diseases activity at the time of conception, which might reduce to the half of the risk for flare.","[{'This': 'O'}, {'improvement': 'O'}, {'can': 'O'}, {'be': 'O'}, {'attributed': 'O'}, {'to': 'O'}, {'increased': 'O'}, {'attention': 'O'}, {'to': 'O'}, {'low': 'O'}, {'diseases': 'O'}, {'activity': 'O'}, {'at': 'O'}, {'the': 'O'}, {'time': 'O'}, {'of': 'O'}, {'conception,': 'O'}, {'which': 'O'}, {'might': 'O'}, {'reduce': 'O'}, {'to': 'O'}, {'the': 'O'}, {'half': 'O'}, {'of': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'for': 'O'}, {'flare.': 'O'}]"
Diagnosis of IgG4-related disease is characterized by both elevated serum IgG4 (>135 mg/dL) and histopathological features including lymphocyte and IgG4(+) plasma cell infiltration (IgG4(+) plasma cells/IgG(+) plasma cells>40%).,"[{'Diagnosis': 'O'}, {'of': 'O'}, {'IgG4-related': 'O'}, {'disease': 'O'}, {'is': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'both': 'O'}, {'elevated': 'O'}, {'serum': 'O'}, {'IgG4': 'O'}, {'(>135': 'O'}, {'mg/dL)': 'O'}, {'and': 'O'}, {'histopathological': 'O'}, {'features': 'O'}, {'including': 'O'}, {'lymphocyte': 'O'}, {'and': 'O'}, {'IgG4(+)': 'O'}, {'plasma': 'O'}, {'cell': 'O'}, {'infiltration': 'O'}, {'(IgG4(+)': 'O'}, {'plasma': 'O'}]"
"Cysts were isolated (n=6, 28.6%) or associated with other lesions, including bronchiectasis (n=5, 23.8%), micronodules (n=5, 23.8%), ground-glass opacity (n=4, 19%) and/or air trapping (n=3, 14.3%).","[{'Cysts': 'I-Entity'}, {'were': 'O'}, {'isolated': 'O'}, {'(n=6,': 'O'}, {'28.6%)': 'O'}, {'or': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'other': 'O'}, {'lesions,': 'O'}, {'including': 'O'}, {'bronchiectasis': 'I-Entity'}, {'(n=5,': 'O'}, {'23.8%),': 'O'}, {'micronodules': 'O'}, {'(n=5,': 'O'}, {'23.8%),': 'O'}, {'ground-glass': 'B-Entity'}, {'opacity': 'I-Entity'}, {'(n=4,': 'O'}]"
"Chinese herbal medicine for strengthening qi, nourishing yin, and removing stasis could alleviate pSS disease and improve the QOL.","[{'Chinese': 'O'}, {'herbal': 'O'}, {'medicine': 'O'}, {'for': 'O'}, {'strengthening': 'O'}, {'qi,': 'O'}, {'nourishing': 'O'}, {'yin,': 'I-Entity'}, {'and': 'O'}, {'removing': 'O'}, {'stasis': 'I-Entity'}, {'could': 'O'}, {'alleviate': 'O'}, {'pSS': 'B-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'improve': 'O'}, {'the': 'O'}, {'QOL.': 'O'}]"
"Twenty-seven (31%) of the 88 patients had peripheral neuropathy as defined by loss of light touch, proprioception, or vibratory sensation.","[{'Twenty-seven': 'O'}, {'(31%)': 'O'}, {'of': 'O'}, {'the': 'O'}, {'88': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'as': 'O'}, {'defined': 'O'}, {'by': 'O'}, {'loss': 'B-Entity'}, {'of': 'I-Entity'}, {'light': 'I-Entity'}, {'touch,': 'I-Entity'}, {'proprioception,': 'I-Entity'}, {'or': 'I-Entity'}, {'vibratory': 'I-Entity'}, {'sensation.': 'I-Entity'}]"
"The study aimed to investigate the pattern of oral yeast colonization of Sjogrens syndrome patients and its correlation to salivary flow rates, age, and time of the disease progression.","[{'The': 'O'}, {'study': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'pattern': 'O'}, {'of': 'O'}, {'oral': 'O'}, {'yeast': 'O'}, {'colonization': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'its': 'O'}, {'correlation': 'O'}, {'to': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'rates,': 'O'}, {'age,': 'O'}, {'and': 'O'}, {'time': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'progression.': 'O'}]"
"Anti-NR2 antibodies in cerebrospinal fluid (CSF) were measured, and hippocampal gray matter volumes were compared between patients who were positive for and those who were negative for anti-NR2 antibodies.","[{'Anti-NR2': 'O'}, {'antibodies': 'O'}, {'in': 'O'}, {'cerebrospinal': 'O'}, {'fluid': 'O'}, {'(CSF)': 'O'}, {'were': 'O'}, {'measured,': 'O'}, {'and': 'O'}, {'hippocampal': 'O'}, {'gray': 'O'}, {'matter': 'O'}, {'volumes': 'O'}, {'were': 'O'}, {'compared': 'O'}, {'between': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'were': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'and': 'O'}, {'those': 'O'}, {'who': 'O'}, {'were': 'O'}, {'negative': 'O'}, {'for': 'O'}, {'anti-NR2': 'O'}, {'antibodies.': 'O'}]"
"Fatigue was suggested to exacerbate other ocular symptoms, posed serious physical limitations and caused psychological distress.","[{'Fatigue': 'I-Entity'}, {'was': 'O'}, {'suggested': 'O'}, {'to': 'O'}, {'exacerbate': 'O'}, {'other': 'O'}, {'ocular': 'B-Entity'}, {'symptoms,': 'I-Entity'}, {'posed': 'O'}, {'serious': 'O'}, {'physical': 'O'}, {'limitations': 'O'}, {'and': 'O'}, {'caused': 'O'}, {'psychological': 'O'}, {'distress.': 'I-Entity'}]"
"For submandibular glands, the mean SWV ¬¨¬®¬¨¬± SD values were 2.25 ¬¨¬®¬¨¬± 0.34 m/s in patients with early-stage primary Sjogren, 1.84 ¬¨¬®¬¨¬± 0.20 m/s in patients without primary Sjogren syndrome, and 1.82 ¬¨¬®¬¨¬± 0.27 m/s in healthy controls (P< .001).","[{'For': 'O'}, {'submandibular': 'O'}, {'glands,': 'O'}, {'the': 'O'}, {'mean': 'O'}, {'SWV': 'O'}, {'¬¨¬®¬¨¬±': 'O'}, {'SD': 'O'}, {'values': 'O'}, {'were': 'O'}, {'2.25': 'O'}, {'¬¨¬®¬¨¬±': 'O'}, {'0.34': 'O'}, {'m/s': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'early-stage': 'O'}, {'primary': 'B-Entity'}, {'Sjogren,': 'I-Entity'}, {'1.84': 'O'}, {'¬¨¬®¬¨¬±': 'O'}]"
"Based on our survey, eight patients were identified with IgG4-RD.","[{'Based': 'O'}, {'on': 'O'}, {'our': 'O'}, {'survey,': 'O'}, {'eight': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'identified': 'O'}, {'with': 'O'}, {'IgG4-RD.': 'O'}]"
Diffuse cystic lung disease (DCLD) is a group of heterogeneous diseases that present as diffuse cystic changes in the lung on computed tomography of the chest.,"[{'Diffuse': 'B-Entity'}, {'cystic': 'I-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(DCLD)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'group': 'O'}, {'of': 'O'}, {'heterogeneous': 'O'}, {'diseases': 'O'}, {'that': 'O'}, {'present': 'O'}, {'as': 'O'}, {'diffuse': 'O'}, {'cystic': 'B-Entity'}, {'changes': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'lung': 'O'}, {'on': 'O'}, {'computed': 'O'}, {'tomography': 'O'}, {'of': 'O'}, {'the': 'O'}, {'chest.': 'O'}]"
"The inflammatory infiltrate showed the most dramatic differences in gene expression and contained up-regulated genes associated with T-cells, natural killer, dendritic and basophils/mast cells.","[{'The': 'O'}, {'inflammatory': 'O'}, {'infiltrate': 'O'}, {'showed': 'O'}, {'the': 'O'}, {'most': 'O'}, {'dramatic': 'O'}, {'differences': 'O'}, {'in': 'O'}, {'gene': 'O'}, {'expression': 'O'}, {'and': 'O'}, {'contained': 'O'}, {'up-regulated': 'O'}, {'genes': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'T-cells,': 'O'}, {'natural': 'O'}, {'killer,': 'O'}, {'dendritic': 'O'}, {'and': 'O'}, {'basophils/mast': 'O'}, {'cells.': 'O'}]"
"Sjogren patients can suffer from debilitating fatigue, sicca symptoms, and autonomic findings; as such manifestations can be complications of various neuropathic agents, neurologists should understand how to minimize such iatrogenic complications.","[{'Sjogren': 'I-Entity'}, {'patients': 'O'}, {'can': 'O'}, {'suffer': 'O'}, {'from': 'O'}, {'debilitating': 'O'}, {'fatigue,': 'I-Entity'}, {'sicca': 'B-Entity'}, {'symptoms,': 'O'}, {'and': 'O'}, {'autonomic': 'O'}, {'findings;': 'O'}, {'as': 'O'}, {'such': 'O'}, {'manifestations': 'O'}, {'can': 'O'}, {'be': 'O'}, {'complications': 'O'}, {'of': 'O'}, {'various': 'O'}, {'neuropathic': 'O'}, {'agents,': 'O'}, {'neurologists': 'O'}, {'should': 'O'}, {'understand': 'O'}, {'how': 'O'}, {'to': 'O'}, {'minimize': 'O'}, {'such': 'O'}, {'iatrogenic': 'O'}, {'complications.': 'O'}]"
Improvement in mouth/throat pain was noted.,"[{'Improvement': 'O'}, {'in': 'O'}, {'mouth/throat': 'B-Entity'}, {'pain': 'I-Entity'}, {'was': 'O'}, {'noted.': 'O'}]"
"The condition can be associated with Sjogrens syndrome (SS), which in turn may predispose the affected patient to the development of malignant lymphoma.","[{'The': 'O'}, {'condition': 'O'}, {'can': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'which': 'O'}, {'in': 'O'}, {'turn': 'O'}, {'may': 'O'}, {'predispose': 'O'}, {'the': 'O'}, {'affected': 'O'}, {'patient': 'O'}, {'to': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'malignant': 'B-Entity'}, {'lymphoma.': 'I-Entity'}]"
"Although patients with pSS reported abdominal discomfort more frequently than healthy control subjects did, such symptoms were not associated with organic GI disease or elevated FC levels.","[{'Although': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'reported': 'O'}, {'abdominal': 'B-Entity'}, {'discomfort': 'I-Entity'}, {'more': 'O'}, {'frequently': 'O'}, {'than': 'O'}, {'healthy': 'O'}, {'control': 'O'}, {'subjects': 'O'}, {'did,': 'O'}, {'such': 'O'}, {'symptoms': 'O'}, {'were': 'O'}, {'not': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'organic': 'B-Entity'}, {'GI': 'I-Entity'}, {'disease': 'I-Entity'}, {'or': 'O'}, {'elevated': 'O'}, {'FC': 'I-Entity'}, {'levels.': 'O'}]"
"When potential associations of the Dry Eye Workshop Study scores and osmolarity scores with the Eular Sjogrens syndrome disease activity index scores were evaluated, the results were found to be statistically significant (p=0.001, p=0.001 respectively).","[{'When': 'O'}, {'potential': 'O'}, {'associations': 'O'}, {'of': 'O'}, {'the': 'O'}, {'Dry': 'B-Entity'}, {'Eye': 'I-Entity'}, {'Workshop': 'O'}, {'Study': 'O'}, {'scores': 'O'}, {'and': 'O'}, {'osmolarity': 'O'}, {'scores': 'O'}, {'with': 'O'}, {'the': 'O'}, {'Eular': 'O'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'disease': 'O'}, {'activity': 'O'}, {'index': 'O'}, {'scores': 'O'}, {'were': 'O'}, {'evaluated,': 'O'}, {'the': 'O'}, {'results': 'O'}, {'were': 'O'}, {'found': 'O'}, {'to': 'O'}, {'be': 'O'}, {'statistically': 'O'}, {'significant': 'O'}, {'(p=0.001,': 'O'}, {'p=0.001': 'O'}, {'respectively).': 'O'}]"
Primary pulmonary disease is bronchocentric and lacks extrathoracic infection consistent with impaired airway surface defenses.,"[{'Primary': 'B-Entity'}, {'pulmonary': 'I-Entity'}, {'disease': 'I-Entity'}, {'is': 'O'}, {'bronchocentric': 'O'}, {'and': 'O'}, {'lacks': 'O'}, {'extrathoracic': 'B-Entity'}, {'infection': 'I-Entity'}, {'consistent': 'O'}, {'with': 'O'}, {'impaired': 'O'}, {'airway': 'O'}, {'surface': 'O'}, {'defenses.': 'O'}]"
"The results showed that recurrent eyes, the worst visual acuities of onset less than 0.1 were independent risk factors of visual impairment (visual activity <0.1), according to at least six months' follow-up of all NMOSD-SS patients (OR=6.410 and 9.434, respectively, P<0.05).","[{'The': 'O'}, {'results': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'recurrent': 'O'}, {'eyes,': 'O'}, {'the': 'O'}, {'worst': 'O'}, {'visual': 'O'}, {'acuities': 'O'}, {'of': 'O'}, {'onset': 'O'}, {'less': 'O'}, {'than': 'O'}, {'0.1': 'O'}, {'were': 'O'}, {'independent': 'O'}, {'risk': 'O'}, {'factors': 'O'}, {'of': 'O'}, {'visual': 'B-Entity'}, {'impairment': 'I-Entity'}, {'(visual': 'O'}, {'activity': 'O'}, {'<0.1),': 'O'}, {'according': 'O'}, {'to': 'O'}, {'at': 'O'}, {'least': 'O'}, {'six': 'O'}, {""months'"": 'O'}, {'follow-up': 'O'}, {'of': 'O'}, {'all': 'O'}, {'NMOSD-SS': 'I-Entity'}, {'patients': 'O'}, {'(OR=6.410': 'O'}]"
Neurologic symptoms frequently present as peripheral neuropathy due to small vessel vasculitis.,"[{'Neurologic': 'O'}, {'symptoms': 'O'}, {'frequently': 'O'}, {'present': 'O'}, {'as': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'small': 'O'}, {'vessel': 'O'}, {'vasculitis.': 'I-Entity'}]"
"Fatigue is prevalent in primary Sjogrens syndrome (pSS), and contributes to the considerably reduced health related quality of life in this disease.","[{'Fatigue': 'I-Entity'}, {'is': 'O'}, {'prevalent': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS),': 'O'}, {'and': 'O'}, {'contributes': 'O'}, {'to': 'O'}, {'the': 'O'}, {'considerably': 'O'}, {'reduced': 'O'}, {'health': 'O'}, {'related': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life': 'O'}, {'in': 'O'}, {'this': 'O'}, {'disease.': 'O'}]"
"Central retinal artery occlusion and ischemic optic neuropathy could be excluded, and a¬¨¬®‚Äö√Ñ‚Ä†diagnosis of PSS was made.","[{'Central': 'B-Entity'}, {'retinal': 'B-Entity'}, {'artery': 'I-Entity'}, {'occlusion': 'I-Entity'}, {'and': 'O'}, {'ischemic': 'B-Entity'}, {'optic': 'I-Entity'}, {'neuropathy': 'I-Entity'}, {'could': 'O'}, {'be': 'O'}, {'excluded,': 'O'}, {'and': 'O'}, {'a¬¨¬®‚Äö√Ñ‚Ä†diagnosis': 'O'}, {'of': 'O'}, {'PSS': 'I-Entity'}, {'was': 'O'}, {'made.': 'O'}]"
Interstitial lung disease and pulmonary hypertension determine the prognosis in collagen vascular disease patients.,"[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'pulmonary': 'B-Entity'}, {'hypertension': 'I-Entity'}, {'determine': 'O'}, {'the': 'O'}, {'prognosis': 'O'}, {'in': 'O'}, {'collagen': 'B-Entity'}, {'vascular': 'I-Entity'}, {'disease': 'I-Entity'}, {'patients.': 'O'}]"
"Obstetricians should be aware of the symptoms and immunological examination results to distinguish pre-eclampsia and underlying SLE for optimal pregnancy outcomes.reserved.Hospital, Tianjin 300052, China.Hospital, Tianjin 300052, China.Hospital, Tianjin 300052, China.Hospital, Tianjin 300052, China.Hospital, Tianjin 300052, China.Hospital, Tianjin 300052, China.Hospital, Tianjin 300052, China.","[{'Obstetricians': 'O'}, {'should': 'O'}, {'be': 'O'}, {'aware': 'O'}, {'of': 'O'}, {'the': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'immunological': 'O'}, {'examination': 'O'}, {'results': 'O'}, {'to': 'O'}, {'distinguish': 'O'}, {'pre-eclampsia': 'I-Entity'}, {'and': 'O'}, {'underlying': 'O'}, {'SLE': 'I-Entity'}, {'for': 'O'}, {'optimal': 'O'}, {'pregnancy': 'O'}, {'outcomes.reserved.Hospital,': 'O'}, {'Tianjin': 'O'}, {'300052,': 'O'}, {'China.Hospital,': 'O'}, {'Tianjin': 'O'}, {'300052,': 'O'}, {'China.Hospital,': 'O'}, {'Tianjin': 'O'}]"
The patient's pulmonary lesions have been successfully treated and remission has been maintained for over three years with corticosteroid treatment alone.,"[{'The': 'O'}, {""patient's"": 'O'}, {'pulmonary': 'B-Entity'}, {'lesions': 'I-Entity'}, {'have': 'O'}, {'been': 'O'}, {'successfully': 'O'}, {'treated': 'O'}, {'and': 'O'}, {'remission': 'O'}, {'has': 'O'}, {'been': 'O'}, {'maintained': 'O'}, {'for': 'O'}, {'over': 'O'}, {'three': 'O'}, {'years': 'O'}, {'with': 'O'}, {'corticosteroid': 'O'}, {'treatment': 'O'}, {'alone.': 'O'}]"
This result suggests that PSS may be one of the causes of musculoskeletal pain that can be seen in patients with PSS.,"[{'This': 'O'}, {'result': 'O'}, {'suggests': 'O'}, {'that': 'O'}, {'PSS': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'musculoskeletal': 'B-Entity'}, {'pain': 'I-Entity'}, {'that': 'O'}, {'can': 'O'}, {'be': 'O'}, {'seen': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'PSS.': 'I-Entity'}]"
Diagnosis is based on clinical findings and skin or synovial biopsy results.,"[{'Diagnosis': 'O'}, {'is': 'O'}, {'based': 'O'}, {'on': 'O'}, {'clinical': 'O'}, {'findings': 'O'}, {'and': 'O'}, {'skin': 'O'}, {'or': 'O'}, {'synovial': 'O'}, {'biopsy': 'O'}, {'results.': 'O'}]"
"Interstitial lung disease, pulmonary hypertension or both are found most commonly in systemic sclerosis.","[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease,': 'I-Entity'}, {'pulmonary': 'B-Entity'}, {'hypertension': 'I-Entity'}, {'or': 'O'}, {'both': 'O'}, {'are': 'O'}, {'found': 'O'}, {'most': 'O'}, {'commonly': 'O'}, {'in': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis.': 'I-Entity'}]"
Further investigation led to the diagnosis of primary Sjogrens syndrome.,"[{'Further': 'O'}, {'investigation': 'O'}, {'led': 'O'}, {'to': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
Management strategies aimed at these aspects should therefore be included in future trials for treatment of fatigue in pSS.Sweden.,"[{'Management': 'O'}, {'strategies': 'O'}, {'aimed': 'O'}, {'at': 'O'}, {'these': 'O'}, {'aspects': 'O'}, {'should': 'O'}, {'therefore': 'O'}, {'be': 'O'}, {'included': 'O'}, {'in': 'O'}, {'future': 'O'}, {'trials': 'O'}, {'for': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'fatigue': 'I-Entity'}, {'in': 'O'}, {'pSS.Sweden.': 'O'}]"
"Here, we show that mice lacking the transcriptional regulator I‚âà√≠‚Äö√†¬¥B-‚âà√≠‚Äö√†√á developed SS-like inflammation characterized by lymphocyte-infiltrated dacryoadenitis and SS-associated autoantibodies.","[{'Here,': 'O'}, {'we': 'O'}, {'show': 'O'}, {'that': 'O'}, {'mice': 'O'}, {'lacking': 'O'}, {'the': 'O'}, {'transcriptional': 'O'}, {'regulator': 'O'}, {'I‚âà√≠‚Äö√†¬¥B-‚âà√≠‚Äö√†√á': 'O'}, {'developed': 'O'}, {'SS-like': 'I-Entity'}, {'inflammation': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'lymphocyte-infiltrated': 'O'}, {'dacryoadenitis': 'I-Entity'}, {'and': 'O'}, {'SS-associated': 'I-Entity'}]"
"Here, we employed the oral moisture meter Mucus III to evaluate dry mouth in head and neck tumor patients before and after they underwent radiotherapy.","[{'Here,': 'O'}, {'we': 'O'}, {'employed': 'O'}, {'the': 'O'}, {'oral': 'O'}, {'moisture': 'O'}, {'meter': 'O'}, {'Mucus': 'O'}, {'III': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'in': 'O'}, {'head': 'B-Entity'}, {'and': 'I-Entity'}, {'neck': 'I-Entity'}, {'tumor': 'I-Entity'}, {'patients': 'O'}, {'before': 'O'}, {'and': 'O'}, {'after': 'O'}, {'they': 'O'}, {'underwent': 'O'}, {'radiotherapy.': 'O'}]"
"Sjogrens syndrome constituted the most common SG aetiology (8/26), followed by idiopathic cases (7/26) and paraneoplasia (5/26).","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'constituted': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'SG': 'O'}, {'aetiology': 'O'}, {'(8/26),': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'idiopathic': 'O'}, {'cases': 'O'}, {'(7/26)': 'O'}, {'and': 'O'}, {'paraneoplasia': 'I-Entity'}, {'(5/26).': 'O'}]"
"In a cohort of 1320 patients, 17 (1.28%) presented muscular weakness [in some cases myalgias (7/17, 41.1%)], accompanied by increased CPK [13/17, (76.4%)] and/or abnormal EMG [13/14, (92.8%)].","[{'In': 'O'}, {'a': 'O'}, {'cohort': 'O'}, {'of': 'O'}, {'1320': 'O'}, {'patients,': 'O'}, {'17': 'O'}, {'(1.28%)': 'O'}, {'presented': 'O'}, {'muscular': 'B-Entity'}, {'weakness': 'I-Entity'}, {'[in': 'O'}, {'some': 'O'}, {'cases': 'O'}, {'myalgias': 'I-Entity'}, {'(7/17,': 'O'}, {'41.1%)],': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'increased': 'O'}, {'CPK': 'O'}, {'[13/17,': 'O'}, {'(76.4%)]': 'O'}, {'and/or': 'O'}, {'abnormal': 'O'}, {'EMG': 'O'}]"
Purtscher-like retinopathy is likely ascribable to the formation of microemboli that results in retinal vascular occlusion and microvascular infarcts.,"[{'Purtscher-like': 'O'}, {'retinopathy': 'I-Entity'}, {'is': 'O'}, {'likely': 'O'}, {'ascribable': 'O'}, {'to': 'O'}, {'the': 'O'}, {'formation': 'O'}, {'of': 'O'}, {'microemboli': 'O'}, {'that': 'O'}, {'results': 'O'}, {'in': 'O'}, {'retinal': 'B-Entity'}, {'vascular': 'I-Entity'}, {'occlusion': 'I-Entity'}, {'and': 'O'}, {'microvascular': 'B-Entity'}, {'infarcts.': 'I-Entity'}]"
The results of this study suggest that HCQ may alleviate symptoms and signs of dry eye in pSS and decreases tear fluid BAFF levels.suleyavuz@gmail.com23.syndrome.,"[{'The': 'O'}, {'results': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'HCQ': 'I-Entity'}, {'may': 'O'}, {'alleviate': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'signs': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'decreases': 'O'}, {'tear': 'O'}, {'fluid': 'O'}, {'BAFF': 'O'}, {'levels.suleyavuz@gmail.com23.syndrome.': 'O'}]"
We report four adult cases of atopic dermatitis (AD) complicated by Sjogrens syndrome (SS).,"[{'We': 'O'}, {'report': 'O'}, {'four': 'O'}, {'adult': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'atopic': 'B-Entity'}, {'dermatitis': 'I-Entity'}, {'(AD)': 'O'}, {'complicated': 'O'}, {'by': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
"The results suggest that the disease per se is involved in the development of COPD in pSS.Respiratory Medicine, and the Department of Clinical Physiology, Sk‚Äö√†√∂‚Äö√Ñ¬¢ne University Hospital, Malm‚Äö√†√∂‚Äö√†√á; Department of Rheumatology, Sk‚Äö√†√∂‚Äö√Ñ¬¢ne University Hospital, Lund, Sweden.A.M.","[{'The': 'O'}, {'results': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'per': 'O'}, {'se': 'O'}, {'is': 'O'}, {'involved': 'O'}, {'in': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'COPD': 'I-Entity'}, {'in': 'O'}, {'pSS.Respiratory': 'O'}, {'Medicine,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'Department': 'O'}, {'of': 'O'}, {'Clinical': 'O'}, {'Physiology,': 'O'}, {'Sk‚Äö√†√∂‚Äö√Ñ¬¢ne': 'O'}, {'University': 'O'}, {'Hospital,': 'O'}, {'Malm‚Äö√†√∂‚Äö√†√á;': 'O'}]"
"Due to the rarity of this disease, patients are frequently misdiagnosed as having primary myelofibrosis, the most common form of bone-marrow fibrosis.","[{'Due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'rarity': 'O'}, {'of': 'O'}, {'this': 'O'}, {'disease,': 'O'}, {'patients': 'O'}, {'are': 'O'}, {'frequently': 'O'}, {'misdiagnosed': 'O'}, {'as': 'O'}, {'having': 'O'}, {'primary': 'B-Entity'}, {'myelofibrosis,': 'I-Entity'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'form': 'O'}, {'of': 'O'}, {'bone-marrow': 'B-Entity'}, {'fibrosis.': 'I-Entity'}]"
"In comparison, systemic disease activity improved 5.5 points and 73% at group level, and 22 (79%) patients reached ESSDAI<5 representing low disease activity.","[{'In': 'O'}, {'comparison,': 'O'}, {'systemic': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'improved': 'O'}, {'5.5': 'O'}, {'points': 'O'}, {'and': 'O'}, {'73%': 'O'}, {'at': 'O'}, {'group': 'O'}, {'level,': 'O'}, {'and': 'O'}, {'22': 'O'}, {'(79%)': 'O'}, {'patients': 'O'}, {'reached': 'O'}, {'ESSDAI<5': 'O'}, {'representing': 'O'}, {'low': 'O'}, {'disease': 'O'}, {'activity.': 'O'}]"
"Sjogren patients can suffer from severe neuropathic pain, with small-fiber neuropathy causing lancinating or burning pain which can disproportionately affect the proximal torso or extremities, and the face (ie, in a ""non-length-dependent distribution"").","[{'Sjogren': 'I-Entity'}, {'patients': 'O'}, {'can': 'O'}, {'suffer': 'O'}, {'from': 'O'}, {'severe': 'O'}, {'neuropathic': 'B-Entity'}, {'pain,': 'I-Entity'}, {'with': 'O'}, {'small-fiber': 'O'}, {'neuropathy': 'I-Entity'}, {'causing': 'O'}, {'lancinating': 'O'}, {'or': 'O'}, {'burning': 'O'}, {'pain': 'I-Entity'}, {'which': 'O'}, {'can': 'O'}, {'disproportionately': 'O'}, {'affect': 'O'}, {'the': 'O'}, {'proximal': 'O'}, {'torso': 'O'}, {'or': 'O'}, {'extremities,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'face': 'O'}, {'(ie,': 'O'}, {'in': 'O'}, {'a': 'O'}, {'""non-length-dependent': 'O'}, {'distribution"").': 'O'}]"
These effects were observed even after adjustment for comorbidities associated with fatigue or medications associated with drowsiness.,"[{'These': 'O'}, {'effects': 'O'}, {'were': 'O'}, {'observed': 'O'}, {'even': 'O'}, {'after': 'O'}, {'adjustment': 'O'}, {'for': 'O'}, {'comorbidities': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'fatigue': 'I-Entity'}, {'or': 'O'}, {'medications': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'drowsiness.': 'O'}]"
Acute systemic inflammation and chronic systemic vasculitis are associated with endothelial dysfunction and atherosclerotic plaque formation.,"[{'Acute': 'O'}, {'systemic': 'O'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'chronic': 'O'}, {'systemic': 'O'}, {'vasculitis': 'I-Entity'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'endothelial': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'and': 'O'}, {'atherosclerotic': 'B-Entity'}, {'plaque': 'I-Entity'}, {'formation.': 'O'}]"
"The underlying conditions were the following: giant cell arteritis (n=13 cases); isolated polymyalgia rheumatica (PMR) (n=11); Sjogrens syndrome (n=2), Takayasu arteritis (n= 1); sarcoidosis (n=1), ulcerative colitis (n=1), psoriatic arthritis (n=1), and large-vessel vasculitis that also involved the aorta (n=2).","[{'The': 'O'}, {'underlying': 'O'}, {'conditions': 'O'}, {'were': 'O'}, {'the': 'O'}, {'following:': 'O'}, {'giant': 'B-Entity'}, {'cell': 'I-Entity'}, {'arteritis': 'I-Entity'}, {'(n=13': 'O'}, {'cases);': 'O'}, {'isolated': 'O'}, {'polymyalgia': 'B-Entity'}, {'rheumatica': 'I-Entity'}, {'(PMR)': 'O'}, {'(n=11);': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(n=2),': 'O'}, {'Takayasu': 'B-Entity'}, {'arteritis': 'I-Entity'}, {'(n=': 'O'}, {'1);': 'O'}]"
A high incidence of extraglandular manifestations was identified: 50% had interstitial lung disease and/or peripheral neuropathy.,"[{'A': 'O'}, {'high': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'extraglandular': 'O'}, {'manifestations': 'O'}, {'was': 'O'}, {'identified:': 'O'}, {'50%': 'O'}, {'had': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'and/or': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy.': 'I-Entity'}]"
There needs to be a paradigm shift in which eye care providers and rheumatologists become more familiar with various SS-related extraglandular ocular manifestations.,"[{'There': 'O'}, {'needs': 'O'}, {'to': 'O'}, {'be': 'O'}, {'a': 'O'}, {'paradigm': 'O'}, {'shift': 'O'}, {'in': 'O'}, {'which': 'O'}, {'eye': 'O'}, {'care': 'O'}, {'providers': 'O'}, {'and': 'O'}, {'rheumatologists': 'O'}, {'become': 'O'}, {'more': 'O'}, {'familiar': 'O'}, {'with': 'O'}, {'various': 'O'}, {'SS-related': 'I-Entity'}, {'extraglandular': 'O'}, {'ocular': 'O'}, {'manifestations.': 'O'}]"
"Edema, fever, and liver involvement occurred significantly more frequently in pSS patients with AIHA than those without AIHA (p‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.035, p‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.029, p‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.024, respectively).","[{'Edema,': 'I-Entity'}, {'fever,': 'I-Entity'}, {'and': 'O'}, {'liver': 'B-Entity'}, {'involvement': 'O'}, {'occurred': 'O'}, {'significantly': 'O'}, {'more': 'O'}, {'frequently': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'AIHA': 'I-Entity'}, {'than': 'O'}, {'those': 'O'}, {'without': 'O'}, {'AIHA': 'I-Entity'}, {'(p‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.035,': 'O'}]"
Radioactive iodine ((131)I) is used effectively for the treatment of differentiated thyroid cancers.,"[{'Radioactive': 'B-Entity'}, {'iodine': 'I-Entity'}, {'((131)I)': 'O'}, {'is': 'O'}, {'used': 'O'}, {'effectively': 'O'}, {'for': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'differentiated': 'B-Entity'}, {'thyroid': 'I-Entity'}, {'cancers.': 'I-Entity'}]"
Neurological symptoms may precede the diagnosis of SS by up to 2 years in about 80% of patients.,"[{'Neurological': 'O'}, {'symptoms': 'O'}, {'may': 'O'}, {'precede': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'by': 'O'}, {'up': 'O'}, {'to': 'O'}, {'2': 'O'}, {'years': 'O'}, {'in': 'O'}, {'about': 'O'}, {'80%': 'O'}, {'of': 'O'}, {'patients.': 'O'}]"
Our aim was to evaluate fatigue and quality of life (QoL) in Moroccan patients with primary Sjogrens syndrome (PSS) and determine their correlates with disease-related parameters.,"[{'Our': 'O'}, {'aim': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'fatigue': 'I-Entity'}, {'and': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life': 'O'}, {'(QoL)': 'O'}, {'in': 'O'}, {'Moroccan': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(PSS)': 'O'}, {'and': 'O'}, {'determine': 'O'}, {'their': 'O'}, {'correlates': 'O'}, {'with': 'O'}, {'disease-related': 'O'}, {'parameters.': 'O'}]"
"To investigate the underlying cause of dry skin in these cases, sweating function was evaluated using a quantitative sudomotor axon reflex test (QSART) in which the axon reflex is stimulated by acetylcholine iontophoresis.","[{'To': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'skin': 'I-Entity'}, {'in': 'O'}, {'these': 'O'}, {'cases,': 'O'}, {'sweating': 'O'}, {'function': 'O'}, {'was': 'O'}, {'evaluated': 'O'}, {'using': 'O'}, {'a': 'O'}, {'quantitative': 'O'}, {'sudomotor': 'O'}, {'axon': 'O'}, {'reflex': 'O'}, {'test': 'O'}, {'(QSART)': 'O'}, {'in': 'O'}, {'which': 'O'}, {'the': 'O'}, {'axon': 'O'}, {'reflex': 'O'}, {'is': 'O'}, {'stimulated': 'O'}, {'by': 'O'}, {'acetylcholine': 'I-Entity'}, {'iontophoresis.': 'O'}]"
An imbalance in the lineages of immunosuppressive regulatory T cells (T(reg) cells) and the inflammatory T(H)17 subset of helper T cells leads to the development of autoimmune and/or inflammatory disease.,"[{'An': 'O'}, {'imbalance': 'O'}, {'in': 'O'}, {'the': 'O'}, {'lineages': 'O'}, {'of': 'O'}, {'immunosuppressive': 'O'}, {'regulatory': 'O'}, {'T': 'O'}, {'cells': 'O'}, {'(T(reg)': 'O'}, {'cells)': 'O'}, {'and': 'O'}, {'the': 'O'}, {'inflammatory': 'O'}, {'T(H)17': 'O'}, {'subset': 'O'}, {'of': 'O'}, {'helper': 'O'}, {'T': 'O'}, {'cells': 'O'}, {'leads': 'O'}, {'to': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'autoimmune': 'B-Entity'}, {'and/or': 'I-Entity'}, {'inflammatory': 'B-Entity'}, {'disease.': 'I-Entity'}]"
"THE RESPECTIVE POPULATION PREVALENCES WERE: dry mouth (5.9%), dry eyes (8.6%), nasal polyps (3.8%), CRS (13.2%) and asthma (12.0%).","[{'THE': 'O'}, {'RESPECTIVE': 'O'}, {'POPULATION': 'O'}, {'PREVALENCES': 'O'}, {'WERE:': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'(5.9%),': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'(8.6%),': 'O'}, {'nasal': 'B-Entity'}, {'polyps': 'I-Entity'}, {'(3.8%),': 'O'}, {'CRS': 'I-Entity'}, {'(13.2%)': 'O'}, {'and': 'O'}, {'asthma': 'O'}]"
Patients with anti-Ro/SSA antibodies had more frequent exocrine gland symptoms and some extraglandular symptoms and immunological alterations.,"[{'Patients': 'O'}, {'with': 'O'}, {'anti-Ro/SSA': 'O'}, {'antibodies': 'O'}, {'had': 'O'}, {'more': 'O'}, {'frequent': 'O'}, {'exocrine': 'B-Entity'}, {'gland': 'I-Entity'}, {'symptoms': 'I-Entity'}, {'and': 'O'}, {'some': 'O'}, {'extraglandular': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'immunological': 'O'}, {'alterations.': 'O'}]"
"Myofascial pain (caused by muscular contracture) was significantly higher in the study group than in the control one (p‚Äö√Ñ√∂‚àö¬¢¬¨√ü 0,05).","[{'Myofascial': 'B-Entity'}, {'pain': 'I-Entity'}, {'(caused': 'O'}, {'by': 'O'}, {'muscular': 'B-Entity'}, {'contracture)': 'I-Entity'}, {'was': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'the': 'O'}, {'study': 'O'}, {'group': 'O'}, {'than': 'O'}, {'in': 'O'}, {'the': 'O'}, {'control': 'O'}, {'one': 'O'}, {'(p‚Äö√Ñ√∂‚àö¬¢¬¨√ü': 'O'}, {'0,05).': 'O'}]"
"However, thyroid uptake seemed to be unaffected in patients with both early-stage and advanced-stage disease.Turkey.","[{'However,': 'O'}, {'thyroid': 'O'}, {'uptake': 'O'}, {'seemed': 'O'}, {'to': 'O'}, {'be': 'O'}, {'unaffected': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'both': 'O'}, {'early-stage': 'O'}, {'and': 'O'}, {'advanced-stage': 'O'}, {'disease.Turkey.': 'O'}]"
"In this multicenter cohort, clinical manifestations that could help to distinguish early SLE from SLE-mimicking conditions were identified.","[{'In': 'O'}, {'this': 'O'}, {'multicenter': 'O'}, {'cohort,': 'O'}, {'clinical': 'O'}, {'manifestations': 'O'}, {'that': 'O'}, {'could': 'O'}, {'help': 'O'}, {'to': 'O'}, {'distinguish': 'O'}, {'early': 'O'}, {'SLE': 'I-Entity'}, {'from': 'O'}, {'SLE-mimicking': 'I-Entity'}, {'conditions': 'O'}, {'were': 'O'}, {'identified.': 'O'}]"
Patients from a dry eye clinic and normal controls were assessed by Schirmer's test for tear flow.,"[{'Patients': 'O'}, {'from': 'O'}, {'a': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'clinic': 'O'}, {'and': 'O'}, {'normal': 'O'}, {'controls': 'O'}, {'were': 'O'}, {'assessed': 'O'}, {'by': 'O'}, {""Schirmer's"": 'O'}, {'test': 'O'}, {'for': 'O'}, {'tear': 'O'}, {'flow.': 'O'}]"
"This study included 199 patients with RA, with mean (SD) age and disease duration of 44 (9.9) and 6.8 (5.5) years, respectively.","[{'This': 'O'}, {'study': 'O'}, {'included': 'O'}, {'199': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'RA,': 'I-Entity'}, {'with': 'O'}, {'mean': 'O'}, {'(SD)': 'O'}, {'age': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'duration': 'O'}, {'of': 'O'}, {'44': 'O'}, {'(9.9)': 'O'}, {'and': 'O'}, {'6.8': 'O'}, {'(5.5)': 'O'}, {'years,': 'O'}, {'respectively.': 'O'}]"
"Conditions of 25[OH]-D3 severe deficiency, deficiency, and insufficiency were defined as levels <10, <20, and 20-30 ng/ml, respectively, and their frequencies were investigated in pSS patients and controls.","[{'Conditions': 'O'}, {'of': 'O'}, {'25[OH]-D3': 'B-Entity'}, {'severe': 'O'}, {'deficiency,': 'O'}, {'deficiency,': 'O'}, {'and': 'O'}, {'insufficiency': 'O'}, {'were': 'O'}, {'defined': 'O'}, {'as': 'O'}, {'levels': 'O'}, {'<10,': 'O'}, {'<20,': 'O'}, {'and': 'O'}, {'20-30': 'O'}, {'ng/ml,': 'O'}, {'respectively,': 'O'}, {'and': 'O'}, {'their': 'O'}, {'frequencies': 'O'}, {'were': 'O'}, {'investigated': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'controls.': 'O'}]"
Distal renal tubular acidosis concerns a third of the patients affected by this auto-immune disease.by Elsevier SAS.,"[{'Distal': 'O'}, {'renal': 'I-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'concerns': 'O'}, {'a': 'O'}, {'third': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'affected': 'O'}, {'by': 'O'}, {'this': 'O'}, {'auto-immune': 'O'}, {'disease.by': 'O'}, {'Elsevier': 'O'}, {'SAS.': 'O'}]"
"The presence of anti-SSB, without anti-SSA antibodies, had no significant association with SS phenotypic features, relative to seronegative participants.","[{'The': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'anti-SSB,': 'O'}, {'without': 'O'}, {'anti-SSA': 'O'}, {'antibodies,': 'O'}, {'had': 'O'}, {'no': 'O'}, {'significant': 'O'}, {'association': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'phenotypic': 'O'}, {'features,': 'O'}, {'relative': 'O'}, {'to': 'O'}, {'seronegative': 'O'}, {'participants.': 'O'}]"
"Yet, the effects of the autoimmune chronic inflammation on the infiltrated tissues and organs generally lead to profound tissue and organ damage with loss of function (i.e., lung, kidney, joints, exocrine glands).","[{'Yet,': 'O'}, {'the': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'the': 'O'}, {'autoimmune': 'B-Entity'}, {'chronic': 'O'}, {'inflammation': 'I-Entity'}, {'on': 'O'}, {'the': 'O'}, {'infiltrated': 'O'}, {'tissues': 'O'}, {'and': 'O'}, {'organs': 'O'}, {'generally': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'profound': 'O'}, {'tissue': 'B-Entity'}, {'and': 'I-Entity'}, {'organ': 'I-Entity'}, {'damage': 'I-Entity'}, {'with': 'O'}, {'loss': 'B-Entity'}, {'of': 'I-Entity'}, {'function': 'I-Entity'}, {'(i.e.,': 'O'}, {'lung,': 'O'}, {'kidney,': 'O'}, {'joints,': 'O'}, {'exocrine': 'O'}, {'glands).': 'O'}]"
The therapy of oral and ocular dryness is mainly symptomatic whereas the treatment of extraglandular manifestations is based on experience with treatment of these manifestations in systemic lupus erythematosus (SLE).Carl-Neuberg-Str.,"[{'The': 'O'}, {'therapy': 'O'}, {'of': 'O'}, {'oral': 'B-Entity'}, {'and': 'I-Entity'}, {'ocular': 'I-Entity'}, {'dryness': 'I-Entity'}, {'is': 'O'}, {'mainly': 'O'}, {'symptomatic': 'O'}, {'whereas': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'extraglandular': 'O'}, {'manifestations': 'O'}, {'is': 'O'}, {'based': 'O'}, {'on': 'O'}, {'experience': 'O'}, {'with': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'these': 'O'}, {'manifestations': 'O'}, {'in': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE).Carl-Neuberg-Str.': 'O'}]"
"Act1 deficiency results in hyperactivated follicular Th17 cells with elevated IL-21 expression, which promotes T-B cell interaction for B cell expansion and antibody production.","[{'Act1': 'O'}, {'deficiency': 'O'}, {'results': 'O'}, {'in': 'O'}, {'hyperactivated': 'O'}, {'follicular': 'O'}, {'Th17': 'O'}, {'cells': 'O'}, {'with': 'O'}, {'elevated': 'O'}, {'IL-21': 'O'}, {'expression,': 'O'}, {'which': 'O'}, {'promotes': 'O'}, {'T-B': 'O'}, {'cell': 'O'}, {'interaction': 'O'}, {'for': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'expansion': 'O'}, {'and': 'O'}, {'antibody': 'O'}, {'production.': 'O'}]"
"In addition, dryness was strongly associated with physical fatigue (p ‚Äö√Ñ√∂‚àö¬¢¬¨√ü 0.0001).","[{'In': 'O'}, {'addition,': 'O'}, {'dryness': 'I-Entity'}, {'was': 'O'}, {'strongly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'physical': 'B-Entity'}, {'fatigue': 'I-Entity'}, {'(p': 'O'}, {'‚Äö√Ñ√∂‚àö¬¢¬¨√ü': 'O'}, {'0.0001).': 'O'}]"
"The most common manifestations of MCTD patients were Raynaud phenomenon, arthralgia, arthritis, fever, acratia, positivities of antinuclear antibodies (anti-ANA) and ribosenuclear protein antibodies (anti-RNP), which were 94.5%,78%,46.2%,48.4%,53.9%,100% and 100%, respectively.Six patients died, and 22 patients were lost in the follow-up after discharge.","[{'The': 'O'}, {'most': 'O'}, {'common': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'MCTD': 'I-Entity'}, {'patients': 'O'}, {'were': 'O'}, {'Raynaud': 'B-Entity'}, {'phenomenon,': 'I-Entity'}, {'arthralgia,': 'I-Entity'}, {'arthritis,': 'I-Entity'}, {'fever,': 'I-Entity'}, {'acratia,': 'I-Entity'}, {'positivities': 'O'}, {'of': 'O'}, {'antinuclear': 'O'}, {'antibodies': 'O'}, {'(anti-ANA)': 'O'}, {'and': 'O'}, {'ribosenuclear': 'O'}, {'protein': 'O'}, {'antibodies': 'O'}, {'(anti-RNP),': 'O'}]"
"Among 1580 patients, 208 (13%) were classified as presenting a severe, potentially life-threatening systemic disease: 193 presented one ESSDAI domain classified as high, 14 presented two high scored domains and only one presented three high activity domains.","[{'Among': 'O'}, {'1580': 'O'}, {'patients,': 'O'}, {'208': 'O'}, {'(13%)': 'O'}, {'were': 'O'}, {'classified': 'O'}, {'as': 'O'}, {'presenting': 'O'}, {'a': 'O'}, {'severe,': 'O'}, {'potentially': 'O'}, {'life-threatening': 'O'}, {'systemic': 'B-Entity'}, {'disease:': 'I-Entity'}, {'193': 'O'}, {'presented': 'O'}, {'one': 'O'}, {'ESSDAI': 'O'}, {'domain': 'O'}, {'classified': 'O'}, {'as': 'O'}, {'high,': 'O'}, {'14': 'O'}, {'presented': 'O'}, {'two': 'O'}, {'high': 'O'}, {'scored': 'O'}, {'domains': 'O'}, {'and': 'O'}, {'only': 'O'}, {'one': 'O'}, {'presented': 'O'}, {'three': 'O'}, {'high': 'O'}, {'activity': 'O'}, {'domains.': 'O'}]"
"Xerostomia (dry mouth) is the cardinal symptom of Sjogrens syndrome (SS), which is an autoimmune disease involving the exocrine glands and other organs.","[{'Xerostomia': 'I-Entity'}, {'(dry': 'O'}, {'mouth)': 'I-Entity'}, {'is': 'O'}, {'the': 'O'}, {'cardinal': 'O'}, {'symptom': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'which': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'involving': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'and': 'O'}, {'other': 'O'}, {'organs.': 'O'}]"
"The disease may be complicated by a systemic involvement, such as a pulmonary fibrosis or the development of lymphoma which severely worsens the prognosis.","[{'The': 'O'}, {'disease': 'O'}, {'may': 'O'}, {'be': 'O'}, {'complicated': 'O'}, {'by': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'involvement,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'a': 'O'}, {'pulmonary': 'B-Entity'}, {'fibrosis': 'I-Entity'}, {'or': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'lymphoma': 'I-Entity'}, {'which': 'O'}, {'severely': 'O'}, {'worsens': 'O'}, {'the': 'O'}, {'prognosis.': 'O'}]"
"In addition, fatigue and musculoskeletal pain, often described as aching, are very common.","[{'In': 'O'}, {'addition,': 'O'}, {'fatigue': 'I-Entity'}, {'and': 'O'}, {'musculoskeletal': 'B-Entity'}, {'pain,': 'I-Entity'}, {'often': 'O'}, {'described': 'O'}, {'as': 'O'}, {'aching,': 'I-Entity'}, {'are': 'O'}, {'very': 'O'}, {'common.': 'O'}]"
"The total effective rate in the observation group was 86.7% (26/30), which was better than 70.0% (21/30) in the control group (P<0.05).","[{'The': 'O'}, {'total': 'O'}, {'effective': 'O'}, {'rate': 'O'}, {'in': 'O'}, {'the': 'O'}, {'observation': 'O'}, {'group': 'O'}, {'was': 'O'}, {'86.7%': 'O'}, {'(26/30),': 'O'}, {'which': 'O'}, {'was': 'O'}, {'better': 'O'}, {'than': 'O'}, {'70.0%': 'O'}, {'(21/30)': 'O'}, {'in': 'O'}, {'the': 'O'}, {'control': 'O'}, {'group': 'O'}, {'(P<0.05).': 'O'}]"
"Clinical evaluation, chest X-ray examination, pulmonary function tests, Tc-99m DTPA aerosol scintigraphy were performed in all the cases.","[{'Clinical': 'O'}, {'evaluation,': 'O'}, {'chest': 'O'}, {'X-ray': 'O'}, {'examination,': 'O'}, {'pulmonary': 'O'}, {'function': 'O'}, {'tests,': 'O'}, {'Tc-99m': 'B-Entity'}, {'DTPA': 'I-Entity'}, {'aerosol': 'O'}, {'scintigraphy': 'O'}, {'were': 'O'}, {'performed': 'O'}, {'in': 'O'}, {'all': 'O'}, {'the': 'O'}, {'cases.': 'O'}]"
Secretory dysfunction associated with SS may be partly caused by the damaging effects of increased glandular concentrations of nitric oxide (NO) derived from up-regulation of inducible NO synthase (iNOS) that accompanies glandular inflammation.,"[{'Secretory': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'partly': 'O'}, {'caused': 'O'}, {'by': 'O'}, {'the': 'O'}, {'damaging': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'increased': 'O'}, {'glandular': 'O'}, {'concentrations': 'O'}, {'of': 'O'}, {'nitric': 'B-Entity'}, {'oxide': 'I-Entity'}, {'(NO)': 'O'}, {'derived': 'O'}, {'from': 'O'}, {'up-regulation': 'O'}, {'of': 'O'}, {'inducible': 'O'}, {'NO': 'I-Entity'}, {'synthase': 'O'}, {'(iNOS)': 'O'}, {'that': 'O'}, {'accompanies': 'O'}, {'glandular': 'O'}, {'inflammation.': 'I-Entity'}]"
"Of the 908 patients who underwent thyroid ultrasonography, salivary gland abnormalities were detected in 36 (4.0%) patients.","[{'Of': 'O'}, {'the': 'O'}, {'908': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'underwent': 'O'}, {'thyroid': 'O'}, {'ultrasonography,': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'abnormalities': 'I-Entity'}, {'were': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'36': 'O'}, {'(4.0%)': 'O'}, {'patients.': 'O'}]"
"Our patient remained stable after corticosteroids and hydoxychloroquine therapy and no progression of disease after 6 months follow-up.Florida, USA.","[{'Our': 'O'}, {'patient': 'O'}, {'remained': 'O'}, {'stable': 'O'}, {'after': 'O'}, {'corticosteroids': 'O'}, {'and': 'O'}, {'hydoxychloroquine': 'I-Entity'}, {'therapy': 'O'}, {'and': 'O'}, {'no': 'O'}, {'progression': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'after': 'O'}, {'6': 'O'}, {'months': 'O'}, {'follow-up.Florida,': 'O'}, {'USA.': 'O'}]"
Subclinical lung disease is even more frequent and often includes evidence of small airways disease and airway inflammation.,"[{'Subclinical': 'O'}, {'lung': 'B-Entity'}, {'disease': 'I-Entity'}, {'is': 'O'}, {'even': 'O'}, {'more': 'O'}, {'frequent': 'O'}, {'and': 'O'}, {'often': 'O'}, {'includes': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'small': 'B-Entity'}, {'airways': 'I-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'airway': 'O'}, {'inflammation.': 'I-Entity'}]"
"These findings give a further evidence of the linkage between EBV and pSS, furthermore, they show the possible role of EBV-EBER1 in the induction of increased TRAF6 expression in the peripheral B cells of Sjogrens patients.Australia, Ltd.Debrecen, Hungary.Debrecen, Hungary.Debrecen, Hungary.Debrecen, Hungary.Debrecen, Hungary.Hungary.Hungary.Debrecen, Hungary.3.sociodemographic factors and comorbidity.","[{'These': 'O'}, {'findings': 'O'}, {'give': 'O'}, {'a': 'O'}, {'further': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'the': 'O'}, {'linkage': 'O'}, {'between': 'O'}, {'EBV': 'O'}, {'and': 'O'}, {'pSS,': 'I-Entity'}, {'furthermore,': 'O'}, {'they': 'O'}, {'show': 'O'}, {'the': 'O'}, {'possible': 'O'}, {'role': 'O'}, {'of': 'O'}, {'EBV-EBER1': 'O'}, {'in': 'O'}, {'the': 'O'}, {'induction': 'O'}, {'of': 'O'}, {'increased': 'O'}, {'TRAF6': 'O'}, {'expression': 'O'}, {'in': 'O'}, {'the': 'O'}, {'peripheral': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'of': 'O'}, {'Sjogrens': 'I-Entity'}, {'patients.Australia,': 'O'}, {'Ltd.Debrecen,': 'O'}]"
Patients with primary SS carry a high risk of oral candidiasis and a high frequency of multiple Candida infections.,"[{'Patients': 'O'}, {'with': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'carry': 'O'}, {'a': 'O'}, {'high': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'oral': 'B-Entity'}, {'candidiasis': 'I-Entity'}, {'and': 'O'}, {'a': 'O'}, {'high': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'multiple': 'O'}, {'Candida': 'B-Entity'}, {'infections.': 'I-Entity'}]"
The disease activity was evaluated by the EULAR-SS Disease Activity Index (ESSDAI).,"[{'The': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'was': 'O'}, {'evaluated': 'O'}, {'by': 'O'}, {'the': 'O'}, {'EULAR-SS': 'O'}, {'Disease': 'O'}, {'Activity': 'O'}, {'Index': 'O'}, {'(ESSDAI).': 'O'}]"
"In conclusion, detection of serum KL-6 levels in ILDs associated with connective tissue diseases may be beneficial to making a definitive diagnosis, predicting the prognosis and monitoring the disease activity, which would be of great help in clinical practice.","[{'In': 'O'}, {'conclusion,': 'O'}, {'detection': 'O'}, {'of': 'O'}, {'serum': 'O'}, {'KL-6': 'O'}, {'levels': 'O'}, {'in': 'O'}, {'ILDs': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'beneficial': 'O'}, {'to': 'O'}, {'making': 'O'}, {'a': 'O'}, {'definitive': 'O'}, {'diagnosis,': 'O'}, {'predicting': 'O'}, {'the': 'O'}, {'prognosis': 'O'}, {'and': 'O'}, {'monitoring': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'which': 'O'}, {'would': 'O'}, {'be': 'O'}, {'of': 'O'}, {'great': 'O'}, {'help': 'O'}, {'in': 'O'}, {'clinical': 'O'}, {'practice.': 'O'}]"
"Careful clinical assessment, gene mutation screening, and bone marrow evaluation can lead to an accurate diagnosis.University, Taiyuan, China.University, Taiyuan, China.University, Taiyuan, China.University, Taiyuan, China.University, Taiyuan, China.Taiyuan, China.Taiyuan, China.University, Taiyuan, China.","[{'Careful': 'O'}, {'clinical': 'O'}, {'assessment,': 'O'}, {'gene': 'O'}, {'mutation': 'O'}, {'screening,': 'O'}, {'and': 'O'}, {'bone': 'O'}, {'marrow': 'O'}, {'evaluation': 'O'}, {'can': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'an': 'O'}, {'accurate': 'O'}, {'diagnosis.University,': 'O'}, {'Taiyuan,': 'O'}, {'China.University,': 'O'}, {'Taiyuan,': 'O'}, {'China.University,': 'O'}, {'Taiyuan,': 'O'}, {'China.University,': 'O'}, {'Taiyuan,': 'O'}, {'China.University,': 'O'}, {'Taiyuan,': 'O'}, {'China.Taiyuan,': 'O'}, {'China.Taiyuan,': 'O'}]"
"A heavy, resistant body and ever-present lack of vitality represented a profound, ever-present lack of energy along with an unfamiliar bodily heaviness quite different from the experience after alleviation by the drug and being healthy.","[{'A': 'O'}, {'heavy,': 'O'}, {'resistant': 'O'}, {'body': 'O'}, {'and': 'O'}, {'ever-present': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'vitality': 'O'}, {'represented': 'O'}, {'a': 'O'}, {'profound,': 'O'}, {'ever-present': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'energy': 'O'}, {'along': 'O'}, {'with': 'O'}, {'an': 'O'}, {'unfamiliar': 'O'}, {'bodily': 'O'}, {'heaviness': 'O'}, {'quite': 'O'}, {'different': 'O'}, {'from': 'O'}, {'the': 'O'}, {'experience': 'O'}, {'after': 'O'}, {'alleviation': 'O'}, {'by': 'O'}, {'the': 'O'}, {'drug': 'O'}, {'and': 'O'}, {'being': 'O'}, {'healthy.': 'O'}]"
"The lung involvement resulted in chronic bronchorrhea, recurrent sinusitis, diffuse bronchiolar nodules with bronchiectasis on the CT scan, and a severe obstructive airway pattern on lung function tests.","[{'The': 'O'}, {'lung': 'O'}, {'involvement': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'chronic': 'O'}, {'bronchorrhea,': 'I-Entity'}, {'recurrent': 'O'}, {'sinusitis,': 'I-Entity'}, {'diffuse': 'O'}, {'bronchiolar': 'B-Entity'}, {'nodules': 'I-Entity'}, {'with': 'O'}, {'bronchiectasis': 'I-Entity'}, {'on': 'O'}, {'the': 'O'}, {'CT': 'O'}, {'scan,': 'O'}, {'and': 'O'}, {'a': 'O'}, {'severe': 'O'}, {'obstructive': 'B-Entity'}, {'airway': 'I-Entity'}, {'pattern': 'I-Entity'}, {'on': 'O'}, {'lung': 'O'}, {'function': 'O'}, {'tests.': 'O'}]"
"Moreover, a large cystic mass was found in the anterior mediastinum on the chest X-ray.","[{'Moreover,': 'O'}, {'a': 'O'}, {'large': 'O'}, {'cystic': 'B-Entity'}, {'mass': 'I-Entity'}, {'was': 'O'}, {'found': 'O'}, {'in': 'O'}, {'the': 'O'}, {'anterior': 'O'}, {'mediastinum': 'O'}, {'on': 'O'}, {'the': 'O'}, {'chest': 'O'}, {'X-ray.': 'O'}]"
"Although the incidence of adverse events was similar between the treatment groups, baminercept therapy was associated with a higher incidence of liver toxicity, including 2 serious adverse events.","[{'Although': 'O'}, {'the': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'adverse': 'O'}, {'events': 'O'}, {'was': 'O'}, {'similar': 'O'}, {'between': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'groups,': 'O'}, {'baminercept': 'I-Entity'}, {'therapy': 'O'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'higher': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'liver': 'B-Entity'}, {'toxicity,': 'I-Entity'}, {'including': 'O'}, {'2': 'O'}, {'serious': 'O'}, {'adverse': 'O'}, {'events.': 'O'}]"
"Cognitive symptoms correlated with verbal memory (P = 0.048), whereas pain correlated with executive function measures (Stroop, P = 0.017) and working memory (Trails B, P = 0.036).","[{'Cognitive': 'O'}, {'symptoms': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'verbal': 'O'}, {'memory': 'O'}, {'(P': 'O'}, {'=': 'O'}, {'0.048),': 'O'}, {'whereas': 'O'}, {'pain': 'I-Entity'}, {'correlated': 'O'}, {'with': 'O'}, {'executive': 'O'}, {'function': 'O'}, {'measures': 'O'}, {'(Stroop,': 'O'}, {'P': 'O'}, {'=': 'O'}, {'0.017)': 'O'}, {'and': 'O'}, {'working': 'O'}, {'memory': 'O'}, {'(Trails': 'O'}, {'B,': 'O'}, {'P': 'O'}, {'=': 'O'}, {'0.036).': 'O'}]"
"This case suggests that even low doses of CSA may be beneficial for treating chronic IC associated with pSS syndrome.Medicine Hospital, 35100, Bornova, Izmir, Turkey.","[{'This': 'O'}, {'case': 'O'}, {'suggests': 'O'}, {'that': 'O'}, {'even': 'O'}, {'low': 'O'}, {'doses': 'O'}, {'of': 'O'}, {'CSA': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'beneficial': 'O'}, {'for': 'O'}, {'treating': 'O'}, {'chronic': 'O'}, {'IC': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'pSS': 'B-Entity'}, {'syndrome.Medicine': 'I-Entity'}, {'Hospital,': 'O'}, {'35100,': 'O'}, {'Bornova,': 'O'}, {'Izmir,': 'O'}, {'Turkey.': 'O'}]"
The assay results obtained by the present method showed that biotin-streptavidin-amplified TRFIA improve the traditional ELISA kit for anti-CCP detection.,"[{'The': 'O'}, {'assay': 'O'}, {'results': 'O'}, {'obtained': 'O'}, {'by': 'O'}, {'the': 'O'}, {'present': 'O'}, {'method': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'biotin-streptavidin-amplified': 'O'}, {'TRFIA': 'O'}, {'improve': 'O'}, {'the': 'O'}, {'traditional': 'O'}, {'ELISA': 'O'}, {'kit': 'O'}, {'for': 'O'}, {'anti-CCP': 'O'}, {'detection.': 'O'}]"
"Instead, diagnosis of MS primarily depends upon clinical criteria, supported by abnormalities characteristic of MS on para-clinical investigations including magnetic resonance imaging of the brain and spine, in the absence of an alternative explanation for underlying neurologic symptoms.","[{'Instead,': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'MS': 'I-Entity'}, {'primarily': 'O'}, {'depends': 'O'}, {'upon': 'O'}, {'clinical': 'O'}, {'criteria,': 'O'}, {'supported': 'O'}, {'by': 'O'}, {'abnormalities': 'O'}, {'characteristic': 'O'}, {'of': 'O'}, {'MS': 'I-Entity'}, {'on': 'O'}, {'para-clinical': 'O'}, {'investigations': 'O'}, {'including': 'O'}, {'magnetic': 'O'}, {'resonance': 'O'}, {'imaging': 'O'}, {'of': 'O'}, {'the': 'O'}, {'brain': 'O'}, {'and': 'O'}, {'spine,': 'O'}, {'in': 'O'}, {'the': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'an': 'O'}, {'alternative': 'O'}, {'explanation': 'O'}, {'for': 'O'}, {'underlying': 'O'}, {'neurologic': 'O'}, {'symptoms.': 'O'}]"
"The decrease in biomarkers of B-cell activation observed at week 28 persisted unchanged until week 52, with RF decreasing further.","[{'The': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'biomarkers': 'O'}, {'of': 'O'}, {'B-cell': 'O'}, {'activation': 'O'}, {'observed': 'O'}, {'at': 'O'}, {'week': 'O'}, {'28': 'O'}, {'persisted': 'O'}, {'unchanged': 'O'}, {'until': 'O'}, {'week': 'O'}, {'52,': 'O'}, {'with': 'O'}, {'RF': 'I-Entity'}, {'decreasing': 'O'}, {'further.': 'O'}]"
Six patients had an underlying inflammatory ocular surface disorder.,"[{'Six': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'an': 'O'}, {'underlying': 'O'}, {'inflammatory': 'B-Entity'}, {'ocular': 'I-Entity'}, {'surface': 'I-Entity'}, {'disorder.': 'I-Entity'}]"
"Patients with Sjogrens syndrome (SS), an autoimmune disease primarily affecting exocrine glands, exhibit enhanced TNF-‚âà√≠¬¨¬± expression in the saliva and salivary glands.","[{'Patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'primarily': 'O'}, {'affecting': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'exhibit': 'O'}, {'enhanced': 'O'}, {'TNF-‚âà√≠¬¨¬±': 'O'}, {'expression': 'O'}, {'in': 'O'}, {'the': 'O'}, {'saliva': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'glands.': 'O'}]"
Local ischemia and hypoxia of neurons caused by inflammation of vasa nervosum represents the second significant mechanism leading to damage of nerve fibres in the peripheral nervous system.,"[{'Local': 'O'}, {'ischemia': 'I-Entity'}, {'and': 'O'}, {'hypoxia': 'I-Entity'}, {'of': 'O'}, {'neurons': 'O'}, {'caused': 'O'}, {'by': 'O'}, {'inflammation': 'I-Entity'}, {'of': 'O'}, {'vasa': 'B-Entity'}, {'nervosum': 'I-Entity'}, {'represents': 'O'}, {'the': 'O'}, {'second': 'O'}, {'significant': 'O'}, {'mechanism': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'damage': 'I-Entity'}, {'of': 'I-Entity'}, {'nerve': 'I-Entity'}, {'fibres': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'peripheral': 'O'}, {'nervous': 'I-Entity'}, {'system.': 'O'}]"
Prednisone therapy induced a significant improvement in symptoms and electrocardiographic readings.,"[{'Prednisone': 'I-Entity'}, {'therapy': 'O'}, {'induced': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'electrocardiographic': 'O'}, {'readings.': 'O'}]"
Seven patients (54%) were diagnosed with immune-mediated disease from autoimmune parotitis (positive Sjogrens antibodies or antinuclear antibodies) or human immunodeficiency virus (HIV) disease.,"[{'Seven': 'O'}, {'patients': 'O'}, {'(54%)': 'O'}, {'were': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'immune-mediated': 'B-Entity'}, {'disease': 'I-Entity'}, {'from': 'O'}, {'autoimmune': 'B-Entity'}, {'parotitis': 'I-Entity'}, {'(positive': 'O'}, {'Sjogrens': 'O'}, {'antibodies': 'O'}, {'or': 'O'}, {'antinuclear': 'O'}, {'antibodies)': 'O'}, {'or': 'O'}, {'human': 'B-Entity'}, {'immunodeficiency': 'I-Entity'}, {'virus': 'I-Entity'}, {'(HIV)': 'I-Entity'}, {'disease.': 'I-Entity'}]"
Fanconi's syndrome is associated with impaired reabsorption in the proximal renal tubule associated with tubulointerstitial nephritis and is associated with renal tubular acidosis and hypophosphatemia.,"[{""Fanconi's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'impaired': 'O'}, {'reabsorption': 'O'}, {'in': 'O'}, {'the': 'O'}, {'proximal': 'O'}, {'renal': 'O'}, {'tubule': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'tubulointerstitial': 'B-Entity'}, {'nephritis': 'I-Entity'}, {'and': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'renal': 'O'}, {'tubular': 'O'}, {'acidosis': 'I-Entity'}, {'and': 'O'}, {'hypophosphatemia.': 'I-Entity'}]"
Preliminary results suggest that biologic therapy will have its place in severe refractory relapsing forms of RP.rovensky.jozef@nurch.skGrowth as Salispheres or Monolayers.,"[{'Preliminary': 'O'}, {'results': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'biologic': 'O'}, {'therapy': 'O'}, {'will': 'O'}, {'have': 'O'}, {'its': 'O'}, {'place': 'O'}, {'in': 'O'}, {'severe': 'O'}, {'refractory': 'O'}, {'relapsing': 'O'}, {'forms': 'O'}, {'of': 'O'}, {'RP.rovensky.jozef@nurch.skGrowth': 'I-Entity'}, {'as': 'O'}, {'Salispheres': 'O'}, {'or': 'O'}, {'Monolayers.': 'O'}]"
"Ulcerative conditions including Behcet and Crohn diseases are discussed, along with rheumatic conditions including Sjogren syndrome, lupus erythematosus, and rheumatoid arthritis.","[{'Ulcerative': 'O'}, {'conditions': 'O'}, {'including': 'O'}, {'Behcet': 'B-Entity'}, {'and': 'I-Entity'}, {'Crohn': 'I-Entity'}, {'diseases': 'I-Entity'}, {'are': 'O'}, {'discussed,': 'O'}, {'along': 'O'}, {'with': 'O'}, {'rheumatic': 'B-Entity'}, {'conditions': 'I-Entity'}, {'including': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'lupus': 'B-Entity'}, {'erythematosus,': 'I-Entity'}, {'and': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis.': 'I-Entity'}]"
"We evaluated patients' serological and (18)F-fluoro-2-deoxyglucose-positron emission tomography/computed tomography ((18)F-FDG-PET/CT) and grouped them as LSG+ (LSG specimens with > 40% IgG4-positive plasma cells/IgG-positive plasma cells, 11 patients) or LSG- (LSG specimens with < 40% IgG4-positive plasma cells/IgG-positive plasma cells, 6 patients).","[{'We': 'O'}, {'evaluated': 'O'}, {""patients'"": 'O'}, {'serological': 'O'}, {'and': 'O'}, {'(18)F-fluoro-2-deoxyglucose-positron': 'O'}, {'emission': 'O'}, {'tomography/computed': 'O'}, {'tomography': 'O'}, {'((18)F-FDG-PET/CT)': 'O'}, {'and': 'O'}, {'grouped': 'O'}, {'them': 'O'}, {'as': 'O'}, {'LSG+': 'I-Entity'}]"
"Laboratory tests revealed: serum potassium 3.0 mEq/L, arterial blood pH 7.28, serum bicarbonate 17.8 mEq/L and urinary pH 7.0.","[{'Laboratory': 'O'}, {'tests': 'O'}, {'revealed:': 'O'}, {'serum': 'O'}, {'potassium': 'I-Entity'}, {'3.0': 'O'}, {'mEq/L,': 'O'}, {'arterial': 'O'}, {'blood': 'O'}, {'pH': 'O'}, {'7.28,': 'O'}, {'serum': 'O'}, {'bicarbonate': 'I-Entity'}, {'17.8': 'O'}, {'mEq/L': 'O'}, {'and': 'O'}, {'urinary': 'O'}, {'pH': 'O'}, {'7.0.': 'O'}]"
The disease can be primary or secondary (if it is associated with another autoimmune disease).,"[{'The': 'O'}, {'disease': 'O'}, {'can': 'O'}, {'be': 'O'}, {'primary': 'O'}, {'or': 'O'}, {'secondary': 'O'}, {'(if': 'O'}, {'it': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'another': 'O'}, {'autoimmune': 'B-Entity'}, {'disease).': 'I-Entity'}]"
Antibodies against the NR2 subtype of the N-methyl-D-aspartate receptor (anti-NR2 antibodies) cause hippocampal atrophy and cognitive impairment in mice and have been associated with memory impairment in both patients with SLE and patients with primary SS.,"[{'Antibodies': 'O'}, {'against': 'O'}, {'the': 'O'}, {'NR2': 'O'}, {'subtype': 'O'}, {'of': 'O'}, {'the': 'O'}, {'N-methyl-D-aspartate': 'B-Entity'}, {'receptor': 'O'}, {'(anti-NR2': 'O'}, {'antibodies)': 'O'}, {'cause': 'O'}, {'hippocampal': 'B-Entity'}, {'atrophy': 'I-Entity'}, {'and': 'O'}, {'cognitive': 'B-Entity'}, {'impairment': 'I-Entity'}, {'in': 'O'}, {'mice': 'O'}, {'and': 'O'}, {'have': 'O'}, {'been': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'memory': 'B-Entity'}, {'impairment': 'I-Entity'}, {'in': 'O'}, {'both': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SLE': 'I-Entity'}, {'and': 'O'}]"
Differences are mainly due to peripheral vascular manifestations.,"[{'Differences': 'O'}, {'are': 'O'}, {'mainly': 'O'}, {'due': 'O'}, {'to': 'O'}, {'peripheral': 'O'}, {'vascular': 'O'}, {'manifestations.': 'O'}]"
The results showed that the percentage of memory CD19(+)CD27(+) B cells was significantly lower in pSS patients compared to in healthy controls.,"[{'The': 'O'}, {'results': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'the': 'O'}, {'percentage': 'O'}, {'of': 'O'}, {'memory': 'O'}, {'CD19(+)CD27(+)': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'lower': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'in': 'O'}, {'healthy': 'O'}, {'controls.': 'O'}]"
Patients with any osteoporotic fractures were identified.,"[{'Patients': 'O'}, {'with': 'O'}, {'any': 'O'}, {'osteoporotic': 'B-Entity'}, {'fractures': 'I-Entity'}, {'were': 'O'}, {'identified.': 'O'}]"
"Therapeutic schedules were classified into 4 categories: no systemic therapies, hydroxychloroquine (HCQ) and/or low dose glucocorticoids (GCS) (<20mg/day), high dose GCS (>20mg/day) and use of second-line therapies (immunosuppressive agents, intravenous immunoglobulins [IVIG] and/or rituximab [RTX]).","[{'Therapeutic': 'O'}, {'schedules': 'O'}, {'were': 'O'}, {'classified': 'O'}, {'into': 'O'}, {'4': 'O'}, {'categories:': 'O'}, {'no': 'O'}, {'systemic': 'O'}, {'therapies,': 'O'}, {'hydroxychloroquine': 'I-Entity'}, {'(HCQ)': 'O'}, {'and/or': 'O'}, {'low': 'O'}, {'dose': 'O'}, {'glucocorticoids': 'O'}, {'(GCS)': 'O'}, {'(<20mg/day),': 'O'}, {'high': 'O'}, {'dose': 'O'}, {'GCS': 'O'}, {'(>20mg/day)': 'O'}]"
"We found that as the disease progressed, both the heterogeneous signal-intensity distribution and the volumes of the parotid and the submandibular glands were significantly related to the stimulated and the unstimulated salivary flow rate.","[{'We': 'O'}, {'found': 'O'}, {'that': 'O'}, {'as': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'progressed,': 'O'}, {'both': 'O'}, {'the': 'O'}, {'heterogeneous': 'O'}, {'signal-intensity': 'O'}, {'distribution': 'O'}, {'and': 'O'}, {'the': 'O'}, {'volumes': 'O'}, {'of': 'O'}, {'the': 'O'}, {'parotid': 'O'}, {'and': 'O'}, {'the': 'O'}, {'submandibular': 'O'}, {'glands': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'related': 'O'}, {'to': 'O'}, {'the': 'O'}, {'stimulated': 'O'}, {'and': 'O'}, {'the': 'O'}, {'unstimulated': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'rate.': 'O'}]"
Similar pregnancy outcome was observed in women with pSS diagnosis before and after the index pregnancy.,"[{'Similar': 'O'}, {'pregnancy': 'O'}, {'outcome': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'women': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'diagnosis': 'O'}, {'before': 'O'}, {'and': 'O'}, {'after': 'O'}, {'the': 'O'}, {'index': 'O'}, {'pregnancy.': 'O'}]"
Appearance of Secondary SS in RA patients is independent of RA duration or activity.10.1590/s0104-42302011000300015.syndrome: a case report and literature review.,"[{'Appearance': 'O'}, {'of': 'O'}, {'Secondary': 'O'}, {'SS': 'I-Entity'}, {'in': 'O'}, {'RA': 'I-Entity'}, {'patients': 'O'}, {'is': 'O'}, {'independent': 'O'}, {'of': 'O'}, {'RA': 'I-Entity'}, {'duration': 'O'}, {'or': 'O'}, {'activity.10.1590/s0104-42302011000300015.syndrome:': 'O'}, {'a': 'O'}, {'case': 'O'}, {'report': 'O'}, {'and': 'O'}, {'literature': 'O'}, {'review.': 'O'}]"
"We identified 26 patients (11 women and 15 men, with a mean age at diagnosis of 63.57 years).","[{'We': 'O'}, {'identified': 'O'}, {'26': 'O'}, {'patients': 'O'}, {'(11': 'O'}, {'women': 'O'}, {'and': 'O'}, {'15': 'O'}, {'men,': 'O'}, {'with': 'O'}, {'a': 'O'}, {'mean': 'O'}, {'age': 'O'}, {'at': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'63.57': 'O'}, {'years).': 'O'}]"
Sjogrens syndrome is primarily a chronic systemic autoimmune disease that affects exocrine organs.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'primarily': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'systemic': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'affects': 'O'}, {'exocrine': 'O'}, {'organs.': 'O'}]"
The BCSI should be a useful tool for the study of cognitive symptoms in SS.,"[{'The': 'O'}, {'BCSI': 'O'}, {'should': 'O'}, {'be': 'O'}, {'a': 'O'}, {'useful': 'O'}, {'tool': 'O'}, {'for': 'O'}, {'the': 'O'}, {'study': 'O'}, {'of': 'O'}, {'cognitive': 'O'}, {'symptoms': 'O'}, {'in': 'O'}, {'SS.': 'I-Entity'}]"
"Resilience was influenced by age, duration of disease, and socioeconomic status.","[{'Resilience': 'O'}, {'was': 'O'}, {'influenced': 'O'}, {'by': 'O'}, {'age,': 'O'}, {'duration': 'O'}, {'of': 'O'}, {'disease,': 'O'}, {'and': 'O'}, {'socioeconomic': 'O'}, {'status.': 'O'}]"
Autoimmune diseases can lead to sensorineural deficits.,"[{'Autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'can': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'sensorineural': 'B-Entity'}, {'deficits.': 'I-Entity'}]"
Dry mouth is a common complaint in patients undergoing radiotherapy.,"[{'Dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'common': 'O'}, {'complaint': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'undergoing': 'O'}, {'radiotherapy.': 'O'}]"
"Hair loss has been reported in several other CTDs, including mixed and undifferentiated CTDs, and primary Sjogrens syndrome, although it is likely to be underestimated in such diseases.nicoletta.cassano@yahoo.com.italiana di dermatologia e sifilografianeuropathies in Sjogrens syndrome.","[{'Hair': 'B-Entity'}, {'loss': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'reported': 'O'}, {'in': 'O'}, {'several': 'O'}, {'other': 'O'}, {'CTDs,': 'I-Entity'}, {'including': 'O'}, {'mixed': 'O'}, {'and': 'O'}, {'undifferentiated': 'O'}, {'CTDs,': 'I-Entity'}, {'and': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'although': 'O'}, {'it': 'O'}, {'is': 'O'}, {'likely': 'O'}, {'to': 'O'}, {'be': 'O'}, {'underestimated': 'O'}, {'in': 'O'}, {'such': 'O'}, {'diseases.nicoletta.cassano@yahoo.com.italiana': 'O'}, {'di': 'O'}]"
"We performed a review of PubMed using the words: older adults, dry mouth, xerostomia, radiation-induced xerostomia, and salivary gland hypofunction.","[{'We': 'O'}, {'performed': 'O'}, {'a': 'O'}, {'review': 'O'}, {'of': 'O'}, {'PubMed': 'O'}, {'using': 'O'}, {'the': 'O'}, {'words:': 'O'}, {'older': 'O'}, {'adults,': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'xerostomia,': 'I-Entity'}, {'radiation-induced': 'I-Entity'}, {'xerostomia,': 'I-Entity'}, {'and': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'hypofunction.': 'I-Entity'}]"
Sjogrens syndrome can also be associated with renal involvement.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'can': 'O'}, {'also': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'renal': 'O'}, {'involvement.': 'O'}]"
Diagnosis was delayed until salivary gland tumors developed in these patients because of the lack of the classic autoantibodies.,"[{'Diagnosis': 'O'}, {'was': 'O'}, {'delayed': 'O'}, {'until': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'tumors': 'I-Entity'}, {'developed': 'O'}, {'in': 'O'}, {'these': 'O'}, {'patients': 'O'}, {'because': 'O'}, {'of': 'O'}, {'the': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'the': 'O'}, {'classic': 'O'}, {'autoantibodies.': 'O'}]"
"Our objectives in this study are to determine its frequency, progression over time, and associated risk factors and complications.","[{'Our': 'O'}, {'objectives': 'O'}, {'in': 'O'}, {'this': 'O'}, {'study': 'O'}, {'are': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'its': 'O'}, {'frequency,': 'O'}, {'progression': 'O'}, {'over': 'O'}, {'time,': 'O'}, {'and': 'O'}, {'associated': 'O'}, {'risk': 'O'}, {'factors': 'O'}, {'and': 'O'}, {'complications.': 'O'}]"
"In RTX-treated patients, a significant reduction in the number of CD20+ B cells/mm(2) parenchyma was observed, while no such reduction was observed in placebo-treated patients.","[{'In': 'O'}, {'RTX-treated': 'I-Entity'}, {'patients,': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'reduction': 'O'}, {'in': 'O'}, {'the': 'O'}, {'number': 'O'}, {'of': 'O'}, {'CD20+': 'O'}, {'B': 'O'}, {'cells/mm(2)': 'O'}, {'parenchyma': 'O'}, {'was': 'O'}, {'observed,': 'O'}, {'while': 'O'}, {'no': 'O'}, {'such': 'O'}, {'reduction': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'placebo-treated': 'O'}, {'patients.': 'O'}]"
"Patients showed minimal response to systemic corticosteroids or steroid dependence, requiring plasmapheresis in the acute phase and immunosuppressive agents for maintenance therapy.","[{'Patients': 'O'}, {'showed': 'O'}, {'minimal': 'O'}, {'response': 'O'}, {'to': 'O'}, {'systemic': 'O'}, {'corticosteroids': 'I-Entity'}, {'or': 'O'}, {'steroid': 'I-Entity'}, {'dependence,': 'O'}, {'requiring': 'O'}, {'plasmapheresis': 'O'}, {'in': 'O'}, {'the': 'O'}, {'acute': 'O'}, {'phase': 'O'}, {'and': 'O'}, {'immunosuppressive': 'O'}, {'agents': 'O'}, {'for': 'O'}, {'maintenance': 'O'}, {'therapy.': 'O'}]"
Hypokalemic paralysis is a rare presentation of Fanconi syndrome (FS) caused by Sjogren Syndrome (SS).,"[{'Hypokalemic': 'I-Entity'}, {'paralysis': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'presentation': 'O'}, {'of': 'O'}, {'Fanconi': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(FS)': 'O'}, {'caused': 'O'}, {'by': 'O'}, {'Sjogren': 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
Aortic stiffness (AS) reflects the mechanical tension and elasticity of the aorta.,"[{'Aortic': 'O'}, {'stiffness': 'O'}, {'(AS)': 'O'}, {'reflects': 'O'}, {'the': 'O'}, {'mechanical': 'O'}, {'tension': 'O'}, {'and': 'O'}, {'elasticity': 'O'}, {'of': 'O'}, {'the': 'O'}, {'aorta.': 'O'}]"
"Neurological involvement has been reported in up to 80% of adults with Primary Sjogren's syndrome (pSS) with psychiatric abnormalities including anxiety, depression, and cognitive dysfunction being common.","[{'Neurological': 'O'}, {'involvement': 'O'}, {'has': 'O'}, {'been': 'O'}, {'reported': 'O'}, {'in': 'O'}, {'up': 'O'}, {'to': 'O'}, {'80%': 'O'}, {'of': 'O'}, {'adults': 'O'}, {'with': 'O'}, {'Primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'with': 'O'}, {'psychiatric': 'B-Entity'}, {'abnormalities': 'I-Entity'}, {'including': 'O'}, {'anxiety,': 'I-Entity'}, {'depression,': 'I-Entity'}, {'and': 'O'}, {'cognitive': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'being': 'O'}, {'common.': 'O'}]"
"Electronic address: cosmiclightbulb@gmail.com.Francisco, San Francisco, California, USA.Francisco, San Francisco, California, USA.Philadelphia, Pennsylvania, USA.Francisco, San Francisco, California, USA.Francisco, San Francisco, California, USA.Francisco, San Francisco, California, USA.12.","[{'Electronic': 'O'}, {'address:': 'O'}, {'cosmiclightbulb@gmail.com.Francisco,': 'O'}, {'San': 'O'}, {'Francisco,': 'O'}, {'California,': 'O'}, {'USA.Francisco,': 'O'}, {'San': 'O'}, {'Francisco,': 'O'}, {'California,': 'O'}, {'USA.Philadelphia,': 'O'}, {'Pennsylvania,': 'O'}, {'USA.Francisco,': 'O'}, {'San': 'O'}, {'Francisco,': 'O'}, {'California,': 'O'}, {'USA.Francisco,': 'O'}, {'San': 'O'}, {'Francisco,': 'O'}, {'California,': 'O'}, {'USA.Francisco,': 'O'}, {'San': 'O'}, {'Francisco,': 'O'}, {'California,': 'O'}]"
Hemophagocytic syndrome is a life-threatening hyperinflammatory fatal disease caused by defect and excessive macrophage activity in natural killer cells.,"[{'Hemophagocytic': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'life-threatening': 'O'}, {'hyperinflammatory': 'O'}, {'fatal': 'O'}, {'disease': 'I-Entity'}, {'caused': 'O'}, {'by': 'O'}, {'defect': 'O'}, {'and': 'O'}, {'excessive': 'O'}, {'macrophage': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'natural': 'O'}, {'killer': 'O'}, {'cells.': 'O'}]"
"Moreover, its associations with antibodies were also evaluated.","[{'Moreover,': 'O'}, {'its': 'O'}, {'associations': 'O'}, {'with': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'also': 'O'}, {'evaluated.': 'O'}]"
Effective induction of salivary gland dysfunction after Ro60 peptide immunization depended on the site of injection.,"[{'Effective': 'O'}, {'induction': 'O'}, {'of': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'dysfunction': 'I-Entity'}, {'after': 'O'}, {'Ro60': 'B-Entity'}, {'peptide': 'I-Entity'}, {'immunization': 'O'}, {'depended': 'O'}, {'on': 'O'}, {'the': 'O'}, {'site': 'O'}, {'of': 'O'}, {'injection.': 'O'}]"
"Smoking patterns were obtained from questionnaire data and disease-related clinical and laboratory data were compared between current, past, ever, and never smokers.","[{'Smoking': 'O'}, {'patterns': 'O'}, {'were': 'O'}, {'obtained': 'O'}, {'from': 'O'}, {'questionnaire': 'O'}, {'data': 'O'}, {'and': 'O'}, {'disease-related': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'data': 'O'}, {'were': 'O'}, {'compared': 'O'}, {'between': 'O'}, {'current,': 'O'}, {'past,': 'O'}, {'ever,': 'O'}, {'and': 'O'}, {'never': 'O'}, {'smokers.': 'O'}]"
"Interstitial lung diseases associated with pSS (pSS-ILDs) usually present as nonspecific interstitial pneumonia or usual interstitial pneumonia; therefore, the present case is extremely unique in that the patient's condition was complicated with CEP.","[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'diseases': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'pSS': 'O'}, {'(pSS-ILDs)': 'O'}, {'usually': 'O'}, {'present': 'O'}, {'as': 'O'}, {'nonspecific': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'or': 'O'}, {'usual': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia;': 'I-Entity'}, {'therefore,': 'O'}, {'the': 'O'}, {'present': 'O'}, {'case': 'O'}, {'is': 'O'}, {'extremely': 'O'}, {'unique': 'O'}, {'in': 'O'}, {'that': 'O'}, {'the': 'O'}, {""patient's"": 'O'}, {'condition': 'O'}, {'was': 'O'}, {'complicated': 'O'}, {'with': 'O'}, {'CEP.': 'I-Entity'}]"
Interstitial lung disease (ILD) and pulmonary hypertension are the most common lung manifestations in CTD.,"[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(ILD)': 'O'}, {'and': 'O'}, {'pulmonary': 'B-Entity'}, {'hypertension': 'I-Entity'}, {'are': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'lung': 'O'}, {'manifestations': 'O'}, {'in': 'O'}, {'CTD.': 'I-Entity'}]"
Right lobe lung biopsy showed diffuse fibrosis with altered alveolar architecture and diffuse infiltration of alveolar septa by lymphocytes and mast cells.,"[{'Right': 'O'}, {'lobe': 'O'}, {'lung': 'O'}, {'biopsy': 'O'}, {'showed': 'O'}, {'diffuse': 'O'}, {'fibrosis': 'I-Entity'}, {'with': 'O'}, {'altered': 'O'}, {'alveolar': 'O'}, {'architecture': 'O'}, {'and': 'O'}, {'diffuse': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'alveolar': 'O'}, {'septa': 'O'}, {'by': 'O'}, {'lymphocytes': 'O'}, {'and': 'O'}, {'mast': 'O'}, {'cells.': 'O'}]"
To compare tear osmolarity (TO) and other dry eye parameters in rheumatoid arthritis (RA) patients with or without secondary Sjogren syndrome (sSS).,"[{'To': 'O'}, {'compare': 'O'}, {'tear': 'O'}, {'osmolarity': 'O'}, {'(TO)': 'O'}, {'and': 'O'}, {'other': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'parameters': 'O'}, {'in': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA)': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'or': 'O'}, {'without': 'O'}, {'secondary': 'O'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(sSS).': 'O'}]"
Immediate corticosteroid therapy resulted in a dramatic recovery.,"[{'Immediate': 'O'}, {'corticosteroid': 'O'}, {'therapy': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'a': 'O'}, {'dramatic': 'O'}, {'recovery.': 'O'}]"
"Sjogrens syndrome (SS)-related peripheral neuropathy is responsible for disability, but no treatment has been shown to improve its outcome.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)-related': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'is': 'O'}, {'responsible': 'O'}, {'for': 'O'}, {'disability,': 'I-Entity'}, {'but': 'O'}, {'no': 'O'}, {'treatment': 'O'}, {'has': 'O'}, {'been': 'O'}, {'shown': 'O'}, {'to': 'O'}, {'improve': 'O'}, {'its': 'O'}, {'outcome.': 'O'}]"
This study suggests that behavioural interventions designed to reduce pain catastrophizing and negative appraisal of illness could be of benefit in pSS patients.,"[{'This': 'O'}, {'study': 'O'}, {'suggests': 'O'}, {'that': 'O'}, {'behavioural': 'O'}, {'interventions': 'O'}, {'designed': 'O'}, {'to': 'O'}, {'reduce': 'O'}, {'pain': 'I-Entity'}, {'catastrophizing': 'O'}, {'and': 'O'}, {'negative': 'O'}, {'appraisal': 'O'}, {'of': 'O'}, {'illness': 'I-Entity'}, {'could': 'O'}, {'be': 'O'}, {'of': 'O'}, {'benefit': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
"To determine whether signs and symptoms of ocular surface disease improve after placement of a self-retained, cryopreserved amniotic membrane (CAM) in patients with Sjogren syndrome (SS).","[{'To': 'O'}, {'determine': 'O'}, {'whether': 'O'}, {'signs': 'O'}, {'and': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'ocular': 'B-Entity'}, {'surface': 'I-Entity'}, {'disease': 'I-Entity'}, {'improve': 'O'}, {'after': 'O'}, {'placement': 'O'}, {'of': 'O'}, {'a': 'O'}, {'self-retained,': 'O'}, {'cryopreserved': 'O'}, {'amniotic': 'O'}, {'membrane': 'O'}, {'(CAM)': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
"These results need to be confirmed in other cohorts and with longitudinal data.Foundation Trust, Birmingham, United Kingdom.Kingdom / Musculoskeletal Research Group, Institute of Cellular Medicine and Newcastle NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Newcastle University, N.Computing Science, Newcastle University, Newcastle upon Tyne, United Kingdom.Kingdom.Chapel Allerton Hospital, Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, United Kingdom.United Kingdom.United Kingdom.United Kingdom.2018.dysfunction in Sjogrens syndrome.","[{'These': 'O'}, {'results': 'O'}, {'need': 'O'}, {'to': 'O'}, {'be': 'O'}, {'confirmed': 'O'}, {'in': 'O'}, {'other': 'O'}, {'cohorts': 'O'}, {'and': 'O'}, {'with': 'O'}, {'longitudinal': 'O'}, {'data.Foundation': 'O'}, {'Trust,': 'O'}, {'Birmingham,': 'O'}, {'United': 'O'}, {'Kingdom.Kingdom': 'O'}, {'/': 'O'}, {'Musculoskeletal': 'O'}, {'Research': 'O'}, {'Group,': 'O'}, {'Institute': 'O'}, {'of': 'O'}, {'Cellular': 'O'}, {'Medicine': 'O'}, {'and': 'O'}, {'Newcastle': 'O'}, {'NIHR': 'O'}, {'Biomedical': 'O'}, {'Research': 'O'}, {'Centre': 'O'}, {'for': 'O'}, {'Ageing': 'O'}, {'and': 'O'}, {'Chronic': 'B-Entity'}, {'Diseases,': 'I-Entity'}, {'Newcastle': 'O'}, {'University,': 'O'}]"
Anti-SS-A antibodies are associated with congenital heart block.,"[{'Anti-SS-A': 'O'}, {'antibodies': 'O'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'congenital': 'B-Entity'}, {'heart': 'I-Entity'}, {'block.': 'I-Entity'}]"
"Anti-nuclear antibodies (ANA) are fundamental for the diagnosis of autoimmune diseases, and have been determined by indirect immunofluorescence assay (IIFA) for decades.","[{'Anti-nuclear': 'O'}, {'antibodies': 'O'}, {'(ANA)': 'O'}, {'are': 'O'}, {'fundamental': 'O'}, {'for': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'and': 'O'}, {'have': 'O'}, {'been': 'O'}, {'determined': 'O'}, {'by': 'O'}, {'indirect': 'O'}, {'immunofluorescence': 'O'}, {'assay': 'O'}, {'(IIFA)': 'O'}, {'for': 'O'}, {'decades.': 'O'}]"
"Infections were more prominently associated with the development of SSA/SSB autoantibody-positive pSS (OR 2.7, 95% CI 2.0-3.5).","[{'Infections': 'I-Entity'}, {'were': 'O'}, {'more': 'O'}, {'prominently': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'SSA/SSB': 'B-Entity'}, {'autoantibody-positive': 'O'}, {'pSS': 'I-Entity'}, {'(OR': 'O'}, {'2.7,': 'O'}, {'95%': 'O'}, {'CI': 'O'}, {'2.0-3.5).': 'O'}]"
NSPT resulted in improved periodontal clinical parameters in both SCP and CP groups (p>0.05).,"[{'NSPT': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'improved': 'O'}, {'periodontal': 'O'}, {'clinical': 'O'}, {'parameters': 'O'}, {'in': 'O'}, {'both': 'O'}, {'SCP': 'I-Entity'}, {'and': 'O'}, {'CP': 'I-Entity'}, {'groups': 'O'}, {'(p>0.05).': 'O'}]"
Sjogren's syndrome (SjS) causes salivary gland impairment leading to oral dryness.,"[{""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SjS)': 'O'}, {'causes': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'impairment': 'I-Entity'}, {'leading': 'O'}, {'to': 'O'}, {'oral': 'B-Entity'}, {'dryness.': 'I-Entity'}]"
"In spite of the protective effects of tobacco on SS manifestations, it is associated with other serious comorbidities such as lung disease, cardiovascular risk and malignancy, and should thus be strongly discouraged in patients with sicca.States of America.Foundation, Oklahoma City, Oklahoma, United States of America.Foundation, Oklahoma City, Oklahoma, United States of America.Antonio, Texas, United States of America.Dentistry, Oklahoma City, Oklahoma, United States of America.City, Oklahoma, United States of America.City, Oklahoma, United States of America.Minneapolis, Minnesota, United States of America.United States of America.United States of America.United States of America.United States of America.Foundation, Oklahoma City, Oklahoma, United States of America.Foundation, Oklahoma City, Oklahoma, United States of America.Foundation, Oklahoma City, Oklahoma, United States of America.City, Oklahoma, United States of America.States of America.Foundation, Oklahoma City, Oklahoma, United States of America.Foundation, Oklahoma City, Oklahoma, United States of America.2017.syndrome: 25-year experience.","[{'In': 'O'}, {'spite': 'O'}, {'of': 'O'}, {'the': 'O'}, {'protective': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'tobacco': 'I-Entity'}, {'on': 'O'}, {'SS': 'I-Entity'}, {'manifestations,': 'O'}, {'it': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'other': 'O'}, {'serious': 'O'}, {'comorbidities': 'O'}, {'such': 'O'}, {'as': 'O'}, {'lung': 'B-Entity'}, {'disease,': 'I-Entity'}, {'cardiovascular': 'O'}, {'risk': 'I-Entity'}, {'and': 'O'}, {'malignancy,': 'I-Entity'}, {'and': 'O'}, {'should': 'O'}, {'thus': 'O'}, {'be': 'O'}, {'strongly': 'O'}, {'discouraged': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'sicca.States': 'I-Entity'}, {'of': 'O'}, {'America.Foundation,': 'O'}, {'Oklahoma': 'O'}, {'City,': 'O'}, {'Oklahoma,': 'O'}, {'United': 'O'}, {'States': 'O'}]"
Cytokine stimulation protected cells from death when co-incubated with an ERAD machinery inhibitor.,"[{'Cytokine': 'O'}, {'stimulation': 'O'}, {'protected': 'O'}, {'cells': 'O'}, {'from': 'O'}, {'death': 'I-Entity'}, {'when': 'O'}, {'co-incubated': 'O'}, {'with': 'O'}, {'an': 'O'}, {'ERAD': 'O'}, {'machinery': 'O'}, {'inhibitor.': 'O'}]"
"Data suggest that the expansion of CD4(+)CD25(low)GITR(+) cells in pSS may represent a counter-regulatory attempt against autoimmune-driven inflammation and may provide a new target for future treatment strategies.Perugia, Via Enrico Dal Pozzo, I-06122 Perugia, Italy.Epub 2013 May 14.","[{'Data': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'the': 'O'}, {'expansion': 'O'}, {'of': 'O'}, {'CD4(+)CD25(low)GITR(+)': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'may': 'O'}, {'represent': 'O'}, {'a': 'O'}, {'counter-regulatory': 'O'}, {'attempt': 'O'}, {'against': 'O'}, {'autoimmune-driven': 'I-Entity'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'may': 'O'}, {'provide': 'O'}, {'a': 'O'}, {'new': 'O'}, {'target': 'O'}, {'for': 'O'}, {'future': 'O'}, {'treatment': 'O'}, {'strategies.Perugia,': 'O'}, {'Via': 'O'}, {'Enrico': 'O'}, {'Dal': 'O'}, {'Pozzo,': 'O'}, {'I-06122': 'O'}]"
"The incidence of SS is higher among aged individuals, which might be due to earlier diagnosis, as the onset of SS in an individual with age-related exocrine gland dysfunction lowers the threshold for sicca complaints.","[{'The': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'is': 'O'}, {'higher': 'O'}, {'among': 'O'}, {'aged': 'O'}, {'individuals,': 'O'}, {'which': 'O'}, {'might': 'O'}, {'be': 'O'}, {'due': 'O'}, {'to': 'O'}, {'earlier': 'O'}, {'diagnosis,': 'O'}, {'as': 'O'}, {'the': 'O'}, {'onset': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'in': 'O'}, {'an': 'O'}, {'individual': 'O'}, {'with': 'O'}, {'age-related': 'O'}, {'exocrine': 'B-Entity'}, {'gland': 'I-Entity'}, {'dysfunction': 'I-Entity'}, {'lowers': 'O'}, {'the': 'O'}, {'threshold': 'O'}, {'for': 'O'}, {'sicca': 'B-Entity'}, {'complaints.': 'O'}]"
"The purpose of this report is to describe 2 patients with persistent severe dry eyes, positive Schirmer tests for Sjogren's syndrome (SS) but lacking antibodies to either Ro or La.","[{'The': 'O'}, {'purpose': 'O'}, {'of': 'O'}, {'this': 'O'}, {'report': 'O'}, {'is': 'O'}, {'to': 'O'}, {'describe': 'O'}, {'2': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'persistent': 'O'}, {'severe': 'O'}, {'dry': 'B-Entity'}, {'eyes,': 'I-Entity'}, {'positive': 'O'}, {'Schirmer': 'O'}, {'tests': 'O'}, {'for': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'but': 'O'}, {'lacking': 'O'}, {'antibodies': 'O'}, {'to': 'O'}, {'either': 'O'}, {'Ro': 'I-Entity'}, {'or': 'O'}, {'La.': 'I-Entity'}]"
"Of interest, besides clinical efficacy, RTX also showed biologic effects, consistently affecting the inflammation and the lymphoid organization that occur in target tissue.","[{'Of': 'O'}, {'interest,': 'O'}, {'besides': 'O'}, {'clinical': 'O'}, {'efficacy,': 'O'}, {'RTX': 'I-Entity'}, {'also': 'O'}, {'showed': 'O'}, {'biologic': 'O'}, {'effects,': 'O'}, {'consistently': 'O'}, {'affecting': 'O'}, {'the': 'O'}, {'inflammation': 'O'}, {'and': 'O'}, {'the': 'O'}, {'lymphoid': 'O'}, {'organization': 'O'}, {'that': 'O'}, {'occur': 'O'}, {'in': 'O'}, {'target': 'O'}, {'tissue.': 'O'}]"
"Although recent genetic association studies have contributed to the discovery of SS susceptible genes, few studies have reported on the Korean population.","[{'Although': 'O'}, {'recent': 'O'}, {'genetic': 'O'}, {'association': 'O'}, {'studies': 'O'}, {'have': 'O'}, {'contributed': 'O'}, {'to': 'O'}, {'the': 'O'}, {'discovery': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'susceptible': 'O'}, {'genes,': 'O'}, {'few': 'O'}, {'studies': 'O'}, {'have': 'O'}, {'reported': 'O'}, {'on': 'O'}, {'the': 'O'}, {'Korean': 'O'}, {'population.': 'O'}]"
"This study also demonstrated that diquafosol treatment is beneficial for TBUT improvement in SS, while it is beneficial for OSS improvement in non-SS dry eye patients.Seongnam, Republic of Korea.Seongnam, Republic of Korea.Seoul, Republic of Korea.Association for Ocular Pharmacology and TherapeuticsJun 13.Sjogrens syndrome.","[{'This': 'O'}, {'study': 'O'}, {'also': 'O'}, {'demonstrated': 'O'}, {'that': 'O'}, {'diquafosol': 'I-Entity'}, {'treatment': 'O'}, {'is': 'O'}, {'beneficial': 'O'}, {'for': 'O'}, {'TBUT': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'SS,': 'I-Entity'}, {'while': 'O'}, {'it': 'O'}, {'is': 'O'}, {'beneficial': 'O'}, {'for': 'O'}, {'OSS': 'I-Entity'}, {'improvement': 'O'}, {'in': 'O'}, {'non-SS': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'patients.Seongnam,': 'O'}, {'Republic': 'O'}, {'of': 'O'}, {'Korea.Seongnam,': 'O'}, {'Republic': 'O'}, {'of': 'O'}, {'Korea.Seoul,': 'O'}, {'Republic': 'O'}, {'of': 'O'}, {'Korea.Association': 'O'}, {'for': 'O'}, {'Ocular': 'O'}]"
Pulmonary diagnostics were performed in 225 patients (86%).,"[{'Pulmonary': 'O'}, {'diagnostics': 'O'}, {'were': 'O'}, {'performed': 'O'}, {'in': 'O'}, {'225': 'O'}, {'patients': 'O'}, {'(86%).': 'O'}]"
Sjogren syndrome (SS) is a chronic inflammatory autoimmune disease of the lacrimal and salivary glands.,"[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'inflammatory': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'lacrimal': 'B-Entity'}, {'and': 'I-Entity'}, {'salivary': 'I-Entity'}, {'glands.': 'I-Entity'}]"
"Further investigation is warranted to determine the possible underlying mechanisms and the potential role of non-hydroxychloroquine immunosuppressants in ameliorating PD.Tri-Service General Hospital, National Defense Medical Center, Taipei.Medicine, China Medical University.University, Taichung.County, China Medical University.University, Taichung.Taichung, Taiwan.Hospital, Changhua, Taiwan.immunoassay.","[{'Further': 'O'}, {'investigation': 'O'}, {'is': 'O'}, {'warranted': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'possible': 'O'}, {'underlying': 'O'}, {'mechanisms': 'O'}, {'and': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'role': 'O'}, {'of': 'O'}, {'non-hydroxychloroquine': 'O'}, {'immunosuppressants': 'O'}, {'in': 'O'}, {'ameliorating': 'O'}, {'PD.Tri-Service': 'I-Entity'}, {'General': 'O'}, {'Hospital,': 'O'}, {'National': 'O'}, {'Defense': 'O'}, {'Medical': 'O'}, {'Center,': 'O'}, {'Taipei.Medicine,': 'O'}, {'China': 'O'}, {'Medical': 'O'}, {'University.University,': 'O'}, {'Taichung.County,': 'O'}]"
"Systolic pulmonary artery pressure (SPAP) >30‚Äö√Ñ√∂‚àö√ë‚àö¬¢mm‚Äö√Ñ√∂‚àö√ë‚àö¬¢Hg values, which were measured at the resting state, were accepted as significant for PAH.","[{'Systolic': 'O'}, {'pulmonary': 'O'}, {'artery': 'O'}, {'pressure': 'O'}, {'(SPAP)': 'O'}, {'>30‚Äö√Ñ√∂‚àö√ë‚àö¬¢mm‚Äö√Ñ√∂‚àö√ë‚àö¬¢Hg': 'O'}, {'values,': 'O'}, {'which': 'O'}, {'were': 'O'}, {'measured': 'O'}, {'at': 'O'}, {'the': 'O'}, {'resting': 'O'}, {'state,': 'O'}, {'were': 'O'}, {'accepted': 'O'}]"
"The levels of Gal3ST activity were significantly decreased in SS patients, without changes in mRNA and protein levels, while the enzymatic activities of glycosyltransferases involved in mucin glycosylation were similar in both groups.","[{'The': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'Gal3ST': 'O'}, {'activity': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'decreased': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients,': 'O'}, {'without': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'mRNA': 'O'}, {'and': 'O'}, {'protein': 'O'}, {'levels,': 'O'}, {'while': 'O'}, {'the': 'O'}, {'enzymatic': 'O'}, {'activities': 'O'}, {'of': 'O'}, {'glycosyltransferases': 'O'}, {'involved': 'O'}, {'in': 'O'}, {'mucin': 'O'}, {'glycosylation': 'O'}, {'were': 'O'}, {'similar': 'O'}, {'in': 'O'}, {'both': 'O'}, {'groups.': 'O'}]"
"Sjogren's syndrome is associated with chronic cough, but sicca symptoms are missing from cough evaluation guidelines.","[{""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'chronic': 'O'}, {'cough,': 'I-Entity'}, {'but': 'O'}, {'sicca': 'B-Entity'}, {'symptoms': 'O'}, {'are': 'O'}, {'missing': 'O'}, {'from': 'O'}, {'cough': 'I-Entity'}, {'evaluation': 'O'}, {'guidelines.': 'O'}]"
"We report a case of such a patient suffering from respiratory failure due to recurrent episodes of right pneumothorax, requiring invasive mechanical ventilation.","[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'such': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'suffering': 'O'}, {'from': 'O'}, {'respiratory': 'B-Entity'}, {'failure': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'recurrent': 'O'}, {'episodes': 'O'}, {'of': 'O'}, {'right': 'O'}, {'pneumothorax,': 'I-Entity'}, {'requiring': 'O'}, {'invasive': 'O'}, {'mechanical': 'O'}, {'ventilation.': 'O'}]"
"Gastroesophageal reflux was reported in 50.0% (40 vs 27 in the CG, P‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢.04) and gastric ulcers in 10.0% (8 vs 3 in the CG, P‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢.13); 20.0% of the cohort had positive Helicobacter pylori serology (16 vs 2 in the CG, P‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢.003).","[{'Gastroesophageal': 'B-Entity'}, {'reflux': 'I-Entity'}, {'was': 'O'}, {'reported': 'O'}, {'in': 'O'}, {'50.0%': 'O'}, {'(40': 'O'}, {'vs': 'O'}, {'27': 'O'}, {'in': 'O'}, {'the': 'O'}, {'CG,': 'O'}, {'P‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢.04)': 'O'}]"
The mean follow-up duration was 9.1 ¬¨¬®¬¨¬± 6.9 years.,"[{'The': 'O'}, {'mean': 'O'}, {'follow-up': 'O'}, {'duration': 'O'}, {'was': 'O'}, {'9.1': 'O'}, {'¬¨¬®¬¨¬±': 'O'}, {'6.9': 'O'}, {'years.': 'O'}]"
"Diagnostics: indirect immunofluorescence (IF; Hep-2 cell line) of antinuclear antibodies (ANA), anti-SS-A anti-SS-B antibodies determined with semi-quantitative method, autoantibody profile (14 antigens, ANA Profil 3 EUROLINE); basic laboratory, ophthalmic examination tests, minor salivary gland biopsy with focus score (FS), joint and lung evaluation, and ESSDAI questionnaire (pSS activity).","[{'Diagnostics:': 'O'}, {'indirect': 'O'}, {'immunofluorescence': 'O'}, {'(IF;': 'O'}, {'Hep-2': 'O'}, {'cell': 'O'}, {'line)': 'O'}, {'of': 'O'}, {'antinuclear': 'O'}, {'antibodies': 'O'}, {'(ANA),': 'O'}, {'anti-SS-A': 'O'}, {'anti-SS-B': 'O'}, {'antibodies': 'O'}, {'determined': 'O'}, {'with': 'O'}, {'semi-quantitative': 'O'}, {'method,': 'O'}, {'autoantibody': 'O'}, {'profile': 'O'}, {'(14': 'O'}, {'antigens,': 'O'}, {'ANA': 'O'}]"
We describe patients in whom unexplained chronic cough was associated with dry eyes.,"[{'We': 'O'}, {'describe': 'O'}, {'patients': 'O'}, {'in': 'O'}, {'whom': 'O'}, {'unexplained': 'O'}, {'chronic': 'B-Entity'}, {'cough': 'I-Entity'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'eyes.': 'I-Entity'}]"
"B cell depletion therapy resulted in a pronounced decrease in circulating TFH cells, whereas Th17 cells were only slightly lowered.","[{'B': 'O'}, {'cell': 'O'}, {'depletion': 'O'}, {'therapy': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'a': 'O'}, {'pronounced': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'circulating': 'O'}, {'TFH': 'O'}, {'cells,': 'O'}, {'whereas': 'O'}, {'Th17': 'O'}, {'cells': 'O'}, {'were': 'O'}, {'only': 'O'}, {'slightly': 'O'}, {'lowered.': 'O'}]"
"Patients with pSS showed an increased work disability, in comparison with the general population, which increased significantly during the first 2 years after diagnosis.","[{'Patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'showed': 'O'}, {'an': 'O'}, {'increased': 'O'}, {'work': 'B-Entity'}, {'disability,': 'I-Entity'}, {'in': 'O'}, {'comparison': 'O'}, {'with': 'O'}, {'the': 'O'}, {'general': 'O'}, {'population,': 'O'}, {'which': 'O'}, {'increased': 'O'}, {'significantly': 'O'}, {'during': 'O'}, {'the': 'O'}, {'first': 'O'}, {'2': 'O'}, {'years': 'O'}, {'after': 'O'}, {'diagnosis.': 'O'}]"
"Due to the temporal relationship of these complications and this patient's history of autoimmune disorders, it is reasonable to believe that an APS was both induced by the tasing event and associated with her lupus.","[{'Due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'temporal': 'O'}, {'relationship': 'O'}, {'of': 'O'}, {'these': 'O'}, {'complications': 'O'}, {'and': 'O'}, {'this': 'O'}, {""patient's"": 'O'}, {'history': 'O'}, {'of': 'O'}, {'autoimmune': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'it': 'O'}, {'is': 'O'}, {'reasonable': 'O'}, {'to': 'O'}, {'believe': 'O'}, {'that': 'O'}, {'an': 'O'}, {'APS': 'I-Entity'}, {'was': 'O'}, {'both': 'O'}, {'induced': 'O'}, {'by': 'O'}, {'the': 'O'}, {'tasing': 'O'}, {'event': 'O'}, {'and': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'her': 'O'}, {'lupus.': 'I-Entity'}]"
Twenty percent (20%) of patients with premature ovarian failure have a concomitant autoimmune disease.,"[{'Twenty': 'O'}, {'percent': 'O'}, {'(20%)': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'premature': 'B-Entity'}, {'ovarian': 'I-Entity'}, {'failure': 'I-Entity'}, {'have': 'O'}, {'a': 'O'}, {'concomitant': 'O'}, {'autoimmune': 'B-Entity'}, {'disease.': 'I-Entity'}]"
"Interstitial lung disease (ILD) is a major pulmonary manifestation of connective tissue disease (CTD), leading to significant morbidity and mortality.","[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(ILD)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'major': 'O'}, {'pulmonary': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'(CTD),': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'significant': 'O'}, {'morbidity': 'O'}, {'and': 'O'}, {'mortality.': 'O'}]"
"New therapeutic strategies, such as B cell targeted therapies, are in clinical testing especially for patients with severe organ manifestations.Lehrkrankenhaus der Charit‚Äö√†√∂¬¨¬©, Berlin, Deutschland.","[{'New': 'O'}, {'therapeutic': 'O'}, {'strategies,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'targeted': 'O'}, {'therapies,': 'O'}, {'are': 'O'}, {'in': 'O'}, {'clinical': 'O'}, {'testing': 'O'}, {'especially': 'O'}, {'for': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'severe': 'O'}, {'organ': 'O'}, {'manifestations.Lehrkrankenhaus': 'O'}, {'der': 'O'}, {'Charit‚Äö√†√∂¬¨¬©,': 'O'}, {'Berlin,': 'O'}, {'Deutschland.': 'O'}]"
To investigate parameters of ocular surface disease in C57BL/6.NOD-Aec1Aec2 (Aec) mice with aging and their correlation with development of Sjogren syndrome (SS)-like lacrimal gland (LG) disease.,"[{'To': 'O'}, {'investigate': 'O'}, {'parameters': 'O'}, {'of': 'O'}, {'ocular': 'B-Entity'}, {'surface': 'I-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'C57BL/6.NOD-Aec1Aec2': 'O'}, {'(Aec)': 'O'}, {'mice': 'O'}, {'with': 'O'}, {'aging': 'O'}, {'and': 'O'}, {'their': 'O'}, {'correlation': 'O'}, {'with': 'O'}, {'development': 'O'}, {'of': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)-like': 'O'}, {'lacrimal': 'B-Entity'}, {'gland': 'I-Entity'}, {'(LG)': 'I-Entity'}, {'disease.': 'I-Entity'}]"
The results indicate that the BAK1 polymorphisms influence the risk of acquiring AIRDs in the population studied and are consistent with the paradigm that autoimmune diseases are likely to share common susceptibility variants.patients: quantitative immunopathology.,"[{'The': 'O'}, {'results': 'O'}, {'indicate': 'O'}, {'that': 'O'}, {'the': 'O'}, {'BAK1': 'O'}, {'polymorphisms': 'O'}, {'influence': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'acquiring': 'O'}, {'AIRDs': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'population': 'O'}, {'studied': 'O'}, {'and': 'O'}, {'are': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'the': 'O'}, {'paradigm': 'O'}, {'that': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'are': 'O'}, {'likely': 'O'}, {'to': 'O'}, {'share': 'O'}, {'common': 'O'}, {'susceptibility': 'O'}, {'variants.patients:': 'O'}, {'quantitative': 'O'}, {'immunopathology.': 'O'}]"
Symptoms in keeping with autonomic dysfunction are commonly described by primary Sjogrens syndrome patients (pSS); whether objective abnormalities of autonomic function occur is unclear.,"[{'Symptoms': 'O'}, {'in': 'O'}, {'keeping': 'O'}, {'with': 'O'}, {'autonomic': 'O'}, {'dysfunction': 'I-Entity'}, {'are': 'O'}, {'commonly': 'O'}, {'described': 'O'}, {'by': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'patients': 'O'}, {'(pSS);': 'O'}, {'whether': 'O'}, {'objective': 'O'}, {'abnormalities': 'O'}, {'of': 'O'}, {'autonomic': 'O'}, {'function': 'O'}, {'occur': 'O'}, {'is': 'O'}, {'unclear.': 'O'}]"
"Knowing that these patients have higher salivary surface tension, we postulated that sleep disordered breathing (SDB) would be more common and would be a contributor to these symptoms amongst pSS patients.","[{'Knowing': 'O'}, {'that': 'O'}, {'these': 'O'}, {'patients': 'O'}, {'have': 'O'}, {'higher': 'O'}, {'salivary': 'O'}, {'surface': 'O'}, {'tension,': 'O'}, {'we': 'O'}, {'postulated': 'O'}, {'that': 'O'}, {'sleep': 'B-Entity'}, {'disordered': 'I-Entity'}, {'breathing': 'I-Entity'}, {'(SDB)': 'O'}, {'would': 'O'}, {'be': 'O'}, {'more': 'O'}, {'common': 'O'}, {'and': 'O'}, {'would': 'O'}, {'be': 'O'}, {'a': 'O'}, {'contributor': 'O'}, {'to': 'O'}, {'these': 'O'}, {'symptoms': 'O'}, {'amongst': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
Hepatocellular carcinoma (HCC) typically originates from HBV or HCV associated liver cirrhosis.,"[{'Hepatocellular': 'B-Entity'}, {'carcinoma': 'I-Entity'}, {'(HCC)': 'O'}, {'typically': 'O'}, {'originates': 'O'}, {'from': 'O'}, {'HBV': 'B-Entity'}, {'or': 'I-Entity'}, {'HCV': 'I-Entity'}, {'associated': 'O'}, {'liver': 'B-Entity'}, {'cirrhosis.': 'I-Entity'}]"
Autoimmune connective tissue diseases predominantly affect women and often occur during the reproductive years.,"[{'Autoimmune': 'B-Entity'}, {'connective': 'I-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'predominantly': 'O'}, {'affect': 'O'}, {'women': 'O'}, {'and': 'O'}, {'often': 'O'}, {'occur': 'O'}, {'during': 'O'}, {'the': 'O'}, {'reproductive': 'O'}, {'years.': 'O'}]"
A lack of true understanding of the underlying immunological pathology of the disease prevents directed therapy.,"[{'A': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'true': 'O'}, {'understanding': 'O'}, {'of': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'immunological': 'O'}, {'pathology': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'prevents': 'O'}, {'directed': 'O'}, {'therapy.': 'O'}]"
"The results were normal in 49 and abnormal in 109 patients, in whom peripheral neuropathy was diagnosed in 102.","[{'The': 'O'}, {'results': 'O'}, {'were': 'O'}, {'normal': 'O'}, {'in': 'O'}, {'49': 'O'}, {'and': 'O'}, {'abnormal': 'O'}, {'in': 'O'}, {'109': 'O'}, {'patients,': 'O'}, {'in': 'O'}, {'whom': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'was': 'O'}, {'diagnosed': 'O'}, {'in': 'O'}, {'102.': 'O'}]"
"Maternal and fetal outcome in pregnancy with renal failure is unpredictable, where each condition can adversely affect the other.","[{'Maternal': 'O'}, {'and': 'O'}, {'fetal': 'O'}, {'outcome': 'O'}, {'in': 'O'}, {'pregnancy': 'O'}, {'with': 'O'}, {'renal': 'B-Entity'}, {'failure': 'I-Entity'}, {'is': 'O'}, {'unpredictable,': 'O'}, {'where': 'O'}, {'each': 'O'}, {'condition': 'O'}, {'can': 'O'}, {'adversely': 'O'}, {'affect': 'O'}, {'the': 'O'}, {'other.': 'O'}]"
"Oral pilocarpine seemed to be effective in improving TMH, and the signs and symptoms of dryness in patients with SS.osamaibrahim82@yahoo.com","[{'Oral': 'O'}, {'pilocarpine': 'I-Entity'}, {'seemed': 'O'}, {'to': 'O'}, {'be': 'O'}, {'effective': 'O'}, {'in': 'O'}, {'improving': 'O'}, {'TMH,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'signs': 'O'}, {'and': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'dryness': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS.osamaibrahim82@yahoo.com': 'I-Entity'}]"
"A mutation in the HMBS gene was detected in the patient and her cousin, but the patient had more severe AIP and more severe symptoms (such as epilepsy and a limp), which may be related to the co-morbidity of PSS.","[{'A': 'O'}, {'mutation': 'O'}, {'in': 'O'}, {'the': 'O'}, {'HMBS': 'O'}, {'gene': 'O'}, {'was': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'and': 'O'}, {'her': 'O'}, {'cousin,': 'O'}, {'but': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'had': 'O'}, {'more': 'O'}, {'severe': 'O'}, {'AIP': 'I-Entity'}, {'and': 'O'}, {'more': 'O'}, {'severe': 'O'}, {'symptoms': 'O'}, {'(such': 'O'}, {'as': 'O'}, {'epilepsy': 'I-Entity'}, {'and': 'O'}, {'a': 'O'}, {'limp),': 'I-Entity'}, {'which': 'O'}, {'may': 'O'}, {'be': 'O'}, {'related': 'O'}, {'to': 'O'}, {'the': 'O'}, {'co-morbidity': 'O'}, {'of': 'O'}, {'PSS.': 'I-Entity'}]"
Tubular atrophy and interstitial fibrosis were also common biopsy findings.,"[{'Tubular': 'B-Entity'}, {'atrophy': 'I-Entity'}, {'and': 'O'}, {'interstitial': 'O'}, {'fibrosis': 'I-Entity'}, {'were': 'O'}, {'also': 'O'}, {'common': 'O'}, {'biopsy': 'O'}, {'findings.': 'O'}]"
Biologic therapies specifically directed against molecules involved in disease pathogenesis represent a potentially more effective approach to therapeutic intervention in rheumatic diseases including PSS.,"[{'Biologic': 'O'}, {'therapies': 'O'}, {'specifically': 'O'}, {'directed': 'O'}, {'against': 'O'}, {'molecules': 'O'}, {'involved': 'O'}, {'in': 'O'}, {'disease': 'O'}, {'pathogenesis': 'O'}, {'represent': 'O'}, {'a': 'O'}, {'potentially': 'O'}, {'more': 'O'}, {'effective': 'O'}, {'approach': 'O'}, {'to': 'O'}, {'therapeutic': 'O'}, {'intervention': 'O'}, {'in': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases': 'I-Entity'}, {'including': 'O'}, {'PSS.': 'I-Entity'}]"
"The presence of EBV EA/D-, EBNA-1-, VCA p23-, and gp350-directed antibodies in each pool was consistent within the obtained ELISA and line blot results, as increased titers of IgG against the four antigens were found in all patient serum pools and also in individual sera regarding gp350.","[{'The': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'EBV': 'O'}, {'EA/D-,': 'O'}, {'EBNA-1-,': 'O'}, {'VCA': 'O'}, {'p23-,': 'O'}, {'and': 'O'}, {'gp350-directed': 'O'}, {'antibodies': 'O'}, {'in': 'O'}, {'each': 'O'}, {'pool': 'O'}, {'was': 'O'}, {'consistent': 'O'}, {'within': 'O'}, {'the': 'O'}, {'obtained': 'O'}, {'ELISA': 'O'}, {'and': 'O'}, {'line': 'O'}, {'blot': 'O'}, {'results,': 'O'}, {'as': 'O'}, {'increased': 'O'}, {'titers': 'O'}, {'of': 'O'}, {'IgG': 'O'}, {'against': 'O'}, {'the': 'O'}, {'four': 'O'}]"
"Other causes of vision loss included pre-existing glaucoma (n=6), sterile vitritis (n=5), cylinder loosening (n=1) and retroprosthetic membrane (n=4).","[{'Other': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'vision': 'B-Entity'}, {'loss': 'I-Entity'}, {'included': 'O'}, {'pre-existing': 'O'}, {'glaucoma': 'I-Entity'}, {'(n=6),': 'O'}, {'sterile': 'O'}, {'vitritis': 'I-Entity'}, {'(n=5),': 'O'}, {'cylinder': 'O'}, {'loosening': 'O'}, {'(n=1)': 'O'}, {'and': 'O'}, {'retroprosthetic': 'O'}, {'membrane': 'O'}, {'(n=4).': 'O'}]"
"The adult patients of FB usually have mild symptoms, ILD and underlying diseases.","[{'The': 'O'}, {'adult': 'O'}, {'patients': 'O'}, {'of': 'O'}, {'FB': 'I-Entity'}, {'usually': 'O'}, {'have': 'O'}, {'mild': 'O'}, {'symptoms,': 'O'}, {'ILD': 'I-Entity'}, {'and': 'O'}, {'underlying': 'O'}, {'diseases.': 'O'}]"
Deaths due to tuberculosis have reached 2.5 million cases per year worldwide.,"[{'Deaths': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'tuberculosis': 'I-Entity'}, {'have': 'O'}, {'reached': 'O'}, {'2.5': 'O'}, {'million': 'O'}, {'cases': 'O'}, {'per': 'O'}, {'year': 'O'}, {'worldwide.': 'O'}]"
"This sequential belimumab-rituximab treatment was followed by a marked amelioration, with the complete and persistent regression of lymphoma and healing of a refractory skin ulcer.","[{'This': 'O'}, {'sequential': 'O'}, {'belimumab-rituximab': 'I-Entity'}, {'treatment': 'O'}, {'was': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'a': 'O'}, {'marked': 'O'}, {'amelioration,': 'O'}, {'with': 'O'}, {'the': 'O'}, {'complete': 'O'}, {'and': 'O'}, {'persistent': 'O'}, {'regression': 'O'}, {'of': 'O'}, {'lymphoma': 'I-Entity'}, {'and': 'O'}, {'healing': 'O'}, {'of': 'O'}, {'a': 'O'}, {'refractory': 'O'}, {'skin': 'O'}, {'ulcer.': 'I-Entity'}]"
Treatment with oral hydroxychloroquine showed dramatic effects and complete hair regrowth was obtained 3 months later.syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise.,"[{'Treatment': 'O'}, {'with': 'O'}, {'oral': 'O'}, {'hydroxychloroquine': 'I-Entity'}, {'showed': 'O'}, {'dramatic': 'O'}, {'effects': 'O'}, {'and': 'O'}, {'complete': 'O'}, {'hair': 'B-Entity'}, {'regrowth': 'O'}, {'was': 'O'}, {'obtained': 'O'}, {'3': 'O'}, {'months': 'O'}, {'later.syndrome': 'O'}, {'using': 'O'}, {'consensual': 'O'}, {'definitions:': 'O'}, {'an': 'O'}, {'OMERACT': 'O'}, {'ultrasound': 'O'}, {'working': 'O'}, {'group': 'O'}, {'reliability': 'O'}, {'exercise.': 'O'}]"
"Antinuclear antibodies were measured by indirect immunofluorescence (IIF) (dilution 1:160) and by BioPlex 2200 ANA screen (antibodies to dsDNA, chromatin, ribosomal protein, SSA-52, SSA-60, SSB, Sm, SmRNP, RNP-A, RNP-68, Scl-70, Jo-1, and centromere B) in 236 patients with a systemic rheumatic disease at the time of diagnosis, 149 blood donors, 139 patients with chronic fatigue syndrome (CFS), and 134 diseased controls.","[{'Antinuclear': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'measured': 'O'}, {'by': 'O'}, {'indirect': 'O'}, {'immunofluorescence': 'O'}, {'(IIF)': 'O'}, {'(dilution': 'O'}, {'1:160)': 'O'}, {'and': 'O'}, {'by': 'O'}, {'BioPlex': 'O'}, {'2200': 'O'}, {'ANA': 'O'}, {'screen': 'O'}, {'(antibodies': 'O'}, {'to': 'O'}, {'dsDNA,': 'O'}, {'chromatin,': 'O'}, {'ribosomal': 'O'}, {'protein,': 'O'}, {'SSA-52,': 'O'}, {'SSA-60,': 'O'}]"
Rheumatoid arthritis has manifestations in various organs including ophthalmic involvement.,"[{'Rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'has': 'O'}, {'manifestations': 'O'}, {'in': 'O'}, {'various': 'O'}, {'organs': 'O'}, {'including': 'O'}, {'ophthalmic': 'O'}, {'involvement.': 'O'}]"
Potential risk factors associated with cardiovascular involvement were determined by multivariate analyses.,"[{'Potential': 'O'}, {'risk': 'O'}, {'factors': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'cardiovascular': 'B-Entity'}, {'involvement': 'I-Entity'}, {'were': 'O'}, {'determined': 'O'}, {'by': 'O'}, {'multivariate': 'O'}, {'analyses.': 'O'}]"
The mean ocular surface grading scores were significantly higher and the mean score of all 12 NEI VFQ subscales was significantly lower in the SJS patients compared to the SS patients and the normal subjects (P < .05).,"[{'The': 'O'}, {'mean': 'O'}, {'ocular': 'O'}, {'surface': 'O'}, {'grading': 'O'}, {'scores': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'and': 'O'}, {'the': 'O'}, {'mean': 'O'}, {'score': 'O'}, {'of': 'O'}, {'all': 'O'}, {'12': 'O'}, {'NEI': 'O'}, {'VFQ': 'O'}, {'subscales': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'lower': 'O'}, {'in': 'O'}, {'the': 'O'}, {'SJS': 'I-Entity'}, {'patients': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'the': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'the': 'O'}, {'normal': 'O'}, {'subjects': 'O'}, {'(P': 'O'}, {'<': 'O'}, {'.05).': 'O'}]"
Interstitial lung disease (ILD) is a significant complication of Sjogren syndrome (SS) associated with increased morbidity and mortality.,"[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(ILD)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'increased': 'O'}, {'morbidity': 'O'}, {'and': 'O'}, {'mortality.': 'O'}]"
Mikulicz Syndrome (MS) is a rare chronic condition characterized by the abnormal enlargement of glandular tissue in the head and neck.,"[{'Mikulicz': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'(MS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'chronic': 'O'}, {'condition': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'the': 'O'}, {'abnormal': 'O'}, {'enlargement': 'O'}, {'of': 'O'}, {'glandular': 'O'}, {'tissue': 'O'}, {'in': 'O'}, {'the': 'O'}, {'head': 'O'}, {'and': 'O'}, {'neck.': 'O'}]"
"Cryoglobulinaemia leads to variable symptoms including characteristic purpura, ischaemia of extremities, renal failure, peripheral neuropathy, abdominal pain secondary to intestinal ischaemia and arthralgias.","[{'Cryoglobulinaemia': 'I-Entity'}, {'leads': 'O'}, {'to': 'O'}, {'variable': 'O'}, {'symptoms': 'O'}, {'including': 'O'}, {'characteristic': 'O'}, {'purpura,': 'I-Entity'}, {'ischaemia': 'B-Entity'}, {'of': 'I-Entity'}, {'extremities,': 'I-Entity'}, {'renal': 'B-Entity'}, {'failure,': 'I-Entity'}, {'peripheral': 'B-Entity'}, {'neuropathy,': 'I-Entity'}, {'abdominal': 'B-Entity'}, {'pain': 'I-Entity'}, {'secondary': 'O'}, {'to': 'O'}, {'intestinal': 'B-Entity'}, {'ischaemia': 'I-Entity'}, {'and': 'O'}, {'arthralgias.': 'I-Entity'}]"
"Pulmonary involvement was confirmed by using pulmonary function tests (PFT) and high-resolution computed tomography (HRCT), atlantoaxial subluxation by cervical spine X-rays.","[{'Pulmonary': 'O'}, {'involvement': 'O'}, {'was': 'O'}, {'confirmed': 'O'}, {'by': 'O'}, {'using': 'O'}, {'pulmonary': 'O'}, {'function': 'O'}, {'tests': 'O'}, {'(PFT)': 'O'}, {'and': 'O'}, {'high-resolution': 'O'}, {'computed': 'O'}, {'tomography': 'O'}, {'(HRCT),': 'O'}, {'atlantoaxial': 'B-Entity'}, {'subluxation': 'I-Entity'}, {'by': 'O'}, {'cervical': 'O'}, {'spine': 'O'}, {'X-rays.': 'O'}]"
"Blood tests revealed an important inflammatory syndrome, hemolytic anemia, elevation of total IgG levels and the presence of ANA autoantibodies specific to anti-SSA (52 and 60 kd).","[{'Blood': 'O'}, {'tests': 'O'}, {'revealed': 'O'}, {'an': 'O'}, {'important': 'O'}, {'inflammatory': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'hemolytic': 'B-Entity'}, {'anemia,': 'I-Entity'}, {'elevation': 'O'}, {'of': 'O'}, {'total': 'O'}, {'IgG': 'O'}, {'levels': 'O'}, {'and': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'ANA': 'O'}, {'autoantibodies': 'O'}, {'specific': 'O'}, {'to': 'O'}, {'anti-SSA': 'O'}, {'(52': 'O'}, {'and': 'O'}, {'60': 'O'}, {'kd).': 'O'}]"
"To determine the effectiveness of autologous platelet lysate (APL) eye drops in patients with primary Sjogren syndrome (SS) dry eye, refractory to standard therapy, in comparison with patients treated with artificial tears.","[{'To': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'effectiveness': 'O'}, {'of': 'O'}, {'autologous': 'O'}, {'platelet': 'O'}, {'lysate': 'O'}, {'(APL)': 'O'}, {'eye': 'O'}, {'drops': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'dry': 'B-Entity'}, {'eye,': 'I-Entity'}, {'refractory': 'O'}, {'to': 'O'}, {'standard': 'O'}, {'therapy,': 'O'}, {'in': 'O'}, {'comparison': 'O'}, {'with': 'O'}, {'patients': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'artificial': 'O'}, {'tears.': 'O'}]"
"They may cause inflammation in the brain, spinal cord and optic nerve.","[{'They': 'O'}, {'may': 'O'}, {'cause': 'O'}, {'inflammation': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'brain,': 'O'}, {'spinal': 'O'}, {'cord': 'O'}, {'and': 'O'}, {'optic': 'O'}, {'nerve.': 'O'}]"
"Surgery was performed 2 months after the administration of prednisolone since the respiratory function had improved, allowing the administration of general anesthesia.","[{'Surgery': 'O'}, {'was': 'O'}, {'performed': 'O'}, {'2': 'O'}, {'months': 'O'}, {'after': 'O'}, {'the': 'O'}, {'administration': 'O'}, {'of': 'O'}, {'prednisolone': 'I-Entity'}, {'since': 'O'}, {'the': 'O'}, {'respiratory': 'O'}, {'function': 'O'}, {'had': 'O'}, {'improved,': 'O'}, {'allowing': 'O'}, {'the': 'O'}, {'administration': 'O'}, {'of': 'O'}, {'general': 'O'}, {'anesthesia.': 'O'}]"
"Further, we observed the activation of SGS in cytotoxic CD8 T cells isolated from patients with SS.","[{'Further,': 'O'}, {'we': 'O'}, {'observed': 'O'}, {'the': 'O'}, {'activation': 'O'}, {'of': 'O'}, {'SGS': 'O'}, {'in': 'O'}, {'cytotoxic': 'O'}, {'CD8': 'O'}, {'T': 'O'}, {'cells': 'O'}, {'isolated': 'O'}, {'from': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS.': 'I-Entity'}]"
The findings of this exploratory study show that clinical inactive pSS patients have an increased frequency of IL-10--producing B cells and IDO-expressing pDC cells.,"[{'The': 'O'}, {'findings': 'O'}, {'of': 'O'}, {'this': 'O'}, {'exploratory': 'O'}, {'study': 'O'}, {'show': 'O'}, {'that': 'O'}, {'clinical': 'O'}, {'inactive': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'have': 'O'}, {'an': 'O'}, {'increased': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'IL-10--producing': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'IDO-expressing': 'O'}, {'pDC': 'O'}, {'cells.': 'O'}]"
"Although many circulatory molecules (DNA, RNA, and proteins) can also be present in saliva, saliva harbors unique molecular constituents that can be discriminatory for oral and systemic disease screening and detection.","[{'Although': 'O'}, {'many': 'O'}, {'circulatory': 'O'}, {'molecules': 'O'}, {'(DNA,': 'O'}, {'RNA,': 'O'}, {'and': 'O'}, {'proteins)': 'O'}, {'can': 'O'}, {'also': 'O'}, {'be': 'O'}, {'present': 'O'}, {'in': 'O'}, {'saliva,': 'O'}, {'saliva': 'O'}, {'harbors': 'O'}, {'unique': 'O'}, {'molecular': 'O'}, {'constituents': 'O'}, {'that': 'O'}, {'can': 'O'}, {'be': 'O'}, {'discriminatory': 'O'}, {'for': 'O'}, {'oral': 'O'}, {'and': 'O'}, {'systemic': 'O'}, {'disease': 'I-Entity'}, {'screening': 'O'}, {'and': 'O'}, {'detection.': 'O'}]"
"Finally, mast cells isolated from peripheral blood mononuclear cells of pSS patients in vitro significantly increased Th17 lymphocytes.","[{'Finally,': 'O'}, {'mast': 'O'}, {'cells': 'O'}, {'isolated': 'O'}, {'from': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'mononuclear': 'O'}, {'cells': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'in': 'O'}, {'vitro': 'O'}, {'significantly': 'O'}, {'increased': 'O'}, {'Th17': 'O'}, {'lymphocytes.': 'O'}]"
"The patient's condition improved after treatment with hydroxychloroquine, vitamin K antagonists and prednisone.permissions.","[{'The': 'O'}, {""patient's"": 'O'}, {'condition': 'O'}, {'improved': 'O'}, {'after': 'O'}, {'treatment': 'O'}, {'with': 'O'}, {'hydroxychloroquine,': 'I-Entity'}, {'vitamin': 'B-Entity'}, {'K': 'I-Entity'}, {'antagonists': 'I-Entity'}, {'and': 'O'}, {'prednisone.permissions.': 'I-Entity'}]"
Increased heart rate associated with fatigue (P = 0.02; r(2) = 0.2) and EQ-5D.,"[{'Increased': 'O'}, {'heart': 'O'}, {'rate': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'fatigue': 'I-Entity'}, {'(P': 'O'}, {'=': 'O'}, {'0.02;': 'O'}, {'r(2)': 'O'}, {'=': 'O'}, {'0.2)': 'O'}, {'and': 'O'}, {'EQ-5D.': 'O'}]"
"Although therapeutic approaches for pSS target both dryness and systemic manifestations, effective treatments are limited.","[{'Although': 'O'}, {'therapeutic': 'O'}, {'approaches': 'O'}, {'for': 'O'}, {'pSS': 'I-Entity'}, {'target': 'O'}, {'both': 'O'}, {'dryness': 'I-Entity'}, {'and': 'O'}, {'systemic': 'O'}, {'manifestations,': 'O'}, {'effective': 'O'}, {'treatments': 'O'}, {'are': 'O'}, {'limited.': 'O'}]"
Six patients had cysts without other radiographic findings.,"[{'Six': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'cysts': 'I-Entity'}, {'without': 'O'}, {'other': 'O'}, {'radiographic': 'O'}, {'findings.': 'O'}]"
Neurologic symptoms associated with cryoglobulinemia remained stable or improved in 86% of patients.,"[{'Neurologic': 'O'}, {'symptoms': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'cryoglobulinemia': 'I-Entity'}, {'remained': 'O'}, {'stable': 'O'}, {'or': 'O'}, {'improved': 'O'}, {'in': 'O'}, {'86%': 'O'}, {'of': 'O'}, {'patients.': 'O'}]"
"Local therapy with liposomal agents is effective in the symptomatic treatment of xerostomia, KCS, and RS in patients with pSS.Universit‚Äö√†√∂¬¨√üt M‚Äö√†√∂¬¨‚à´nchen, Ismaningerstr.","[{'Local': 'O'}, {'therapy': 'O'}, {'with': 'O'}, {'liposomal': 'O'}, {'agents': 'O'}, {'is': 'O'}, {'effective': 'O'}, {'in': 'O'}, {'the': 'O'}, {'symptomatic': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'xerostomia,': 'I-Entity'}, {'KCS,': 'I-Entity'}, {'and': 'O'}, {'RS': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS.Universit‚Äö√†√∂¬¨√üt': 'I-Entity'}, {'M‚Äö√†√∂¬¨‚à´nchen,': 'O'}]"
"However, these antibodies have also been detected in patients with other types of chronic inflammatory rheumatism.","[{'However,': 'O'}, {'these': 'O'}, {'antibodies': 'O'}, {'have': 'O'}, {'also': 'O'}, {'been': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'other': 'O'}, {'types': 'O'}, {'of': 'O'}, {'chronic': 'B-Entity'}, {'inflammatory': 'I-Entity'}, {'rheumatism.': 'I-Entity'}]"
"However, potential medications were limited by AIP, so mycophenolate mofetil was eventually added to delay the progression of the primary disease.Advancement.Shijiazhuang, Hebei, China.Shijiazhuang, Hebei, China.Shijiazhuang, Hebei, China.Guangdong, China.China.China.Shijiazhuang, Hebei, China.Management.","[{'However,': 'O'}, {'potential': 'O'}, {'medications': 'O'}, {'were': 'O'}, {'limited': 'O'}, {'by': 'O'}, {'AIP,': 'I-Entity'}, {'so': 'O'}, {'mycophenolate': 'B-Entity'}, {'mofetil': 'I-Entity'}, {'was': 'O'}, {'eventually': 'O'}, {'added': 'O'}, {'to': 'O'}, {'delay': 'O'}, {'the': 'O'}, {'progression': 'O'}, {'of': 'O'}, {'the': 'O'}, {'primary': 'O'}, {'disease.Advancement.Shijiazhuang,': 'O'}, {'Hebei,': 'O'}, {'China.Shijiazhuang,': 'O'}, {'Hebei,': 'O'}, {'China.Shijiazhuang,': 'O'}]"
Cystic lung disease is very significant but exceptionally recounted in the literature.,"[{'Cystic': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'is': 'O'}, {'very': 'O'}, {'significant': 'O'}, {'but': 'O'}, {'exceptionally': 'O'}, {'recounted': 'O'}, {'in': 'O'}, {'the': 'O'}, {'literature.': 'O'}]"
"In this population of patients with pSS, low C3 and C4 levels at diagnosis were associated with extraglandular manifestations such as vasculitis and interstitial lung disease, as well as disease activity and damage accrual.","[{'In': 'O'}, {'this': 'O'}, {'population': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS,': 'I-Entity'}, {'low': 'O'}, {'C3': 'O'}, {'and': 'O'}, {'C4': 'O'}, {'levels': 'O'}, {'at': 'O'}, {'diagnosis': 'O'}, {'were': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'extraglandular': 'O'}, {'manifestations': 'O'}, {'such': 'O'}, {'as': 'O'}, {'vasculitis': 'I-Entity'}, {'and': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease,': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'damage': 'O'}, {'accrual.': 'O'}]"
"In the present retrospective claims-based cohort of older patients with DLBCL, concomitant AI disease was uncommon and was more likely to occur in female DLBCL patients, which likely reflects the greater incidence of AI disease in women.","[{'In': 'O'}, {'the': 'O'}, {'present': 'O'}, {'retrospective': 'O'}, {'claims-based': 'O'}, {'cohort': 'O'}, {'of': 'O'}, {'older': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'DLBCL,': 'I-Entity'}, {'concomitant': 'O'}, {'AI': 'B-Entity'}, {'disease': 'I-Entity'}, {'was': 'O'}, {'uncommon': 'O'}, {'and': 'O'}, {'was': 'O'}, {'more': 'O'}, {'likely': 'O'}, {'to': 'O'}, {'occur': 'O'}, {'in': 'O'}, {'female': 'O'}, {'DLBCL': 'I-Entity'}, {'patients,': 'O'}, {'which': 'O'}, {'likely': 'O'}, {'reflects': 'O'}, {'the': 'O'}, {'greater': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'AI': 'B-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'women.': 'O'}]"
"However, due to the low quality of included studies, further well-designed multicenter and large-scale RCTs are still needed to evaluate the beneficial effects of CHM.100029, China.","[{'However,': 'O'}, {'due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'low': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'included': 'O'}, {'studies,': 'O'}, {'further': 'O'}, {'well-designed': 'O'}, {'multicenter': 'O'}, {'and': 'O'}, {'large-scale': 'O'}, {'RCTs': 'O'}, {'are': 'O'}, {'still': 'O'}, {'needed': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'beneficial': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'CHM.100029,': 'I-Entity'}, {'China.': 'O'}]"
Almost all symptoms found in patients with the CNS-SS involvement described above could be attributed to the concomitant presence of MS.,"[{'Almost': 'O'}, {'all': 'O'}, {'symptoms': 'O'}, {'found': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'the': 'O'}, {'CNS-SS': 'O'}, {'involvement': 'O'}, {'described': 'O'}, {'above': 'O'}, {'could': 'O'}, {'be': 'O'}, {'attributed': 'O'}, {'to': 'O'}, {'the': 'O'}, {'concomitant': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'MS.': 'I-Entity'}]"
"Our data indicate that a considerable proportion of Swedish patients with SLE lose ANA-positivity over time, whereas consistent staining patterns were frequent.","[{'Our': 'O'}, {'data': 'O'}, {'indicate': 'O'}, {'that': 'O'}, {'a': 'O'}, {'considerable': 'O'}, {'proportion': 'O'}, {'of': 'O'}, {'Swedish': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SLE': 'I-Entity'}, {'lose': 'O'}, {'ANA-positivity': 'O'}, {'over': 'O'}, {'time,': 'O'}, {'whereas': 'O'}, {'consistent': 'O'}, {'staining': 'O'}, {'patterns': 'O'}, {'were': 'O'}, {'frequent.': 'O'}]"
"Urgent amniotic membrane transplantation was arranged while topical dexamethasone, moxifloxacin, and autologous serum eye drops were administered.","[{'Urgent': 'O'}, {'amniotic': 'O'}, {'membrane': 'O'}, {'transplantation': 'O'}, {'was': 'O'}, {'arranged': 'O'}, {'while': 'O'}, {'topical': 'O'}, {'dexamethasone,': 'I-Entity'}, {'moxifloxacin,': 'I-Entity'}, {'and': 'O'}, {'autologous': 'O'}, {'serum': 'O'}, {'eye': 'O'}, {'drops': 'O'}, {'were': 'O'}, {'administered.': 'O'}]"
"While blood B cell depletion was associated with an increase in serum BAFF levels, no significant changes were observed in the levels of serum anti-Ro/SSA, anti-La/SSB, and anti-type 3 muscarinic acetylcholine receptor autoantibodies or in the blood interferon signature.","[{'While': 'O'}, {'blood': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'depletion': 'O'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'an': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'serum': 'O'}, {'BAFF': 'O'}, {'levels,': 'O'}, {'no': 'O'}, {'significant': 'O'}, {'changes': 'O'}, {'were': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'the': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'serum': 'O'}, {'anti-Ro/SSA,': 'O'}, {'anti-La/SSB,': 'O'}, {'and': 'O'}, {'anti-type': 'O'}, {'3': 'O'}, {'muscarinic': 'O'}, {'acetylcholine': 'I-Entity'}, {'receptor': 'O'}, {'autoantibodies': 'O'}]"
"The current studies evaluated these autoantibodies in patients with long-standing SS expressing high levels of anti-Ro antibodies and in patients with Sjogren's syndrome secondary to systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and mixed connective tissue disease (MCTD).","[{'The': 'O'}, {'current': 'O'}, {'studies': 'O'}, {'evaluated': 'O'}, {'these': 'O'}, {'autoantibodies': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'long-standing': 'O'}, {'SS': 'I-Entity'}, {'expressing': 'O'}, {'high': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'anti-Ro': 'O'}, {'antibodies': 'O'}, {'and': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'secondary': 'O'}, {'to': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE),': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(SSc)': 'O'}, {'and': 'O'}, {'mixed': 'B-Entity'}, {'connective': 'I-Entity'}]"
"We investigated the therapeutic effect of metformin in non-obese diabetic (NOD)/ShiLtJ mice, an animal model of SS.","[{'We': 'O'}, {'investigated': 'O'}, {'the': 'O'}, {'therapeutic': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'metformin': 'I-Entity'}, {'in': 'O'}, {'non-obese': 'O'}, {'diabetic': 'I-Entity'}, {'(NOD)/ShiLtJ': 'O'}, {'mice,': 'O'}, {'an': 'O'}, {'animal': 'O'}, {'model': 'O'}, {'of': 'O'}, {'SS.': 'I-Entity'}]"
Our results suggest that the ECS represents an appropriate diagnostic tool for ANA screening.,"[{'Our': 'O'}, {'results': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'the': 'O'}, {'ECS': 'O'}, {'represents': 'O'}, {'an': 'O'}, {'appropriate': 'O'}, {'diagnostic': 'O'}, {'tool': 'O'}, {'for': 'O'}, {'ANA': 'I-Entity'}, {'screening.': 'O'}]"
Renal pathology revealed minimal change disease and thin basement membrane nephropathy.,"[{'Renal': 'O'}, {'pathology': 'O'}, {'revealed': 'O'}, {'minimal': 'B-Entity'}, {'change': 'I-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'thin': 'O'}, {'basement': 'O'}, {'membrane': 'O'}, {'nephropathy.': 'I-Entity'}]"
"Patients who have symptoms of sicca, such as dry eyes and mouth, may have Sjogrens syndrome (SS).","[{'Patients': 'O'}, {'who': 'O'}, {'have': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'sicca,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'I-Entity'}, {'mouth,': 'I-Entity'}, {'may': 'O'}, {'have': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
"Mean pulmonary arterialpressure (mPAP) was 48(38, 55.75)mmHg, pulmonary vascularresistance (PVR) was 11.23 (6.17,14.69)IU, and mean cardiac index was 2.59(2.04,2.98)L¬¨¬®‚Äö√†√´min(-1)¬¨¬®‚Äö√†√´m(-2) in this group.","[{'Mean': 'O'}, {'pulmonary': 'O'}, {'arterialpressure': 'O'}, {'(mPAP)': 'O'}, {'was': 'O'}, {'48(38,': 'O'}, {'55.75)mmHg,': 'O'}, {'pulmonary': 'O'}, {'vascularresistance': 'O'}, {'(PVR)': 'O'}, {'was': 'O'}, {'11.23': 'O'}, {'(6.17,14.69)IU,': 'O'}, {'and': 'O'}, {'mean': 'O'}, {'cardiac': 'O'}, {'index': 'O'}, {'was': 'O'}, {'2.59(2.04,2.98)L¬¨¬®‚Äö√†√´min(-1)¬¨¬®‚Äö√†√´m(-2)': 'O'}]"
Botulinum toxin may be a safe and effective method of treating Sjogren syndrome-associated recurrent parotitis.by Elsevier Inc. All rights reserved.Australia.,"[{'Botulinum': 'B-Entity'}, {'toxin': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'a': 'O'}, {'safe': 'O'}, {'and': 'O'}, {'effective': 'O'}, {'method': 'O'}, {'of': 'O'}, {'treating': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome-associated': 'I-Entity'}, {'recurrent': 'O'}, {'parotitis.by': 'I-Entity'}, {'Elsevier': 'O'}, {'Inc.': 'O'}, {'All': 'O'}, {'rights': 'O'}, {'reserved.Australia.': 'O'}]"
The presence of multiple high-signal-intensity spots on an MR sialogram in the parotid gland should be considered the best diagnostic indicator for Sjogrens syndrome.,"[{'The': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'multiple': 'O'}, {'high-signal-intensity': 'O'}, {'spots': 'O'}, {'on': 'O'}, {'an': 'O'}, {'MR': 'O'}, {'sialogram': 'O'}, {'in': 'O'}, {'the': 'O'}, {'parotid': 'O'}, {'gland': 'O'}, {'should': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'the': 'O'}, {'best': 'O'}, {'diagnostic': 'O'}, {'indicator': 'O'}, {'for': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"Symptoms at the time of initial presentation were dry eyes and mouth, arthralgias, and Raynaud's phenomenon.","[{'Symptoms': 'O'}, {'at': 'O'}, {'the': 'O'}, {'time': 'O'}, {'of': 'O'}, {'initial': 'O'}, {'presentation': 'O'}, {'were': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'I-Entity'}, {'mouth,': 'I-Entity'}, {'arthralgias,': 'I-Entity'}, {'and': 'O'}, {""Raynaud's"": 'B-Entity'}, {'phenomenon.': 'I-Entity'}]"
"Systemic autoimmune and inflammatory diseases often manifest oral lesions in their earliest stages, and early diagnosis, which may be spurred by a dental examination, is key for improved outcomes.","[{'Systemic': 'O'}, {'autoimmune': 'B-Entity'}, {'and': 'I-Entity'}, {'inflammatory': 'I-Entity'}, {'diseases': 'I-Entity'}, {'often': 'O'}, {'manifest': 'O'}, {'oral': 'B-Entity'}, {'lesions': 'I-Entity'}, {'in': 'O'}, {'their': 'O'}, {'earliest': 'O'}, {'stages,': 'O'}, {'and': 'O'}, {'early': 'O'}, {'diagnosis,': 'O'}, {'which': 'O'}, {'may': 'O'}, {'be': 'O'}, {'spurred': 'O'}, {'by': 'O'}, {'a': 'O'}, {'dental': 'O'}, {'examination,': 'O'}, {'is': 'O'}, {'key': 'O'}, {'for': 'O'}, {'improved': 'O'}, {'outcomes.': 'O'}]"
A burning sensation in the mouth was the most prevalent in patients with systemic diseases or those who were taking medications while altered taste perception was the most prevalent in patients taking antipsychotics.,"[{'A': 'O'}, {'burning': 'B-Entity'}, {'sensation': 'O'}, {'in': 'O'}, {'the': 'O'}, {'mouth': 'O'}, {'was': 'O'}, {'the': 'O'}, {'most': 'O'}, {'prevalent': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'systemic': 'O'}, {'diseases': 'I-Entity'}, {'or': 'O'}, {'those': 'O'}, {'who': 'O'}, {'were': 'O'}, {'taking': 'O'}, {'medications': 'O'}, {'while': 'O'}, {'altered': 'O'}, {'taste': 'O'}, {'perception': 'O'}, {'was': 'O'}, {'the': 'O'}, {'most': 'O'}, {'prevalent': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'taking': 'O'}, {'antipsychotics.': 'O'}]"
The result of the study might offer a new option to treat pSS and might be a clinical proof that acupuncture has beneficial effects on pSS.,"[{'The': 'O'}, {'result': 'O'}, {'of': 'O'}, {'the': 'O'}, {'study': 'O'}, {'might': 'O'}, {'offer': 'O'}, {'a': 'O'}, {'new': 'O'}, {'option': 'O'}, {'to': 'O'}, {'treat': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'might': 'O'}, {'be': 'O'}, {'a': 'O'}, {'clinical': 'O'}, {'proof': 'O'}, {'that': 'O'}, {'acupuncture': 'O'}, {'has': 'O'}, {'beneficial': 'O'}, {'effects': 'O'}, {'on': 'O'}, {'pSS.': 'I-Entity'}]"
Electronic address: highlak@ccf.org.25.tubular acidosis in a patient with thin basement membrane nephropathy: A case report.,"[{'Electronic': 'O'}, {'address:': 'O'}, {'highlak@ccf.org.25.tubular': 'O'}, {'acidosis': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'thin': 'O'}, {'basement': 'O'}, {'membrane': 'O'}, {'nephropathy:': 'I-Entity'}, {'A': 'O'}, {'case': 'O'}, {'report.': 'O'}]"
Sjogrens syndrome is associated with the production of autoantibodies because B-cell activation is a consistent immunoregulatory abnormality.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'production': 'O'}, {'of': 'O'}, {'autoantibodies': 'O'}, {'because': 'O'}, {'B-cell': 'O'}, {'activation': 'O'}, {'is': 'O'}, {'a': 'O'}, {'consistent': 'O'}, {'immunoregulatory': 'O'}, {'abnormality.': 'O'}]"
"Of the 136 patients, 9 (9/136, 6.6%) presented with a history of SS, and 9 additional patients (9/127, 7%) received a new diagnosis of SS as a result of evaluations.","[{'Of': 'O'}, {'the': 'O'}, {'136': 'O'}, {'patients,': 'O'}, {'9': 'O'}, {'(9/136,': 'O'}, {'6.6%)': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'a': 'O'}, {'history': 'O'}, {'of': 'O'}, {'SS,': 'I-Entity'}, {'and': 'O'}, {'9': 'O'}, {'additional': 'O'}, {'patients': 'O'}, {'(9/127,': 'O'}, {'7%)': 'O'}, {'received': 'O'}, {'a': 'O'}, {'new': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'result': 'O'}, {'of': 'O'}, {'evaluations.': 'O'}]"
"A total of 28, 6, 7 and 12 protein spots were found to be significantly different in pSS samples with respect to healthy volunteers, non-SS sicca syndrome, SSc-sSS and rheumatoid arthritis-sSS, leading to the identification of 15 differently expressed proteins.","[{'A': 'O'}, {'total': 'O'}, {'of': 'O'}, {'28,': 'O'}, {'6,': 'O'}, {'7': 'O'}, {'and': 'O'}, {'12': 'O'}, {'protein': 'O'}, {'spots': 'O'}, {'were': 'O'}, {'found': 'O'}, {'to': 'O'}, {'be': 'O'}, {'significantly': 'O'}, {'different': 'O'}, {'in': 'O'}, {'pSS': 'O'}, {'samples': 'O'}, {'with': 'O'}, {'respect': 'O'}, {'to': 'O'}, {'healthy': 'O'}, {'volunteers,': 'O'}, {'non-SS': 'O'}, {'sicca': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'SSc-sSS': 'I-Entity'}, {'and': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis-sSS,': 'I-Entity'}, {'leading': 'O'}, {'to': 'O'}, {'the': 'O'}, {'identification': 'O'}, {'of': 'O'}, {'15': 'O'}, {'differently': 'O'}, {'expressed': 'O'}, {'proteins.': 'O'}]"
Tissue diagnosis was obtained by resection of the mediastinal tumor and open fine needle aspiration of the right pulmonary tissue through a median sternotomy.,"[{'Tissue': 'O'}, {'diagnosis': 'O'}, {'was': 'O'}, {'obtained': 'O'}, {'by': 'O'}, {'resection': 'O'}, {'of': 'O'}, {'the': 'O'}, {'mediastinal': 'B-Entity'}, {'tumor': 'I-Entity'}, {'and': 'O'}, {'open': 'O'}, {'fine': 'O'}, {'needle': 'O'}, {'aspiration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'right': 'O'}, {'pulmonary': 'O'}, {'tissue': 'O'}, {'through': 'O'}, {'a': 'O'}, {'median': 'O'}, {'sternotomy.': 'O'}]"
Eye examination revealed dry eyes after having a positive Schirmer test.,"[{'Eye': 'O'}, {'examination': 'O'}, {'revealed': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'after': 'O'}, {'having': 'O'}, {'a': 'O'}, {'positive': 'O'}, {'Schirmer': 'O'}, {'test.': 'O'}]"
"There were no differences in pain intensity, pain quality, and treatment characteristics in the comparison of 13 patients with pure SFN versus 10 patients with mixed SFN.","[{'There': 'O'}, {'were': 'O'}, {'no': 'O'}, {'differences': 'O'}, {'in': 'O'}, {'pain': 'I-Entity'}, {'intensity,': 'O'}, {'pain': 'I-Entity'}, {'quality,': 'O'}, {'and': 'O'}, {'treatment': 'O'}, {'characteristics': 'O'}, {'in': 'O'}, {'the': 'O'}, {'comparison': 'O'}, {'of': 'O'}, {'13': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pure': 'O'}, {'SFN': 'I-Entity'}, {'versus': 'O'}, {'10': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'mixed': 'O'}, {'SFN.': 'O'}]"
We observed a strong heterogeneity of standardized mortality rates across all countries analyzed for 6 autoimmune diseases.,"[{'We': 'O'}, {'observed': 'O'}, {'a': 'O'}, {'strong': 'O'}, {'heterogeneity': 'O'}, {'of': 'O'}, {'standardized': 'O'}, {'mortality': 'O'}, {'rates': 'O'}, {'across': 'O'}, {'all': 'O'}, {'countries': 'O'}, {'analyzed': 'O'}, {'for': 'O'}, {'6': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
Sicca syndrome and renal interstitial infiltrates indicated SS as the underlying cause of the RTA and osteomalacia.,"[{'Sicca': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'renal': 'O'}, {'interstitial': 'O'}, {'infiltrates': 'I-Entity'}, {'indicated': 'O'}, {'SS': 'I-Entity'}, {'as': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'the': 'O'}, {'RTA': 'I-Entity'}, {'and': 'O'}, {'osteomalacia.': 'I-Entity'}]"
"Although autonomic neuropathy may occur as a secondary consequence of various diseases, other patients without any obvious underlying diseases show profound autonomic dysfunctions from the early phase of the disease.","[{'Although': 'O'}, {'autonomic': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'may': 'O'}, {'occur': 'O'}, {'as': 'O'}, {'a': 'O'}, {'secondary': 'O'}, {'consequence': 'O'}, {'of': 'O'}, {'various': 'O'}, {'diseases,': 'O'}, {'other': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'any': 'O'}, {'obvious': 'O'}, {'underlying': 'O'}, {'diseases': 'O'}, {'show': 'O'}, {'profound': 'O'}, {'autonomic': 'B-Entity'}, {'dysfunctions': 'I-Entity'}, {'from': 'O'}, {'the': 'O'}, {'early': 'O'}, {'phase': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
"To overcome current challenges in tear proteomic measurements, we report on the first microfluidic homogeneous immunoassay capable of making rapid, quantitative, and specific measurements of endogenous tear protein biomarkers in human tear fluid.","[{'To': 'O'}, {'overcome': 'O'}, {'current': 'O'}, {'challenges': 'O'}, {'in': 'O'}, {'tear': 'O'}, {'proteomic': 'O'}, {'measurements,': 'O'}, {'we': 'O'}, {'report': 'O'}, {'on': 'O'}, {'the': 'O'}, {'first': 'O'}, {'microfluidic': 'O'}, {'homogeneous': 'O'}, {'immunoassay': 'O'}, {'capable': 'O'}, {'of': 'O'}, {'making': 'O'}, {'rapid,': 'O'}, {'quantitative,': 'O'}, {'and': 'O'}, {'specific': 'O'}, {'measurements': 'O'}, {'of': 'O'}, {'endogenous': 'O'}, {'tear': 'O'}, {'protein': 'O'}, {'biomarkers': 'O'}, {'in': 'O'}, {'human': 'O'}, {'tear': 'O'}, {'fluid.': 'O'}]"
Most cases of retroperitoneal fibrosis are associated with IgG4-related disease or other autoimmune disease.,"[{'Most': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'retroperitoneal': 'O'}, {'fibrosis': 'I-Entity'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'IgG4-related': 'O'}, {'disease': 'I-Entity'}, {'or': 'O'}, {'other': 'O'}, {'autoimmune': 'B-Entity'}, {'disease.': 'I-Entity'}]"
"Sjogren syndrome affecting the major cerebral arteries is rare, and an optimal therapeutic strategy to counteract such a lesion has not yet been established.","[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'affecting': 'O'}, {'the': 'O'}, {'major': 'O'}, {'cerebral': 'O'}, {'arteries': 'O'}, {'is': 'O'}, {'rare,': 'O'}, {'and': 'O'}, {'an': 'O'}, {'optimal': 'O'}, {'therapeutic': 'O'}, {'strategy': 'O'}, {'to': 'O'}, {'counteract': 'O'}, {'such': 'O'}, {'a': 'O'}, {'lesion': 'O'}, {'has': 'O'}, {'not': 'O'}, {'yet': 'O'}, {'been': 'O'}, {'established.': 'O'}]"
"In patients with underlying CTD and symptoms of abdominal emergency, recruitment of multidisciplinary teams, including rheumatologist, gastroenterologist, imaging specialist and surgeons familiar with intestinal complications of CTD-related conditions, is warranted.to original US government works.a_balbir@rambam.health.gov.ildiagnosed Sjogrens syndrome: A nationwide, population-based case-control study.","[{'In': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'underlying': 'O'}, {'CTD': 'I-Entity'}, {'and': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'abdominal': 'B-Entity'}, {'emergency,': 'I-Entity'}, {'recruitment': 'O'}, {'of': 'O'}, {'multidisciplinary': 'O'}, {'teams,': 'O'}, {'including': 'O'}, {'rheumatologist,': 'O'}, {'gastroenterologist,': 'O'}, {'imaging': 'O'}, {'specialist': 'O'}, {'and': 'O'}, {'surgeons': 'O'}, {'familiar': 'O'}, {'with': 'O'}, {'intestinal': 'B-Entity'}, {'complications': 'I-Entity'}, {'of': 'O'}, {'CTD-related': 'I-Entity'}, {'conditions,': 'O'}, {'is': 'O'}, {'warranted.to': 'O'}, {'original': 'O'}, {'US': 'O'}, {'government': 'O'}, {'works.a_balbir@rambam.health.gov.ildiagnosed': 'O'}]"
"Multiple sclerosis (MS), systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), Sjogren's syndrome (SS) and Behcet disease (BD) are chronic, immune-mediated disorders affecting young adults, the pathogenesis of which is still largely unknown.","[{'Multiple': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(MS),': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE),': 'O'}, {'antiphospholipid': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(APS),': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'and': 'O'}, {'Behcet': 'B-Entity'}, {'disease': 'I-Entity'}, {'(BD)': 'O'}, {'are': 'O'}, {'chronic,': 'O'}, {'immune-mediated': 'O'}, {'disorders': 'I-Entity'}, {'affecting': 'O'}, {'young': 'O'}]"
"Patients were evaluated in a dedicated clinic by a pulmonologist, rheumatologist, and ophthalmologist specializing in autoimmune disease.","[{'Patients': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'in': 'O'}, {'a': 'O'}, {'dedicated': 'O'}, {'clinic': 'O'}, {'by': 'O'}, {'a': 'O'}, {'pulmonologist,': 'O'}, {'rheumatologist,': 'O'}, {'and': 'O'}, {'ophthalmologist': 'O'}, {'specializing': 'O'}, {'in': 'O'}, {'autoimmune': 'B-Entity'}, {'disease.': 'I-Entity'}]"
"Therapeutic management included measures directed to treat sicca symptoms and therapies against autoimmune-mediated manifestations (glucocorticoids in 42%, second/third-line therapies in 31%); therapeutic response for systemic features was observed in 8/11 (73%).","[{'Therapeutic': 'O'}, {'management': 'O'}, {'included': 'O'}, {'measures': 'O'}, {'directed': 'O'}, {'to': 'O'}, {'treat': 'O'}, {'sicca': 'B-Entity'}, {'symptoms': 'I-Entity'}, {'and': 'O'}, {'therapies': 'O'}, {'against': 'O'}, {'autoimmune-mediated': 'O'}, {'manifestations': 'O'}, {'(glucocorticoids': 'O'}, {'in': 'O'}, {'42%,': 'O'}, {'second/third-line': 'O'}, {'therapies': 'O'}, {'in': 'O'}, {'31%);': 'O'}, {'therapeutic': 'O'}, {'response': 'O'}, {'for': 'O'}, {'systemic': 'O'}, {'features': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'8/11': 'O'}, {'(73%).': 'O'}]"
"The underlying diseases included Still disease (n = 4), systemic lupus erythematosus(n = 3), and rheumatoid arthritis, primary Sjogrens syndrome, Wegener granulomatosis and Crohn disease in each one case.","[{'The': 'O'}, {'underlying': 'O'}, {'diseases': 'O'}, {'included': 'O'}, {'Still': 'B-Entity'}, {'disease': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'4),': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus(n': 'I-Entity'}, {'=': 'O'}, {'3),': 'O'}, {'and': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'Wegener': 'B-Entity'}, {'granulomatosis': 'I-Entity'}, {'and': 'O'}, {'Crohn': 'B-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'each': 'O'}, {'one': 'O'}, {'case.': 'O'}]"
We here investigated whether infections increase the risk of developing primary Sjogrens syndrome (pSS).,"[{'We': 'O'}, {'here': 'O'}, {'investigated': 'O'}, {'whether': 'O'}, {'infections': 'I-Entity'}, {'increase': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'developing': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
"While conventional Coombs' tests were negative, the level of red blood cell (RBC)-bound immunoglobulin G (IgG) was increased.","[{'While': 'O'}, {'conventional': 'O'}, {""Coombs'"": 'O'}, {'tests': 'O'}, {'were': 'O'}, {'negative,': 'O'}, {'the': 'O'}, {'level': 'O'}, {'of': 'O'}, {'red': 'O'}, {'blood': 'O'}, {'cell': 'O'}, {'(RBC)-bound': 'O'}, {'immunoglobulin': 'O'}, {'G': 'O'}, {'(IgG)': 'O'}, {'was': 'O'}, {'increased.': 'O'}]"
Only cerebral cortical symptoms with a cerebral white matter lesion could be observed in NMOSDs.life and mortality--a retrospective study based on registry data.,"[{'Only': 'O'}, {'cerebral': 'B-Entity'}, {'cortical': 'I-Entity'}, {'symptoms': 'I-Entity'}, {'with': 'O'}, {'a': 'O'}, {'cerebral': 'O'}, {'white': 'B-Entity'}, {'matter': 'I-Entity'}, {'lesion': 'I-Entity'}, {'could': 'O'}, {'be': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'NMOSDs.life': 'I-Entity'}, {'and': 'O'}, {'mortality--a': 'O'}, {'retrospective': 'O'}, {'study': 'O'}, {'based': 'O'}, {'on': 'O'}, {'registry': 'O'}, {'data.': 'O'}]"
Patients were also assessed regarding symptoms of functional bowel syndrome.,"[{'Patients': 'O'}, {'were': 'O'}, {'also': 'O'}, {'assessed': 'O'}, {'regarding': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'functional': 'B-Entity'}, {'bowel': 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
"Fabry disease is often responsible for musculoskeletal manifestations, of which the most common are pain in the extremities and osteoporosis.","[{'Fabry': 'B-Entity'}, {'disease': 'I-Entity'}, {'is': 'O'}, {'often': 'O'}, {'responsible': 'O'}, {'for': 'O'}, {'musculoskeletal': 'O'}, {'manifestations,': 'O'}, {'of': 'O'}, {'which': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'are': 'O'}, {'pain': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'extremities': 'O'}, {'and': 'O'}, {'osteoporosis.': 'I-Entity'}]"
"Cholestasis, acute rejection, or both were observed in 3 of the 4 patients with a positive T cell crossmatch with an MCS approximately greater than 300.","[{'Cholestasis,': 'I-Entity'}, {'acute': 'O'}, {'rejection,': 'O'}, {'or': 'O'}, {'both': 'O'}, {'were': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'3': 'O'}, {'of': 'O'}, {'the': 'O'}, {'4': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'a': 'O'}, {'positive': 'O'}, {'T': 'O'}, {'cell': 'O'}, {'crossmatch': 'O'}, {'with': 'O'}, {'an': 'O'}, {'MCS': 'O'}, {'approximately': 'O'}, {'greater': 'O'}, {'than': 'O'}, {'300.': 'O'}]"
"Although subclinical pulmonary inflammation exists in more than 50% of patients, clinically significant pulmonary involvement affects approximately 10% of patients and may be the first manifestation of the disease.","[{'Although': 'O'}, {'subclinical': 'O'}, {'pulmonary': 'B-Entity'}, {'inflammation': 'I-Entity'}, {'exists': 'O'}, {'in': 'O'}, {'more': 'O'}, {'than': 'O'}, {'50%': 'O'}, {'of': 'O'}, {'patients,': 'O'}, {'clinically': 'O'}, {'significant': 'O'}, {'pulmonary': 'O'}, {'involvement': 'O'}, {'affects': 'O'}, {'approximately': 'O'}, {'10%': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'and': 'O'}, {'may': 'O'}, {'be': 'O'}, {'the': 'O'}, {'first': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
"The error associated with repeated measurements within a session in the patients without dry eye (10.5 mOsm/L [95% CI, 9.0-12.4]) was significantly lower than in the patients with blepharitis (14.6 mOsm/L [95% CI, 12.5-17.5]; P‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢.006) and patients with SS (15.8 mOsm/L [95% CI, 14.2-17.8]; P‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢.001) but a difference in the error of repeated measurements between patients with blepharitis and patients with SS was not identified (P‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢.46).","[{'The': 'O'}, {'error': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'repeated': 'O'}, {'measurements': 'O'}, {'within': 'O'}, {'a': 'O'}, {'session': 'O'}, {'in': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'(10.5': 'O'}, {'mOsm/L': 'O'}, {'[95%': 'O'}, {'CI,': 'O'}, {'9.0-12.4])': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'lower': 'O'}, {'than': 'O'}, {'in': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'blepharitis': 'I-Entity'}, {'(14.6': 'O'}, {'mOsm/L': 'O'}, {'[95%': 'O'}]"
"A small ROI DWI can provide morphological and functional information on the parotid gland in Sjogrens syndrome patients, and can aid in the diagnosis and evaluation of therapeutic efficacy.Liaoning, PR China.Liaoning, PR China.Liaoning, PR China guo_qiyong@126.com.Chinese Medicine, Shenyang, Liaoning, PR China.University, Shenyang, Liaoning, PR China.University, Shenyang, Liaoning, PR China.","[{'A': 'O'}, {'small': 'O'}, {'ROI': 'O'}, {'DWI': 'O'}, {'can': 'O'}, {'provide': 'O'}, {'morphological': 'O'}, {'and': 'O'}, {'functional': 'O'}, {'information': 'O'}, {'on': 'O'}, {'the': 'O'}, {'parotid': 'O'}, {'gland': 'O'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'patients,': 'O'}, {'and': 'O'}, {'can': 'O'}, {'aid': 'O'}, {'in': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'therapeutic': 'O'}, {'efficacy.Liaoning,': 'O'}, {'PR': 'O'}, {'China.Liaoning,': 'O'}, {'PR': 'O'}, {'China.Liaoning,': 'O'}, {'PR': 'O'}, {'China': 'O'}, {'guo_qiyong@126.com.Chinese': 'O'}]"
"Flt-3L is associated with lymphoma in primary SS, and constitutes a good biologic marker.","[{'Flt-3L': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'lymphoma': 'I-Entity'}, {'in': 'O'}, {'primary': 'O'}, {'SS,': 'I-Entity'}, {'and': 'O'}, {'constitutes': 'O'}, {'a': 'O'}, {'good': 'O'}, {'biologic': 'O'}, {'marker.': 'O'}]"
"Here, we review several neurological conditions that can occur in Sjogrens syndrome: sensory ganglionopathy, painful small fibre neuropathy, and transverse myelitis (independently or as part of neuromyelitis optica).","[{'Here,': 'O'}, {'we': 'O'}, {'review': 'O'}, {'several': 'O'}, {'neurological': 'O'}, {'conditions': 'O'}, {'that': 'O'}, {'can': 'O'}, {'occur': 'O'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome:': 'I-Entity'}, {'sensory': 'B-Entity'}, {'ganglionopathy,': 'I-Entity'}, {'painful': 'O'}, {'small': 'O'}, {'fibre': 'I-Entity'}, {'neuropathy,': 'I-Entity'}, {'and': 'O'}, {'transverse': 'B-Entity'}, {'myelitis': 'I-Entity'}, {'(independently': 'O'}, {'or': 'O'}, {'as': 'O'}, {'part': 'O'}, {'of': 'O'}, {'neuromyelitis': 'B-Entity'}, {'optica).': 'I-Entity'}]"
"Anti-HP1 antibodies were mostly associated with the CREST and Sjogren's syndromes (70% and 44.4%, respectively).","[{'Anti-HP1': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'mostly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'CREST': 'I-Entity'}, {'and': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndromes': 'I-Entity'}, {'(70%': 'O'}, {'and': 'O'}, {'44.4%,': 'O'}, {'respectively).': 'O'}]"
"The results show a cumulative positive effect of the device over the period of the study, from baseline to the end of the trial.and histological findings related to dry eye severity.","[{'The': 'O'}, {'results': 'O'}, {'show': 'O'}, {'a': 'O'}, {'cumulative': 'O'}, {'positive': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'the': 'O'}, {'device': 'O'}, {'over': 'O'}, {'the': 'O'}, {'period': 'O'}, {'of': 'O'}, {'the': 'O'}, {'study,': 'O'}, {'from': 'O'}, {'baseline': 'O'}, {'to': 'O'}, {'the': 'O'}, {'end': 'O'}, {'of': 'O'}, {'the': 'O'}, {'trial.and': 'O'}, {'histological': 'O'}, {'findings': 'O'}, {'related': 'O'}, {'to': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'severity.': 'O'}]"
"Implant-prosthetic treatment guidelines regarding healthy patients should be strictly followed, but frequent recall is recommended in patients affected with oLp, SjS, EB, SSc, Pe or sLE.Maxillary Medicine, Department for Oral Medicine Dental Radiology, and Oral Surgery, Assmannshauser Str.","[{'Implant-prosthetic': 'O'}, {'treatment': 'O'}, {'guidelines': 'O'}, {'regarding': 'O'}, {'healthy': 'O'}, {'patients': 'O'}, {'should': 'O'}, {'be': 'O'}, {'strictly': 'O'}, {'followed,': 'O'}, {'but': 'O'}, {'frequent': 'O'}, {'recall': 'O'}, {'is': 'O'}, {'recommended': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'affected': 'O'}, {'with': 'O'}, {'oLp,': 'O'}, {'SjS,': 'O'}, {'EB,': 'O'}, {'SSc,': 'I-Entity'}, {'Pe': 'I-Entity'}, {'or': 'O'}, {'sLE.Maxillary': 'O'}, {'Medicine,': 'O'}, {'Department': 'O'}, {'for': 'O'}, {'Oral': 'O'}, {'Medicine': 'O'}, {'Dental': 'O'}, {'Radiology,': 'O'}, {'and': 'O'}, {'Oral': 'O'}, {'Surgery,': 'O'}]"
Sjogrens syndrome is an autoimmune disease associated with inflammation of exocrine glands with clinical manifestations of dry eye and dry mouth.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'inflammation': 'I-Entity'}, {'of': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'with': 'O'}, {'clinical': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth.': 'I-Entity'}]"
"We conclude that bortezomib should be considered for patients with TTP refractory to PE, steroids, and rituximab due to its efficacy and relatively favorable side effect profile.Changzhou, China.","[{'We': 'O'}, {'conclude': 'O'}, {'that': 'O'}, {'bortezomib': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'for': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'TTP': 'I-Entity'}, {'refractory': 'O'}, {'to': 'O'}, {'PE,': 'I-Entity'}, {'steroids,': 'I-Entity'}, {'and': 'O'}, {'rituximab': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'its': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'relatively': 'O'}, {'favorable': 'O'}, {'side': 'O'}, {'effect': 'O'}, {'profile.Changzhou,': 'O'}, {'China.': 'O'}]"
The patient presented normal renal function but important neurological impairment.,"[{'The': 'O'}, {'patient': 'O'}, {'presented': 'O'}, {'normal': 'O'}, {'renal': 'O'}, {'function': 'O'}, {'but': 'O'}, {'important': 'O'}, {'neurological': 'B-Entity'}, {'impairment.': 'I-Entity'}]"
"We also briefly review several aspects of type 1 renal tubular acidosis related to autoimmune disease, drugs and thyroid disorders.Physicians.Medical Centre, Melbourne, Victoria, Australia; Department of General Medicine, Dandenong Hospital, Melbourne, Victoria, Australia.","[{'We': 'O'}, {'also': 'O'}, {'briefly': 'O'}, {'review': 'O'}, {'several': 'O'}, {'aspects': 'O'}, {'of': 'O'}, {'type': 'O'}, {'1': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'related': 'O'}, {'to': 'O'}, {'autoimmune': 'B-Entity'}, {'disease,': 'I-Entity'}, {'drugs': 'O'}, {'and': 'O'}, {'thyroid': 'B-Entity'}, {'disorders.Physicians.Medical': 'I-Entity'}, {'Centre,': 'O'}, {'Melbourne,': 'O'}, {'Victoria,': 'O'}, {'Australia;': 'O'}, {'Department': 'O'}, {'of': 'O'}, {'General': 'O'}, {'Medicine,': 'O'}, {'Dandenong': 'O'}, {'Hospital,': 'O'}, {'Melbourne,': 'O'}, {'Victoria,': 'O'}, {'Australia.': 'O'}]"
"The results of the blood tests performed to screen for thrombophilic diseases were normal for his age, and his perinatal history was unremarkable.","[{'The': 'O'}, {'results': 'O'}, {'of': 'O'}, {'the': 'O'}, {'blood': 'O'}, {'tests': 'O'}, {'performed': 'O'}, {'to': 'O'}, {'screen': 'O'}, {'for': 'O'}, {'thrombophilic': 'B-Entity'}, {'diseases': 'I-Entity'}, {'were': 'O'}, {'normal': 'O'}, {'for': 'O'}, {'his': 'O'}, {'age,': 'O'}, {'and': 'O'}, {'his': 'O'}, {'perinatal': 'O'}, {'history': 'O'}, {'was': 'O'}, {'unremarkable.': 'O'}]"
"Less common is brain diseases (9.6% in multiple system atrophy, etc.).","[{'Less': 'O'}, {'common': 'O'}, {'is': 'O'}, {'brain': 'B-Entity'}, {'diseases': 'I-Entity'}, {'(9.6%': 'O'}, {'in': 'O'}, {'multiple': 'B-Entity'}, {'system': 'I-Entity'}, {'atrophy,': 'I-Entity'}, {'etc.).': 'O'}]"
PSS patients had a significantly higher cardiovascular involvement rate than that of the controls (61.6% versus 29.7%; p<0.01).,"[{'PSS': 'I-Entity'}, {'patients': 'O'}, {'had': 'O'}, {'a': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'cardiovascular': 'O'}, {'involvement': 'O'}, {'rate': 'O'}, {'than': 'O'}, {'that': 'O'}, {'of': 'O'}, {'the': 'O'}, {'controls': 'O'}, {'(61.6%': 'O'}, {'versus': 'O'}, {'29.7%;': 'O'}, {'p<0.01).': 'O'}]"
Peripheral neuropathies namely sensory axonal neuropathy and painful small fiber neuropathy are the most frequent neurological manifestations.,"[{'Peripheral': 'B-Entity'}, {'neuropathies': 'I-Entity'}, {'namely': 'O'}, {'sensory': 'O'}, {'axonal': 'O'}, {'neuropathy': 'I-Entity'}, {'and': 'O'}, {'painful': 'O'}, {'small': 'O'}, {'fiber': 'I-Entity'}, {'neuropathy': 'I-Entity'}, {'are': 'O'}, {'the': 'O'}, {'most': 'O'}, {'frequent': 'O'}, {'neurological': 'O'}, {'manifestations.': 'O'}]"
Inactivated vaccines are well tolerated and efficacy was demonstrated for influenza vaccine.,"[{'Inactivated': 'O'}, {'vaccines': 'O'}, {'are': 'O'}, {'well': 'O'}, {'tolerated': 'O'}, {'and': 'O'}, {'efficacy': 'O'}, {'was': 'O'}, {'demonstrated': 'O'}, {'for': 'O'}, {'influenza': 'I-Entity'}, {'vaccine.': 'O'}]"
"In spite of therapy, clinical progression measured by the MOHS scale was observed in 12% of patients with axonal polyneuropathy, 13% of those with mononeuropathy multiplex and 47% of those with neuronopathy.","[{'In': 'O'}, {'spite': 'O'}, {'of': 'O'}, {'therapy,': 'O'}, {'clinical': 'O'}, {'progression': 'O'}, {'measured': 'O'}, {'by': 'O'}, {'the': 'O'}, {'MOHS': 'O'}, {'scale': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'12%': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'axonal': 'B-Entity'}, {'polyneuropathy,': 'I-Entity'}, {'13%': 'O'}, {'of': 'O'}, {'those': 'O'}, {'with': 'O'}, {'mononeuropathy': 'B-Entity'}, {'multiplex': 'I-Entity'}, {'and': 'O'}, {'47%': 'O'}, {'of': 'O'}, {'those': 'O'}, {'with': 'O'}, {'neuronopathy.': 'I-Entity'}]"
"We reported previously that the green tea polyphenol epigallocatechin-3-gallate (EGCG) normalizes the elevated levels of proliferating cell nuclear antigen (PCNA), a key component of DNA repair, in the NOD mouse model for SS and type 1 diabetes.","[{'We': 'O'}, {'reported': 'O'}, {'previously': 'O'}, {'that': 'O'}, {'the': 'O'}, {'green': 'B-Entity'}, {'tea': 'I-Entity'}, {'polyphenol': 'I-Entity'}, {'epigallocatechin-3-gallate': 'I-Entity'}, {'(EGCG)': 'O'}, {'normalizes': 'O'}, {'the': 'O'}, {'elevated': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'proliferating': 'O'}, {'cell': 'O'}, {'nuclear': 'O'}, {'antigen': 'O'}, {'(PCNA),': 'O'}, {'a': 'O'}, {'key': 'O'}, {'component': 'O'}, {'of': 'O'}, {'DNA': 'O'}, {'repair,': 'O'}, {'in': 'O'}, {'the': 'O'}, {'NOD': 'O'}, {'mouse': 'O'}, {'model': 'O'}, {'for': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}]"
Central and peripheral nervous system involvement was observed in 81 patients with a prevalence of 67.5%.,"[{'Central': 'B-Entity'}, {'and': 'I-Entity'}, {'peripheral': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'involvement': 'I-Entity'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'81': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'a': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'67.5%.': 'O'}]"
PATIENTS AND 21 fetuses of pregnant women with collagen vascular diseases were included in the study group and 59 healthy fetuses served as controls.,"[{'PATIENTS': 'O'}, {'AND': 'O'}, {'21': 'O'}, {'fetuses': 'O'}, {'of': 'O'}, {'pregnant': 'O'}, {'women': 'O'}, {'with': 'O'}, {'collagen': 'B-Entity'}, {'vascular': 'I-Entity'}, {'diseases': 'I-Entity'}, {'were': 'O'}, {'included': 'O'}, {'in': 'O'}, {'the': 'O'}, {'study': 'O'}, {'group': 'O'}, {'and': 'O'}, {'59': 'O'}, {'healthy': 'O'}, {'fetuses': 'O'}, {'served': 'O'}, {'as': 'O'}, {'controls.': 'O'}]"
"The underlying cornea was thin, firm, stable and vascularised.","[{'The': 'O'}, {'underlying': 'O'}, {'cornea': 'O'}, {'was': 'O'}, {'thin,': 'O'}, {'firm,': 'O'}, {'stable': 'O'}, {'and': 'O'}, {'vascularised.': 'O'}]"
Sjogrens syndrome is a heterogeneous inflammatory disorder frequently involving peripheral nerves with a wide spectrum of sensory modalities and distribution patterns.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'heterogeneous': 'O'}, {'inflammatory': 'B-Entity'}, {'disorder': 'I-Entity'}, {'frequently': 'O'}, {'involving': 'O'}, {'peripheral': 'O'}, {'nerves': 'O'}, {'with': 'O'}, {'a': 'O'}, {'wide': 'O'}, {'spectrum': 'O'}, {'of': 'O'}, {'sensory': 'O'}, {'modalities': 'O'}, {'and': 'O'}, {'distribution': 'O'}, {'patterns.': 'O'}]"
"Sjogrens syndrome is a chronic illness manifested characteristically by immune injury to the salivary and lacrimal glands, resulting in dry mouth/eyes.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'illness': 'I-Entity'}, {'manifested': 'O'}, {'characteristically': 'O'}, {'by': 'O'}, {'immune': 'B-Entity'}, {'injury': 'I-Entity'}, {'to': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands,': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'dry': 'B-Entity'}, {'mouth/eyes.': 'I-Entity'}]"
"Here we report that mice with T-cell-targeted deletion of Stromal Interaction Molecule (STIM) 1 and STIM2 [double-knockout (DKO)] mice develop spontaneous and severe pSS-like autoimmune disease, displaying major hallmarks of the disease.","[{'Here': 'O'}, {'we': 'O'}, {'report': 'O'}, {'that': 'O'}, {'mice': 'O'}, {'with': 'O'}, {'T-cell-targeted': 'O'}, {'deletion': 'O'}, {'of': 'O'}, {'Stromal': 'O'}, {'Interaction': 'O'}, {'Molecule': 'O'}, {'(STIM)': 'O'}, {'1': 'O'}, {'and': 'O'}, {'STIM2': 'O'}, {'[double-knockout': 'O'}, {'(DKO)]': 'O'}, {'mice': 'O'}, {'develop': 'O'}, {'spontaneous': 'O'}, {'and': 'O'}, {'severe': 'O'}, {'pSS-like': 'I-Entity'}, {'autoimmune': 'B-Entity'}, {'disease,': 'I-Entity'}, {'displaying': 'O'}, {'major': 'O'}, {'hallmarks': 'O'}, {'of': 'O'}, {'the': 'O'}]"
"The most common cause of a dry mouth is related to medication use, however patients with Sjogrens syndrome, a multisystem autoimmune condition, may present to their dentist rather than their GP complaining of dry mouth and dry eyes.","[{'The': 'O'}, {'most': 'O'}, {'common': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'a': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'is': 'O'}, {'related': 'O'}, {'to': 'O'}, {'medication': 'O'}, {'use,': 'O'}, {'however': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'a': 'O'}, {'multisystem': 'O'}, {'autoimmune': 'B-Entity'}, {'condition,': 'O'}, {'may': 'O'}, {'present': 'O'}, {'to': 'O'}, {'their': 'O'}, {'dentist': 'O'}, {'rather': 'O'}, {'than': 'O'}, {'their': 'O'}, {'GP': 'O'}, {'complaining': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'eyes.': 'I-Entity'}]"
"Unrecognized autoimmune systemic rheumatic disorders are associated with a significant proportion of preeclampsia and fetal growth failure, suggesting that their role in the etiology of adverse pregnancy outcome is probably undervalued.Matteo Foundation, P.le Golgi 19, 27100, Pavia, Italy.","[{'Unrecognized': 'O'}, {'autoimmune': 'B-Entity'}, {'systemic': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'disorders': 'I-Entity'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'proportion': 'O'}, {'of': 'O'}, {'preeclampsia': 'I-Entity'}, {'and': 'O'}, {'fetal': 'B-Entity'}, {'growth': 'I-Entity'}, {'failure,': 'I-Entity'}, {'suggesting': 'O'}, {'that': 'O'}, {'their': 'O'}, {'role': 'O'}, {'in': 'O'}, {'the': 'O'}, {'etiology': 'O'}, {'of': 'O'}, {'adverse': 'O'}, {'pregnancy': 'O'}, {'outcome': 'O'}, {'is': 'O'}, {'probably': 'O'}, {'undervalued.Matteo': 'O'}, {'Foundation,': 'O'}, {'P.le': 'O'}, {'Golgi': 'O'}, {'19,': 'O'}, {'27100,': 'O'}]"
"Immunosuppressive drugs promptly improved clinical signs concurrently with the abnormal sonographic findings, indicating the feasibility of ultrasonography in monitoring therapeutic outcomes.","[{'Immunosuppressive': 'O'}, {'drugs': 'O'}, {'promptly': 'O'}, {'improved': 'O'}, {'clinical': 'O'}, {'signs': 'O'}, {'concurrently': 'O'}, {'with': 'O'}, {'the': 'O'}, {'abnormal': 'O'}, {'sonographic': 'O'}, {'findings,': 'O'}, {'indicating': 'O'}, {'the': 'O'}, {'feasibility': 'O'}, {'of': 'O'}, {'ultrasonography': 'O'}, {'in': 'O'}, {'monitoring': 'O'}, {'therapeutic': 'O'}, {'outcomes.': 'O'}]"
"Nivolumab treatment caused marked tumor shrinkage, but xerostomia developed after two cycles.","[{'Nivolumab': 'I-Entity'}, {'treatment': 'O'}, {'caused': 'O'}, {'marked': 'O'}, {'tumor': 'I-Entity'}, {'shrinkage,': 'O'}, {'but': 'O'}, {'xerostomia': 'I-Entity'}, {'developed': 'O'}, {'after': 'O'}, {'two': 'O'}, {'cycles.': 'O'}]"
"Prolonged work at the WTC site, independent of acute exposure, was an important predictor of post-9/11 systemic autoimmune diseases.","[{'Prolonged': 'O'}, {'work': 'O'}, {'at': 'O'}, {'the': 'O'}, {'WTC': 'O'}, {'site,': 'O'}, {'independent': 'O'}, {'of': 'O'}, {'acute': 'O'}, {'exposure,': 'O'}, {'was': 'O'}, {'an': 'O'}, {'important': 'O'}, {'predictor': 'O'}, {'of': 'O'}, {'post-9/11': 'O'}, {'systemic': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"Considering these, breast cancer in patients with SS can be misdiagnosed as being in an advanced stage particularly in the presence of axillary lymphadenopathy.","[{'Considering': 'O'}, {'these,': 'O'}, {'breast': 'B-Entity'}, {'cancer': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'misdiagnosed': 'O'}, {'as': 'O'}, {'being': 'O'}, {'in': 'O'}, {'an': 'O'}, {'advanced': 'O'}, {'stage': 'O'}, {'particularly': 'O'}, {'in': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'axillary': 'O'}, {'lymphadenopathy.': 'I-Entity'}]"
"However, considering her prior diagnosis, we assumed that the clinical presentation was consistent with an acute exacerbation of Sjogrens syndrome.","[{'However,': 'O'}, {'considering': 'O'}, {'her': 'O'}, {'prior': 'O'}, {'diagnosis,': 'O'}, {'we': 'O'}, {'assumed': 'O'}, {'that': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'presentation': 'O'}, {'was': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'an': 'O'}, {'acute': 'O'}, {'exacerbation': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"Symptoms of xerostomia include ; burning sensation in the mouth, poor oral hygiene, inflammatory change of oral mucosa, high incidence of periodontal disease or caries, and impairment of oral function (dysphagia, dysgeusia, and speech disorder) .","[{'Symptoms': 'O'}, {'of': 'O'}, {'xerostomia': 'I-Entity'}, {'include': 'O'}, {';': 'O'}, {'burning': 'O'}, {'sensation': 'O'}, {'in': 'O'}, {'the': 'O'}, {'mouth,': 'O'}, {'poor': 'O'}, {'oral': 'O'}, {'hygiene,': 'O'}, {'inflammatory': 'O'}, {'change': 'O'}, {'of': 'O'}, {'oral': 'O'}, {'mucosa,': 'O'}, {'high': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'periodontal': 'B-Entity'}, {'disease': 'I-Entity'}, {'or': 'O'}, {'caries,': 'I-Entity'}, {'and': 'O'}, {'impairment': 'B-Entity'}, {'of': 'I-Entity'}, {'oral': 'I-Entity'}, {'function': 'I-Entity'}, {'(dysphagia,': 'O'}, {'dysgeusia,': 'I-Entity'}, {'and': 'O'}, {'speech': 'I-Entity'}]"
This review discusses difficulties in diagnosing childhood Sjogren syndrome and highlights recent findings in Sjogren syndrome treatment and pathogenesis from studies in adults and animal models over the past 18 months.,"[{'This': 'O'}, {'review': 'O'}, {'discusses': 'O'}, {'difficulties': 'O'}, {'in': 'O'}, {'diagnosing': 'O'}, {'childhood': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'highlights': 'O'}, {'recent': 'O'}, {'findings': 'O'}, {'in': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'treatment': 'O'}, {'and': 'O'}, {'pathogenesis': 'O'}, {'from': 'O'}, {'studies': 'O'}, {'in': 'O'}, {'adults': 'O'}, {'and': 'O'}, {'animal': 'O'}, {'models': 'O'}, {'over': 'O'}, {'the': 'O'}, {'past': 'O'}, {'18': 'O'}, {'months.': 'O'}]"
"Shrinking lung syndrome is a rare complication of systemic autoimmune diseases, mainly systemic lupus erythematosus, but also Sjogrens syndrome and polymyositis.","[{'Shrinking': 'B-Entity'}, {'lung': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'autoimmune': 'I-Entity'}, {'diseases,': 'I-Entity'}, {'mainly': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'but': 'O'}, {'also': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'polymyositis.': 'I-Entity'}]"
Splenic artery aneurysm is rare occurring in less than 1% of the population that usually appears as an incidental finding.,"[{'Splenic': 'B-Entity'}, {'artery': 'I-Entity'}, {'aneurysm': 'I-Entity'}, {'is': 'O'}, {'rare': 'O'}, {'occurring': 'O'}, {'in': 'O'}, {'less': 'O'}, {'than': 'O'}, {'1%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'population': 'O'}, {'that': 'O'}, {'usually': 'O'}, {'appears': 'O'}, {'as': 'O'}, {'an': 'O'}, {'incidental': 'O'}, {'finding.': 'O'}]"
"All cytokine levels except for IL-2 were highest in the SS group, followed by non-SS dry eye group and control subjects.","[{'All': 'O'}, {'cytokine': 'O'}, {'levels': 'O'}, {'except': 'O'}, {'for': 'O'}, {'IL-2': 'O'}, {'were': 'O'}, {'highest': 'O'}, {'in': 'O'}, {'the': 'O'}, {'SS': 'I-Entity'}, {'group,': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'non-SS': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'group': 'O'}, {'and': 'O'}, {'control': 'O'}, {'subjects.': 'O'}]"
"The most consistent result might be the association between rituximab response and the levels of memory B cells before therapy, although some studies were controversial.","[{'The': 'O'}, {'most': 'O'}, {'consistent': 'O'}, {'result': 'O'}, {'might': 'O'}, {'be': 'O'}, {'the': 'O'}, {'association': 'O'}, {'between': 'O'}, {'rituximab': 'I-Entity'}, {'response': 'O'}, {'and': 'O'}, {'the': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'memory': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'before': 'O'}, {'therapy,': 'O'}, {'although': 'O'}, {'some': 'O'}, {'studies': 'O'}, {'were': 'O'}, {'controversial.': 'O'}]"
"Telomere intensity in the Sjogren syndrome group (6,785.0¬¨¬®¬¨¬±455) was significantly lower than that in the non-Sjogren syndrome group (7,494.7¬¨¬®¬¨¬±477; p=0.02).","[{'Telomere': 'O'}, {'intensity': 'O'}, {'in': 'O'}, {'the': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'group': 'O'}, {'(6,785.0¬¨¬®¬¨¬±455)': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'lower': 'O'}, {'than': 'O'}, {'that': 'O'}, {'in': 'O'}, {'the': 'O'}, {'non-Sjogren': 'O'}, {'syndrome': 'I-Entity'}, {'group': 'O'}, {'(7,494.7¬¨¬®¬¨¬±477;': 'O'}, {'p=0.02).': 'O'}]"
"In addition, our results suggest another possible pathogenic role of IL-17 in pSS, further supporting its therapeutic targeting in this disease.Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.University of Florence, Florence, Italy.University of Florence, Florence, Italy.University of Florence, Florence, Italy.antinuclear antibodies.","[{'In': 'O'}, {'addition,': 'O'}, {'our': 'O'}, {'results': 'O'}, {'suggest': 'O'}, {'another': 'O'}, {'possible': 'O'}, {'pathogenic': 'O'}, {'role': 'O'}, {'of': 'O'}, {'IL-17': 'O'}, {'in': 'O'}, {'pSS,': 'I-Entity'}, {'further': 'O'}, {'supporting': 'O'}, {'its': 'O'}, {'therapeutic': 'O'}, {'targeting': 'O'}, {'in': 'O'}, {'this': 'O'}, {'disease.Wiley': 'O'}, {'&': 'O'}, {'Sons': 'O'}, {'Ltd': 'O'}, {'and': 'O'}, {'Foundation': 'O'}, {'for': 'O'}, {'Cellular': 'O'}, {'and': 'O'}, {'Molecular': 'O'}, {'Medicine.University': 'O'}, {'of': 'O'}, {'Florence,': 'O'}, {'Florence,': 'O'}, {'Italy.University': 'O'}, {'of': 'O'}, {'Florence,': 'O'}, {'Florence,': 'O'}, {'Italy.University': 'O'}, {'of': 'O'}, {'Florence,': 'O'}, {'Florence,': 'O'}]"
"Corneal nerve fiber density, Langerhans cell count, and cell density in the nerve plexus images were also evaluated.","[{'Corneal': 'O'}, {'nerve': 'O'}, {'fiber': 'O'}, {'density,': 'O'}, {'Langerhans': 'O'}, {'cell': 'O'}, {'count,': 'O'}, {'and': 'O'}, {'cell': 'O'}, {'density': 'O'}, {'in': 'O'}, {'the': 'O'}, {'nerve': 'O'}, {'plexus': 'O'}, {'images': 'O'}, {'were': 'O'}, {'also': 'O'}, {'evaluated.': 'O'}]"
Macrophage activation syndrome (MAS) is a relatively rare but potentially fatal complication of childhood rheumatic illnesses.,"[{'Macrophage': 'O'}, {'activation': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(MAS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'relatively': 'O'}, {'rare': 'O'}, {'but': 'O'}, {'potentially': 'O'}, {'fatal': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'childhood': 'O'}, {'rheumatic': 'B-Entity'}, {'illnesses.': 'I-Entity'}]"
Patients were on average relatively stoical for both types of dryness symptoms (mean ¬¨¬®¬¨¬± SD ocular dryness -0.42 ¬¨¬®¬¨¬± 2.2 and -1.24 ¬¨¬®¬¨¬± 1.6 oral dryness).,"[{'Patients': 'O'}, {'were': 'O'}, {'on': 'O'}, {'average': 'O'}, {'relatively': 'O'}, {'stoical': 'O'}, {'for': 'O'}, {'both': 'O'}, {'types': 'O'}, {'of': 'O'}, {'dryness': 'I-Entity'}, {'symptoms': 'O'}, {'(mean': 'O'}, {'¬¨¬®¬¨¬±': 'O'}, {'SD': 'O'}, {'ocular': 'B-Entity'}, {'dryness': 'I-Entity'}, {'-0.42': 'O'}, {'¬¨¬®¬¨¬±': 'O'}, {'2.2': 'O'}, {'and': 'O'}, {'-1.24': 'O'}, {'¬¨¬®¬¨¬±': 'O'}, {'1.6': 'O'}]"
"The most common neurological complication of pSS is peripheral neuropathy, and in particular sensory polyneuropathy.","[{'The': 'O'}, {'most': 'O'}, {'common': 'O'}, {'neurological': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'is': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy,': 'I-Entity'}, {'and': 'O'}, {'in': 'O'}, {'particular': 'O'}, {'sensory': 'O'}, {'polyneuropathy.': 'I-Entity'}]"
The pathologic features of the salivary glands resulting from Sjogren syndrome and systemic lupus erythematosus can be managed successfully using an endoscopic approach.by Elsevier Inc. All rights reserved.Israel.Association of Oral and Maxillofacial Surgeons2010 Dec 8.,"[{'The': 'O'}, {'pathologic': 'O'}, {'features': 'O'}, {'of': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'resulting': 'O'}, {'from': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'managed': 'O'}, {'successfully': 'O'}, {'using': 'O'}, {'an': 'O'}, {'endoscopic': 'O'}, {'approach.by': 'O'}, {'Elsevier': 'O'}, {'Inc.': 'O'}, {'All': 'O'}, {'rights': 'O'}, {'reserved.Israel.Association': 'O'}, {'of': 'O'}, {'Oral': 'O'}, {'and': 'O'}, {'Maxillofacial': 'O'}, {'Surgeons2010': 'O'}]"
Sjogrens syndrome is a chronic autoimmune disorder characterized by inflammation of salivary glands resulting in impaired secretory function.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'autoimmune': 'B-Entity'}, {'disorder': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'inflammation': 'I-Entity'}, {'of': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'impaired': 'B-Entity'}, {'secretory': 'I-Entity'}, {'function.': 'I-Entity'}]"
"Further studies are necessary to assess the efficacy of current therapies in diffuse septal amyloidosis secondary to SS.Research (PGIMER), Chandigarh, India.","[{'Further': 'O'}, {'studies': 'O'}, {'are': 'O'}, {'necessary': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'current': 'O'}, {'therapies': 'O'}, {'in': 'O'}, {'diffuse': 'O'}, {'septal': 'O'}, {'amyloidosis': 'I-Entity'}, {'secondary': 'O'}, {'to': 'O'}, {'SS.Research': 'I-Entity'}, {'(PGIMER),': 'O'}, {'Chandigarh,': 'O'}, {'India.': 'O'}]"
"Considering the implications of B, T, and natural killer (NK) cells in the pathophysiology of systemic autoimmune diseases, the assessment of their distribution in the blood could be helpful for physicians in the complex process of determining a precise diagnosis.","[{'Considering': 'O'}, {'the': 'O'}, {'implications': 'O'}, {'of': 'O'}, {'B,': 'O'}, {'T,': 'O'}, {'and': 'O'}, {'natural': 'O'}, {'killer': 'O'}, {'(NK)': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'the': 'O'}, {'pathophysiology': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'the': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'their': 'O'}, {'distribution': 'O'}, {'in': 'O'}, {'the': 'O'}, {'blood': 'O'}, {'could': 'O'}, {'be': 'O'}, {'helpful': 'O'}, {'for': 'O'}, {'physicians': 'O'}, {'in': 'O'}, {'the': 'O'}, {'complex': 'O'}, {'process': 'O'}, {'of': 'O'}, {'determining': 'O'}, {'a': 'O'}, {'precise': 'O'}, {'diagnosis.': 'O'}]"
To assess the efficacy and safety of abatacept for secondary Sjogrens syndrome (SS) associated with rheumatoid arthritis (RA).,"[{'To': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'safety': 'O'}, {'of': 'O'}, {'abatacept': 'I-Entity'}, {'for': 'O'}, {'secondary': 'O'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA).': 'O'}]"
"Whether IBP, SI joint inflammation and radiologic sacroiliitis is due to the co-existence of SpA and primary SS or IBP is an underdiagnosed clinical feature of SS deserves further studies of large patient numbers.Research Hospital, Istanbul, Turkey.Turkey.Turkey.Istanbul,Turkey.Turkey.Turkey.Turkey.Turkey.2018.and/or Antinuclear Antibodies as Substitute Immunological Criterion in Sjogren Syndrome with Negative Anti-SSA/SSB Antibodies.","[{'Whether': 'O'}, {'IBP,': 'I-Entity'}, {'SI': 'O'}, {'joint': 'O'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'radiologic': 'O'}, {'sacroiliitis': 'I-Entity'}, {'is': 'O'}, {'due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'co-existence': 'O'}, {'of': 'O'}, {'SpA': 'I-Entity'}, {'and': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'or': 'O'}, {'IBP': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'underdiagnosed': 'O'}, {'clinical': 'O'}, {'feature': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'deserves': 'O'}, {'further': 'O'}, {'studies': 'O'}, {'of': 'O'}, {'large': 'O'}, {'patient': 'O'}, {'numbers.Research': 'O'}, {'Hospital,': 'O'}, {'Istanbul,': 'O'}, {'Turkey.Turkey.Turkey.Istanbul,Turkey.Turkey.Turkey.Turkey.Turkey.2018.and/or': 'O'}]"
Sjogren syndrome is an autoimmune disease characterized by targeted destruction of the lacrimal and salivary glands resulting in symptoms of severe ocular and oral dryness.,"[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'targeted': 'O'}, {'destruction': 'O'}, {'of': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}, {'and': 'I-Entity'}, {'salivary': 'I-Entity'}, {'glands': 'I-Entity'}, {'resulting': 'O'}, {'in': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'severe': 'O'}, {'ocular': 'B-Entity'}, {'and': 'I-Entity'}, {'oral': 'I-Entity'}, {'dryness.': 'I-Entity'}]"
The likely diagnosis proceeds from the more to the less common in patients without a history of allergy or infection.,"[{'The': 'O'}, {'likely': 'O'}, {'diagnosis': 'O'}, {'proceeds': 'O'}, {'from': 'O'}, {'the': 'O'}, {'more': 'O'}, {'to': 'O'}, {'the': 'O'}, {'less': 'O'}, {'common': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'a': 'O'}, {'history': 'O'}, {'of': 'O'}, {'allergy': 'I-Entity'}, {'or': 'O'}, {'infection.': 'I-Entity'}]"
"Patients with SS showed higher meibomian gland dropout scores and reduced LLT and NITBUT, which likely contribute to the severe dry eye symptoms reported by SS subjects.School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada.School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada.Canada.School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada.prognosis of 188 patients.","[{'Patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'showed': 'O'}, {'higher': 'O'}, {'meibomian': 'O'}, {'gland': 'O'}, {'dropout': 'O'}, {'scores': 'O'}, {'and': 'O'}, {'reduced': 'O'}, {'LLT': 'O'}, {'and': 'O'}, {'NITBUT,': 'O'}, {'which': 'O'}, {'likely': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'the': 'O'}, {'severe': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'symptoms': 'I-Entity'}, {'reported': 'O'}, {'by': 'O'}, {'SS': 'I-Entity'}, {'subjects.School': 'O'}, {'of': 'O'}, {'Optometry': 'O'}, {'&': 'O'}, {'Vision': 'O'}, {'Science,': 'O'}, {'University': 'O'}, {'of': 'O'}, {'Waterloo,': 'O'}, {'Waterloo,': 'O'}, {'Ontario,': 'O'}, {'Canada.School': 'O'}, {'of': 'O'}, {'Optometry': 'O'}]"
The most common symptoms were arthritis (60 %)followed by malar rash (40 %).,"[{'The': 'O'}, {'most': 'O'}, {'common': 'O'}, {'symptoms': 'O'}, {'were': 'O'}, {'arthritis': 'I-Entity'}, {'(60': 'O'}, {'%)followed': 'O'}, {'by': 'O'}, {'malar': 'B-Entity'}, {'rash': 'I-Entity'}, {'(40': 'O'}, {'%).': 'O'}]"
"In contrast, cough improved in most (64%) patients without SS; the majority (eight/nine) report intensified disease-specific treatment (five allergic and three GERD).","[{'In': 'O'}, {'contrast,': 'O'}, {'cough': 'I-Entity'}, {'improved': 'O'}, {'in': 'O'}, {'most': 'O'}, {'(64%)': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'SS;': 'I-Entity'}, {'the': 'O'}, {'majority': 'O'}, {'(eight/nine)': 'O'}, {'report': 'O'}, {'intensified': 'O'}, {'disease-specific': 'O'}, {'treatment': 'O'}, {'(five': 'O'}, {'allergic': 'I-Entity'}, {'and': 'O'}, {'three': 'O'}, {'GERD).': 'I-Entity'}]"
"A significant percentage of patients with anti-Ro/SSA antibodies were negative for anti-Ro52 antibodies (22%), while 13 patients (12%) were negative for anti-Ro/SSA antibodies but positive for anti-Ro52 antibodies, meaning that they fulfilled the 2002 SS criteria while avoiding the need for a salivary biopsy.","[{'A': 'O'}, {'significant': 'O'}, {'percentage': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'anti-Ro/SSA': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'negative': 'O'}, {'for': 'O'}, {'anti-Ro52': 'O'}, {'antibodies': 'O'}, {'(22%),': 'O'}, {'while': 'O'}, {'13': 'O'}, {'patients': 'O'}, {'(12%)': 'O'}, {'were': 'O'}, {'negative': 'O'}, {'for': 'O'}, {'anti-Ro/SSA': 'O'}, {'antibodies': 'O'}, {'but': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'anti-Ro52': 'O'}, {'antibodies,': 'O'}, {'meaning': 'O'}, {'that': 'O'}, {'they': 'O'}, {'fulfilled': 'O'}]"
The most frequent germs found in the samples were coagulase-negative Staphylococcus (48.6%).,"[{'The': 'O'}, {'most': 'O'}, {'frequent': 'O'}, {'germs': 'O'}, {'found': 'O'}, {'in': 'O'}, {'the': 'O'}, {'samples': 'O'}, {'were': 'O'}, {'coagulase-negative': 'O'}, {'Staphylococcus': 'I-Entity'}, {'(48.6%).': 'O'}]"
ILC1 frequencies were increased in peripheral blood of patients with SLE as compared with healthy controls and correlate with disease activity in pSS patients.,"[{'ILC1': 'O'}, {'frequencies': 'O'}, {'were': 'O'}, {'increased': 'O'}, {'in': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SLE': 'I-Entity'}, {'as': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'healthy': 'O'}, {'controls': 'O'}, {'and': 'O'}, {'correlate': 'O'}, {'with': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
"Even though exocrinopathy is the hallmark of Sjogrens syndrome, systemic symptoms are observed in one-third of patients.","[{'Even': 'O'}, {'though': 'O'}, {'exocrinopathy': 'I-Entity'}, {'is': 'O'}, {'the': 'O'}, {'hallmark': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'systemic': 'O'}, {'symptoms': 'O'}, {'are': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'one-third': 'O'}, {'of': 'O'}, {'patients.': 'O'}]"
"We describe a case of a 67-year-old woman whose principal symptom was recurrent perioral edema, which was characteristically induced by cold.","[{'We': 'O'}, {'describe': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'67-year-old': 'O'}, {'woman': 'O'}, {'whose': 'O'}, {'principal': 'O'}, {'symptom': 'O'}, {'was': 'O'}, {'recurrent': 'O'}, {'perioral': 'B-Entity'}, {'edema,': 'I-Entity'}, {'which': 'O'}, {'was': 'O'}, {'characteristically': 'O'}, {'induced': 'O'}, {'by': 'O'}, {'cold.': 'O'}]"
Sensory neuropathy was the presenting symptom and the course was subacute in all cases.,"[{'Sensory': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'was': 'O'}, {'the': 'O'}, {'presenting': 'O'}, {'symptom': 'O'}, {'and': 'O'}, {'the': 'O'}, {'course': 'O'}, {'was': 'O'}, {'subacute': 'O'}, {'in': 'O'}, {'all': 'O'}, {'cases.': 'O'}]"
"(2) LABORATORY FINDINGS: the platelet count and inflammatory markers such as erythrocyte sedimentation rate, C-reactive protein (CRP) were usually normal.","[{'(2)': 'O'}, {'LABORATORY': 'O'}, {'FINDINGS:': 'O'}, {'the': 'O'}, {'platelet': 'O'}, {'count': 'O'}, {'and': 'O'}, {'inflammatory': 'O'}, {'markers': 'O'}, {'such': 'O'}, {'as': 'O'}, {'erythrocyte': 'O'}, {'sedimentation': 'O'}, {'rate,': 'O'}, {'C-reactive': 'O'}, {'protein': 'O'}, {'(CRP)': 'O'}, {'were': 'O'}, {'usually': 'O'}, {'normal.': 'O'}]"
We attempted to determine whether clinical features could differentiate painful small-fiber neuropathy related to primary Sj‚Äö√Ñ√∂‚àö√°¬¨¬Æogren's syndrome (pSS-SFN) from idiopathic SFN (idio-SFN).,"[{'We': 'O'}, {'attempted': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'whether': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'could': 'O'}, {'differentiate': 'O'}, {'painful': 'O'}, {'small-fiber': 'O'}, {'neuropathy': 'I-Entity'}, {'related': 'O'}, {'to': 'O'}, {'primary': 'O'}, {""Sj‚Äö√Ñ√∂‚àö√°¬¨¬Æogren's"": 'O'}, {'syndrome': 'I-Entity'}, {'(pSS-SFN)': 'O'}, {'from': 'O'}, {'idiopathic': 'B-Entity'}, {'SFN': 'I-Entity'}, {'(idio-SFN).': 'O'}]"
"Based on treating underlying infections and use of corticosteroids and immunosuppressive agents in combination with intravenous immunoglobulins (IVIG) therapy, 5 patients recovered, 6 patients died.","[{'Based': 'O'}, {'on': 'O'}, {'treating': 'O'}, {'underlying': 'O'}, {'infections': 'I-Entity'}, {'and': 'O'}, {'use': 'O'}, {'of': 'O'}, {'corticosteroids': 'O'}, {'and': 'O'}, {'immunosuppressive': 'O'}, {'agents': 'O'}, {'in': 'O'}, {'combination': 'O'}, {'with': 'O'}, {'intravenous': 'O'}, {'immunoglobulins': 'O'}, {'(IVIG)': 'O'}, {'therapy,': 'O'}, {'5': 'O'}, {'patients': 'O'}, {'recovered,': 'O'}, {'6': 'O'}, {'patients': 'O'}, {'died.': 'O'}]"
"Anti-Sjogren's syndrome A antigen antibodies were elevated, and there was reduced salivary flow on scintigraphy.","[{""Anti-Sjogren's"": 'O'}, {'syndrome': 'I-Entity'}, {'A': 'I-Entity'}, {'antigen': 'I-Entity'}, {'antibodies': 'O'}, {'were': 'O'}, {'elevated,': 'O'}, {'and': 'O'}, {'there': 'O'}, {'was': 'O'}, {'reduced': 'B-Entity'}, {'salivary': 'O'}, {'flow': 'O'}, {'on': 'O'}, {'scintigraphy.': 'O'}]"
"The causes of this type of neuropathy, such as Sjogrens syndrome, sarcoidosis, and celiac disease, may be treatable.124, 630 West 168th Street, New York, NY 10032, USA.","[{'The': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'this': 'O'}, {'type': 'O'}, {'of': 'O'}, {'neuropathy,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'sarcoidosis,': 'I-Entity'}, {'and': 'O'}, {'celiac': 'B-Entity'}, {'disease,': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'treatable.124,': 'O'}, {'630': 'O'}, {'West': 'O'}, {'168th': 'O'}, {'Street,': 'O'}, {'New': 'O'}, {'York,': 'O'}, {'NY': 'O'}, {'10032,': 'O'}, {'USA.': 'O'}]"
"Sjogrens syndrome associated with glomerulonephritis and interstitial lung disease was diagnosed, and she received pulse methylprednisololone followed by oral prednisone with dramatic improvement.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'glomerulonephritis': 'I-Entity'}, {'and': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'was': 'O'}, {'diagnosed,': 'O'}, {'and': 'O'}, {'she': 'O'}, {'received': 'O'}, {'pulse': 'O'}, {'methylprednisololone': 'I-Entity'}, {'followed': 'O'}, {'by': 'O'}, {'oral': 'O'}, {'prednisone': 'I-Entity'}, {'with': 'O'}, {'dramatic': 'O'}, {'improvement.': 'O'}]"
Rituximab treatment resulted in significant improvement of patient-reported symptoms.,"[{'Rituximab': 'I-Entity'}, {'treatment': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'significant': 'O'}, {'improvement': 'O'}, {'of': 'O'}, {'patient-reported': 'O'}, {'symptoms.': 'O'}]"
"Although the possibility of infectious, metabolic or toxic aetiologies should be carefully excluded in these forms of autonomic neuropathy, the monophasic clinical course and the presence of antecedent infections suggest the involvement of immune mechanisms similar to Guillain-Barr‚Äö√†√∂¬¨¬© syndrome.","[{'Although': 'O'}, {'the': 'O'}, {'possibility': 'O'}, {'of': 'O'}, {'infectious,': 'O'}, {'metabolic': 'I-Entity'}, {'or': 'O'}, {'toxic': 'I-Entity'}, {'aetiologies': 'O'}, {'should': 'O'}, {'be': 'O'}, {'carefully': 'O'}, {'excluded': 'O'}, {'in': 'O'}, {'these': 'O'}, {'forms': 'O'}, {'of': 'O'}, {'autonomic': 'B-Entity'}, {'neuropathy,': 'I-Entity'}, {'the': 'O'}, {'monophasic': 'O'}, {'clinical': 'O'}, {'course': 'O'}, {'and': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'antecedent': 'O'}, {'infections': 'I-Entity'}, {'suggest': 'O'}, {'the': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'immune': 'O'}, {'mechanisms': 'O'}, {'similar': 'O'}, {'to': 'O'}, {'Guillain-Barr‚Äö√†√∂¬¨¬©': 'B-Entity'}]"
Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) are chronic inflammatory diseases of the central nervous system (CNS).,"[{'Multiple': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(MS)': 'O'}, {'and': 'O'}, {'neuromyelitis': 'B-Entity'}, {'optica': 'I-Entity'}, {'spectrum': 'I-Entity'}, {'disorder': 'I-Entity'}, {'(NMOSD)': 'O'}, {'are': 'O'}, {'chronic': 'B-Entity'}, {'inflammatory': 'B-Entity'}, {'diseases': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'central': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'(CNS).': 'O'}]"
We identified seven RCTs carried out in primary SjS patients.,"[{'We': 'O'}, {'identified': 'O'}, {'seven': 'O'}, {'RCTs': 'O'}, {'carried': 'O'}, {'out': 'O'}, {'in': 'O'}, {'primary': 'O'}, {'SjS': 'I-Entity'}, {'patients.': 'O'}]"
"Finally, her symptoms stabilized after the inclusion of oral D-penicillamine to her treatment regimen.","[{'Finally,': 'O'}, {'her': 'O'}, {'symptoms': 'O'}, {'stabilized': 'O'}, {'after': 'O'}, {'the': 'O'}, {'inclusion': 'O'}, {'of': 'O'}, {'oral': 'O'}, {'D-penicillamine': 'B-Entity'}, {'to': 'O'}, {'her': 'O'}, {'treatment': 'O'}, {'regimen.': 'O'}]"
"Sjogrens syndrome is a systemic autoimmune disease which is characterized by xerosis, and multiple organs can be affected, causing interstitial lung disease, renal tubular acidosis, blood system involvement, peripheral neuropathy, and liver damage, but cardiac involvement is rare.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'which': 'O'}, {'is': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'xerosis,': 'I-Entity'}, {'and': 'O'}, {'multiple': 'O'}, {'organs': 'O'}, {'can': 'O'}, {'be': 'O'}, {'affected,': 'O'}, {'causing': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease,': 'I-Entity'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis,': 'I-Entity'}, {'blood': 'O'}, {'system': 'O'}, {'involvement,': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy,': 'I-Entity'}, {'and': 'O'}, {'liver': 'B-Entity'}, {'damage,': 'I-Entity'}, {'but': 'O'}, {'cardiac': 'O'}, {'involvement': 'O'}, {'is': 'O'}, {'rare.': 'O'}]"
"A positive relationship between dyslipidemia and morphological changes in labial salivary glands was obtained.Hadassah Faculty of Dental Medicine, Jerusalem, Israel.","[{'A': 'O'}, {'positive': 'O'}, {'relationship': 'O'}, {'between': 'O'}, {'dyslipidemia': 'I-Entity'}, {'and': 'O'}, {'morphological': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'labial': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'was': 'O'}, {'obtained.Hadassah': 'O'}, {'Faculty': 'O'}, {'of': 'O'}, {'Dental': 'O'}, {'Medicine,': 'O'}, {'Jerusalem,': 'O'}, {'Israel.': 'O'}]"
"Moreover, removal of ovarian sex hormones accelerated these effects in the genetically predisposed animal and these effects were more severe and persistent compared to control animals.","[{'Moreover,': 'O'}, {'removal': 'O'}, {'of': 'O'}, {'ovarian': 'O'}, {'sex': 'O'}, {'hormones': 'O'}, {'accelerated': 'O'}, {'these': 'O'}, {'effects': 'O'}, {'in': 'O'}, {'the': 'O'}, {'genetically': 'O'}, {'predisposed': 'O'}, {'animal': 'O'}, {'and': 'O'}, {'these': 'O'}, {'effects': 'O'}, {'were': 'O'}, {'more': 'O'}, {'severe': 'O'}, {'and': 'O'}, {'persistent': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'control': 'O'}, {'animals.': 'O'}]"
"DM with secondary SS in adult is a unique disease entity, with predominantly myopathic symptoms and satisfactory therapeutic response as its characteristics.","[{'DM': 'I-Entity'}, {'with': 'O'}, {'secondary': 'O'}, {'SS': 'I-Entity'}, {'in': 'O'}, {'adult': 'O'}, {'is': 'O'}, {'a': 'O'}, {'unique': 'O'}, {'disease': 'O'}, {'entity,': 'O'}, {'with': 'O'}, {'predominantly': 'O'}, {'myopathic': 'I-Entity'}, {'symptoms': 'O'}, {'and': 'O'}, {'satisfactory': 'O'}, {'therapeutic': 'O'}, {'response': 'O'}, {'as': 'O'}, {'its': 'O'}, {'characteristics.': 'O'}]"
"Sicca symptoms of the mouth and eyes, salivary gland capacity, tear secretion, minor salivary gland inflammation, serum autoantibodies, and fatigue were also investigated.","[{'Sicca': 'B-Entity'}, {'symptoms': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'mouth': 'I-Entity'}, {'and': 'I-Entity'}, {'eyes,': 'I-Entity'}, {'salivary': 'O'}, {'gland': 'O'}, {'capacity,': 'O'}, {'tear': 'O'}, {'secretion,': 'O'}, {'minor': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'inflammation,': 'I-Entity'}, {'serum': 'O'}, {'autoantibodies,': 'O'}, {'and': 'O'}, {'fatigue': 'I-Entity'}, {'were': 'O'}, {'also': 'O'}, {'investigated.': 'O'}]"
Patients with renal involvement were compared with their age- and gender-matched controls (pSS without renal involvement).,"[{'Patients': 'O'}, {'with': 'O'}, {'renal': 'B-Entity'}, {'involvement': 'I-Entity'}, {'were': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'their': 'O'}, {'age-': 'O'}, {'and': 'O'}, {'gender-matched': 'O'}, {'controls': 'O'}, {'(pSS': 'O'}, {'without': 'O'}, {'renal': 'O'}, {'involvement).': 'O'}]"
Radiologic findings showed bilateral pulmonary nodules associated to mediastinal lymph nodes.,"[{'Radiologic': 'O'}, {'findings': 'O'}, {'showed': 'O'}, {'bilateral': 'O'}, {'pulmonary': 'B-Entity'}, {'nodules': 'I-Entity'}, {'associated': 'O'}, {'to': 'O'}, {'mediastinal': 'O'}, {'lymph': 'O'}, {'nodes.': 'O'}]"
We similarly identified immune-mediated and inflammatory markers of injury in a psoriatic arthritis patient who developed an amyotrophic lateral sclerosis (ALS)-plus syndrome after tumor necrosis factor (TNF)-inhibitor therapy.We have described a diverse spectrum of movement and other neurodegenerative disorders in our rheumatic disease patients.,"[{'We': 'O'}, {'similarly': 'O'}, {'identified': 'O'}, {'immune-mediated': 'O'}, {'and': 'O'}, {'inflammatory': 'O'}, {'markers': 'O'}, {'of': 'O'}, {'injury': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'psoriatic': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'patient': 'O'}, {'who': 'O'}, {'developed': 'O'}, {'an': 'O'}, {'amyotrophic': 'B-Entity'}, {'lateral': 'I-Entity'}, {'sclerosis': 'I-Entity'}, {'(ALS)-plus': 'O'}, {'syndrome': 'I-Entity'}, {'after': 'O'}, {'tumor': 'B-Entity'}, {'necrosis': 'I-Entity'}, {'factor': 'I-Entity'}, {'(TNF)-inhibitor': 'I-Entity'}, {'therapy.We': 'O'}, {'have': 'O'}, {'described': 'O'}, {'a': 'O'}, {'diverse': 'O'}, {'spectrum': 'O'}, {'of': 'O'}, {'movement': 'O'}, {'and': 'O'}, {'other': 'O'}]"
"Clinical trials assessing the efficacy of biological therapies in PSS should be encouraged but patient selection and outcome measures used in these studies must be carefully considered to ensure that the true effects of biological therapies on the outcomes of PSS are being appropriately evaluated.Group, Newcastle upon Tyne, NE2 4HH, UK.","[{'Clinical': 'O'}, {'trials': 'O'}, {'assessing': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'biological': 'O'}, {'therapies': 'O'}, {'in': 'O'}, {'PSS': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'encouraged': 'O'}, {'but': 'O'}, {'patient': 'O'}, {'selection': 'O'}, {'and': 'O'}, {'outcome': 'O'}, {'measures': 'O'}, {'used': 'O'}, {'in': 'O'}, {'these': 'O'}, {'studies': 'O'}, {'must': 'O'}, {'be': 'O'}, {'carefully': 'O'}, {'considered': 'O'}, {'to': 'O'}, {'ensure': 'O'}, {'that': 'O'}, {'the': 'O'}, {'true': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'biological': 'O'}, {'therapies': 'O'}, {'on': 'O'}, {'the': 'O'}, {'outcomes': 'O'}, {'of': 'O'}, {'PSS': 'I-Entity'}, {'are': 'O'}, {'being': 'O'}, {'appropriately': 'O'}, {'evaluated.Group,': 'O'}, {'Newcastle': 'O'}, {'upon': 'O'}, {'Tyne,': 'O'}, {'NE2': 'O'}, {'4HH,': 'O'}]"
"Interstitial lung disease (ILD) is one of the most serious pulmonary complications associated with connective tissue diseases (CTDs), resulting in significant morbidity and mortality.","[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(ILD)': 'O'}, {'is': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'most': 'O'}, {'serious': 'O'}, {'pulmonary': 'O'}, {'complications': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'(CTDs),': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'significant': 'O'}, {'morbidity': 'O'}, {'and': 'O'}, {'mortality.': 'O'}]"
"Interstitial lung disease (ILD) is one of the most serious pulmonary complications associated with connective tissue diseases (CTDs), resulting in significant morbidity and mortality.","[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(ILD)': 'O'}, {'is': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'most': 'O'}, {'serious': 'O'}, {'pulmonary': 'O'}, {'complications': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'(CTDs),': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'significant': 'O'}, {'morbidity': 'O'}, {'and': 'O'}, {'mortality.': 'O'}]"
"Whether heavy metal, particularly chromium or nickel is a novel environmental risk factor for sicca syndrome needs more studies to confirm.University of Education, Changhua, Taiwan.","[{'Whether': 'O'}, {'heavy': 'O'}, {'metal,': 'I-Entity'}, {'particularly': 'O'}, {'chromium': 'I-Entity'}, {'or': 'O'}, {'nickel': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'novel': 'O'}, {'environmental': 'O'}, {'risk': 'O'}, {'factor': 'O'}, {'for': 'O'}, {'sicca': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'needs': 'O'}, {'more': 'O'}, {'studies': 'O'}, {'to': 'O'}, {'confirm.University': 'O'}, {'of': 'O'}, {'Education,': 'O'}, {'Changhua,': 'O'}, {'Taiwan.': 'O'}]"
"TNF-‚âà√≠¬¨¬± stimulation increased exocytic events in the basal pole, which was further enhanced by Syt-1 overexpression.","[{'TNF-‚âà√≠¬¨¬±': 'I-Entity'}, {'stimulation': 'O'}, {'increased': 'O'}, {'exocytic': 'O'}, {'events': 'O'}, {'in': 'O'}, {'the': 'O'}, {'basal': 'O'}, {'pole,': 'O'}, {'which': 'O'}, {'was': 'O'}, {'further': 'O'}, {'enhanced': 'O'}, {'by': 'O'}, {'Syt-1': 'O'}, {'overexpression.': 'O'}]"
Administration of high doses of methylprednisolone and cyclophosphamide leads to substantial improvement in the cerebellar symptoms of this case.,"[{'Administration': 'O'}, {'of': 'O'}, {'high': 'O'}, {'doses': 'O'}, {'of': 'O'}, {'methylprednisolone': 'I-Entity'}, {'and': 'O'}, {'cyclophosphamide': 'I-Entity'}, {'leads': 'O'}, {'to': 'O'}, {'substantial': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'the': 'O'}, {'cerebellar': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'this': 'O'}, {'case.': 'O'}]"
"No lung dysfunction was observed, although 46% (n=16) had a positive bronchial response.","[{'No': 'O'}, {'lung': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'was': 'O'}, {'observed,': 'O'}, {'although': 'O'}, {'46%': 'O'}, {'(n=16)': 'O'}, {'had': 'O'}, {'a': 'O'}, {'positive': 'O'}, {'bronchial': 'O'}, {'response.': 'O'}]"
"The percentage of patients with glandular swelling decreased from 41.7% to 0.0% in the group A and from 30.0% to 0.0% in the group B, respectively.","[{'The': 'O'}, {'percentage': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'glandular': 'B-Entity'}, {'swelling': 'I-Entity'}, {'decreased': 'O'}, {'from': 'O'}, {'41.7%': 'O'}, {'to': 'O'}, {'0.0%': 'O'}, {'in': 'O'}, {'the': 'O'}, {'group': 'O'}, {'A': 'O'}, {'and': 'O'}, {'from': 'O'}, {'30.0%': 'O'}, {'to': 'O'}, {'0.0%': 'O'}, {'in': 'O'}, {'the': 'O'}, {'group': 'O'}, {'B,': 'O'}, {'respectively.': 'O'}]"
To determine whether ocular phenotypic features of keratoconjunctivitis sicca (KCS) and/or participant-reported symptoms of dry eye disease are associated with depression in women participants enrolled in the Sjogrens International Collaborative Clinical Alliance (SICCA).,"[{'To': 'O'}, {'determine': 'O'}, {'whether': 'O'}, {'ocular': 'O'}, {'phenotypic': 'O'}, {'features': 'O'}, {'of': 'O'}, {'keratoconjunctivitis': 'B-Entity'}, {'sicca': 'I-Entity'}, {'(KCS)': 'O'}, {'and/or': 'O'}, {'participant-reported': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease': 'I-Entity'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'depression': 'I-Entity'}, {'in': 'O'}, {'women': 'O'}, {'participants': 'O'}, {'enrolled': 'O'}, {'in': 'O'}, {'the': 'O'}, {'Sjogrens': 'O'}, {'International': 'O'}, {'Collaborative': 'O'}, {'Clinical': 'O'}, {'Alliance': 'O'}, {'(SICCA).': 'O'}]"
"Compared to mimickers, patients with SSc were more likely to have skin thickening (OR 427); telangiectasias (OR 91); anti-RNA polymerase III antibody (OR 75); puffy fingers (OR 35); finger flexion contractures (OR 29); tendon/bursal friction rubs (OR 27); anti-topoisomerase I antibody (OR 25); RP (OR 24); fingertip ulcers/pitting scars (OR 19); anticentromere antibody (OR 14); abnormal nailfold capillaries (OR 10); gastroesophageal reflux disease symptoms (OR 8); antinuclear antibody, calcinosis, dysphagia, and esophageal dilation (all OR 6); interstitial lung disease/pulmonary fibrosis (OR 5); and anti-PM-Scl antibody (OR 2).","[{'Compared': 'O'}, {'to': 'O'}, {'mimickers,': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SSc': 'I-Entity'}, {'were': 'O'}, {'more': 'O'}, {'likely': 'O'}, {'to': 'O'}, {'have': 'O'}, {'skin': 'B-Entity'}, {'thickening': 'I-Entity'}, {'(OR': 'O'}, {'427);': 'O'}, {'telangiectasias': 'I-Entity'}, {'(OR': 'O'}, {'91);': 'O'}, {'anti-RNA': 'O'}, {'polymerase': 'O'}, {'III': 'O'}, {'antibody': 'O'}, {'(OR': 'O'}, {'75);': 'O'}, {'puffy': 'B-Entity'}, {'fingers': 'I-Entity'}, {'(OR': 'O'}, {'35);': 'O'}, {'finger': 'B-Entity'}, {'flexion': 'I-Entity'}, {'contractures': 'I-Entity'}, {'(OR': 'O'}]"
"Patients referred to our pulmonary clinic (Sheba Medical Center, 2009 to 2012) with unexplained cough and concomitant dry eyes were selected for evaluation.","[{'Patients': 'O'}, {'referred': 'O'}, {'to': 'O'}, {'our': 'O'}, {'pulmonary': 'O'}, {'clinic': 'O'}, {'(Sheba': 'O'}, {'Medical': 'O'}, {'Center,': 'O'}, {'2009': 'O'}, {'to': 'O'}, {'2012)': 'O'}, {'with': 'O'}, {'unexplained': 'O'}, {'cough': 'I-Entity'}, {'and': 'O'}, {'concomitant': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'were': 'O'}, {'selected': 'O'}, {'for': 'O'}, {'evaluation.': 'O'}]"
"Routine laboratory tests are useful to confirm a suspected diagnosis, to assess disease activity, and to measure the response and toxicity to treatment.","[{'Routine': 'O'}, {'laboratory': 'O'}, {'tests': 'O'}, {'are': 'O'}, {'useful': 'O'}, {'to': 'O'}, {'confirm': 'O'}, {'a': 'O'}, {'suspected': 'O'}, {'diagnosis,': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'and': 'O'}, {'to': 'O'}, {'measure': 'O'}, {'the': 'O'}, {'response': 'O'}, {'and': 'O'}, {'toxicity': 'I-Entity'}, {'to': 'O'}, {'treatment.': 'O'}]"
The most common symptom was persistent or progressive swelling of the salivary glands without pain or facial palsy.,"[{'The': 'O'}, {'most': 'O'}, {'common': 'O'}, {'symptom': 'O'}, {'was': 'O'}, {'persistent': 'O'}, {'or': 'O'}, {'progressive': 'O'}, {'swelling': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'salivary': 'I-Entity'}, {'glands': 'I-Entity'}, {'without': 'O'}, {'pain': 'I-Entity'}, {'or': 'O'}, {'facial': 'B-Entity'}, {'palsy.': 'I-Entity'}]"
Early diagnosis can help prevent potentially life-threatening infections.,"[{'Early': 'O'}, {'diagnosis': 'O'}, {'can': 'O'}, {'help': 'O'}, {'prevent': 'O'}, {'potentially': 'O'}, {'life-threatening': 'O'}, {'infections.': 'I-Entity'}]"
"Treatment of young Id3-/- mice with anti-IL-13 antibodies over a two-month period resulted in a reduction of both serum IL-13 levels and the number of mast cells in the salivary gland tissues, as well as correspondingly improved saliva production.","[{'Treatment': 'O'}, {'of': 'O'}, {'young': 'O'}, {'Id3-/-': 'O'}, {'mice': 'O'}, {'with': 'O'}, {'anti-IL-13': 'O'}, {'antibodies': 'O'}, {'over': 'O'}, {'a': 'O'}, {'two-month': 'O'}, {'period': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'a': 'O'}, {'reduction': 'O'}, {'of': 'O'}, {'both': 'O'}, {'serum': 'O'}, {'IL-13': 'O'}, {'levels': 'O'}, {'and': 'O'}, {'the': 'O'}, {'number': 'O'}, {'of': 'O'}, {'mast': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'tissues,': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'correspondingly': 'O'}, {'improved': 'O'}, {'saliva': 'O'}, {'production.': 'O'}]"
Early diagnosis of SS in children with rheumatic diseases significantly affects to the choice of treatment and prognosis.,"[{'Early': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'in': 'O'}, {'children': 'O'}, {'with': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases': 'I-Entity'}, {'significantly': 'O'}, {'affects': 'O'}, {'to': 'O'}, {'the': 'O'}, {'choice': 'O'}, {'of': 'O'}, {'treatment': 'O'}, {'and': 'O'}, {'prognosis.': 'O'}]"
"To evaluate the efficacy of hydroxychloroquine for the main symptoms of primary Sjogren syndrome: dryness, pain, and fatigue.","[{'To': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'hydroxychloroquine': 'I-Entity'}, {'for': 'O'}, {'the': 'O'}, {'main': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome:': 'I-Entity'}, {'dryness,': 'I-Entity'}, {'pain,': 'I-Entity'}, {'and': 'O'}, {'fatigue.': 'I-Entity'}]"
"Treatment with immune-modulating therapy, cyclophosphamide, resulted in significant improvement in subjective and objective clinical presentation.","[{'Treatment': 'O'}, {'with': 'O'}, {'immune-modulating': 'O'}, {'therapy,': 'O'}, {'cyclophosphamide,': 'I-Entity'}, {'resulted': 'O'}, {'in': 'O'}, {'significant': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'subjective': 'O'}, {'and': 'O'}, {'objective': 'O'}, {'clinical': 'O'}, {'presentation.': 'O'}]"
"Disease profiling indicated that SS-non-susceptible C57BL/6J mice whose salivary glands received the Ad5-IL17A vector developed a SS-like disease profile, including the appearance of lymphocytic foci, increased cytokine levels, changes in antinuclear antibody profiles, and temporal loss of saliva flow.","[{'Disease': 'O'}, {'profiling': 'O'}, {'indicated': 'O'}, {'that': 'O'}, {'SS-non-susceptible': 'I-Entity'}, {'C57BL/6J': 'O'}, {'mice': 'O'}, {'whose': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'received': 'O'}, {'the': 'O'}, {'Ad5-IL17A': 'O'}, {'vector': 'O'}, {'developed': 'O'}, {'a': 'O'}, {'SS-like': 'I-Entity'}, {'disease': 'O'}, {'profile,': 'O'}, {'including': 'O'}, {'the': 'O'}, {'appearance': 'O'}, {'of': 'O'}, {'lymphocytic': 'O'}, {'foci,': 'O'}, {'increased': 'O'}, {'cytokine': 'O'}, {'levels,': 'O'}, {'changes': 'O'}, {'in': 'O'}]"
"Photosensitivity, oral ulcers, Raynaud's phenomenon, anti-Ro antibodies, and anti-La antibodies had a significant positive association while renal disease, anti-ribonucleoprotein (RNP) antibodies, and anti-dsDNA antibodies had a negative association with the presence of SS after adjustment for age (at last cohort visit), gender, ethnicity, and anti-Ro antibodies.","[{'Photosensitivity,': 'I-Entity'}, {'oral': 'B-Entity'}, {'ulcers,': 'I-Entity'}, {""Raynaud's"": 'B-Entity'}, {'phenomenon,': 'I-Entity'}, {'anti-Ro': 'O'}, {'antibodies,': 'O'}, {'and': 'O'}, {'anti-La': 'O'}, {'antibodies': 'O'}, {'had': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'positive': 'O'}, {'association': 'O'}, {'while': 'O'}, {'renal': 'B-Entity'}, {'disease,': 'I-Entity'}, {'anti-ribonucleoprotein': 'O'}, {'(RNP)': 'O'}, {'antibodies,': 'O'}, {'and': 'O'}, {'anti-dsDNA': 'O'}, {'antibodies': 'O'}]"
"Connective tissue disease (CTDs), though rare in childhood, are an important cause of morbidity.","[{'Connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'(CTDs),': 'O'}, {'though': 'O'}, {'rare': 'O'}, {'in': 'O'}, {'childhood,': 'O'}, {'are': 'O'}, {'an': 'O'}, {'important': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'morbidity.': 'O'}]"
We have previously demonstrated that the majority of salivary microRNAs are within exosomes.,"[{'We': 'O'}, {'have': 'O'}, {'previously': 'O'}, {'demonstrated': 'O'}, {'that': 'O'}, {'the': 'O'}, {'majority': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'microRNAs': 'O'}, {'are': 'O'}, {'within': 'O'}, {'exosomes.': 'O'}]"
"Epidemiological studies demonstrated that hematopoietic, lung, skin, and prostate cancers are increased in RA, while breast and colon cancers are decreased, with an overall slight increase in all cancers.","[{'Epidemiological': 'O'}, {'studies': 'O'}, {'demonstrated': 'O'}, {'that': 'O'}, {'hematopoietic,': 'B-Entity'}, {'lung,': 'I-Entity'}, {'skin,': 'I-Entity'}, {'and': 'I-Entity'}, {'prostate': 'I-Entity'}, {'cancers': 'I-Entity'}, {'are': 'O'}, {'increased': 'O'}, {'in': 'O'}, {'RA,': 'I-Entity'}, {'while': 'O'}, {'breast': 'B-Entity'}, {'and': 'I-Entity'}, {'colon': 'I-Entity'}, {'cancers': 'I-Entity'}, {'are': 'O'}, {'decreased,': 'O'}, {'with': 'O'}, {'an': 'O'}, {'overall': 'O'}, {'slight': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'all': 'O'}, {'cancers.': 'I-Entity'}]"
"Sicca symptoms, oral health, and RA disease activity were assessed.","[{'Sicca': 'I-Entity'}, {'symptoms,': 'O'}, {'oral': 'O'}, {'health,': 'O'}, {'and': 'O'}, {'RA': 'I-Entity'}, {'disease': 'O'}, {'activity': 'O'}, {'were': 'O'}, {'assessed.': 'O'}]"
Additional investigations led to the diagnosis of primary Sjogrens syndrome associated with Hashimoto's thyro‚Äö√†√∂‚àö√≤ditis.,"[{'Additional': 'O'}, {'investigations': 'O'}, {'led': 'O'}, {'to': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {""Hashimoto's"": 'B-Entity'}, {'thyro‚Äö√†√∂‚àö√≤ditis.': 'I-Entity'}]"
"Patients with rheumatic disease may present with a myriad of symptoms, from joint pain and rashes to more subtle findings, such as dry eyes and dry mouth.","[{'Patients': 'O'}, {'with': 'O'}, {'rheumatic': 'B-Entity'}, {'disease': 'I-Entity'}, {'may': 'O'}, {'present': 'O'}, {'with': 'O'}, {'a': 'O'}, {'myriad': 'O'}, {'of': 'O'}, {'symptoms,': 'O'}, {'from': 'O'}, {'joint': 'B-Entity'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'rashes': 'I-Entity'}, {'to': 'O'}, {'more': 'O'}, {'subtle': 'O'}, {'findings,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth.': 'I-Entity'}]"
"In 21 (6%) patients, disease onset occurred after the age of 65 years.","[{'In': 'O'}, {'21': 'O'}, {'(6%)': 'O'}, {'patients,': 'O'}, {'disease': 'O'}, {'onset': 'O'}, {'occurred': 'O'}, {'after': 'O'}, {'the': 'O'}, {'age': 'O'}, {'of': 'O'}, {'65': 'O'}, {'years.': 'O'}]"
In the cases above more agressive immunosuppressive therapy may be required.Zs.,"[{'In': 'O'}, {'the': 'O'}, {'cases': 'O'}, {'above': 'O'}, {'more': 'O'}, {'agressive': 'O'}, {'immunosuppressive': 'O'}, {'therapy': 'O'}, {'may': 'O'}, {'be': 'O'}, {'required.Zs.': 'O'}]"
"Multiple sclerosis (MS) is a progressive demyelinating-inflammatory disease of the central nervous system, probably of autoimmune etiology.","[{'Multiple': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(MS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'progressive': 'O'}, {'demyelinating-inflammatory': 'B-Entity'}, {'disease': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'central': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system,': 'I-Entity'}, {'probably': 'O'}, {'of': 'O'}, {'autoimmune': 'O'}, {'etiology.': 'O'}]"
"We measured concentrations of IL-17 in tears of normal subjects (n = 28) and patients (n = 141) with meibomian gland dysfunction (MGD), dry eye syndrome (DES), Sjogren syndrome (SS), Stevens-Johnson syndrome (SJS), graft-versus-host disease (GVHD), filamentary keratitis, and autoimmune keratitis associated with rheumatoid arthritis or systemic lupus erythematosus.","[{'We': 'O'}, {'measured': 'O'}, {'concentrations': 'O'}, {'of': 'O'}, {'IL-17': 'O'}, {'in': 'O'}, {'tears': 'O'}, {'of': 'O'}, {'normal': 'O'}, {'subjects': 'O'}, {'(n': 'O'}, {'=': 'O'}, {'28)': 'O'}, {'and': 'O'}, {'patients': 'O'}, {'(n': 'O'}, {'=': 'O'}, {'141)': 'O'}, {'with': 'O'}, {'meibomian': 'B-Entity'}, {'gland': 'I-Entity'}, {'dysfunction': 'I-Entity'}, {'(MGD),': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(DES),': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'Stevens-Johnson': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SJS),': 'O'}]"
"Sicca syndrome as a presenting symptom occurred in only 2/8 of children, recurrent parotid swelling in 3/8; whereas anti-SSA/SSB antibodies and typical salivary-gland histology were found in 6/8 patients.","[{'Sicca': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'presenting': 'O'}, {'symptom': 'O'}, {'occurred': 'O'}, {'in': 'O'}, {'only': 'O'}, {'2/8': 'O'}, {'of': 'O'}, {'children,': 'O'}, {'recurrent': 'O'}, {'parotid': 'B-Entity'}, {'swelling': 'I-Entity'}, {'in': 'O'}, {'3/8;': 'O'}, {'whereas': 'O'}, {'anti-SSA/SSB': 'O'}, {'antibodies': 'O'}, {'and': 'O'}, {'typical': 'O'}, {'salivary-gland': 'O'}, {'histology': 'O'}, {'were': 'O'}, {'found': 'O'}, {'in': 'O'}, {'6/8': 'O'}, {'patients.': 'O'}]"
"Studies on cardiovascular or cerebrovascular events in primary Sjogrens syndrome (pSS) are limited, with conflicting results.","[{'Studies': 'O'}, {'on': 'O'}, {'cardiovascular': 'O'}, {'or': 'O'}, {'cerebrovascular': 'O'}, {'events': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'are': 'O'}, {'limited,': 'O'}, {'with': 'O'}, {'conflicting': 'O'}, {'results.': 'O'}]"
Recognition of inflammation may allow for targeted perioperative therapeutic management of care for patients who undergo cataract and refractive surgery and improve outcomes.,"[{'Recognition': 'O'}, {'of': 'O'}, {'inflammation': 'I-Entity'}, {'may': 'O'}, {'allow': 'O'}, {'for': 'O'}, {'targeted': 'O'}, {'perioperative': 'O'}, {'therapeutic': 'O'}, {'management': 'O'}, {'of': 'O'}, {'care': 'O'}, {'for': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'undergo': 'O'}, {'cataract': 'I-Entity'}, {'and': 'O'}, {'refractive': 'O'}, {'surgery': 'O'}, {'and': 'O'}, {'improve': 'O'}, {'outcomes.': 'O'}]"
Her laboratory test results showed positive anti-Ro (SSA) and anti-Ro-52 antibodies.,"[{'Her': 'O'}, {'laboratory': 'O'}, {'test': 'O'}, {'results': 'O'}, {'showed': 'O'}, {'positive': 'O'}, {'anti-Ro': 'O'}, {'(SSA)': 'O'}, {'and': 'O'}, {'anti-Ro-52': 'O'}, {'antibodies.': 'O'}]"
"Most cases had an acute, often recurrent course with spontaneous remission or only mild neurological impairment.","[{'Most': 'O'}, {'cases': 'O'}, {'had': 'O'}, {'an': 'O'}, {'acute,': 'O'}, {'often': 'O'}, {'recurrent': 'O'}, {'course': 'O'}, {'with': 'O'}, {'spontaneous': 'O'}, {'remission': 'O'}, {'or': 'O'}, {'only': 'O'}, {'mild': 'O'}, {'neurological': 'B-Entity'}, {'impairment.': 'I-Entity'}]"
"The effects of dental treatment, pregnancy outcomes and neonatal health status were observed.","[{'The': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'dental': 'O'}, {'treatment,': 'O'}, {'pregnancy': 'O'}, {'outcomes': 'O'}, {'and': 'O'}, {'neonatal': 'O'}, {'health': 'O'}, {'status': 'O'}, {'were': 'O'}, {'observed.': 'O'}]"
Interstitial lung disease (ILD) is one of the major causes of morbidity and mortality in patients with connective tissue disease (CTD) and the treatments available until nowadays are in most cases unable to halt disease progression.,"[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(ILD)': 'O'}, {'is': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'major': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'morbidity': 'O'}, {'and': 'O'}, {'mortality': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'(CTD)': 'O'}, {'and': 'O'}, {'the': 'O'}, {'treatments': 'O'}, {'available': 'O'}, {'until': 'O'}, {'nowadays': 'O'}, {'are': 'O'}, {'in': 'O'}, {'most': 'O'}, {'cases': 'O'}, {'unable': 'O'}, {'to': 'O'}, {'halt': 'O'}, {'disease': 'O'}, {'progression.': 'O'}]"
"Peripapillary retinal nerve fiber layer (pRNFL) thickness, macular ganglion cell-inner plexiform layer (mGCIPL) thickness, and optic nerve head parameters were compared between groups.","[{'Peripapillary': 'O'}, {'retinal': 'O'}, {'nerve': 'O'}, {'fiber': 'O'}, {'layer': 'O'}, {'(pRNFL)': 'O'}, {'thickness,': 'O'}, {'macular': 'O'}, {'ganglion': 'O'}, {'cell-inner': 'O'}, {'plexiform': 'O'}, {'layer': 'O'}, {'(mGCIPL)': 'O'}, {'thickness,': 'O'}, {'and': 'O'}, {'optic': 'O'}, {'nerve': 'O'}, {'head': 'O'}, {'parameters': 'O'}, {'were': 'O'}, {'compared': 'O'}, {'between': 'O'}, {'groups.': 'O'}]"
Multiple sclerosis (MS) is very similar to the Sjogrens syndrome (SS) by its clinical presentations.,"[{'Multiple': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(MS)': 'O'}, {'is': 'O'}, {'very': 'O'}, {'similar': 'O'}, {'to': 'O'}, {'the': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'by': 'O'}, {'its': 'O'}, {'clinical': 'O'}, {'presentations.': 'O'}]"
Fifty-five pSS patients and 52 controls were analysed.,"[{'Fifty-five': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'52': 'O'}, {'controls': 'O'}, {'were': 'O'}, {'analysed.': 'O'}]"
To investigate the anti-inflammatory effect of peroxisome proliferator-activated receptor-‚âà√≠‚Äö√¢‚Ä¢ (PPAR-‚âà√≠‚Äö√¢‚Ä¢) on non-obese diabetic mice (NOD mice) with Sjogren's syndrome.,"[{'To': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'anti-inflammatory': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'peroxisome': 'O'}, {'proliferator-activated': 'O'}, {'receptor-‚âà√≠‚Äö√¢‚Ä¢': 'O'}, {'(PPAR-‚âà√≠‚Äö√¢‚Ä¢)': 'O'}, {'on': 'O'}, {'non-obese': 'O'}, {'diabetic': 'I-Entity'}, {'mice': 'O'}, {'(NOD': 'O'}]"
"Sjogren's syndrome (SS), a chronic autoimmune disease, typically causes or involves inflammation in the salivary and lacrimal glands.","[{""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'a': 'O'}, {'chronic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease,': 'I-Entity'}, {'typically': 'O'}, {'causes': 'O'}, {'or': 'O'}, {'involves': 'O'}, {'inflammation': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands.': 'O'}]"
We aimed to determine the cut-off levels of salivary ‚âà√≠‚Äö√¢¬ß2MG and Na+ which differentiate SS patients from non-SS patients and healthy controls.,"[{'We': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'cut-off': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'‚âà√≠‚Äö√¢¬ß2MG': 'O'}, {'and': 'O'}, {'Na+': 'I-Entity'}, {'which': 'O'}, {'differentiate': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'from': 'O'}, {'non-SS': 'O'}, {'patients': 'O'}, {'and': 'O'}, {'healthy': 'O'}, {'controls.': 'O'}]"
"Her laboratory test results showed positive anti-nuclear antibodies (ANA) with raised titer, anti-double-stranded DNA, anti-ribonucleoprotein, anti-Sjogrens syndrome-related antigen A, anti-Sjogrens syndrome-related antigen B, and anti-smooth muscle antibodies.","[{'Her': 'O'}, {'laboratory': 'O'}, {'test': 'O'}, {'results': 'O'}, {'showed': 'O'}, {'positive': 'O'}, {'anti-nuclear': 'O'}, {'antibodies': 'O'}, {'(ANA)': 'O'}, {'with': 'O'}, {'raised': 'O'}, {'titer,': 'O'}, {'anti-double-stranded': 'O'}, {'DNA,': 'O'}, {'anti-ribonucleoprotein,': 'O'}, {'anti-Sjogrens': 'O'}, {'syndrome-related': 'I-Entity'}, {'antigen': 'O'}, {'A,': 'O'}, {'anti-Sjogrens': 'O'}, {'syndrome-related': 'I-Entity'}, {'antigen': 'O'}, {'B,': 'O'}]"
Vaccination of patients with rheumatic disease has been reported to result in lower antibody titres than in healthy individuals.,"[{'Vaccination': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'rheumatic': 'B-Entity'}, {'disease': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'reported': 'O'}, {'to': 'O'}, {'result': 'O'}, {'in': 'O'}, {'lower': 'O'}, {'antibody': 'O'}, {'titres': 'O'}, {'than': 'O'}, {'in': 'O'}, {'healthy': 'O'}, {'individuals.': 'O'}]"
"Less common is brain/mental diseases (20.0% in psychogenic bladder dysfunction, 8.1% in Parkinson's disease, etc.).","[{'Less': 'O'}, {'common': 'O'}, {'is': 'O'}, {'brain/mental': 'B-Entity'}, {'diseases': 'I-Entity'}, {'(20.0%': 'O'}, {'in': 'O'}, {'psychogenic': 'O'}, {'bladder': 'B-Entity'}, {'dysfunction,': 'I-Entity'}, {'8.1%': 'O'}, {'in': 'O'}, {""Parkinson's"": 'B-Entity'}, {'disease,': 'I-Entity'}, {'etc.).': 'O'}]"
"Major clinical manifestations were vision loss in 4 cases, nausea and vomiting in 4 cases, limbs numbness and weakness in 6 cases.","[{'Major': 'O'}, {'clinical': 'O'}, {'manifestations': 'O'}, {'were': 'O'}, {'vision': 'B-Entity'}, {'loss': 'I-Entity'}, {'in': 'O'}, {'4': 'O'}, {'cases,': 'O'}, {'nausea': 'I-Entity'}, {'and': 'O'}, {'vomiting': 'I-Entity'}, {'in': 'O'}, {'4': 'O'}, {'cases,': 'O'}, {'limbs': 'O'}, {'numbness': 'I-Entity'}, {'and': 'O'}, {'weakness': 'I-Entity'}, {'in': 'O'}, {'6': 'O'}, {'cases.': 'O'}]"
"Prevalence per 100,000 are: 552 rheumatoid arthritis, 124 ulcerative colitis, 15 Crohn's disease, 464 type 1 diabetes, 81 systemic lupus erythematosus, 124 celiac disease, 35 myasthenia gravis, 939 psoriasis/psoriatic arthritis, 35 systemic sclerosis, 224 multiple sclerosis, 31 Sjogren's syndrome, and 2,619 autoimmune thyroiditis.","[{'Prevalence': 'O'}, {'per': 'O'}, {'100,000': 'O'}, {'are:': 'O'}, {'552': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {'124': 'O'}, {'ulcerative': 'B-Entity'}, {'colitis,': 'I-Entity'}, {'15': 'O'}, {""Crohn's"": 'B-Entity'}, {'disease,': 'I-Entity'}, {'464': 'O'}, {'type': 'B-Entity'}, {'1': 'I-Entity'}, {'diabetes,': 'I-Entity'}, {'81': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'124': 'O'}, {'celiac': 'I-Entity'}, {'disease,': 'I-Entity'}, {'35': 'O'}, {'myasthenia': 'I-Entity'}]"
"To determine the partner chromosome associated with the IGH rearrangement, further FISH tests were set up for t(4;14)(p16;q32) followed by t(14;16)(q32;q22) on fresh slides.","[{'To': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'partner': 'O'}, {'chromosome': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'IGH': 'O'}, {'rearrangement,': 'O'}, {'further': 'O'}, {'FISH': 'O'}, {'tests': 'O'}, {'were': 'O'}, {'set': 'O'}, {'up': 'O'}, {'for': 'O'}, {'t(4;14)(p16;q32)': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'t(14;16)(q32;q22)': 'O'}, {'on': 'O'}, {'fresh': 'O'}, {'slides.': 'O'}]"
"AT-RvD1 treatment administered post-disease onset reduces T helper 17 cells and successfully restores salivary gland function in a SS mouse model with variable effects noted by sex, thus warranting further examination of both the causes for the sex differences and the mechanisms responsible for the observed treatment effect.Society for Rheumatology.","[{'AT-RvD1': 'O'}, {'treatment': 'O'}, {'administered': 'O'}, {'post-disease': 'O'}, {'onset': 'O'}, {'reduces': 'O'}, {'T': 'O'}, {'helper': 'O'}, {'17': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'successfully': 'O'}, {'restores': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'function': 'O'}, {'in': 'O'}, {'a': 'O'}, {'SS': 'I-Entity'}, {'mouse': 'O'}, {'model': 'O'}, {'with': 'O'}, {'variable': 'O'}, {'effects': 'O'}, {'noted': 'O'}, {'by': 'O'}, {'sex,': 'O'}, {'thus': 'O'}, {'warranting': 'O'}, {'further': 'O'}, {'examination': 'O'}, {'of': 'O'}, {'both': 'O'}, {'the': 'O'}, {'causes': 'O'}, {'for': 'O'}, {'the': 'O'}, {'sex': 'O'}, {'differences': 'O'}, {'and': 'O'}, {'the': 'O'}, {'mechanisms': 'O'}, {'responsible': 'O'}, {'for': 'O'}, {'the': 'O'}, {'observed': 'O'}, {'treatment': 'O'}, {'effect.Society': 'O'}]"
"Antibodies against orfK8.1 were detected in 2 SLE patients, 1 patient suffering from Sjogrens syndrome and 2 patients with vasculitis.","[{'Antibodies': 'O'}, {'against': 'O'}, {'orfK8.1': 'O'}, {'were': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'2': 'O'}, {'SLE': 'I-Entity'}, {'patients,': 'O'}, {'1': 'O'}, {'patient': 'O'}, {'suffering': 'O'}, {'from': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'2': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'vasculitis.': 'I-Entity'}]"
Sjogrens syndrome is a common autoimmune disorder characterized by dry mouth and dry eyes.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'common': 'O'}, {'autoimmune': 'B-Entity'}, {'disorder': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'eyes.': 'I-Entity'}]"
Positive screen results were further examined by quantitative fluoroenzymeimmunoassays and/or immunoblots for antibody identification.,"[{'Positive': 'O'}, {'screen': 'O'}, {'results': 'O'}, {'were': 'O'}, {'further': 'O'}, {'examined': 'O'}, {'by': 'O'}, {'quantitative': 'O'}, {'fluoroenzymeimmunoassays': 'O'}, {'and/or': 'O'}, {'immunoblots': 'O'}, {'for': 'O'}, {'antibody': 'O'}, {'identification.': 'O'}]"
"The patients complain of symptoms of dry eyes and dry mouth, but up to 50‚Äö√Ñ√∂‚àö√ë‚àö¬ß% may additionally develop extraglandular manifestations such as arthritis, vasculitis, polyneuropathy, pulmonary fibrosis or interstitial nephritis.","[{'The': 'O'}, {'patients': 'O'}, {'complain': 'O'}, {'of': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'but': 'O'}, {'up': 'O'}, {'to': 'O'}, {'50‚Äö√Ñ√∂‚àö√ë‚àö¬ß%': 'O'}, {'may': 'O'}, {'additionally': 'O'}, {'develop': 'O'}, {'extraglandular': 'O'}, {'manifestations': 'O'}, {'such': 'O'}, {'as': 'O'}, {'arthritis,': 'I-Entity'}, {'vasculitis,': 'I-Entity'}, {'polyneuropathy,': 'I-Entity'}, {'pulmonary': 'B-Entity'}]"
"Very recently, cardiac involvement and peripheral neuropathy associated with a new p.Leu102Ser variant of lysozyme have been documented.","[{'Very': 'O'}, {'recently,': 'O'}, {'cardiac': 'O'}, {'involvement': 'O'}, {'and': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'new': 'O'}, {'p.Leu102Ser': 'O'}, {'variant': 'O'}, {'of': 'O'}, {'lysozyme': 'O'}, {'have': 'O'}, {'been': 'O'}, {'documented.': 'O'}]"
"To evaluate the efficacy and safety of an intraoral electrostimulation device, consisting of stimulating electrodes, an electronic circuit, and a power source, in treating xerostomia.","[{'To': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'safety': 'O'}, {'of': 'O'}, {'an': 'O'}, {'intraoral': 'O'}, {'electrostimulation': 'O'}, {'device,': 'O'}, {'consisting': 'O'}, {'of': 'O'}, {'stimulating': 'O'}, {'electrodes,': 'O'}, {'an': 'O'}, {'electronic': 'O'}, {'circuit,': 'O'}, {'and': 'O'}, {'a': 'O'}, {'power': 'O'}, {'source,': 'O'}, {'in': 'O'}, {'treating': 'O'}, {'xerostomia.': 'I-Entity'}]"
"While severe adverse effects are rare, evidence suggests significant physiological effects may be associated with the use of electrical incapacitation devices, or TASERs.","[{'While': 'O'}, {'severe': 'O'}, {'adverse': 'O'}, {'effects': 'O'}, {'are': 'O'}, {'rare,': 'O'}, {'evidence': 'O'}, {'suggests': 'O'}, {'significant': 'O'}, {'physiological': 'O'}, {'effects': 'O'}, {'may': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'use': 'O'}, {'of': 'O'}, {'electrical': 'O'}, {'incapacitation': 'O'}, {'devices,': 'O'}, {'or': 'O'}, {'TASERs.': 'O'}]"
"This can result in difficulties for the clinician, patient and researcher if signs and symptoms are either overlooked or are incorrectly included in the nosology or classification of diseases.","[{'This': 'O'}, {'can': 'O'}, {'result': 'O'}, {'in': 'O'}, {'difficulties': 'O'}, {'for': 'O'}, {'the': 'O'}, {'clinician,': 'O'}, {'patient': 'O'}, {'and': 'O'}, {'researcher': 'O'}, {'if': 'O'}, {'signs': 'O'}, {'and': 'O'}, {'symptoms': 'O'}, {'are': 'O'}, {'either': 'O'}, {'overlooked': 'O'}, {'or': 'O'}, {'are': 'O'}, {'incorrectly': 'O'}, {'included': 'O'}, {'in': 'O'}, {'the': 'O'}, {'nosology': 'O'}, {'or': 'O'}, {'classification': 'O'}, {'of': 'O'}, {'diseases.': 'O'}]"
"TG treatment induced autophagy, as indicated by enhanced protein expression of LC3II.","[{'TG': 'I-Entity'}, {'treatment': 'O'}, {'induced': 'O'}, {'autophagy,': 'O'}, {'as': 'O'}, {'indicated': 'O'}, {'by': 'O'}, {'enhanced': 'O'}, {'protein': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'LC3II.': 'O'}]"
"We described the incidence, clinical characteristics, treatment, and outcome.","[{'We': 'O'}, {'described': 'O'}, {'the': 'O'}, {'incidence,': 'O'}, {'clinical': 'O'}, {'characteristics,': 'O'}, {'treatment,': 'O'}, {'and': 'O'}, {'outcome.': 'O'}]"
"The underlying diseases, clinical features, laboratory findings and treatment outcomes were retrospectively analyzed.","[{'The': 'O'}, {'underlying': 'O'}, {'diseases,': 'O'}, {'clinical': 'O'}, {'features,': 'O'}, {'laboratory': 'O'}, {'findings': 'O'}, {'and': 'O'}, {'treatment': 'O'}, {'outcomes': 'O'}, {'were': 'O'}, {'retrospectively': 'O'}, {'analyzed.': 'O'}]"
We found that TSP-1 null mice develop inflammation in the conjunctiva and associated loss of goblet cell function similar to that seen in patients with SS.,"[{'We': 'O'}, {'found': 'O'}, {'that': 'O'}, {'TSP-1': 'O'}, {'null': 'O'}, {'mice': 'O'}, {'develop': 'O'}, {'inflammation': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'conjunctiva': 'O'}, {'and': 'O'}, {'associated': 'O'}, {'loss': 'O'}, {'of': 'O'}, {'goblet': 'O'}, {'cell': 'O'}, {'function': 'O'}, {'similar': 'O'}, {'to': 'O'}, {'that': 'O'}, {'seen': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS.': 'I-Entity'}]"
"The results indicate increased sensitivity of immune cells from pSS patients to STAT1-activating signals, and may partly explain the IFN signature observed in pSS.Hospital, Tampere, Finland; School of Medicine, University of Tampere, Tampere, Finland.","[{'The': 'O'}, {'results': 'O'}, {'indicate': 'O'}, {'increased': 'O'}, {'sensitivity': 'O'}, {'of': 'O'}, {'immune': 'O'}, {'cells': 'O'}, {'from': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'to': 'O'}, {'STAT1-activating': 'O'}, {'signals,': 'O'}, {'and': 'O'}, {'may': 'O'}, {'partly': 'O'}, {'explain': 'O'}, {'the': 'O'}, {'IFN': 'O'}, {'signature': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'pSS.Hospital,': 'I-Entity'}, {'Tampere,': 'O'}, {'Finland;': 'O'}, {'School': 'O'}, {'of': 'O'}, {'Medicine,': 'O'}, {'University': 'O'}, {'of': 'O'}, {'Tampere,': 'O'}, {'Tampere,': 'O'}, {'Finland.': 'O'}]"
SLE patients are susceptible to infection due to the disease itself or to the immunosuppressive therapy.,"[{'SLE': 'I-Entity'}, {'patients': 'O'}, {'are': 'O'}, {'susceptible': 'O'}, {'to': 'O'}, {'infection': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'itself': 'O'}, {'or': 'O'}, {'to': 'O'}, {'the': 'O'}, {'immunosuppressive': 'O'}, {'therapy.': 'O'}]"
"By eight weeks after treatment, the saliva production in the alum-treated mice was significantly decreased in comparison to the PBS-treated mice.","[{'By': 'O'}, {'eight': 'O'}, {'weeks': 'O'}, {'after': 'O'}, {'treatment,': 'O'}, {'the': 'O'}, {'saliva': 'O'}, {'production': 'O'}, {'in': 'O'}, {'the': 'O'}, {'alum-treated': 'I-Entity'}, {'mice': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'decreased': 'O'}, {'in': 'O'}, {'comparison': 'O'}, {'to': 'O'}, {'the': 'O'}, {'PBS-treated': 'O'}, {'mice.': 'O'}]"
"Investigations for other conditions, including human immunodeficiency virus infection, were negative.","[{'Investigations': 'O'}, {'for': 'O'}, {'other': 'O'}, {'conditions,': 'O'}, {'including': 'O'}, {'human': 'B-Entity'}, {'immunodeficiency': 'I-Entity'}, {'virus': 'I-Entity'}, {'infection,': 'I-Entity'}, {'were': 'O'}, {'negative.': 'O'}]"
"Although the cause and molecular pathways of Sjogrens syndrome are still unknown, basic, clinical, and translational science have started to identify linkages to other known processes.","[{'Although': 'O'}, {'the': 'O'}, {'cause': 'O'}, {'and': 'O'}, {'molecular': 'O'}, {'pathways': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'are': 'O'}, {'still': 'O'}, {'unknown,': 'O'}, {'basic,': 'O'}, {'clinical,': 'O'}, {'and': 'O'}, {'translational': 'O'}, {'science': 'O'}, {'have': 'O'}, {'started': 'O'}, {'to': 'O'}, {'identify': 'O'}, {'linkages': 'O'}, {'to': 'O'}, {'other': 'O'}, {'known': 'O'}, {'processes.': 'O'}]"
"In contrast, motor impairment is apparent in multiple mononeuropathy, multiple cranial neuropathy, and radiculoneuropathy.","[{'In': 'O'}, {'contrast,': 'O'}, {'motor': 'B-Entity'}, {'impairment': 'I-Entity'}, {'is': 'O'}, {'apparent': 'O'}, {'in': 'O'}, {'multiple': 'B-Entity'}, {'mononeuropathy,': 'I-Entity'}, {'multiple': 'B-Entity'}, {'cranial': 'I-Entity'}, {'neuropathy,': 'I-Entity'}, {'and': 'O'}, {'radiculoneuropathy.': 'I-Entity'}]"
"The mechanisms by which decreased levels of sex hormones caused lymphocytic infiltration and apoptosis and the interaction of lack of sex hormones with the genetic elements remain to be elucidated.Florida Atlantic University, Boca Raton, FL 33431-0991, USA.28.improved understanding of rheumatic diseases.","[{'The': 'O'}, {'mechanisms': 'O'}, {'by': 'O'}, {'which': 'O'}, {'decreased': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'sex': 'O'}, {'hormones': 'O'}, {'caused': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'and': 'O'}, {'apoptosis': 'O'}, {'and': 'O'}, {'the': 'O'}, {'interaction': 'O'}, {'of': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'sex': 'O'}, {'hormones': 'O'}, {'with': 'O'}, {'the': 'O'}, {'genetic': 'O'}, {'elements': 'O'}, {'remain': 'O'}, {'to': 'O'}, {'be': 'O'}, {'elucidated.Florida': 'O'}, {'Atlantic': 'O'}, {'University,': 'O'}, {'Boca': 'O'}, {'Raton,': 'O'}, {'FL': 'O'}, {'33431-0991,': 'O'}, {'USA.28.improved': 'O'}]"
Our study has shown an increased risk of cardiovascular or cerebrovascular disease in patients with pSS.,"[{'Our': 'O'}, {'study': 'O'}, {'has': 'O'}, {'shown': 'O'}, {'an': 'O'}, {'increased': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'cardiovascular': 'B-Entity'}, {'or': 'I-Entity'}, {'cerebrovascular': 'I-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS.': 'I-Entity'}]"
"Characterized by chronic inflammation, dysfunction of exocrine glands, and systemic autoimmunity, primary Sjogren syndrome (pSS) is a common autoimmune disease in elderly women.","[{'Characterized': 'O'}, {'by': 'O'}, {'chronic': 'O'}, {'inflammation,': 'I-Entity'}, {'dysfunction': 'B-Entity'}, {'of': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'and': 'O'}, {'systemic': 'B-Entity'}, {'autoimmunity,': 'I-Entity'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'common': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'elderly': 'O'}, {'women.': 'O'}]"
Patients with a history of radiation therapy displayed the most decreased values of salivary flow rates and the most severe associated symptoms and behaviours while patients with unknown aetiology displayed the least decreased values of salivary flow rates and relatively favourable symptoms and behaviours.,"[{'Patients': 'O'}, {'with': 'O'}, {'a': 'O'}, {'history': 'O'}, {'of': 'O'}, {'radiation': 'I-Entity'}, {'therapy': 'O'}, {'displayed': 'O'}, {'the': 'O'}, {'most': 'O'}, {'decreased': 'O'}, {'values': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'rates': 'O'}, {'and': 'O'}, {'the': 'O'}, {'most': 'O'}, {'severe': 'O'}, {'associated': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'behaviours': 'O'}, {'while': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'unknown': 'O'}, {'aetiology': 'O'}, {'displayed': 'O'}, {'the': 'O'}, {'least': 'O'}, {'decreased': 'O'}, {'values': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'rates': 'O'}, {'and': 'O'}, {'relatively': 'O'}, {'favourable': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'behaviours.': 'O'}]"
"Heightened interest in oral health has lead to an increase in patients complaining of xerostomia, which is associated with various oral mucosal disorders.","[{'Heightened': 'O'}, {'interest': 'O'}, {'in': 'O'}, {'oral': 'O'}, {'health': 'O'}, {'has': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'an': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'complaining': 'O'}, {'of': 'O'}, {'xerostomia,': 'I-Entity'}, {'which': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'various': 'O'}, {'oral': 'B-Entity'}, {'mucosal': 'I-Entity'}, {'disorders.': 'I-Entity'}]"
"SG swelling and cryoglobulinaemia were present in 24/30 (80%) cases the time of lymphoma diagnosis, and lymphoma itself was usually of MALT/marginal zone histotype (90%), leading to peculiar manifestation of lymphoma in pSS.","[{'SG': 'O'}, {'swelling': 'I-Entity'}, {'and': 'O'}, {'cryoglobulinaemia': 'I-Entity'}, {'were': 'O'}, {'present': 'O'}, {'in': 'O'}, {'24/30': 'O'}, {'(80%)': 'O'}, {'cases': 'O'}, {'the': 'O'}, {'time': 'O'}, {'of': 'O'}, {'lymphoma': 'I-Entity'}, {'diagnosis,': 'O'}, {'and': 'O'}, {'lymphoma': 'I-Entity'}, {'itself': 'O'}, {'was': 'O'}, {'usually': 'O'}, {'of': 'O'}, {'MALT/marginal': 'O'}, {'zone': 'O'}, {'histotype': 'O'}, {'(90%),': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'peculiar': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'lymphoma': 'I-Entity'}, {'in': 'O'}, {'pSS.': 'O'}]"
"B6‚âà√≠‚Äö√¢‚Ä¢KO mice were resistant to DS-induced apoptosis; however, B6‚âà√≠‚Äö√¢‚Ä¢KO mice receiving IFN-‚âà√≠‚Äö√¢‚Ä¢ developed apoptosis similar to that observed in B6 wild-type mice.","[{'B6‚âà√≠‚Äö√¢‚Ä¢KO': 'O'}, {'mice': 'O'}, {'were': 'O'}, {'resistant': 'O'}, {'to': 'O'}, {'DS-induced': 'I-Entity'}, {'apoptosis;': 'O'}, {'however,': 'O'}, {'B6‚âà√≠‚Äö√¢‚Ä¢KO': 'O'}, {'mice': 'O'}, {'receiving': 'O'}, {'IFN-‚âà√≠‚Äö√¢‚Ä¢': 'O'}]"
"Sicca symptoms were significantly associated with higher EDSS scores (P = 0.018), a low frequency of gadolinium-enhanced MRI-positive lesions (P = 0.018) and cerebral disturbances (P = 0.001).","[{'Sicca': 'I-Entity'}, {'symptoms': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'higher': 'O'}, {'EDSS': 'O'}, {'scores': 'O'}, {'(P': 'O'}, {'=': 'O'}, {'0.018),': 'O'}, {'a': 'O'}, {'low': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'gadolinium-enhanced': 'I-Entity'}, {'MRI-positive': 'O'}, {'lesions': 'O'}, {'(P': 'O'}, {'=': 'O'}, {'0.018)': 'O'}, {'and': 'O'}, {'cerebral': 'B-Entity'}, {'disturbances': 'I-Entity'}, {'(P': 'O'}, {'=': 'O'}, {'0.001).': 'O'}]"
"Since her urine pH was 7.0 despite metabolic acidosis with normal AG, we diagnosed distal renal tubular acidosis (RTA).","[{'Since': 'O'}, {'her': 'O'}, {'urine': 'O'}, {'pH': 'O'}, {'was': 'O'}, {'7.0': 'O'}, {'despite': 'O'}, {'metabolic': 'B-Entity'}, {'acidosis': 'I-Entity'}, {'with': 'O'}, {'normal': 'O'}, {'AG,': 'O'}, {'we': 'O'}, {'diagnosed': 'O'}, {'distal': 'B-Entity'}, {'renal': 'I-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'(RTA).': 'O'}]"
The results from GT analysis showed slowly increasing internet searches for SLE in recent years.,"[{'The': 'O'}, {'results': 'O'}, {'from': 'O'}, {'GT': 'O'}, {'analysis': 'O'}, {'showed': 'O'}, {'slowly': 'O'}, {'increasing': 'O'}, {'internet': 'O'}, {'searches': 'O'}, {'for': 'O'}, {'SLE': 'I-Entity'}, {'in': 'O'}, {'recent': 'O'}, {'years.': 'O'}]"
"Twenty five patients with primary (pjSS) and secondary jSS (sjSS) were included in the study (n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢25, 21 female, 4 male), with a median age of 15.3‚Äö√Ñ√∂‚àö√ë‚àö¬¢years at the time of first visit and a mean disease duration of 4.9‚Äö√Ñ√∂‚àö√ë‚àö¬¢years.","[{'Twenty': 'O'}, {'five': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'O'}, {'(pjSS)': 'O'}, {'and': 'O'}, {'secondary': 'O'}, {'jSS': 'I-Entity'}, {'(sjSS)': 'O'}, {'were': 'O'}, {'included': 'O'}, {'in': 'O'}, {'the': 'O'}, {'study': 'O'}, {'(n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢25,': 'O'}]"
"Next, we examined Opn transgenic (Opn Tg) mice for evidence of SS.","[{'Next,': 'O'}, {'we': 'O'}, {'examined': 'O'}, {'Opn': 'O'}, {'transgenic': 'O'}, {'(Opn': 'O'}, {'Tg)': 'O'}, {'mice': 'O'}, {'for': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'SS.': 'I-Entity'}]"
"Although anti-tuberculosis medications were administered soon after a positive acid-fast stain of incisional muscular tissue, he died of rapidly progressive tuberculous myositis and multiorgan failure following 18 days of hospitalization.","[{'Although': 'O'}, {'anti-tuberculosis': 'O'}, {'medications': 'O'}, {'were': 'O'}, {'administered': 'O'}, {'soon': 'O'}, {'after': 'O'}, {'a': 'O'}, {'positive': 'O'}, {'acid-fast': 'O'}, {'stain': 'O'}, {'of': 'O'}, {'incisional': 'O'}, {'muscular': 'O'}, {'tissue,': 'O'}, {'he': 'O'}, {'died': 'O'}, {'of': 'O'}, {'rapidly': 'O'}, {'progressive': 'O'}, {'tuberculous': 'B-Entity'}, {'myositis': 'I-Entity'}, {'and': 'O'}, {'multiorgan': 'B-Entity'}, {'failure': 'I-Entity'}, {'following': 'O'}, {'18': 'O'}, {'days': 'O'}, {'of': 'O'}, {'hospitalization.': 'O'}]"
Thirty-eight patients were identified as having donated blood samples prior to symptom onset.,"[{'Thirty-eight': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'identified': 'O'}, {'as': 'O'}, {'having': 'O'}, {'donated': 'O'}, {'blood': 'O'}, {'samples': 'O'}, {'prior': 'O'}, {'to': 'O'}, {'symptom': 'O'}, {'onset.': 'O'}]"
"Laboratory investigations revealed chronic kidney disease with serum creatinine of 2.3 mg/dL and creatinine clearance of 40 mL/min, hypokalemia (3.2 mmol/L), hypophosphatemia (0.4 mmol/L), hypocalcemia (2.14 mmol/L) and hyperchloremic metabolic acidosis (chlorine: 114 mmol/L; alkaline reserve: 14 mmol/L).","[{'Laboratory': 'O'}, {'investigations': 'O'}, {'revealed': 'O'}, {'chronic': 'B-Entity'}, {'kidney': 'I-Entity'}, {'disease': 'I-Entity'}, {'with': 'O'}, {'serum': 'O'}, {'creatinine': 'I-Entity'}, {'of': 'O'}, {'2.3': 'O'}, {'mg/dL': 'O'}, {'and': 'O'}, {'creatinine': 'I-Entity'}, {'clearance': 'O'}, {'of': 'O'}, {'40': 'O'}, {'mL/min,': 'O'}, {'hypokalemia': 'I-Entity'}, {'(3.2': 'O'}, {'mmol/L),': 'O'}, {'hypophosphatemia': 'I-Entity'}, {'(0.4': 'O'}, {'mmol/L),': 'O'}]"
ANA-positive patients were identified via electronic data capture from the electronic patient record database of Leumit Health care Services (LHS) of Israel.,"[{'ANA-positive': 'I-Entity'}, {'patients': 'O'}, {'were': 'O'}, {'identified': 'O'}, {'via': 'O'}, {'electronic': 'O'}, {'data': 'O'}, {'capture': 'O'}, {'from': 'O'}, {'the': 'O'}, {'electronic': 'O'}, {'patient': 'O'}, {'record': 'O'}, {'database': 'O'}, {'of': 'O'}, {'Leumit': 'O'}, {'Health': 'O'}, {'care': 'O'}, {'Services': 'O'}, {'(LHS)': 'O'}, {'of': 'O'}, {'Israel.': 'O'}]"
Lung involvement as defined by symptoms and either pulmonary function testing or radiographic abnormalities occurs in approximately 10 to 20% of patients.,"[{'Lung': 'B-Entity'}, {'involvement': 'I-Entity'}, {'as': 'O'}, {'defined': 'O'}, {'by': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'either': 'O'}, {'pulmonary': 'O'}, {'function': 'O'}, {'testing': 'O'}, {'or': 'O'}, {'radiographic': 'O'}, {'abnormalities': 'O'}, {'occurs': 'O'}, {'in': 'O'}, {'approximately': 'O'}, {'10': 'O'}, {'to': 'O'}, {'20%': 'O'}, {'of': 'O'}, {'patients.': 'O'}]"
"Sicca symptoms were present in four patients, but only two patients reported these symptoms before the onset of optic neuropathy.","[{'Sicca': 'O'}, {'symptoms': 'O'}, {'were': 'O'}, {'present': 'O'}, {'in': 'O'}, {'four': 'O'}, {'patients,': 'O'}, {'but': 'O'}, {'only': 'O'}, {'two': 'O'}, {'patients': 'O'}, {'reported': 'O'}, {'these': 'O'}, {'symptoms': 'O'}, {'before': 'O'}, {'the': 'O'}, {'onset': 'O'}, {'of': 'O'}, {'optic': 'B-Entity'}, {'neuropathy.': 'I-Entity'}]"
"Patient was prescribed subcutaneous insulin, multivitamins, tear substitutes and alternate patching.","[{'Patient': 'O'}, {'was': 'O'}, {'prescribed': 'O'}, {'subcutaneous': 'O'}, {'insulin,': 'I-Entity'}, {'multivitamins,': 'O'}, {'tear': 'O'}, {'substitutes': 'O'}, {'and': 'O'}, {'alternate': 'O'}, {'patching.': 'O'}]"
Connective tissue diseases are known to be one of the causes of organising pneumonia (OP).,"[{'Connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'are': 'O'}, {'known': 'O'}, {'to': 'O'}, {'be': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'organising': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'(OP).': 'O'}]"
Sjogren syndrome is autoimmune disease that typically produces symptoms of dry mouth and eyes.,"[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'typically': 'O'}, {'produces': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'and': 'I-Entity'}, {'eyes.': 'I-Entity'}]"
Isolated lymphocytic hidradenitis was found most frequently in middle-aged women.,"[{'Isolated': 'O'}, {'lymphocytic': 'B-Entity'}, {'hidradenitis': 'I-Entity'}, {'was': 'O'}, {'found': 'O'}, {'most': 'O'}, {'frequently': 'O'}, {'in': 'O'}, {'middle-aged': 'O'}, {'women.': 'O'}]"
Sensory peripheral neuropathy is a common manifestation of the disease.,"[{'Sensory': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'common': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
Our previous proteomic study indicated that connective tissue growth factor (CTGF) may be a potential biomarker for rheumatoid arthritis (RA) diagnosis.,"[{'Our': 'O'}, {'previous': 'O'}, {'proteomic': 'O'}, {'study': 'O'}, {'indicated': 'O'}, {'that': 'O'}, {'connective': 'O'}, {'tissue': 'O'}, {'growth': 'O'}, {'factor': 'O'}, {'(CTGF)': 'O'}, {'may': 'O'}, {'be': 'O'}, {'a': 'O'}, {'potential': 'O'}, {'biomarker': 'O'}, {'for': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA)': 'O'}, {'diagnosis.': 'O'}]"
"Sjogren syndrome has been associated with small cyst formation in salivary glands, thymus, and lungs and has been recently brought to the forefront by radiologists due to high-resolution techniques.","[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'small': 'O'}, {'cyst': 'O'}, {'formation': 'O'}, {'in': 'O'}, {'salivary': 'O'}, {'glands,': 'O'}, {'thymus,': 'O'}, {'and': 'O'}, {'lungs': 'O'}, {'and': 'O'}, {'has': 'O'}, {'been': 'O'}, {'recently': 'O'}, {'brought': 'O'}, {'to': 'O'}, {'the': 'O'}, {'forefront': 'O'}, {'by': 'O'}, {'radiologists': 'O'}, {'due': 'O'}, {'to': 'O'}, {'high-resolution': 'O'}, {'techniques.': 'O'}]"
"PGA had good correlation with dryness, limb pain, fatigue and mental fatigue (r=0.49-0.59, all p<0.0001), but correlated less well with individual dryness features.","[{'PGA': 'O'}, {'had': 'O'}, {'good': 'O'}, {'correlation': 'O'}, {'with': 'O'}, {'dryness,': 'I-Entity'}, {'limb': 'O'}, {'pain,': 'I-Entity'}, {'fatigue': 'I-Entity'}, {'and': 'O'}, {'mental': 'O'}, {'fatigue': 'I-Entity'}, {'(r=0.49-0.59,': 'O'}, {'all': 'O'}, {'p<0.0001),': 'O'}, {'but': 'O'}, {'correlated': 'O'}, {'less': 'O'}, {'well': 'O'}, {'with': 'O'}, {'individual': 'O'}, {'dryness': 'I-Entity'}, {'features.': 'O'}]"
To compare the stability of the tear film after instillation of eye drops containing hyaluronic acid (HA) or crosslinked hyaluronic acid (CLHA)-based in patients with Sjogren syndrome-related dry eye (SSDE).,"[{'To': 'O'}, {'compare': 'O'}, {'the': 'O'}, {'stability': 'O'}, {'of': 'O'}, {'the': 'O'}, {'tear': 'O'}, {'film': 'O'}, {'after': 'O'}, {'instillation': 'O'}, {'of': 'O'}, {'eye': 'O'}, {'drops': 'O'}, {'containing': 'O'}, {'hyaluronic': 'B-Entity'}, {'acid': 'I-Entity'}, {'(HA)': 'O'}, {'or': 'O'}, {'crosslinked': 'O'}, {'hyaluronic': 'B-Entity'}, {'acid': 'I-Entity'}, {'(CLHA)-based': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome-related': 'I-Entity'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'(SSDE).': 'O'}]"
"In our sample, fatigue appears to be related to disease activity, functional disability, structural damage, and immunological status and had a negative impact on QoL.11000 Sale, Morocco.","[{'In': 'O'}, {'our': 'O'}, {'sample,': 'O'}, {'fatigue': 'I-Entity'}, {'appears': 'O'}, {'to': 'O'}, {'be': 'O'}, {'related': 'O'}, {'to': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'functional': 'B-Entity'}, {'disability,': 'I-Entity'}, {'structural': 'B-Entity'}, {'damage,': 'I-Entity'}, {'and': 'O'}, {'immunological': 'O'}, {'status': 'O'}, {'and': 'O'}, {'had': 'O'}, {'a': 'O'}, {'negative': 'O'}, {'impact': 'O'}, {'on': 'O'}, {'QoL.11000': 'O'}, {'Sale,': 'O'}, {'Morocco.': 'O'}]"
Accelerated atherosclerosis is a distinct feature of some inflammatory and autoimmune disorders and several specific autoimmune mechanisms and persistent inflammation have been identified to exert a pivotal role in precocious atherosclerotic damage in these disorders.,"[{'Accelerated': 'O'}, {'atherosclerosis': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'distinct': 'O'}, {'feature': 'O'}, {'of': 'O'}, {'some': 'O'}, {'inflammatory': 'B-Entity'}, {'and': 'I-Entity'}, {'autoimmune': 'I-Entity'}, {'disorders': 'I-Entity'}, {'and': 'O'}, {'several': 'O'}, {'specific': 'O'}, {'autoimmune': 'O'}, {'mechanisms': 'O'}, {'and': 'O'}, {'persistent': 'O'}, {'inflammation': 'I-Entity'}, {'have': 'O'}, {'been': 'O'}, {'identified': 'O'}, {'to': 'O'}, {'exert': 'O'}, {'a': 'O'}, {'pivotal': 'O'}, {'role': 'O'}, {'in': 'O'}, {'precocious': 'O'}, {'atherosclerotic': 'B-Entity'}, {'damage': 'I-Entity'}, {'in': 'O'}, {'these': 'O'}, {'disorders.': 'O'}]"
"A major potential contributor is oxidative stress associated with damage to cellular components, including DNA.","[{'A': 'O'}, {'major': 'O'}, {'potential': 'O'}, {'contributor': 'O'}, {'is': 'O'}, {'oxidative': 'O'}, {'stress': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'damage': 'O'}, {'to': 'O'}, {'cellular': 'O'}, {'components,': 'O'}, {'including': 'O'}, {'DNA.': 'O'}]"
"Sjogrens syndrome is a systemic autoimmune disease characterized by exocrine glands damage, resulting in the development of dry eyes and dry mouth, as well as extraglandular manifestation.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'exocrine': 'O'}, {'glands': 'I-Entity'}, {'damage,': 'I-Entity'}, {'resulting': 'O'}, {'in': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'extraglandular': 'O'}, {'manifestation.': 'O'}]"
"Its clinical symptoms include muscle weakness, periodic paralysis, and bone pain due to metabolic acidosis and electrolyte imbalance.","[{'Its': 'O'}, {'clinical': 'O'}, {'symptoms': 'O'}, {'include': 'O'}, {'muscle': 'B-Entity'}, {'weakness,': 'I-Entity'}, {'periodic': 'O'}, {'paralysis,': 'I-Entity'}, {'and': 'O'}, {'bone': 'B-Entity'}, {'pain': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'metabolic': 'B-Entity'}, {'acidosis': 'I-Entity'}, {'and': 'O'}, {'electrolyte': 'O'}, {'imbalance.': 'O'}]"
"Previously, we have shown that removal of ovarian hormones through ovariectomy accelerated the symptoms of this disease, and in early events of SS in the lacrimal glands, lymphocytic infiltration preceded acinar cell apoptosis.","[{'Previously,': 'O'}, {'we': 'O'}, {'have': 'O'}, {'shown': 'O'}, {'that': 'O'}, {'removal': 'O'}, {'of': 'O'}, {'ovarian': 'O'}, {'hormones': 'O'}, {'through': 'O'}, {'ovariectomy': 'O'}, {'accelerated': 'O'}, {'the': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'this': 'O'}, {'disease,': 'O'}, {'and': 'O'}, {'in': 'O'}, {'early': 'O'}, {'events': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}, {'glands,': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'preceded': 'O'}, {'acinar': 'O'}, {'cell': 'O'}, {'apoptosis.': 'O'}]"
"LSCM is a promising tool that should profoundly change the study of the ocular surface, but it requires accurate standardization before it is used in clinical practice.Gland Epithelial Progenitor Cells.","[{'LSCM': 'O'}, {'is': 'O'}, {'a': 'O'}, {'promising': 'O'}, {'tool': 'O'}, {'that': 'O'}, {'should': 'O'}, {'profoundly': 'O'}, {'change': 'O'}, {'the': 'O'}, {'study': 'O'}, {'of': 'O'}, {'the': 'O'}, {'ocular': 'O'}, {'surface,': 'O'}, {'but': 'O'}, {'it': 'O'}, {'requires': 'O'}, {'accurate': 'O'}, {'standardization': 'O'}, {'before': 'O'}, {'it': 'O'}, {'is': 'O'}, {'used': 'O'}, {'in': 'O'}, {'clinical': 'O'}, {'practice.Gland': 'O'}, {'Epithelial': 'O'}, {'Progenitor': 'O'}, {'Cells.': 'O'}]"
"According to low quality evidence, no differences were observed in the evaluation after 24 weeks regarding fatigue reduction (30% VAS), serious adverse events occurrence, quality of life improvement and disease activity.","[{'According': 'O'}, {'to': 'O'}, {'low': 'O'}, {'quality': 'O'}, {'evidence,': 'O'}, {'no': 'O'}, {'differences': 'O'}, {'were': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'the': 'O'}, {'evaluation': 'O'}, {'after': 'O'}, {'24': 'O'}, {'weeks': 'O'}, {'regarding': 'O'}, {'fatigue': 'I-Entity'}, {'reduction': 'O'}, {'(30%': 'O'}, {'VAS),': 'O'}, {'serious': 'O'}, {'adverse': 'O'}, {'events': 'O'}, {'occurrence,': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life': 'O'}, {'improvement': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'activity.': 'O'}]"
Sjogrens syndrome (SS) is a chronic inflammatory autoimmune disease affecting mainly the salivary and lacrimal glands characterized by lymphocytic infiltration which results in gland destruction and impairment of functions.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'inflammatory': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'affecting': 'O'}, {'mainly': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'I-Entity'}, {'glands': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'which': 'O'}, {'results': 'O'}, {'in': 'O'}, {'gland': 'O'}, {'destruction': 'O'}, {'and': 'O'}, {'impairment': 'B-Entity'}, {'of': 'I-Entity'}, {'functions.': 'I-Entity'}]"
"Specifically for SAD, ultrasonography helps examine the salivary glands in Sjogrens syndrome, determines the presence of the halo sign in giant cell arteritis and the presence of tendon or joint inflammation, quantifies pulmonary hypertension in scleroderma and assesses the presence of interstitial pulmonary disease in dermatomyositis.","[{'Specifically': 'O'}, {'for': 'O'}, {'SAD,': 'I-Entity'}, {'ultrasonography': 'O'}, {'helps': 'O'}, {'examine': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'determines': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'the': 'O'}, {'halo': 'O'}, {'sign': 'O'}, {'in': 'O'}, {'giant': 'B-Entity'}, {'cell': 'I-Entity'}, {'arteritis': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'tendon': 'B-Entity'}, {'or': 'I-Entity'}, {'joint': 'I-Entity'}, {'inflammation,': 'I-Entity'}, {'quantifies': 'O'}, {'pulmonary': 'B-Entity'}, {'hypertension': 'I-Entity'}, {'in': 'O'}, {'scleroderma': 'I-Entity'}, {'and': 'O'}, {'assesses': 'O'}]"
To comparatively evaluate the efficacy of a bandage contact lens (BCL) and autologous serum (AS) eye drops in the management of severe dry eye caused by Sjogren syndrome (SS).,"[{'To': 'O'}, {'comparatively': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'a': 'O'}, {'bandage': 'O'}, {'contact': 'O'}, {'lens': 'O'}, {'(BCL)': 'O'}, {'and': 'O'}, {'autologous': 'O'}, {'serum': 'O'}, {'(AS)': 'O'}, {'eye': 'O'}, {'drops': 'O'}, {'in': 'O'}, {'the': 'O'}, {'management': 'O'}, {'of': 'O'}, {'severe': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'caused': 'O'}, {'by': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
"Sjogren syndrome (SS) can occur alone, primary Sjogren syndrome, or in association with other rheumatic diseases, secondary Sjogren syndrome (sSS), such as Rheumatoid arthritis (RA).","[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'can': 'O'}, {'occur': 'O'}, {'alone,': 'O'}, {'primary': 'O'}, {'Sjogren': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'or': 'O'}, {'in': 'O'}, {'association': 'O'}, {'with': 'O'}, {'other': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'secondary': 'O'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(sSS),': 'O'}, {'such': 'O'}, {'as': 'O'}, {'Rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA).': 'O'}]"
"The diagnosis of duration infection was confirmed by culture from the skin biopsy and spinal fluid specimens; in addition, the presence of lymphopenia, positive anti Ro-SSA antibodies, poor concentration of the tracer in scintigraphy and lymphocytic infiltration in salivary glands confirmed the diagnosis of Sjogrens syndrome.","[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'duration': 'B-Entity'}, {'infection': 'I-Entity'}, {'was': 'O'}, {'confirmed': 'O'}, {'by': 'O'}, {'culture': 'O'}, {'from': 'O'}, {'the': 'O'}, {'skin': 'O'}, {'biopsy': 'O'}, {'and': 'O'}, {'spinal': 'O'}, {'fluid': 'O'}, {'specimens;': 'O'}, {'in': 'O'}, {'addition,': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'lymphopenia,': 'I-Entity'}, {'positive': 'O'}, {'anti': 'O'}, {'Ro-SSA': 'O'}, {'antibodies,': 'O'}, {'poor': 'O'}, {'concentration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'tracer': 'O'}, {'in': 'O'}, {'scintigraphy': 'O'}, {'and': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'in': 'O'}, {'salivary': 'O'}]"
"For some, eye fatigue was pervasive, and daily activities involving the eyes such as reading, using the computer and driving were impaired.","[{'For': 'O'}, {'some,': 'O'}, {'eye': 'B-Entity'}, {'fatigue': 'I-Entity'}, {'was': 'O'}, {'pervasive,': 'O'}, {'and': 'O'}, {'daily': 'O'}, {'activities': 'O'}, {'involving': 'O'}, {'the': 'O'}, {'eyes': 'O'}, {'such': 'O'}, {'as': 'O'}, {'reading,': 'O'}, {'using': 'O'}, {'the': 'O'}, {'computer': 'O'}, {'and': 'O'}, {'driving': 'O'}, {'were': 'O'}, {'impaired.': 'O'}]"
"Primary Sjogren syndrome (PSS) is an autoimmune disease characterized by symptoms of a dry mouth and eyes, in which other organs and systems are widely involved.","[{'Primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(PSS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'a': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'and': 'I-Entity'}, {'eyes,': 'I-Entity'}, {'in': 'O'}, {'which': 'O'}, {'other': 'O'}, {'organs': 'O'}, {'and': 'O'}, {'systems': 'O'}, {'are': 'O'}, {'widely': 'O'}, {'involved.': 'O'}]"
"Sleep disorders are a prominent, but overlooked problem in patients with dry eye disease (DED), characterized by a poor sleep index, short sleep duration, long sleep latency, and poor subjective sleep.","[{'Sleep': 'B-Entity'}, {'disorders': 'I-Entity'}, {'are': 'O'}, {'a': 'O'}, {'prominent,': 'O'}, {'but': 'O'}, {'overlooked': 'O'}, {'problem': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease': 'I-Entity'}, {'(DED),': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'a': 'O'}, {'poor': 'O'}, {'sleep': 'O'}, {'index,': 'O'}, {'short': 'O'}, {'sleep': 'O'}, {'duration,': 'O'}, {'long': 'O'}, {'sleep': 'O'}, {'latency,': 'O'}, {'and': 'O'}, {'poor': 'O'}, {'subjective': 'O'}, {'sleep.': 'O'}]"
"In addition to fetal echocardiography, fetal magnetocardiography (fMCG) was used to investigate precise electrophysiological fetal cardiac time intervals (fCTIs).","[{'In': 'O'}, {'addition': 'O'}, {'to': 'O'}, {'fetal': 'O'}, {'echocardiography,': 'O'}, {'fetal': 'O'}, {'magnetocardiography': 'O'}, {'(fMCG)': 'O'}, {'was': 'O'}, {'used': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'precise': 'O'}, {'electrophysiological': 'O'}, {'fetal': 'O'}, {'cardiac': 'O'}, {'time': 'O'}, {'intervals': 'O'}, {'(fCTIs).': 'O'}]"
The most common probable cause of xerostomia was side effect of pharmacotherapy.,"[{'The': 'O'}, {'most': 'O'}, {'common': 'O'}, {'probable': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'xerostomia': 'I-Entity'}, {'was': 'O'}, {'side': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'pharmacotherapy.': 'O'}]"
"Related symptoms, such as intractable pain due to central nervous system involvement, are very rare.","[{'Related': 'O'}, {'symptoms,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'intractable': 'O'}, {'pain': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'central': 'O'}, {'nervous': 'O'}, {'system': 'O'}, {'involvement,': 'O'}, {'are': 'O'}, {'very': 'O'}, {'rare.': 'O'}]"
But the underlying SjS could result in MALT lymphoma with lung cysts.,"[{'But': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'SjS': 'I-Entity'}, {'could': 'O'}, {'result': 'O'}, {'in': 'O'}, {'MALT': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'with': 'O'}, {'lung': 'B-Entity'}, {'cysts.': 'I-Entity'}]"
"B(-/-) NOD.H-2h4 mice, normally resistant to spontaneous autoimmune thyroiditis (SAT), develop SAT when Treg cells are depleted, suggesting that Treg cells are preferentially activated when autoantigen is initially presented by non-B-cell antigen-presenting cells.","[{'B(-/-)': 'O'}, {'NOD.H-2h4': 'O'}, {'mice,': 'O'}, {'normally': 'O'}, {'resistant': 'O'}, {'to': 'O'}, {'spontaneous': 'O'}, {'autoimmune': 'B-Entity'}, {'thyroiditis': 'I-Entity'}, {'(SAT),': 'O'}, {'develop': 'O'}, {'SAT': 'I-Entity'}, {'when': 'O'}, {'Treg': 'O'}, {'cells': 'O'}, {'are': 'O'}, {'depleted,': 'O'}, {'suggesting': 'O'}, {'that': 'O'}, {'Treg': 'O'}, {'cells': 'O'}, {'are': 'O'}, {'preferentially': 'O'}, {'activated': 'O'}, {'when': 'O'}, {'autoantigen': 'O'}, {'is': 'O'}, {'initially': 'O'}, {'presented': 'O'}, {'by': 'O'}, {'non-B-cell': 'O'}]"
"Sjogren syndrome (SS) is a chronic autoimmune inflammatory disease that involves primarily the exocrine glands, resulting in their functional impairment.","[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'autoimmune': 'B-Entity'}, {'inflammatory': 'I-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'involves': 'O'}, {'primarily': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'their': 'O'}, {'functional': 'O'}, {'impairment.': 'O'}]"
Autonomic nervous function was evaluated by 5 objective autonomic reflex tests (ART) and by the Autonomic Symptom Profile (ASP) questionnaire evaluating AD symptoms.,"[{'Autonomic': 'O'}, {'nervous': 'O'}, {'function': 'O'}, {'was': 'O'}, {'evaluated': 'O'}, {'by': 'O'}, {'5': 'O'}, {'objective': 'O'}, {'autonomic': 'O'}, {'reflex': 'O'}, {'tests': 'O'}, {'(ART)': 'O'}, {'and': 'O'}, {'by': 'O'}, {'the': 'O'}, {'Autonomic': 'O'}, {'Symptom': 'O'}, {'Profile': 'O'}, {'(ASP)': 'O'}, {'questionnaire': 'O'}, {'evaluating': 'O'}, {'AD': 'I-Entity'}, {'symptoms.': 'O'}]"
The lower incidence of EGM was observed in patients on HCQ therapy supports its efficacy in pSS.,"[{'The': 'O'}, {'lower': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'EGM': 'I-Entity'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'on': 'O'}, {'HCQ': 'I-Entity'}, {'therapy': 'O'}, {'supports': 'O'}, {'its': 'O'}, {'efficacy': 'O'}, {'in': 'O'}, {'pSS.': 'I-Entity'}]"
"Castleman disease is a rare cause of lymphoid hyperplasia and may result in localized symptoms or an aggressive, multisystem disorder.","[{'Castleman': 'B-Entity'}, {'disease': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'lymphoid': 'B-Entity'}, {'hyperplasia': 'I-Entity'}, {'and': 'O'}, {'may': 'O'}, {'result': 'O'}, {'in': 'O'}, {'localized': 'O'}, {'symptoms': 'O'}, {'or': 'O'}, {'an': 'O'}, {'aggressive,': 'O'}, {'multisystem': 'O'}, {'disorder.': 'I-Entity'}]"
Chronic inflammatory demyelinating polyneuropathy (CIDP) has been reported in patients with multiple sclerosis (MS).,"[{'Chronic': 'O'}, {'inflammatory': 'B-Entity'}, {'demyelinating': 'I-Entity'}, {'polyneuropathy': 'I-Entity'}, {'(CIDP)': 'O'}, {'has': 'O'}, {'been': 'O'}, {'reported': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'multiple': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(MS).': 'O'}]"
A major problem with currently-available SS disease activity measurement instruments is the lack of domains evaluating dry eye-related visual dysfunction.,"[{'A': 'O'}, {'major': 'O'}, {'problem': 'O'}, {'with': 'O'}, {'currently-available': 'O'}, {'SS': 'I-Entity'}, {'disease': 'O'}, {'activity': 'O'}, {'measurement': 'O'}, {'instruments': 'O'}, {'is': 'O'}, {'the': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'domains': 'O'}, {'evaluating': 'O'}, {'dry': 'B-Entity'}, {'eye-related': 'I-Entity'}, {'visual': 'B-Entity'}, {'dysfunction.': 'I-Entity'}]"
Immediate intravenous and oral potassium and phosphate replacement was initiated with objective improvement in weakness with replenished electrolyte levels.,"[{'Immediate': 'O'}, {'intravenous': 'O'}, {'and': 'O'}, {'oral': 'O'}, {'potassium': 'I-Entity'}, {'and': 'O'}, {'phosphate': 'I-Entity'}, {'replacement': 'O'}, {'was': 'O'}, {'initiated': 'O'}, {'with': 'O'}, {'objective': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'weakness': 'I-Entity'}, {'with': 'O'}, {'replenished': 'O'}, {'electrolyte': 'O'}, {'levels.': 'O'}]"
Our data investigates the often-anecdotal evidence that thicker preparations are more effective.,"[{'Our': 'O'}, {'data': 'O'}, {'investigates': 'O'}, {'the': 'O'}, {'often-anecdotal': 'O'}, {'evidence': 'O'}, {'that': 'O'}, {'thicker': 'O'}, {'preparations': 'O'}, {'are': 'O'}, {'more': 'O'}, {'effective.': 'O'}]"
To investigate predictors of discordance between symptoms and signs in dry eye disease (DED).,"[{'To': 'O'}, {'investigate': 'O'}, {'predictors': 'O'}, {'of': 'O'}, {'discordance': 'O'}, {'between': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'signs': 'O'}, {'in': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease': 'I-Entity'}, {'(DED).': 'O'}]"
The objective was to provide preliminary information about the efficacy and safety of immunologically safe plasma rich in growth factor (immunosafe PRGF) eye drops in the treatment of moderate to severe dry eye in patients with primary and secondary Sjogrens syndrome (SS) and to analyze the influence of several variables on treatment outcomes.,"[{'The': 'O'}, {'objective': 'O'}, {'was': 'O'}, {'to': 'O'}, {'provide': 'O'}, {'preliminary': 'O'}, {'information': 'O'}, {'about': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'safety': 'O'}, {'of': 'O'}, {'immunologically': 'O'}, {'safe': 'O'}, {'plasma': 'O'}, {'rich': 'O'}, {'in': 'O'}, {'growth': 'O'}, {'factor': 'O'}, {'(immunosafe': 'O'}, {'PRGF)': 'O'}, {'eye': 'O'}, {'drops': 'O'}, {'in': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'moderate': 'O'}, {'to': 'O'}, {'severe': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'O'}, {'and': 'O'}, {'secondary': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'and': 'O'}, {'to': 'O'}, {'analyze': 'O'}, {'the': 'O'}]"
Evaluation should include symptoms of both discomfort and visual disturbance as well as determination of the relative contribution of aqueous production deficiency and evaporative loss of tear volume.,"[{'Evaluation': 'O'}, {'should': 'O'}, {'include': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'both': 'O'}, {'discomfort': 'O'}, {'and': 'O'}, {'visual': 'B-Entity'}, {'disturbance': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'determination': 'O'}, {'of': 'O'}, {'the': 'O'}, {'relative': 'O'}, {'contribution': 'O'}, {'of': 'O'}, {'aqueous': 'O'}, {'production': 'I-Entity'}, {'deficiency': 'O'}, {'and': 'O'}, {'evaporative': 'O'}, {'loss': 'O'}, {'of': 'O'}, {'tear': 'O'}, {'volume.': 'O'}]"
"Rheumatic diseases frequently affect the kidneys, either the glomeruli or the interstitial tissues.","[{'Rheumatic': 'B-Entity'}, {'diseases': 'I-Entity'}, {'frequently': 'O'}, {'affect': 'O'}, {'the': 'O'}, {'kidneys,': 'O'}, {'either': 'O'}, {'the': 'O'}, {'glomeruli': 'O'}, {'or': 'O'}, {'the': 'O'}, {'interstitial': 'O'}, {'tissues.': 'O'}]"
"In addition, systemic manifestations, like arthritis, skin vasculitis, peripheral neuropathy, glomerulonephritis, may also be present in a consistent number of patients.","[{'In': 'O'}, {'addition,': 'O'}, {'systemic': 'O'}, {'manifestations,': 'O'}, {'like': 'O'}, {'arthritis,': 'I-Entity'}, {'skin': 'O'}, {'vasculitis,': 'I-Entity'}, {'peripheral': 'B-Entity'}, {'neuropathy,': 'I-Entity'}, {'glomerulonephritis,': 'I-Entity'}, {'may': 'O'}, {'also': 'O'}, {'be': 'O'}, {'present': 'O'}, {'in': 'O'}, {'a': 'O'}, {'consistent': 'O'}, {'number': 'O'}, {'of': 'O'}, {'patients.': 'O'}]"
"In addition, systemic manifestations, like arthritis, skin vasculitis, peripheral neuropathy, glomerulonephritis, may also be present in a consistent number of patients.","[{'In': 'O'}, {'addition,': 'O'}, {'systemic': 'O'}, {'manifestations,': 'O'}, {'like': 'O'}, {'arthritis,': 'I-Entity'}, {'skin': 'O'}, {'vasculitis,': 'I-Entity'}, {'peripheral': 'B-Entity'}, {'neuropathy,': 'I-Entity'}, {'glomerulonephritis,': 'I-Entity'}, {'may': 'O'}, {'also': 'O'}, {'be': 'O'}, {'present': 'O'}, {'in': 'O'}, {'a': 'O'}, {'consistent': 'O'}, {'number': 'O'}, {'of': 'O'}, {'patients.': 'O'}]"
Significant differences in dry eye scores were found between the patients with migraine and the control subjects.,"[{'Significant': 'O'}, {'differences': 'O'}, {'in': 'O'}, {'dry': 'O'}, {'eye': 'I-Entity'}, {'scores': 'O'}, {'were': 'O'}, {'found': 'O'}, {'between': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'migraine': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'control': 'O'}, {'subjects.': 'O'}]"
"We believe that prolonged P300 potential latencies without associated white matter lesions in brain imaging may be associated with subclinical CNS involvement.Ankara , Turkey.Ankara , Turkey.2019 Apr 23.","[{'We': 'O'}, {'believe': 'O'}, {'that': 'O'}, {'prolonged': 'O'}, {'P300': 'O'}, {'potential': 'O'}, {'latencies': 'O'}, {'without': 'O'}, {'associated': 'O'}, {'white': 'B-Entity'}, {'matter': 'I-Entity'}, {'lesions': 'I-Entity'}, {'in': 'O'}, {'brain': 'O'}, {'imaging': 'O'}, {'may': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'subclinical': 'O'}, {'CNS': 'O'}, {'involvement.Ankara': 'O'}, {',': 'O'}, {'Turkey.Ankara': 'O'}, {',': 'O'}, {'Turkey.2019': 'O'}, {'Apr': 'O'}, {'23.': 'O'}]"
"Botulinum toxin has been shown to reduce salivary flow, and consequently, the results of its use in the management of recurrent parotitis have been encouraging.","[{'Botulinum': 'B-Entity'}, {'toxin': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'shown': 'O'}, {'to': 'O'}, {'reduce': 'O'}, {'salivary': 'O'}, {'flow,': 'O'}, {'and': 'O'}, {'consequently,': 'O'}, {'the': 'O'}, {'results': 'O'}, {'of': 'O'}, {'its': 'O'}, {'use': 'O'}, {'in': 'O'}, {'the': 'O'}, {'management': 'O'}, {'of': 'O'}, {'recurrent': 'O'}, {'parotitis': 'I-Entity'}, {'have': 'O'}, {'been': 'O'}, {'encouraging.': 'O'}]"
Eight patients (62%) remained stable or their renal function improved after a median follow-up of 12 months.,"[{'Eight': 'O'}, {'patients': 'O'}, {'(62%)': 'O'}, {'remained': 'O'}, {'stable': 'O'}, {'or': 'O'}, {'their': 'O'}, {'renal': 'O'}, {'function': 'O'}, {'improved': 'O'}, {'after': 'O'}, {'a': 'O'}, {'median': 'O'}, {'follow-up': 'O'}, {'of': 'O'}, {'12': 'O'}, {'months.': 'O'}]"
"The awareness that extraglandular manifestations, such as polyneuropathy, arthritis or recurrent airway infections may indicate Sjogrens syndrome is important.","[{'The': 'O'}, {'awareness': 'O'}, {'that': 'O'}, {'extraglandular': 'O'}, {'manifestations,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'polyneuropathy,': 'I-Entity'}, {'arthritis': 'I-Entity'}, {'or': 'O'}, {'recurrent': 'O'}, {'airway': 'B-Entity'}, {'infections': 'I-Entity'}, {'may': 'O'}, {'indicate': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'important.': 'O'}]"
"Screening should be targeted toward persons with clinical suspicion.Korea.Korea.Korea, fc21@inha.ac.kr.","[{'Screening': 'O'}, {'should': 'O'}, {'be': 'O'}, {'targeted': 'O'}, {'toward': 'O'}, {'persons': 'O'}, {'with': 'O'}, {'clinical': 'O'}, {'suspicion.Korea.Korea.Korea,': 'O'}, {'fc21@inha.ac.kr.': 'O'}]"
The mean LFS was significantly higher in patients developing NHL (3.0¬¨¬®¬¨¬±0.894 vs 2.25¬¨¬®¬¨¬±1.086; p=0.021).,"[{'The': 'O'}, {'mean': 'O'}, {'LFS': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'developing': 'O'}, {'NHL': 'I-Entity'}, {'(3.0¬¨¬®¬¨¬±0.894': 'O'}, {'vs': 'O'}, {'2.25¬¨¬®¬¨¬±1.086;': 'O'}, {'p=0.021).': 'O'}]"
Sjogrens syndrome (SS) is primarily defined by its impact on the oral and ocular system resulting in xerostomia and xerophthalmia.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'primarily': 'O'}, {'defined': 'O'}, {'by': 'O'}, {'its': 'O'}, {'impact': 'O'}, {'on': 'O'}, {'the': 'O'}, {'oral': 'O'}, {'and': 'I-Entity'}, {'ocular': 'I-Entity'}, {'system': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'xerostomia': 'I-Entity'}, {'and': 'O'}, {'xerophthalmia.': 'I-Entity'}]"
"Of 238 publications identified initially, 9 were included in the study.","[{'Of': 'O'}, {'238': 'O'}, {'publications': 'O'}, {'identified': 'O'}, {'initially,': 'O'}, {'9': 'O'}, {'were': 'O'}, {'included': 'O'}, {'in': 'O'}, {'the': 'O'}, {'study.': 'O'}]"
"In rheumatoid arthritis and systemic lupus erythematosus, cardiovascular disease is frequently one of the leading causes of mortality or morbidity.","[{'In': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'and': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'cardiovascular': 'B-Entity'}, {'disease': 'I-Entity'}, {'is': 'O'}, {'frequently': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'leading': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'mortality': 'O'}, {'or': 'O'}, {'morbidity.': 'O'}]"
We reviewed the records of subjects having biopsy-proven pulmonary amyloidosis with cystic lung disease demonstrated at high-resolution computed tomography (HRCT).,"[{'We': 'O'}, {'reviewed': 'O'}, {'the': 'O'}, {'records': 'O'}, {'of': 'O'}, {'subjects': 'O'}, {'having': 'O'}, {'biopsy-proven': 'O'}, {'pulmonary': 'B-Entity'}, {'amyloidosis': 'I-Entity'}, {'with': 'O'}, {'cystic': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'demonstrated': 'O'}, {'at': 'O'}, {'high-resolution': 'O'}, {'computed': 'O'}, {'tomography': 'O'}, {'(HRCT).': 'O'}]"
"Therefore, xerotic skin lesions seen in SS and AD might be attributable to different pathomechanisms with similar dry skin manifestations.","[{'Therefore,': 'O'}, {'xerotic': 'B-Entity'}, {'skin': 'O'}, {'lesions': 'I-Entity'}, {'seen': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'AD': 'I-Entity'}, {'might': 'O'}, {'be': 'O'}, {'attributable': 'O'}, {'to': 'O'}, {'different': 'O'}, {'pathomechanisms': 'O'}, {'with': 'O'}, {'similar': 'O'}, {'dry': 'O'}, {'skin': 'I-Entity'}, {'manifestations.': 'O'}]"
"A significant improvement in OHIP-14 was identified in the treatment group, while no significant differences were observed in the control group.","[{'A': 'O'}, {'significant': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'OHIP-14': 'O'}, {'was': 'O'}, {'identified': 'O'}, {'in': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'group,': 'O'}, {'while': 'O'}, {'no': 'O'}, {'significant': 'O'}, {'differences': 'O'}, {'were': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'the': 'O'}, {'control': 'O'}, {'group.': 'O'}]"
"Chest CT findings showed multiple cystic shadows, ground glass opacity, and small nodule-like lymphocytic interstitial pneumonia (LIP), which have been previously reported.","[{'Chest': 'O'}, {'CT': 'O'}, {'findings': 'O'}, {'showed': 'O'}, {'multiple': 'O'}, {'cystic': 'O'}, {'shadows,': 'O'}, {'ground': 'O'}, {'glass': 'O'}, {'opacity,': 'O'}, {'and': 'O'}, {'small': 'O'}, {'nodule-like': 'O'}, {'lymphocytic': 'B-Entity'}, {'interstitial': 'I-Entity'}, {'pneumonia': 'I-Entity'}, {'(LIP),': 'O'}, {'which': 'O'}, {'have': 'O'}, {'been': 'O'}, {'previously': 'O'}, {'reported.': 'O'}]"
"Sj‚Äö√Ñ√π‚àö√ºgren's Syndrome seems to play a role in temporomandibular joint disorders.of Bari, Italy.patients with primary Sjogrens syndrome.","[{""Sj‚Äö√Ñ√π‚àö√ºgren's"": 'O'}, {'Syndrome': 'I-Entity'}, {'seems': 'O'}, {'to': 'O'}, {'play': 'O'}, {'a': 'O'}, {'role': 'O'}, {'in': 'O'}, {'temporomandibular': 'B-Entity'}, {'joint': 'I-Entity'}, {'disorders.of': 'I-Entity'}, {'Bari,': 'O'}, {'Italy.patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
"Late complications may include blindness, dental tissue destruction, oral candidiasis and lymphoma.","[{'Late': 'O'}, {'complications': 'O'}, {'may': 'O'}, {'include': 'O'}, {'blindness,': 'I-Entity'}, {'dental': 'O'}, {'tissue': 'O'}, {'destruction,': 'O'}, {'oral': 'B-Entity'}, {'candidiasis': 'I-Entity'}, {'and': 'O'}, {'lymphoma.': 'I-Entity'}]"
"Evaluation for underlying connective tissue disorder was positive for SS-B/La antibody and, the rheumatoid factor, anti nuclear antibody, anti neutrophil cytoplasmic antibody titres were negative.","[{'Evaluation': 'O'}, {'for': 'O'}, {'underlying': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disorder': 'I-Entity'}, {'was': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'SS-B/La': 'B-Entity'}, {'antibody': 'O'}, {'and,': 'O'}, {'the': 'O'}, {'rheumatoid': 'B-Entity'}, {'factor,': 'O'}, {'anti': 'O'}, {'nuclear': 'O'}, {'antibody,': 'O'}, {'anti': 'O'}, {'neutrophil': 'O'}, {'cytoplasmic': 'O'}, {'antibody': 'O'}, {'titres': 'O'}, {'were': 'O'}, {'negative.': 'O'}]"
"Patients with isolated anti-Ro52 had a wider variety of diseases associated, but among auto-immune diseases they were more prone to inflammatory myositis (OR 10.5 [1.4-81.7], p = 0.02) and inflammatory rheumatism (OR 4.6 [1.6-13.8], p = 0.006) in contrast to systemic lupus (OR 0.2 [0.1-0.3], p < 10(-4)) or primary Sjogrens syndrome (OR 0.1 [0.06-0.2], p < 10(-4)).","[{'Patients': 'O'}, {'with': 'O'}, {'isolated': 'O'}, {'anti-Ro52': 'O'}, {'had': 'O'}, {'a': 'O'}, {'wider': 'O'}, {'variety': 'O'}, {'of': 'O'}, {'diseases': 'O'}, {'associated,': 'O'}, {'but': 'O'}, {'among': 'O'}, {'auto-immune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'they': 'O'}, {'were': 'O'}, {'more': 'O'}, {'prone': 'O'}, {'to': 'O'}, {'inflammatory': 'B-Entity'}, {'myositis': 'I-Entity'}, {'(OR': 'O'}, {'10.5': 'O'}, {'[1.4-81.7],': 'O'}, {'p': 'O'}, {'=': 'O'}, {'0.02)': 'O'}, {'and': 'O'}, {'inflammatory': 'B-Entity'}, {'rheumatism': 'I-Entity'}, {'(OR': 'O'}]"
PAH treatment goals were defined by the 5th World Symposium on Pulmonary Hypertension.,"[{'PAH': 'I-Entity'}, {'treatment': 'O'}, {'goals': 'O'}, {'were': 'O'}, {'defined': 'O'}, {'by': 'O'}, {'the': 'O'}, {'5th': 'O'}, {'World': 'O'}, {'Symposium': 'O'}, {'on': 'O'}, {'Pulmonary': 'B-Entity'}, {'Hypertension.': 'I-Entity'}]"
"Patient characteristics, drugs (commonly used for SS), resource utilisation, and medical costs were evaluated for 12 months pre- and post-diagnosis.","[{'Patient': 'O'}, {'characteristics,': 'O'}, {'drugs': 'O'}, {'(commonly': 'O'}, {'used': 'O'}, {'for': 'O'}, {'SS),': 'I-Entity'}, {'resource': 'O'}, {'utilisation,': 'O'}, {'and': 'O'}, {'medical': 'O'}, {'costs': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'for': 'O'}, {'12': 'O'}, {'months': 'O'}, {'pre-': 'O'}, {'and': 'O'}, {'post-diagnosis.': 'O'}]"
Sjogrens syndrome (SS) is an inflammatory autoimmune disease that causes secretory dysfunction of the salivary glands.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'inflammatory': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'causes': 'O'}, {'secretory': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'salivary': 'I-Entity'}, {'glands.': 'I-Entity'}]"
Collagen vascular diseases represent another area where the Burn Center may be the appropriate site for therapy.Associationdisorders and related MR-imaging findings.,"[{'Collagen': 'B-Entity'}, {'vascular': 'I-Entity'}, {'diseases': 'I-Entity'}, {'represent': 'O'}, {'another': 'O'}, {'area': 'O'}, {'where': 'O'}, {'the': 'O'}, {'Burn': 'O'}, {'Center': 'O'}, {'may': 'O'}, {'be': 'O'}, {'the': 'O'}, {'appropriate': 'O'}, {'site': 'O'}, {'for': 'O'}, {'therapy.Associationdisorders': 'O'}, {'and': 'O'}, {'related': 'O'}, {'MR-imaging': 'O'}, {'findings.': 'O'}]"
"Strict restriction of dietary fat reduced serum triglycerides, but she continued to experience recurrent pancreatitis.","[{'Strict': 'O'}, {'restriction': 'O'}, {'of': 'O'}, {'dietary': 'O'}, {'fat': 'I-Entity'}, {'reduced': 'O'}, {'serum': 'O'}, {'triglycerides,': 'I-Entity'}, {'but': 'O'}, {'she': 'O'}, {'continued': 'O'}, {'to': 'O'}, {'experience': 'O'}, {'recurrent': 'O'}, {'pancreatitis.': 'I-Entity'}]"
Rituximab treatment was followed by improvement of psychiatric symptoms in all patients.,"[{'Rituximab': 'I-Entity'}, {'treatment': 'O'}, {'was': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'improvement': 'O'}, {'of': 'O'}, {'psychiatric': 'I-Entity'}, {'symptoms': 'O'}, {'in': 'O'}, {'all': 'O'}, {'patients.': 'O'}]"
"A wide range of disorders can cause LETM, but usually the first line diagnosis is neuromyelitis optica (NMO).","[{'A': 'O'}, {'wide': 'O'}, {'range': 'O'}, {'of': 'O'}, {'disorders': 'O'}, {'can': 'O'}, {'cause': 'O'}, {'LETM,': 'I-Entity'}, {'but': 'O'}, {'usually': 'O'}, {'the': 'O'}, {'first': 'O'}, {'line': 'O'}, {'diagnosis': 'O'}, {'is': 'O'}, {'neuromyelitis': 'B-Entity'}, {'optica': 'I-Entity'}, {'(NMO).': 'O'}]"
The disease could be divided into three stages according to severity of glandular fibrosis.,"[{'The': 'O'}, {'disease': 'O'}, {'could': 'O'}, {'be': 'O'}, {'divided': 'O'}, {'into': 'O'}, {'three': 'O'}, {'stages': 'O'}, {'according': 'O'}, {'to': 'O'}, {'severity': 'O'}, {'of': 'O'}, {'glandular': 'B-Entity'}, {'fibrosis.': 'I-Entity'}]"
"Moreover, hypocomplementemia and FS resulted the only variables associated with lymphoma at univariate analysis, and FS appeared to be associated with lymphoma independently on complement fraction concentrations.","[{'Moreover,': 'O'}, {'hypocomplementemia': 'I-Entity'}, {'and': 'O'}, {'FS': 'O'}, {'resulted': 'O'}, {'the': 'O'}, {'only': 'O'}, {'variables': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'lymphoma': 'I-Entity'}, {'at': 'O'}, {'univariate': 'O'}, {'analysis,': 'O'}, {'and': 'O'}, {'FS': 'O'}, {'appeared': 'O'}, {'to': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'lymphoma': 'I-Entity'}, {'independently': 'O'}, {'on': 'O'}, {'complement': 'O'}, {'fraction': 'O'}, {'concentrations.': 'O'}]"
"Pulmonary manifestations of SLE and Sjogren syndrome can be classified based on anatomical site of involvement; and the large and small airways, lung parenchyma, lung vasculature, pleura and respiratory muscles can be involved.","[{'Pulmonary': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'SLE': 'I-Entity'}, {'and': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'classified': 'O'}, {'based': 'O'}, {'on': 'O'}, {'anatomical': 'O'}, {'site': 'O'}, {'of': 'O'}, {'involvement;': 'O'}, {'and': 'O'}, {'the': 'O'}, {'large': 'O'}, {'and': 'O'}, {'small': 'O'}, {'airways,': 'O'}, {'lung': 'O'}, {'parenchyma,': 'O'}, {'lung': 'O'}, {'vasculature,': 'O'}, {'pleura': 'O'}, {'and': 'O'}, {'respiratory': 'O'}, {'muscles': 'O'}, {'can': 'O'}, {'be': 'O'}, {'involved.': 'O'}]"
"Twenty-one subjects (13 female, eight male; median age, 61 years) with cystic pulmonary amyloidosis were identified.","[{'Twenty-one': 'O'}, {'subjects': 'O'}, {'(13': 'O'}, {'female,': 'O'}, {'eight': 'O'}, {'male;': 'O'}, {'median': 'O'}, {'age,': 'O'}, {'61': 'O'}, {'years)': 'O'}, {'with': 'O'}, {'cystic': 'B-Entity'}, {'pulmonary': 'I-Entity'}, {'amyloidosis': 'I-Entity'}, {'were': 'O'}, {'identified.': 'O'}]"
"CONCLUSIONS TN is seldom mentioned as a neurological manifestation of SLE; hence, we recommend further studies to investigate the SLE-mediated injury to trigeminal fibers to make a timely diagnosis of TN and to prevent progressive autoimmune process-related vasculitic and demyelinating changes.Hospital Center, Jamaica, NY, USA.Hospital Center, Jamaica, NY, USA.Hospital Center, Jamaica, NY, USA.Hospital Center, Jamaica, NY, USA.retrospective cohort study.","[{'CONCLUSIONS': 'O'}, {'TN': 'I-Entity'}, {'is': 'O'}, {'seldom': 'O'}, {'mentioned': 'O'}, {'as': 'O'}, {'a': 'O'}, {'neurological': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'SLE;': 'I-Entity'}, {'hence,': 'O'}, {'we': 'O'}, {'recommend': 'O'}, {'further': 'O'}, {'studies': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'SLE-mediated': 'I-Entity'}, {'injury': 'O'}, {'to': 'O'}, {'trigeminal': 'O'}, {'fibers': 'O'}, {'to': 'O'}, {'make': 'O'}, {'a': 'O'}, {'timely': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'TN': 'I-Entity'}, {'and': 'O'}, {'to': 'O'}, {'prevent': 'O'}, {'progressive': 'O'}, {'autoimmune': 'O'}, {'process-related': 'O'}]"
"All 3 patients experienced vertigo, as well as severe otalgia which persisted after mild facial weakness had completely resolved within 1 to 4 weeks.","[{'All': 'O'}, {'3': 'O'}, {'patients': 'O'}, {'experienced': 'O'}, {'vertigo,': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'severe': 'O'}, {'otalgia': 'I-Entity'}, {'which': 'O'}, {'persisted': 'O'}, {'after': 'O'}, {'mild': 'O'}, {'facial': 'B-Entity'}, {'weakness': 'I-Entity'}, {'had': 'O'}, {'completely': 'O'}, {'resolved': 'O'}, {'within': 'O'}, {'1': 'O'}, {'to': 'O'}, {'4': 'O'}, {'weeks.': 'O'}]"
Non-SS dry eye patients (n = 25; 40 eyes) and normal subjects (n = 21; 35 eyes) were also enrolled.,"[{'Non-SS': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'patients': 'O'}, {'(n': 'O'}, {'=': 'O'}, {'25;': 'O'}, {'40': 'O'}, {'eyes)': 'O'}, {'and': 'O'}, {'normal': 'O'}, {'subjects': 'O'}, {'(n': 'O'}, {'=': 'O'}, {'21;': 'O'}, {'35': 'O'}, {'eyes)': 'O'}, {'were': 'O'}, {'also': 'O'}, {'enrolled.': 'O'}]"
"Systemic complications can occur in pSS, but renal involvement is rare, affecting <10% patients.","[{'Systemic': 'O'}, {'complications': 'O'}, {'can': 'O'}, {'occur': 'O'}, {'in': 'O'}, {'pSS,': 'I-Entity'}, {'but': 'O'}, {'renal': 'O'}, {'involvement': 'O'}, {'is': 'O'}, {'rare,': 'O'}, {'affecting': 'O'}, {'<10%': 'O'}, {'patients.': 'O'}]"
"The results of this study showed that OVX caused a significant increase in the expression and levels of the cytokines IL-1‚âà√≠‚Äö√¢¬ß, TNF-‚âà√≠¬¨¬±, and IL-4 in the lacrimal glands of the NOD.B10.H2(b) mice starting at 3 days after OVX, while a significant increase of IL-10 gene expression and levels was observed only at later experimental time points.","[{'The': 'O'}, {'results': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'OVX': 'O'}, {'caused': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'the': 'O'}, {'expression': 'O'}, {'and': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'the': 'O'}, {'cytokines': 'O'}, {'IL-1‚âà√≠‚Äö√¢¬ß,': 'O'}, {'TNF-‚âà√≠¬¨¬±,': 'O'}, {'and': 'O'}, {'IL-4': 'O'}, {'in': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}]"
"Videothoracoscopic lung biopsy demonstrated high grade, B-cell, CD20+, large-cell lymphoma, associated with Epstein-Barr virus (RNA EBERs of the virus were expressed by the lymphoma cells).","[{'Videothoracoscopic': 'O'}, {'lung': 'O'}, {'biopsy': 'O'}, {'demonstrated': 'O'}, {'high': 'O'}, {'grade,': 'O'}, {'B-cell,': 'O'}, {'CD20+,': 'O'}, {'large-cell': 'B-Entity'}, {'lymphoma,': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'Epstein-Barr': 'B-Entity'}, {'virus': 'O'}, {'(RNA': 'O'}, {'EBERs': 'O'}, {'of': 'O'}, {'the': 'O'}, {'virus': 'O'}, {'were': 'O'}, {'expressed': 'O'}, {'by': 'O'}, {'the': 'O'}, {'lymphoma': 'I-Entity'}, {'cells).': 'O'}]"
We identified 9 publically available datasets that included gene expression data from saliva and salivary gland biopsy samples of 52 patients with SS and 51 controls.,"[{'We': 'O'}, {'identified': 'O'}, {'9': 'O'}, {'publically': 'O'}, {'available': 'O'}, {'datasets': 'O'}, {'that': 'O'}, {'included': 'O'}, {'gene': 'O'}, {'expression': 'O'}, {'data': 'O'}, {'from': 'O'}, {'saliva': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'biopsy': 'O'}, {'samples': 'O'}, {'of': 'O'}, {'52': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'51': 'O'}, {'controls.': 'O'}]"
"The mean age of IgG4-related sialadenitis group and Sjogrens syndrome group was 49.23 years and 50.44 years, respectively.","[{'The': 'O'}, {'mean': 'O'}, {'age': 'O'}, {'of': 'O'}, {'IgG4-related': 'O'}, {'sialadenitis': 'I-Entity'}, {'group': 'O'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'group': 'O'}, {'was': 'O'}, {'49.23': 'O'}, {'years': 'O'}, {'and': 'O'}, {'50.44': 'O'}, {'years,': 'O'}, {'respectively.': 'O'}]"
"Among patients with oral candidiasis, Candida albicans was isolated from the tongue mucosa and Candida glabrata was isolated from the angle of the mouth.","[{'Among': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'oral': 'B-Entity'}, {'candidiasis,': 'I-Entity'}, {'Candida': 'B-Entity'}, {'albicans': 'I-Entity'}, {'was': 'O'}, {'isolated': 'O'}, {'from': 'O'}, {'the': 'O'}, {'tongue': 'O'}, {'mucosa': 'O'}, {'and': 'O'}, {'Candida': 'B-Entity'}, {'glabrata': 'I-Entity'}, {'was': 'O'}, {'isolated': 'O'}, {'from': 'O'}, {'the': 'O'}, {'angle': 'O'}, {'of': 'O'}, {'the': 'O'}, {'mouth.': 'O'}]"
The decrease in total EGF output was especially high in patients with long disease duration and poor oral health-related quality of life (OHRQoL).,"[{'The': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'total': 'O'}, {'EGF': 'O'}, {'output': 'O'}, {'was': 'O'}, {'especially': 'O'}, {'high': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'long': 'O'}, {'disease': 'O'}, {'duration': 'O'}, {'and': 'O'}, {'poor': 'O'}, {'oral': 'O'}, {'health-related': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life': 'O'}, {'(OHRQoL).': 'O'}]"
"All subjective symptoms (burning and pricking sensation, light sensitivity and pain) were statistically significantly improved after 1-week and 1-month follow-up examinations (p = 0.0001).","[{'All': 'O'}, {'subjective': 'O'}, {'symptoms': 'O'}, {'(burning': 'O'}, {'and': 'O'}, {'pricking': 'I-Entity'}, {'sensation,': 'O'}, {'light': 'O'}, {'sensitivity': 'O'}, {'and': 'O'}, {'pain)': 'I-Entity'}, {'were': 'O'}, {'statistically': 'O'}, {'significantly': 'O'}, {'improved': 'O'}, {'after': 'O'}, {'1-week': 'O'}, {'and': 'O'}, {'1-month': 'O'}, {'follow-up': 'O'}, {'examinations': 'O'}, {'(p': 'O'}, {'=': 'O'}, {'0.0001).': 'O'}]"
Rheumatologic autoantibodies are frequently found in MS patients and are not associated with disease severity or systemic rheumatologic disease.,"[{'Rheumatologic': 'O'}, {'autoantibodies': 'O'}, {'are': 'O'}, {'frequently': 'O'}, {'found': 'O'}, {'in': 'O'}, {'MS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'are': 'O'}, {'not': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'disease': 'O'}, {'severity': 'O'}, {'or': 'O'}, {'systemic': 'B-Entity'}, {'rheumatologic': 'I-Entity'}, {'disease.': 'I-Entity'}]"
Gastrointestinal infections were not significantly associated with a risk of pSS.,"[{'Gastrointestinal': 'B-Entity'}, {'infections': 'I-Entity'}, {'were': 'O'}, {'not': 'O'}, {'significantly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'pSS.': 'I-Entity'}]"
"These systemic diseases include collagen vascular diseases, vasculitides, granulomatous diseases, neoplasms, hematologic and metabolic abnormalities, neurocutaneous syndromes, deposition disease, and miscellaneous conditions such as cystic fibrosis and Goodpasture's syndrome.","[{'These': 'O'}, {'systemic': 'O'}, {'diseases': 'O'}, {'include': 'O'}, {'collagen': 'B-Entity'}, {'vascular': 'I-Entity'}, {'diseases,': 'I-Entity'}, {'vasculitides,': 'I-Entity'}, {'granulomatous': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'neoplasms,': 'I-Entity'}, {'hematologic': 'B-Entity'}, {'and': 'I-Entity'}, {'metabolic': 'I-Entity'}, {'abnormalities,': 'I-Entity'}, {'neurocutaneous': 'B-Entity'}, {'syndromes,': 'I-Entity'}, {'deposition': 'B-Entity'}, {'disease,': 'I-Entity'}, {'and': 'O'}, {'miscellaneous': 'O'}, {'conditions': 'O'}, {'such': 'O'}, {'as': 'O'}, {'cystic': 'B-Entity'}, {'fibrosis': 'I-Entity'}, {'and': 'O'}]"
Airway disease has little effect on respiratory function and is rarely the cause of death in Sjogrens syndrome patients.,"[{'Airway': 'B-Entity'}, {'disease': 'I-Entity'}, {'has': 'O'}, {'little': 'O'}, {'effect': 'O'}, {'on': 'O'}, {'respiratory': 'O'}, {'function': 'O'}, {'and': 'O'}, {'is': 'O'}, {'rarely': 'O'}, {'the': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'death': 'I-Entity'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'patients.': 'O'}]"
"Sjogrens syndrome (SS) is a chronic, inflammatory, autoimmune disease characterized by lymphocytic infiltration of the exocrine glands leading to qualitatively altered and diminished or absent salivary and lachrymal secretion, and by marked B-cell hyperreactivity.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic,': 'O'}, {'inflammatory,': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'qualitatively': 'O'}, {'altered': 'O'}, {'and': 'O'}, {'diminished': 'O'}, {'or': 'O'}, {'absent': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lachrymal': 'O'}, {'secretion,': 'O'}, {'and': 'O'}, {'by': 'O'}, {'marked': 'O'}, {'B-cell': 'O'}]"
"Sweet disease (SD) is a multisystem inflammatory disorder characterised by fever, cutaneous erythematous plaques and aseptic neutrophilic infiltration of various organs.","[{'Sweet': 'B-Entity'}, {'disease': 'I-Entity'}, {'(SD)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'multisystem': 'O'}, {'inflammatory': 'B-Entity'}, {'disorder': 'I-Entity'}, {'characterised': 'O'}, {'by': 'O'}, {'fever,': 'I-Entity'}, {'cutaneous': 'O'}, {'erythematous': 'I-Entity'}, {'plaques': 'I-Entity'}, {'and': 'O'}, {'aseptic': 'O'}, {'neutrophilic': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'various': 'O'}, {'organs.': 'O'}]"
To assess disease features in Sle1.Yaa mice with genetic interleukin-6 (IL-6) deficiency.,"[{'To': 'O'}, {'assess': 'O'}, {'disease': 'O'}, {'features': 'O'}, {'in': 'O'}, {'Sle1.Yaa': 'O'}, {'mice': 'O'}, {'with': 'O'}, {'genetic': 'O'}, {'interleukin-6': 'O'}, {'(IL-6)': 'O'}, {'deficiency.': 'O'}]"
We should aware that SSA can occur at younger age and cause symptomatic ureteral stenosis.,"[{'We': 'O'}, {'should': 'O'}, {'aware': 'O'}, {'that': 'O'}, {'SSA': 'I-Entity'}, {'can': 'O'}, {'occur': 'O'}, {'at': 'O'}, {'younger': 'O'}, {'age': 'O'}, {'and': 'O'}, {'cause': 'O'}, {'symptomatic': 'O'}, {'ureteral': 'B-Entity'}, {'stenosis.': 'I-Entity'}]"
We describe herein a case of hypokalemia due to proximal renal tubular acidosis (RTA) and Fanconi's syndrome (FS) and nephrogenic diabetes insipidus with DIC - a rare complication of Sjogrens syndrome (SS) and brucellosis.,"[{'We': 'O'}, {'describe': 'O'}, {'herein': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'hypokalemia': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'proximal': 'O'}, {'renal': 'O'}, {'tubular': 'O'}, {'acidosis': 'I-Entity'}, {'(RTA)': 'O'}, {'and': 'O'}, {""Fanconi's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(FS)': 'O'}, {'and': 'O'}, {'nephrogenic': 'B-Entity'}, {'diabetes': 'B-Entity'}, {'insipidus': 'I-Entity'}, {'with': 'O'}, {'DIC': 'I-Entity'}, {'-': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}]"
The symptoms resolved in response to steroid therapy and serum analysis was positive for anti SSA antibodies.,"[{'The': 'O'}, {'symptoms': 'O'}, {'resolved': 'O'}, {'in': 'O'}, {'response': 'O'}, {'to': 'O'}, {'steroid': 'I-Entity'}, {'therapy': 'O'}, {'and': 'O'}, {'serum': 'O'}, {'analysis': 'O'}, {'was': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'anti': 'O'}, {'SSA': 'O'}, {'antibodies.': 'O'}]"
Sjogrens syndrome (SS) is a common autoimmune disease affecting about four million Americans.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'common': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'affecting': 'O'}, {'about': 'O'}, {'four': 'O'}, {'million': 'O'}, {'Americans.': 'O'}]"
"However, the patient's edema and albumin level improved dramatically in response to a 3-month regime of oral prednisolone followed by oral hydroxychloroquine.ericliao0217@gmail.com.candidate gene study.","[{'However,': 'O'}, {'the': 'O'}, {""patient's"": 'O'}, {'edema': 'I-Entity'}, {'and': 'O'}, {'albumin': 'O'}, {'level': 'O'}, {'improved': 'O'}, {'dramatically': 'O'}, {'in': 'O'}, {'response': 'O'}, {'to': 'O'}, {'a': 'O'}, {'3-month': 'O'}, {'regime': 'O'}, {'of': 'O'}, {'oral': 'O'}, {'prednisolone': 'I-Entity'}, {'followed': 'O'}, {'by': 'O'}, {'oral': 'O'}, {'hydroxychloroquine.ericliao0217@gmail.com.candidate': 'I-Entity'}, {'gene': 'O'}, {'study.': 'O'}]"
Rheumatoid arthritis (RA) is one of the most common chronic inflammatory diseases.,"[{'Rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA)': 'O'}, {'is': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'chronic': 'O'}, {'inflammatory': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"These histological findings were probably responsible for the ""slowly progressive"" renal impairment over the years without causing typical SRC.University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.","[{'These': 'O'}, {'histological': 'O'}, {'findings': 'O'}, {'were': 'O'}, {'probably': 'O'}, {'responsible': 'O'}, {'for': 'O'}, {'the': 'O'}, {'""slowly': 'O'}, {'progressive""': 'O'}, {'renal': 'B-Entity'}, {'impairment': 'I-Entity'}, {'over': 'O'}, {'the': 'O'}, {'years': 'O'}, {'without': 'O'}, {'causing': 'O'}, {'typical': 'O'}, {'SRC.University': 'I-Entity'}, {'School': 'O'}, {'of': 'O'}, {'Medicine,': 'O'}, {'3-25-8': 'O'}, {'Nishi-Shimbashi,': 'O'}, {'Minato-Ku,': 'O'}, {'Tokyo,': 'O'}, {'105-8461,': 'O'}, {'Japan.': 'O'}]"
"The diagnosis of cystic lung revealing a primary Sjogren's syndrome was held before a group of radio-clinical, immunological and histological arguments.","[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'cystic': 'B-Entity'}, {'lung': 'I-Entity'}, {'revealing': 'O'}, {'a': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome': 'I-Entity'}, {'was': 'O'}, {'held': 'O'}, {'before': 'O'}, {'a': 'O'}, {'group': 'O'}, {'of': 'O'}, {'radio-clinical,': 'O'}, {'immunological': 'O'}, {'and': 'O'}, {'histological': 'O'}, {'arguments.': 'O'}]"
"The possibility of an underlying autoimmune disorder should be considered in a patient presenting with distal tubular acidosis or recurrent hypokalemic periodic paralysis as treatment of primary disease improves the outcome of illness.India.India.India.the Saudi Center for Organ Transplantation, Saudi Arabia10.4103/1319-2442.229289.Sjogren syndrome.","[{'The': 'O'}, {'possibility': 'O'}, {'of': 'O'}, {'an': 'O'}, {'underlying': 'O'}, {'autoimmune': 'B-Entity'}, {'disorder': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'in': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'presenting': 'O'}, {'with': 'O'}, {'distal': 'O'}, {'tubular': 'O'}, {'acidosis': 'I-Entity'}, {'or': 'O'}, {'recurrent': 'O'}, {'hypokalemic': 'I-Entity'}, {'periodic': 'O'}, {'paralysis': 'I-Entity'}, {'as': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'primary': 'O'}, {'disease': 'O'}, {'improves': 'O'}, {'the': 'O'}, {'outcome': 'O'}, {'of': 'O'}, {'illness.India.India.India.the': 'O'}, {'Saudi': 'O'}, {'Center': 'O'}, {'for': 'O'}, {'Organ': 'O'}, {'Transplantation,': 'O'}]"
"Meanwhile, in peripheral blood mononuclear cells from pSS patients, pIKK‚âà√≠¬¨¬µ, total IKK‚âà√≠¬¨¬µ, pIKK‚âà√≠¬¨¬±/‚âà√≠‚Äö√¢¬ß, and p-p65 were significantly increased by western blot, compared to healthy controls.","[{'Meanwhile,': 'O'}, {'in': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'mononuclear': 'O'}, {'cells': 'O'}, {'from': 'O'}, {'pSS': 'I-Entity'}, {'patients,': 'O'}, {'pIKK‚âà√≠¬¨¬µ,': 'O'}, {'total': 'O'}, {'IKK‚âà√≠¬¨¬µ,': 'O'}, {'pIKK‚âà√≠¬¨¬±/‚âà√≠‚Äö√¢¬ß,': 'O'}]"
The patient's symptoms eventually improved after she underwent psychotherapy treatment for a few months.,"[{'The': 'O'}, {""patient's"": 'O'}, {'symptoms': 'O'}, {'eventually': 'O'}, {'improved': 'O'}, {'after': 'O'}, {'she': 'O'}, {'underwent': 'O'}, {'psychotherapy': 'O'}, {'treatment': 'O'}, {'for': 'O'}, {'a': 'O'}, {'few': 'O'}, {'months.': 'O'}]"
Sjogrens syndrome is a chronic autoimmune disease whose main clinical manifestation is oral dryness (xerostomia) and ocular dryness (xerophthalmia).,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'whose': 'O'}, {'main': 'O'}, {'clinical': 'O'}, {'manifestation': 'O'}, {'is': 'O'}, {'oral': 'B-Entity'}, {'dryness': 'I-Entity'}, {'(xerostomia)': 'O'}, {'and': 'O'}, {'ocular': 'B-Entity'}, {'dryness': 'I-Entity'}, {'(xerophthalmia).': 'O'}]"
The mechanism underlying this disease remains poorly understood.,"[{'The': 'O'}, {'mechanism': 'O'}, {'underlying': 'O'}, {'this': 'O'}, {'disease': 'O'}, {'remains': 'O'}, {'poorly': 'O'}, {'understood.': 'O'}]"
"Some patients develop genuine classic rheumatic and musculoskeletal diseases, but a number of rheumatic immune-related adverse events mimic rheumatic and musculoskeletal diseases with atypical features, mainly polymyalgia rheumatica, rheumatoid arthritis and myositis, as well as several systemic conditions, including sicca syndrome, vasculitis, sarcoidosis, systemic sclerosis and lupus.Society for Rheumatology.10.1093/rheumatology/kez295.","[{'Some': 'O'}, {'patients': 'O'}, {'develop': 'O'}, {'genuine': 'O'}, {'classic': 'O'}, {'rheumatic': 'B-Entity'}, {'and': 'I-Entity'}, {'musculoskeletal': 'I-Entity'}, {'diseases,': 'I-Entity'}, {'but': 'O'}, {'a': 'O'}, {'number': 'O'}, {'of': 'O'}, {'rheumatic': 'B-Entity'}, {'immune-related': 'I-Entity'}, {'adverse': 'O'}, {'events': 'O'}, {'mimic': 'O'}, {'rheumatic': 'B-Entity'}, {'and': 'I-Entity'}, {'musculoskeletal': 'I-Entity'}, {'diseases': 'I-Entity'}, {'with': 'O'}, {'atypical': 'O'}, {'features,': 'O'}, {'mainly': 'O'}, {'polymyalgia': 'B-Entity'}, {'rheumatica,': 'I-Entity'}, {'rheumatoid': 'B-Entity'}]"
Sjogrens syndrome (SS) is an inflammatory autoimmune disease that causes hyposecretion in salivary glands.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'inflammatory': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'causes': 'O'}, {'hyposecretion': 'O'}, {'in': 'O'}, {'salivary': 'O'}, {'glands.': 'O'}]"
A damaged joint count was done using Norfolk Arthritis Register Damaged Joint Count (NOAR-DJC).,"[{'A': 'O'}, {'damaged': 'O'}, {'joint': 'O'}, {'count': 'O'}, {'was': 'O'}, {'done': 'O'}, {'using': 'O'}, {'Norfolk': 'O'}, {'Arthritis': 'I-Entity'}, {'Register': 'O'}, {'Damaged': 'O'}, {'Joint': 'O'}, {'Count': 'O'}, {'(NOAR-DJC).': 'O'}]"
"We hypothesized that, because of these local failures, DHEA replacement therapy would be unable to improve the local androgen deficiency in SS salivary glands.","[{'We': 'O'}, {'hypothesized': 'O'}, {'that,': 'O'}, {'because': 'O'}, {'of': 'O'}, {'these': 'O'}, {'local': 'O'}, {'failures,': 'O'}, {'DHEA': 'I-Entity'}, {'replacement': 'O'}, {'therapy': 'O'}, {'would': 'O'}, {'be': 'O'}, {'unable': 'O'}, {'to': 'O'}, {'improve': 'O'}, {'the': 'O'}, {'local': 'O'}, {'androgen': 'O'}, {'deficiency': 'O'}, {'in': 'O'}, {'SS': 'O'}, {'salivary': 'O'}, {'glands.': 'O'}]"
Sjogrens syndrome (SS) is a debilitating systemic disease that may have oral complications.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'debilitating': 'O'}, {'systemic': 'O'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'may': 'O'}, {'have': 'O'}, {'oral': 'O'}, {'complications.': 'O'}]"
"We conclude that EDR data could be used for characterizing the treatments received by SSP and for assessing treatment outcomes.Indiana, USA.Indiana, USA.Indiana, USA.Indiana, USA.","[{'We': 'O'}, {'conclude': 'O'}, {'that': 'O'}, {'EDR': 'O'}, {'data': 'O'}, {'could': 'O'}, {'be': 'O'}, {'used': 'O'}, {'for': 'O'}, {'characterizing': 'O'}, {'the': 'O'}, {'treatments': 'O'}, {'received': 'O'}, {'by': 'O'}, {'SSP': 'I-Entity'}, {'and': 'O'}, {'for': 'O'}, {'assessing': 'O'}, {'treatment': 'O'}, {'outcomes.Indiana,': 'O'}, {'USA.Indiana,': 'O'}, {'USA.Indiana,': 'O'}, {'USA.Indiana,': 'O'}, {'USA.': 'O'}]"
TGP can alleviate some dryness symptoms as well as disease activity in pSS patients over 24¬¨¬®‚Äö√Ñ‚Ä†weeks.,"[{'TGP': 'I-Entity'}, {'can': 'O'}, {'alleviate': 'O'}, {'some': 'O'}, {'dryness': 'I-Entity'}, {'symptoms': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'over': 'O'}, {'24¬¨¬®‚Äö√Ñ‚Ä†weeks.': 'O'}]"
"Patients with a simultaneous diagnosis of PAH and CTD, including SLE, MCTD, and primary SS, should receive intensive IS treatment regimens to achieve better short- and long-term outcomes.Medicine.Medicine.Medicine.Medicine.Medicine.non-obese diabetic mice with Sjogren's syndrome.","[{'Patients': 'O'}, {'with': 'O'}, {'a': 'O'}, {'simultaneous': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'PAH': 'I-Entity'}, {'and': 'O'}, {'CTD,': 'I-Entity'}, {'including': 'O'}, {'SLE,': 'I-Entity'}, {'MCTD,': 'I-Entity'}, {'and': 'O'}, {'primary': 'O'}, {'SS,': 'I-Entity'}, {'should': 'O'}, {'receive': 'O'}, {'intensive': 'O'}, {'IS': 'O'}, {'treatment': 'O'}, {'regimens': 'O'}, {'to': 'O'}, {'achieve': 'O'}, {'better': 'O'}, {'short-': 'O'}, {'and': 'O'}, {'long-term': 'O'}, {'outcomes.Medicine.Medicine.Medicine.Medicine.Medicine.non-obese': 'O'}, {'diabetic': 'I-Entity'}, {'mice': 'O'}]"
"The percentages of CD4+CXCR5+Tfh cells in peripheral blood were increased in pSS patients, but decreased after treatment with glucocorticoid and/or immunosuppressive drugs.","[{'The': 'O'}, {'percentages': 'O'}, {'of': 'O'}, {'CD4+CXCR5+Tfh': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'were': 'O'}, {'increased': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients,': 'O'}, {'but': 'O'}, {'decreased': 'O'}, {'after': 'O'}, {'treatment': 'O'}, {'with': 'O'}, {'glucocorticoid': 'O'}, {'and/or': 'O'}, {'immunosuppressive': 'O'}, {'drugs.': 'O'}]"
"The most common abnormal findings on the chest CT scan were pulmonary nodules (n = 14), followed by cysts (n = 6) and reticular opacities (n = 4).","[{'The': 'O'}, {'most': 'O'}, {'common': 'O'}, {'abnormal': 'O'}, {'findings': 'O'}, {'on': 'O'}, {'the': 'O'}, {'chest': 'O'}, {'CT': 'O'}, {'scan': 'O'}, {'were': 'O'}, {'pulmonary': 'B-Entity'}, {'nodules': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'14),': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'cysts': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'6)': 'O'}, {'and': 'O'}, {'reticular': 'B-Entity'}, {'opacities': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'4).': 'O'}]"
"Peripheral neurological complications in primary Sjogrens syndrome (pSS) seem the most common, however the involvement of central nervous system (CNS) remains unclear.","[{'Peripheral': 'O'}, {'neurological': 'I-Entity'}, {'complications': 'I-Entity'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'seem': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common,': 'O'}, {'however': 'O'}, {'the': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'central': 'O'}, {'nervous': 'O'}, {'system': 'O'}, {'(CNS)': 'O'}, {'remains': 'O'}, {'unclear.': 'O'}]"
Ten randomized controlled trials investigating the effect of acupuncture were included.,"[{'Ten': 'O'}, {'randomized': 'O'}, {'controlled': 'O'}, {'trials': 'O'}, {'investigating': 'O'}, {'the': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'acupuncture': 'O'}, {'were': 'O'}, {'included.': 'O'}]"
Urinary alkalinisation using potassium bicarbonate was instituted; the patient responded well to treatment and is having outpatient follow-up.mattjulian@doctors.org.ukpresence of systemic auto-antibodies and/or hypergammaglobulinemia?,"[{'Urinary': 'O'}, {'alkalinisation': 'O'}, {'using': 'O'}, {'potassium': 'B-Entity'}, {'bicarbonate': 'I-Entity'}, {'was': 'O'}, {'instituted;': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'responded': 'O'}, {'well': 'O'}, {'to': 'O'}, {'treatment': 'O'}, {'and': 'O'}, {'is': 'O'}, {'having': 'O'}, {'outpatient': 'O'}, {'follow-up.mattjulian@doctors.org.ukpresence': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'auto-antibodies': 'O'}, {'and/or': 'O'}, {'hypergammaglobulinemia?': 'I-Entity'}]"
"We propose that the information offered by these technologies will enhance our ability to diagnose, treat, and further understand the pathogenesis of multiple oral diseases.Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.","[{'We': 'O'}, {'propose': 'O'}, {'that': 'O'}, {'the': 'O'}, {'information': 'O'}, {'offered': 'O'}, {'by': 'O'}, {'these': 'O'}, {'technologies': 'O'}, {'will': 'O'}, {'enhance': 'O'}, {'our': 'O'}, {'ability': 'O'}, {'to': 'O'}, {'diagnose,': 'O'}, {'treat,': 'O'}, {'and': 'O'}, {'further': 'O'}, {'understand': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'multiple': 'O'}, {'oral': 'B-Entity'}, {'diseases.Institute': 'I-Entity'}, {'of': 'O'}, {'Dental': 'O'}, {'and': 'O'}, {'Craniofacial': 'O'}, {'Research,': 'O'}, {'National': 'O'}, {'Institutes': 'O'}, {'of': 'O'}, {'Health,': 'O'}, {'Bethesda,': 'O'}, {'MD,': 'O'}, {'USA.': 'O'}]"
Increased adoption of electronic dental records (EDR) could help in leveraging information from these records to assess dental treatment outcomes in SSP.,"[{'Increased': 'O'}, {'adoption': 'O'}, {'of': 'O'}, {'electronic': 'O'}, {'dental': 'O'}, {'records': 'O'}, {'(EDR)': 'O'}, {'could': 'O'}, {'help': 'O'}, {'in': 'O'}, {'leveraging': 'O'}, {'information': 'O'}, {'from': 'O'}, {'these': 'O'}, {'records': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'dental': 'O'}, {'treatment': 'O'}, {'outcomes': 'O'}, {'in': 'O'}, {'SSP.': 'I-Entity'}]"
"Sjogren syndrome is an autoimmune disease characterized by dry mouth and eyes, known as sicca symptoms.","[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'and': 'I-Entity'}, {'eyes,': 'I-Entity'}, {'known': 'O'}, {'as': 'O'}, {'sicca': 'B-Entity'}, {'symptoms.': 'O'}]"
"A 47-year-old female patient presented progressively worsening pain in the chest wall, back and bilateral lower extremities as well as muscle weakness was referred to our department.","[{'A': 'O'}, {'47-year-old': 'O'}, {'female': 'O'}, {'patient': 'O'}, {'presented': 'O'}, {'progressively': 'O'}, {'worsening': 'O'}, {'pain': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'chest': 'I-Entity'}, {'wall,': 'I-Entity'}, {'back': 'O'}, {'and': 'O'}, {'bilateral': 'O'}, {'lower': 'O'}, {'extremities': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'muscle': 'B-Entity'}, {'weakness': 'I-Entity'}, {'was': 'O'}, {'referred': 'O'}, {'to': 'O'}, {'our': 'O'}, {'department.': 'O'}]"
"Twenty-two trials examined ocular and oral dryness, for which only 2 and 4 trials showed statistically significant improvements, respectively.","[{'Twenty-two': 'O'}, {'trials': 'O'}, {'examined': 'O'}, {'ocular': 'B-Entity'}, {'and': 'I-Entity'}, {'oral': 'I-Entity'}, {'dryness,': 'I-Entity'}, {'for': 'O'}, {'which': 'O'}, {'only': 'O'}, {'2': 'O'}, {'and': 'O'}, {'4': 'O'}, {'trials': 'O'}, {'showed': 'O'}, {'statistically': 'O'}, {'significant': 'O'}, {'improvements,': 'O'}, {'respectively.': 'O'}]"
"Inflammation, nonetheless, seems to play a central role in this pathology especially in the form of Th-1, Th-2 and Th-17 cytokines release within different aspects, concentrations and connections involved in the maintenance of the syndrome.","[{'Inflammation,': 'O'}, {'nonetheless,': 'O'}, {'seems': 'O'}, {'to': 'O'}, {'play': 'O'}, {'a': 'O'}, {'central': 'O'}, {'role': 'O'}, {'in': 'O'}, {'this': 'O'}, {'pathology': 'O'}, {'especially': 'O'}, {'in': 'O'}, {'the': 'O'}, {'form': 'O'}, {'of': 'O'}, {'Th-1,': 'O'}, {'Th-2': 'O'}, {'and': 'O'}, {'Th-17': 'O'}, {'cytokines': 'O'}, {'release': 'O'}, {'within': 'O'}, {'different': 'O'}, {'aspects,': 'O'}, {'concentrations': 'O'}, {'and': 'O'}, {'connections': 'O'}, {'involved': 'O'}, {'in': 'O'}, {'the': 'O'}, {'maintenance': 'O'}, {'of': 'O'}, {'the': 'O'}, {'syndrome.': 'O'}]"
"A long disease duration is associated with subclinical atherosclerosis in pSS.Delinassios), All rights reserved.Italy e.zardi@unicampus.it.Italy.Italy.syndrome.","[{'A': 'O'}, {'long': 'O'}, {'disease': 'O'}, {'duration': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'subclinical': 'O'}, {'atherosclerosis': 'I-Entity'}, {'in': 'O'}, {'pSS.Delinassios),': 'O'}, {'All': 'O'}, {'rights': 'O'}, {'reserved.Italy': 'O'}, {'e.zardi@unicampus.it.Italy.Italy.syndrome.': 'O'}]"
Several studies indicate that there is an inflammatory component of fatigue in pSS and other chronic inflammatory rheumatic diseases.,"[{'Several': 'O'}, {'studies': 'O'}, {'indicate': 'O'}, {'that': 'O'}, {'there': 'O'}, {'is': 'O'}, {'an': 'O'}, {'inflammatory': 'O'}, {'component': 'O'}, {'of': 'O'}, {'fatigue': 'I-Entity'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'other': 'O'}, {'chronic': 'O'}, {'inflammatory': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'diseases.': 'I-Entity'}]"
"Recent developments in the understanding of the pathogenesis of SS provided evidence that the ocular dryness is associated with pathologic infiltration and dysfunction of the lacrimal glands and changes in the tear composition, together with abnormalities involving the neurosecreting circuits.","[{'Recent': 'O'}, {'developments': 'O'}, {'in': 'O'}, {'the': 'O'}, {'understanding': 'O'}, {'of': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'provided': 'O'}, {'evidence': 'O'}, {'that': 'O'}, {'the': 'O'}, {'ocular': 'B-Entity'}, {'dryness': 'I-Entity'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'pathologic': 'O'}, {'infiltration': 'O'}, {'and': 'O'}, {'dysfunction': 'O'}, {'of': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}, {'glands': 'O'}, {'and': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'the': 'O'}, {'tear': 'O'}, {'composition,': 'O'}, {'together': 'O'}, {'with': 'O'}, {'abnormalities': 'O'}, {'involving': 'O'}, {'the': 'O'}, {'neurosecreting': 'O'}, {'circuits.': 'O'}]"
"To evaluate the effectiveness of low-level laser therapy (LLLT) in the treatment of xerostomia in primary Sjogrens syndrome (SS), a randomized clinical trial of patients with dry mouth symptoms associated with primary SS receiving care at a university hospital was conducted.","[{'To': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'effectiveness': 'O'}, {'of': 'O'}, {'low-level': 'O'}, {'laser': 'O'}, {'therapy': 'O'}, {'(LLLT)': 'O'}, {'in': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'xerostomia': 'I-Entity'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'a': 'O'}, {'randomized': 'O'}, {'clinical': 'O'}, {'trial': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'symptoms': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'receiving': 'O'}, {'care': 'O'}, {'at': 'O'}, {'a': 'O'}, {'university': 'O'}, {'hospital': 'O'}, {'was': 'O'}, {'conducted.': 'O'}]"
"Although the incidence of hepatocellular carcinoma, end-stage renal disease, variceal bleeding, and hypothyroidism were all higher in the PBC-SS group than in the PBC-only group, the differences were not significant.Our study suggests that PBC-SS patients have a higher risk of developing interstitial lung disease and spontaneous bacterial peritonitis and have a poor prognosis.","[{'Although': 'O'}, {'the': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'hepatocellular': 'B-Entity'}, {'carcinoma,': 'I-Entity'}, {'end-stage': 'B-Entity'}, {'renal': 'I-Entity'}, {'disease,': 'I-Entity'}, {'variceal': 'B-Entity'}, {'bleeding,': 'I-Entity'}, {'and': 'O'}, {'hypothyroidism': 'I-Entity'}, {'were': 'O'}, {'all': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'the': 'O'}, {'PBC-SS': 'I-Entity'}, {'group': 'O'}, {'than': 'O'}, {'in': 'O'}, {'the': 'O'}, {'PBC-only': 'O'}, {'group,': 'O'}, {'the': 'O'}, {'differences': 'O'}, {'were': 'O'}, {'not': 'O'}, {'significant.Our': 'O'}, {'study': 'O'}, {'suggests': 'O'}, {'that': 'O'}, {'PBC-SS': 'I-Entity'}]"
"In addition, the finding of thyroid peroxidase, thyroglobulin antibodies, and hypothyroidism led us to the diagnosis of Hashimoto thyroiditis.","[{'In': 'O'}, {'addition,': 'O'}, {'the': 'O'}, {'finding': 'O'}, {'of': 'O'}, {'thyroid': 'O'}, {'peroxidase,': 'O'}, {'thyroglobulin': 'O'}, {'antibodies,': 'O'}, {'and': 'O'}, {'hypothyroidism': 'I-Entity'}, {'led': 'O'}, {'us': 'O'}, {'to': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'Hashimoto': 'B-Entity'}, {'thyroiditis.': 'I-Entity'}]"
"The most prevalent species found was Candida albicans followed by Candida tropicalis, Candida glabrata, Candida parapsilosis, and Candida krusei.","[{'The': 'O'}, {'most': 'O'}, {'prevalent': 'O'}, {'species': 'O'}, {'found': 'O'}, {'was': 'O'}, {'Candida': 'B-Entity'}, {'albicans': 'I-Entity'}, {'followed': 'O'}, {'by': 'O'}, {'Candida': 'B-Entity'}, {'tropicalis,': 'I-Entity'}, {'Candida': 'B-Entity'}, {'glabrata,': 'I-Entity'}, {'Candida': 'B-Entity'}, {'parapsilosis,': 'I-Entity'}, {'and': 'O'}, {'Candida': 'B-Entity'}, {'krusei.': 'I-Entity'}]"
Eleven patients (mean age 55 years [38-77]) were treated with rituximab for their neurological involvement.,"[{'Eleven': 'O'}, {'patients': 'O'}, {'(mean': 'O'}, {'age': 'O'}, {'55': 'O'}, {'years': 'O'}, {'[38-77])': 'O'}, {'were': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'rituximab': 'I-Entity'}, {'for': 'O'}, {'their': 'O'}, {'neurological': 'O'}, {'involvement.': 'O'}]"
"To reveal dental implants survival rates in patients with oral mucosal diseases: oral lichen planus (OLP), Sjogrens syndrome (SjS), epidermolysis bullosa (EB) and systemic sclerosis (SSc).","[{'To': 'O'}, {'reveal': 'O'}, {'dental': 'O'}, {'implants': 'O'}, {'survival': 'O'}, {'rates': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'oral': 'B-Entity'}, {'mucosal': 'I-Entity'}, {'diseases:': 'I-Entity'}, {'oral': 'B-Entity'}, {'lichen': 'I-Entity'}, {'planus': 'I-Entity'}, {'(OLP),': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SjS),': 'O'}, {'epidermolysis': 'B-Entity'}, {'bullosa': 'I-Entity'}, {'(EB)': 'O'}, {'and': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(SSc).': 'O'}]"
"Patients with BD showed an improvement of scintigraphic findings (5/5 patients), while a similar result was obtained only in 2 of the patients with pSS.","[{'Patients': 'O'}, {'with': 'O'}, {'BD': 'I-Entity'}, {'showed': 'O'}, {'an': 'O'}, {'improvement': 'O'}, {'of': 'O'}, {'scintigraphic': 'O'}, {'findings': 'O'}, {'(5/5': 'O'}, {'patients),': 'O'}, {'while': 'O'}, {'a': 'O'}, {'similar': 'O'}, {'result': 'O'}, {'was': 'O'}, {'obtained': 'O'}, {'only': 'O'}, {'in': 'O'}, {'2': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS.': 'I-Entity'}]"
"In blood, we identified a 6-cell disease signature defined by decreased numbers of CD4 and memory B lymphocytes, decreased plasmacytoid dendritic cell numbers, and increased representation of activated CD4 and CD8 T¬¨¬®‚Äö√Ñ‚Ä†cells and plasmablasts.","[{'In': 'O'}, {'blood,': 'O'}, {'we': 'O'}, {'identified': 'O'}, {'a': 'O'}, {'6-cell': 'O'}, {'disease': 'O'}, {'signature': 'O'}, {'defined': 'O'}, {'by': 'O'}, {'decreased': 'O'}, {'numbers': 'O'}, {'of': 'O'}, {'CD4': 'O'}, {'and': 'O'}, {'memory': 'O'}, {'B': 'O'}, {'lymphocytes,': 'O'}, {'decreased': 'O'}, {'plasmacytoid': 'O'}, {'dendritic': 'O'}, {'cell': 'O'}, {'numbers,': 'O'}, {'and': 'O'}, {'increased': 'O'}, {'representation': 'O'}, {'of': 'O'}, {'activated': 'O'}, {'CD4': 'O'}, {'and': 'O'}, {'CD8': 'O'}, {'T¬¨¬®‚Äö√Ñ‚Ä†cells': 'O'}, {'and': 'O'}, {'plasmablasts.': 'O'}]"
Store-operated calcium entry was also reduced in peripheral blood mononuclear cells from pSS patients compared with those from healthy controls.,"[{'Store-operated': 'O'}, {'calcium': 'I-Entity'}, {'entry': 'O'}, {'was': 'O'}, {'also': 'O'}, {'reduced': 'O'}, {'in': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'mononuclear': 'O'}, {'cells': 'O'}, {'from': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'those': 'O'}, {'from': 'O'}, {'healthy': 'O'}, {'controls.': 'O'}]"
The purpose of this study is to determine the tear and serum protein levels of interleukin-33 (IL-33) and its correlation with Th cytokines and disease severity in dry eye (DE) syndrome.,"[{'The': 'O'}, {'purpose': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'is': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'tear': 'O'}, {'and': 'O'}, {'serum': 'O'}, {'protein': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'interleukin-33': 'O'}, {'(IL-33)': 'O'}, {'and': 'O'}, {'its': 'O'}, {'correlation': 'O'}, {'with': 'O'}, {'Th': 'O'}, {'cytokines': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'severity': 'O'}, {'in': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'(DE)': 'O'}, {'syndrome.': 'I-Entity'}]"
"We analyzed the presence of Chlamydia psittaci, Chlamydia pneumoniae, and Chlamydia trachomatis DNA in 47 nongastrointestinal and 14 gastrointestinal MALT lymphomas, 37 nonmalignant control samples, and 27 autoimmune precursor lesions by polymerase chain reaction amplification and direct sequencing.","[{'We': 'O'}, {'analyzed': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'Chlamydia': 'B-Entity'}, {'psittaci,': 'I-Entity'}, {'Chlamydia': 'B-Entity'}, {'pneumoniae,': 'I-Entity'}, {'and': 'O'}, {'Chlamydia': 'B-Entity'}, {'trachomatis': 'I-Entity'}, {'DNA': 'O'}, {'in': 'O'}, {'47': 'O'}, {'nongastrointestinal': 'O'}, {'and': 'O'}, {'14': 'O'}, {'gastrointestinal': 'B-Entity'}, {'MALT': 'B-Entity'}, {'lymphomas,': 'I-Entity'}, {'37': 'O'}, {'nonmalignant': 'O'}, {'control': 'O'}, {'samples,': 'O'}]"
"However, we cannot exclude the possibility that a higher PWV in pSS patients is caused, not by pSS itself, but by the use of steroids, hypertension and dyslipidemia.1.- A Case Report.","[{'However,': 'O'}, {'we': 'O'}, {'cannot': 'O'}, {'exclude': 'O'}, {'the': 'O'}, {'possibility': 'O'}, {'that': 'O'}, {'a': 'O'}, {'higher': 'O'}, {'PWV': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'is': 'O'}, {'caused,': 'O'}, {'not': 'O'}, {'by': 'O'}, {'pSS': 'I-Entity'}, {'itself,': 'O'}, {'but': 'O'}, {'by': 'O'}, {'the': 'O'}, {'use': 'O'}, {'of': 'O'}, {'steroids,': 'I-Entity'}, {'hypertension': 'I-Entity'}, {'and': 'O'}, {'dyslipidemia.1.-': 'I-Entity'}, {'A': 'O'}, {'Case': 'O'}, {'Report.': 'O'}]"
"Commonly observed features in previously reported patients with childhood Sjogren syndrome and central nervous system complications have included fever at the time of neurologic presentation, cerebrospinal fluid pleocytosis, abnormal neuroimaging, and positivity for several specific antibodies.","[{'Commonly': 'O'}, {'observed': 'O'}, {'features': 'O'}, {'in': 'O'}, {'previously': 'O'}, {'reported': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'childhood': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'central': 'B-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'complications': 'I-Entity'}, {'have': 'O'}, {'included': 'O'}, {'fever': 'I-Entity'}, {'at': 'O'}, {'the': 'O'}, {'time': 'O'}, {'of': 'O'}, {'neurologic': 'O'}, {'presentation,': 'O'}, {'cerebrospinal': 'O'}, {'fluid': 'O'}, {'pleocytosis,': 'I-Entity'}, {'abnormal': 'O'}, {'neuroimaging,': 'O'}, {'and': 'O'}, {'positivity': 'O'}, {'for': 'O'}, {'several': 'O'}, {'specific': 'O'}, {'antibodies.': 'O'}]"
RDW and NLR may prove to be useful indices to estimate pSS disease activity.Inc.,"[{'RDW': 'O'}, {'and': 'O'}, {'NLR': 'O'}, {'may': 'O'}, {'prove': 'O'}, {'to': 'O'}, {'be': 'O'}, {'useful': 'O'}, {'indices': 'O'}, {'to': 'O'}, {'estimate': 'O'}, {'pSS': 'I-Entity'}, {'disease': 'O'}, {'activity.Inc.': 'O'}]"
"In addition some drugs used in rheumatic disease such as anti-tumor necrosis factor biologics may induce inflammatory disease of the CNS and should be avoided in MS. An interdisciplinary approach between neuroimmunology and rheumatology is important for optimal care and treatment in such patients.Ludwig-Maximilians-Universit‚Äö√†√∂¬¨√üt M‚Äö√†√∂¬¨‚à´nchen, Marchioninistr.¬¨¬®‚Äö√Ñ‚Ä†15, 81377, M‚Äö√†√∂¬¨‚à´nchen, Deutschland.","[{'In': 'O'}, {'addition': 'O'}, {'some': 'O'}, {'drugs': 'O'}, {'used': 'O'}, {'in': 'O'}, {'rheumatic': 'B-Entity'}, {'disease': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'anti-tumor': 'O'}, {'necrosis': 'I-Entity'}, {'factor': 'O'}, {'biologics': 'O'}, {'may': 'O'}, {'induce': 'O'}, {'inflammatory': 'B-Entity'}, {'disease': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'CNS': 'I-Entity'}, {'and': 'O'}, {'should': 'O'}, {'be': 'O'}, {'avoided': 'O'}, {'in': 'O'}, {'MS.': 'I-Entity'}, {'An': 'O'}, {'interdisciplinary': 'O'}, {'approach': 'O'}, {'between': 'O'}, {'neuroimmunology': 'O'}, {'and': 'O'}, {'rheumatology': 'O'}, {'is': 'O'}, {'important': 'O'}, {'for': 'O'}, {'optimal': 'O'}, {'care': 'O'}, {'and': 'O'}, {'treatment': 'O'}, {'in': 'O'}, {'such': 'O'}, {'patients.Ludwig-Maximilians-Universit‚Äö√†√∂¬¨√üt': 'O'}]"
The main problems involve tear film disturbances leading to severe forms of dry eye.,"[{'The': 'O'}, {'main': 'O'}, {'problems': 'O'}, {'involve': 'O'}, {'tear': 'B-Entity'}, {'film': 'I-Entity'}, {'disturbances': 'I-Entity'}, {'leading': 'O'}, {'to': 'O'}, {'severe': 'O'}, {'forms': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye.': 'I-Entity'}]"
"This pilot study showed that LDS improved symptoms, ocular staining, and meibomian gland function for the group that received LDS.","[{'This': 'O'}, {'pilot': 'O'}, {'study': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'LDS': 'I-Entity'}, {'improved': 'O'}, {'symptoms,': 'O'}, {'ocular': 'B-Entity'}, {'staining,': 'I-Entity'}, {'and': 'O'}, {'meibomian': 'O'}, {'gland': 'O'}, {'function': 'O'}, {'for': 'O'}, {'the': 'O'}, {'group': 'O'}, {'that': 'O'}, {'received': 'O'}, {'LDS.': 'I-Entity'}]"
"Sjogrens syndrome, epithelial cysts, lymphoepithelial lesions, and marked plasmacytic differentiation.","[{'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'epithelial': 'B-Entity'}, {'cysts,': 'I-Entity'}, {'lymphoepithelial': 'B-Entity'}, {'lesions,': 'I-Entity'}, {'and': 'O'}, {'marked': 'O'}, {'plasmacytic': 'O'}, {'differentiation.': 'O'}]"
"To evaluate the efficacy of a thermo-sensitive punctum plug, (SmartPlug‚Äö√Ñ√∂‚àö√´¬¨¬¢) in Primary Sjogren's Syndrome (pSS) patients with dry eyes, whose symptoms persist despite preservative-free artificial tear treatment.","[{'To': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'a': 'O'}, {'thermo-sensitive': 'O'}, {'punctum': 'O'}, {'plug,': 'O'}, {'(SmartPlug‚Äö√Ñ√∂‚àö√´¬¨¬¢)': 'O'}, {'in': 'O'}, {'Primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'eyes,': 'I-Entity'}, {'whose': 'O'}, {'symptoms': 'O'}, {'persist': 'O'}, {'despite': 'O'}, {'preservative-free': 'O'}]"
"The main considerations in the interdisciplinary care of patients with Sjogrens disease are measures to improve quality of life, pharmacological and non-pharmacological treatments to keep disease activity in check, and management of the risk of lymphoma.","[{'The': 'O'}, {'main': 'O'}, {'considerations': 'O'}, {'in': 'O'}, {'the': 'O'}, {'interdisciplinary': 'O'}, {'care': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'disease': 'I-Entity'}, {'are': 'O'}, {'measures': 'O'}, {'to': 'O'}, {'improve': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life,': 'O'}, {'pharmacological': 'O'}, {'and': 'O'}, {'non-pharmacological': 'O'}, {'treatments': 'O'}, {'to': 'O'}, {'keep': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'check,': 'O'}, {'and': 'O'}, {'management': 'O'}, {'of': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'lymphoma.': 'I-Entity'}]"
"Due to a lack of awareness and/or the lack of specific biomarkers, clinicians may not associate psychiatric symptoms with autoimmune disease, including primary Sjogren's syndrome.","[{'Due': 'O'}, {'to': 'O'}, {'a': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'awareness': 'O'}, {'and/or': 'O'}, {'the': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'specific': 'O'}, {'biomarkers,': 'O'}, {'clinicians': 'O'}, {'may': 'O'}, {'not': 'O'}, {'associate': 'O'}, {'psychiatric': 'I-Entity'}, {'symptoms': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'disease,': 'I-Entity'}, {'including': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
We recently reported that SS promotes dry skin when complicated with AD possibly due to acceleration of hypoidrosis.,"[{'We': 'O'}, {'recently': 'O'}, {'reported': 'O'}, {'that': 'O'}, {'SS': 'I-Entity'}, {'promotes': 'O'}, {'dry': 'B-Entity'}, {'skin': 'I-Entity'}, {'when': 'O'}, {'complicated': 'O'}, {'with': 'O'}, {'AD': 'I-Entity'}, {'possibly': 'O'}, {'due': 'O'}, {'to': 'O'}, {'acceleration': 'O'}, {'of': 'O'}, {'hypoidrosis.': 'I-Entity'}]"
"To precisely diagnose radiotherapy-induced dry mouth, further improvement to the method is needed.University of Tokyo, Tokyo, Japan; Department of Artificial Organs and Otolaryngology, National Institute of Sensory Organs, Tokyo, Japan.Association of Oral Pathologists and the American Academy of Oral Pathologysensory neuronopathies: Diagnostic assessment, indications of treatment response, and impact of autoimmunity: A case report.","[{'To': 'O'}, {'precisely': 'O'}, {'diagnose': 'O'}, {'radiotherapy-induced': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'further': 'O'}, {'improvement': 'O'}, {'to': 'O'}, {'the': 'O'}, {'method': 'O'}, {'is': 'O'}, {'needed.University': 'O'}, {'of': 'O'}, {'Tokyo,': 'O'}, {'Tokyo,': 'O'}, {'Japan;': 'O'}, {'Department': 'O'}, {'of': 'O'}, {'Artificial': 'O'}, {'Organs': 'O'}, {'and': 'O'}, {'Otolaryngology,': 'O'}, {'National': 'O'}, {'Institute': 'O'}, {'of': 'O'}, {'Sensory': 'O'}, {'Organs,': 'O'}, {'Tokyo,': 'O'}, {'Japan.Association': 'O'}, {'of': 'O'}, {'Oral': 'O'}, {'Pathologists': 'O'}]"
The result clearly indicates that there was a unique difference between BAFF and IL14 in association with autoantibodies.,"[{'The': 'O'}, {'result': 'O'}, {'clearly': 'O'}, {'indicates': 'O'}, {'that': 'O'}, {'there': 'O'}, {'was': 'O'}, {'a': 'O'}, {'unique': 'O'}, {'difference': 'O'}, {'between': 'O'}, {'BAFF': 'O'}, {'and': 'O'}, {'IL14': 'O'}, {'in': 'O'}, {'association': 'O'}, {'with': 'O'}, {'autoantibodies.': 'O'}]"
A quantitative sweating test showed impaired sweating of both lesional and non-lesional skin due to underlying hypohidrosis that was related to AD and SS.,"[{'A': 'O'}, {'quantitative': 'O'}, {'sweating': 'O'}, {'test': 'O'}, {'showed': 'O'}, {'impaired': 'B-Entity'}, {'sweating': 'I-Entity'}, {'of': 'O'}, {'both': 'O'}, {'lesional': 'O'}, {'and': 'O'}, {'non-lesional': 'O'}, {'skin': 'O'}, {'due': 'O'}, {'to': 'O'}, {'underlying': 'O'}, {'hypohidrosis': 'I-Entity'}, {'that': 'O'}, {'was': 'O'}, {'related': 'O'}, {'to': 'O'}, {'AD': 'I-Entity'}, {'and': 'O'}, {'SS.': 'I-Entity'}]"
"As a result, low E values appeared in systemic sclerosis, mixed connective tissue disease, Sjogrens syndrome, and polymyositis/dermatomyositis.","[{'As': 'O'}, {'a': 'O'}, {'result,': 'O'}, {'low': 'O'}, {'E': 'O'}, {'values': 'O'}, {'appeared': 'O'}, {'in': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis,': 'I-Entity'}, {'mixed': 'B-Entity'}, {'connective': 'I-Entity'}, {'tissue': 'I-Entity'}, {'disease,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'polymyositis/dermatomyositis.': 'I-Entity'}]"
The organism did grow when the urine was cultured overnight on blood agar under anaerobic conditions.,"[{'The': 'O'}, {'organism': 'O'}, {'did': 'O'}, {'grow': 'O'}, {'when': 'O'}, {'the': 'O'}, {'urine': 'O'}, {'was': 'O'}, {'cultured': 'O'}, {'overnight': 'O'}, {'on': 'O'}, {'blood': 'O'}, {'agar': 'O'}, {'under': 'O'}, {'anaerobic': 'O'}, {'conditions.': 'O'}]"
Plasma cells producing these autoantibodies are mainly high affinity plasma cells originating from germinal centre reactions.,"[{'Plasma': 'O'}, {'cells': 'O'}, {'producing': 'O'}, {'these': 'O'}, {'autoantibodies': 'O'}, {'are': 'O'}, {'mainly': 'O'}, {'high': 'O'}, {'affinity': 'O'}, {'plasma': 'O'}, {'cells': 'O'}, {'originating': 'O'}, {'from': 'O'}, {'germinal': 'O'}, {'centre': 'O'}, {'reactions.': 'O'}]"
The most common complication was stromal melting that threatened anatomical success.,"[{'The': 'O'}, {'most': 'O'}, {'common': 'O'}, {'complication': 'O'}, {'was': 'O'}, {'stromal': 'O'}, {'melting': 'I-Entity'}, {'that': 'O'}, {'threatened': 'O'}, {'anatomical': 'O'}, {'success.': 'O'}]"
"In addition, anti-centromere antibodies have been associated with a clinical phenotype intermediate between primary SS and systemic sclerosis, while antibodies against carbonic anhydrase have been related to renal tubular acidosis.","[{'In': 'O'}, {'addition,': 'O'}, {'anti-centromere': 'O'}, {'antibodies': 'O'}, {'have': 'O'}, {'been': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'clinical': 'O'}, {'phenotype': 'O'}, {'intermediate': 'O'}, {'between': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis,': 'I-Entity'}, {'while': 'O'}, {'antibodies': 'O'}, {'against': 'O'}, {'carbonic': 'O'}, {'anhydrase': 'O'}, {'have': 'O'}, {'been': 'O'}, {'related': 'O'}, {'to': 'O'}, {'renal': 'O'}, {'tubular': 'I-Entity'}, {'acidosis.': 'I-Entity'}]"
"To provide an update on infections in systemic lupus erythematosus (SLE) and Sjogrens syndrome, particularly addressing their role as triggers of autoimmunity, their impact on mortality, the main microorganisms, the approaches to differential diagnosis with disease flares and recommendations for vaccination.","[{'To': 'O'}, {'provide': 'O'}, {'an': 'O'}, {'update': 'O'}, {'on': 'O'}, {'infections': 'I-Entity'}, {'in': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE)': 'O'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'particularly': 'O'}, {'addressing': 'O'}, {'their': 'O'}, {'role': 'O'}, {'as': 'O'}, {'triggers': 'O'}, {'of': 'O'}, {'autoimmunity,': 'I-Entity'}, {'their': 'O'}, {'impact': 'O'}, {'on': 'O'}, {'mortality,': 'O'}, {'the': 'O'}, {'main': 'O'}, {'microorganisms,': 'O'}, {'the': 'O'}, {'approaches': 'O'}, {'to': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'with': 'O'}, {'disease': 'O'}, {'flares': 'O'}, {'and': 'O'}]"
Sjogren syndrome is the prototypic disease associated with dryness of the eyes and mouth and predominantly affects women in their perimenopausal and postmenopausal years.,"[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'the': 'O'}, {'prototypic': 'O'}, {'disease': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'dryness': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'eyes': 'I-Entity'}, {'and': 'I-Entity'}, {'mouth': 'I-Entity'}, {'and': 'O'}, {'predominantly': 'O'}, {'affects': 'O'}, {'women': 'O'}, {'in': 'O'}, {'their': 'O'}, {'perimenopausal': 'O'}, {'and': 'O'}, {'postmenopausal': 'O'}, {'years.': 'O'}]"
Sjogren syndrome is the prototypical disease associated with dryness of the eyes and mouth and predominantly affects women in their perimenopausal and postmenopausal years.,"[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'the': 'O'}, {'prototypical': 'O'}, {'disease': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'dryness': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'eyes': 'I-Entity'}, {'and': 'I-Entity'}, {'mouth': 'I-Entity'}, {'and': 'O'}, {'predominantly': 'O'}, {'affects': 'O'}, {'women': 'O'}, {'in': 'O'}, {'their': 'O'}, {'perimenopausal': 'O'}, {'and': 'O'}, {'postmenopausal': 'O'}, {'years.': 'O'}]"
Close monitoring for high risk pregnancies can help to diagnose first and second degrees heart block and treatments can be offered when the block is still reversible.,"[{'Close': 'O'}, {'monitoring': 'O'}, {'for': 'O'}, {'high': 'O'}, {'risk': 'O'}, {'pregnancies': 'O'}, {'can': 'O'}, {'help': 'O'}, {'to': 'O'}, {'diagnose': 'O'}, {'first': 'O'}, {'and': 'O'}, {'second': 'O'}, {'degrees': 'O'}, {'heart': 'B-Entity'}, {'block': 'I-Entity'}, {'and': 'O'}, {'treatments': 'O'}, {'can': 'O'}, {'be': 'O'}, {'offered': 'O'}, {'when': 'O'}, {'the': 'O'}, {'block': 'I-Entity'}, {'is': 'O'}, {'still': 'O'}, {'reversible.': 'O'}]"
Thyroid disease was diagnosed on the basis of the results of the visual assessment of tracer uptake in the thyroid gland on SGS images as well as serological thyroid function tests.,"[{'Thyroid': 'B-Entity'}, {'disease': 'I-Entity'}, {'was': 'O'}, {'diagnosed': 'O'}, {'on': 'O'}, {'the': 'O'}, {'basis': 'O'}, {'of': 'O'}, {'the': 'O'}, {'results': 'O'}, {'of': 'O'}, {'the': 'O'}, {'visual': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'tracer': 'O'}, {'uptake': 'O'}, {'in': 'O'}, {'the': 'O'}, {'thyroid': 'O'}, {'gland': 'O'}, {'on': 'O'}, {'SGS': 'O'}, {'images': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'serological': 'O'}, {'thyroid': 'O'}, {'function': 'O'}, {'tests.': 'O'}]"
"Although survival has improved, a majority suffers from one or more symptom complexes associated with PBC.","[{'Although': 'O'}, {'survival': 'O'}, {'has': 'O'}, {'improved,': 'O'}, {'a': 'O'}, {'majority': 'O'}, {'suffers': 'O'}, {'from': 'O'}, {'one': 'O'}, {'or': 'O'}, {'more': 'O'}, {'symptom': 'O'}, {'complexes': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'PBC.': 'I-Entity'}]"
"Sjogren's syndrome (SS) is a chronic autoimmune¬¨¬®‚Äö√Ñ‚Ä†disorder that causes the inflammation of the lacrimal and salivary glands, resulting in dryness of the eyes and mouth.","[{""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'autoimmune¬¨¬®‚Äö√Ñ‚Ä†disorder': 'I-Entity'}, {'that': 'O'}, {'causes': 'O'}, {'the': 'O'}, {'inflammation': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}, {'and': 'I-Entity'}, {'salivary': 'I-Entity'}, {'glands,': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'dryness': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'eyes': 'I-Entity'}, {'and': 'I-Entity'}, {'mouth.': 'I-Entity'}]"
"Therefore, pSS patients with anemia may be associated with destruction of peripheral mature blood cells, impaired red cells production, and hematopoietic abnormalities due to an immune mechanism, although the concrete pathogenesis is still unclear.Medical College, Nanchong, China.","[{'Therefore,': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'anemia': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'destruction': 'O'}, {'of': 'O'}, {'peripheral': 'O'}, {'mature': 'O'}, {'blood': 'O'}, {'cells,': 'O'}, {'impaired': 'O'}, {'red': 'O'}, {'cells': 'O'}, {'production,': 'O'}, {'and': 'O'}, {'hematopoietic': 'B-Entity'}, {'abnormalities': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'an': 'O'}, {'immune': 'O'}, {'mechanism,': 'O'}, {'although': 'O'}, {'the': 'O'}, {'concrete': 'O'}, {'pathogenesis': 'O'}, {'is': 'O'}, {'still': 'O'}, {'unclear.Medical': 'O'}, {'College,': 'O'}, {'Nanchong,': 'O'}, {'China.': 'O'}]"
"A combination therapy comprising steroid pulse therapy and plasmapheresis improved her clinical symptoms, and the administration of oral prednisolone (20 mg/ day) was effective in preventing the recurrence of NMO.","[{'A': 'O'}, {'combination': 'O'}, {'therapy': 'O'}, {'comprising': 'O'}, {'steroid': 'I-Entity'}, {'pulse': 'O'}, {'therapy': 'O'}, {'and': 'O'}, {'plasmapheresis': 'O'}, {'improved': 'O'}, {'her': 'O'}, {'clinical': 'O'}, {'symptoms,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'administration': 'O'}, {'of': 'O'}, {'oral': 'O'}, {'prednisolone': 'I-Entity'}, {'(20': 'O'}, {'mg/': 'O'}, {'day)': 'O'}, {'was': 'O'}, {'effective': 'O'}, {'in': 'O'}, {'preventing': 'O'}, {'the': 'O'}, {'recurrence': 'O'}, {'of': 'O'}, {'NMO.': 'I-Entity'}]"
Circulating CD4+CD161+ T cell populations associated with pSS disease activity and severity.,"[{'Circulating': 'O'}, {'CD4+CD161+': 'O'}, {'T': 'O'}, {'cell': 'O'}, {'populations': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'severity.': 'O'}]"
My long scientific journey studying as a disease model Sjogren's syndrome (SS) gave me the opportunity to uncover the mysteries of systemic autoimmune diseases.,"[{'My': 'O'}, {'long': 'O'}, {'scientific': 'O'}, {'journey': 'O'}, {'studying': 'O'}, {'as': 'O'}, {'a': 'O'}, {'disease': 'O'}, {'model': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'gave': 'O'}, {'me': 'O'}, {'the': 'O'}, {'opportunity': 'O'}, {'to': 'O'}, {'uncover': 'O'}, {'the': 'O'}, {'mysteries': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"This is the first study demonstrating not only the presence of disturbed sleep, but also that nightly musculoskeletal pain and other sleep disturbing factors and anxiety significantly influence fatigue.","[{'This': 'O'}, {'is': 'O'}, {'the': 'O'}, {'first': 'O'}, {'study': 'O'}, {'demonstrating': 'O'}, {'not': 'O'}, {'only': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'disturbed': 'O'}, {'sleep,': 'I-Entity'}, {'but': 'O'}, {'also': 'O'}, {'that': 'O'}, {'nightly': 'O'}, {'musculoskeletal': 'B-Entity'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'other': 'O'}, {'sleep': 'O'}, {'disturbing': 'O'}, {'factors': 'O'}, {'and': 'O'}, {'anxiety': 'I-Entity'}, {'significantly': 'O'}, {'influence': 'O'}, {'fatigue.': 'I-Entity'}]"
"The dry eye group without SPK showed minor visual deterioration compared with normal eyes, as detected only by VMR (P < 0.05).","[{'The': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'group': 'O'}, {'without': 'O'}, {'SPK': 'O'}, {'showed': 'O'}, {'minor': 'O'}, {'visual': 'B-Entity'}, {'deterioration': 'I-Entity'}, {'compared': 'O'}, {'with': 'O'}, {'normal': 'O'}, {'eyes,': 'O'}, {'as': 'O'}, {'detected': 'O'}, {'only': 'O'}, {'by': 'O'}, {'VMR': 'O'}, {'(P': 'O'}, {'<': 'O'}, {'0.05).': 'O'}]"
"such as nausea, vomiting, abdominal pain and early satiety.","[{'such': 'O'}, {'as': 'O'}, {'nausea,': 'I-Entity'}, {'vomiting,': 'I-Entity'}, {'abdominal': 'B-Entity'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'early': 'O'}, {'satiety.': 'O'}]"
"Recently, several studies reported both malignant lymphoma developed on the background of IgG4-associated conditions and IgG4-producing malignant lymphoma (non-IgG4-related disease).","[{'Recently,': 'O'}, {'several': 'O'}, {'studies': 'O'}, {'reported': 'O'}, {'both': 'O'}, {'malignant': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'developed': 'O'}, {'on': 'O'}, {'the': 'O'}, {'background': 'O'}, {'of': 'O'}, {'IgG4-associated': 'O'}, {'conditions': 'O'}, {'and': 'O'}, {'IgG4-producing': 'O'}, {'malignant': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'(non-IgG4-related': 'O'}, {'disease).': 'O'}]"
Sjogrens syndrome (SS) may be complicated by neurological manifestations.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'may': 'O'}, {'be': 'O'}, {'complicated': 'O'}, {'by': 'O'}, {'neurological': 'O'}, {'manifestations.': 'O'}]"
We identified 25 patients.,"[{'We': 'O'}, {'identified': 'O'}, {'25': 'O'}, {'patients.': 'O'}]"
Lung involvement is an increasing cause of morbidity and mortality in the connective tissue diseases.,"[{'Lung': 'O'}, {'involvement': 'O'}, {'is': 'O'}, {'an': 'O'}, {'increasing': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'morbidity': 'O'}, {'and': 'O'}, {'mortality': 'O'}, {'in': 'O'}, {'the': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases.': 'I-Entity'}]"
CSLM pachymetric data and the superficial epithelium cell density were significantly lower in pSS versus no-SS dry eye (p < 0.0001); keratocyte activation and sub-basal nerve abnormalities were also more frequent in pSS patients (p < 0.0001).,"[{'CSLM': 'O'}, {'pachymetric': 'O'}, {'data': 'O'}, {'and': 'O'}, {'the': 'O'}, {'superficial': 'O'}, {'epithelium': 'O'}, {'cell': 'O'}, {'density': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'lower': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'versus': 'O'}, {'no-SS': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'(p': 'O'}, {'<': 'O'}, {'0.0001);': 'O'}, {'keratocyte': 'O'}, {'activation': 'O'}, {'and': 'O'}, {'sub-basal': 'O'}, {'nerve': 'B-Entity'}, {'abnormalities': 'I-Entity'}, {'were': 'O'}, {'also': 'O'}, {'more': 'O'}, {'frequent': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'(p': 'O'}, {'<': 'O'}, {'0.0001).': 'O'}]"
"Neurological symptoms occur in approximately 20% of patients with Sjogrens syndrome, and may be the presenting manifestations of the disease.","[{'Neurological': 'O'}, {'symptoms': 'O'}, {'occur': 'O'}, {'in': 'O'}, {'approximately': 'O'}, {'20%': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'may': 'O'}, {'be': 'O'}, {'the': 'O'}, {'presenting': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
To evaluate the efficacy and safety of low-dose rituximab in the treatment of hematologic abnormalities in patients with connective tissue disease.,"[{'To': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'safety': 'O'}, {'of': 'O'}, {'low-dose': 'O'}, {'rituximab': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'hematologic': 'B-Entity'}, {'abnormalities': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease.': 'I-Entity'}]"
The patient was initially treated with methylprednisolone with no change in her neurological deficits.,"[{'The': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'initially': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'methylprednisolone': 'I-Entity'}, {'with': 'O'}, {'no': 'O'}, {'change': 'O'}, {'in': 'O'}, {'her': 'O'}, {'neurological': 'B-Entity'}, {'deficits.': 'I-Entity'}]"
"In addition, we identified a homozygous frameshift deletion in MS4A12 that may contribute to inflammatory bowel disease, further demonstrating usefulness of WES in dual molecular diagnoses.Sp.","[{'In': 'O'}, {'addition,': 'O'}, {'we': 'O'}, {'identified': 'O'}, {'a': 'O'}, {'homozygous': 'O'}, {'frameshift': 'O'}, {'deletion': 'O'}, {'in': 'O'}, {'MS4A12': 'O'}, {'that': 'O'}, {'may': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'inflammatory': 'B-Entity'}, {'bowel': 'I-Entity'}, {'disease,': 'I-Entity'}, {'further': 'O'}, {'demonstrating': 'O'}, {'usefulness': 'O'}, {'of': 'O'}, {'WES': 'O'}, {'in': 'O'}, {'dual': 'O'}, {'molecular': 'O'}, {'diagnoses.Sp.': 'O'}]"
The main pregnancy complication associated to anti-Ro/SS-A antibodies is CHB.,"[{'The': 'O'}, {'main': 'O'}, {'pregnancy': 'O'}, {'complication': 'O'}, {'associated': 'O'}, {'to': 'O'}, {'anti-Ro/SS-A': 'O'}, {'antibodies': 'O'}, {'is': 'O'}, {'CHB.': 'I-Entity'}]"
"Main causes of DCLD include lymphangioleiomyomatosis, Birt-Hogg-Dub‚Äö√†√∂¬¨¬© syndrome, pulmonary Langerhans cell histiocytosis, lymphoid interstitial pneumonia, amyloidosis, light-chain deposition disease, Sjogren syndrome, and primary or metastatic neoplasm.","[{'Main': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'DCLD': 'I-Entity'}, {'include': 'O'}, {'lymphangioleiomyomatosis,': 'I-Entity'}, {'Birt-Hogg-Dub‚Äö√†√∂¬¨¬©': 'B-Entity'}, {'syndrome,': 'O'}, {'pulmonary': 'O'}, {'Langerhans': 'B-Entity'}, {'cell': 'I-Entity'}, {'histiocytosis,': 'I-Entity'}, {'lymphoid': 'B-Entity'}, {'interstitial': 'I-Entity'}, {'pneumonia,': 'I-Entity'}, {'amyloidosis,': 'I-Entity'}, {'light-chain': 'O'}]"
We aimed to investigate differences in cytokine and autoantibody levels with regard to patient characteristics in patients with primary Sjogrens syndrome (pSS) receiving oral steroids or antimalarial drugs (AM) after a longer period of time.,"[{'We': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'differences': 'O'}, {'in': 'O'}, {'cytokine': 'O'}, {'and': 'O'}, {'autoantibody': 'O'}, {'levels': 'O'}, {'with': 'O'}, {'regard': 'O'}, {'to': 'O'}, {'patient': 'O'}, {'characteristics': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'receiving': 'O'}, {'oral': 'O'}, {'steroids': 'I-Entity'}, {'or': 'O'}, {'antimalarial': 'O'}, {'drugs': 'O'}, {'(AM)': 'O'}, {'after': 'O'}, {'a': 'O'}, {'longer': 'O'}, {'period': 'O'}, {'of': 'O'}, {'time.': 'O'}]"
"The common initial symptom was non-mass lesions (65.5%), such as skin purpura, peripheral neuropathy; 13 patients (33.3% )were accompanied by autoimmune phenomenon, and most were with Sjogren's syndrome.","[{'The': 'O'}, {'common': 'O'}, {'initial': 'O'}, {'symptom': 'O'}, {'was': 'O'}, {'non-mass': 'O'}, {'lesions': 'O'}, {'(65.5%),': 'O'}, {'such': 'O'}, {'as': 'O'}, {'skin': 'O'}, {'purpura,': 'I-Entity'}, {'peripheral': 'B-Entity'}, {'neuropathy;': 'I-Entity'}, {'13': 'O'}, {'patients': 'O'}, {'(33.3%': 'O'}, {')were': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'autoimmune': 'B-Entity'}, {'phenomenon,': 'I-Entity'}, {'and': 'O'}, {'most': 'O'}, {'were': 'O'}, {'with': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
To investigate the association between dry eye syndrome (DE) and serum levels of interleukin (IL)-17 in patients with systemic immune-mediated diseases.,"[{'To': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'association': 'O'}, {'between': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(DE)': 'O'}, {'and': 'O'}, {'serum': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'interleukin': 'O'}, {'(IL)-17': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'systemic': 'O'}, {'immune-mediated': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"Pathological FDG uptake was observed in 75% of patients (24/32): lymph-nodes (n=19, 60%), salivary glands (n=17, 53%), lungs (n=9, 28%), and thyroid (n=2).","[{'Pathological': 'O'}, {'FDG': 'I-Entity'}, {'uptake': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'75%': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'(24/32):': 'O'}, {'lymph-nodes': 'O'}, {'(n=19,': 'O'}, {'60%),': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'(n=17,': 'O'}, {'53%),': 'O'}, {'lungs': 'O'}, {'(n=9,': 'O'}, {'28%),': 'O'}, {'and': 'O'}, {'thyroid': 'O'}, {'(n=2).': 'O'}]"
"Other therapeutic modalities such as external beam radiation has been shown to be promising; however, further data are still needed.","[{'Other': 'O'}, {'therapeutic': 'O'}, {'modalities': 'O'}, {'such': 'O'}, {'as': 'O'}, {'external': 'O'}, {'beam': 'O'}, {'radiation': 'O'}, {'has': 'O'}, {'been': 'O'}, {'shown': 'O'}, {'to': 'O'}, {'be': 'O'}, {'promising;': 'O'}, {'however,': 'O'}, {'further': 'O'}, {'data': 'O'}, {'are': 'O'}, {'still': 'O'}, {'needed.': 'O'}]"
The results confirm high levels of ocular lubricant use in the BSSA population.,"[{'The': 'O'}, {'results': 'O'}, {'confirm': 'O'}, {'high': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'ocular': 'O'}, {'lubricant': 'O'}, {'use': 'O'}, {'in': 'O'}, {'the': 'O'}, {'BSSA': 'O'}, {'population.': 'O'}]"
Biologic agents are targeted immune modulating agents that have been widely used in the treatment of inflammatory and neoplastic conditions with favorable results.,"[{'Biologic': 'O'}, {'agents': 'O'}, {'are': 'O'}, {'targeted': 'O'}, {'immune': 'O'}, {'modulating': 'O'}, {'agents': 'O'}, {'that': 'O'}, {'have': 'O'}, {'been': 'O'}, {'widely': 'O'}, {'used': 'O'}, {'in': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'inflammatory': 'O'}, {'and': 'O'}, {'neoplastic': 'I-Entity'}, {'conditions': 'O'}, {'with': 'O'}, {'favorable': 'O'}, {'results.': 'O'}]"
The results show that the ultrasound had a positive predictive value of 85% and a striking negative predicative value of 96% of the histology results.,"[{'The': 'O'}, {'results': 'O'}, {'show': 'O'}, {'that': 'O'}, {'the': 'O'}, {'ultrasound': 'O'}, {'had': 'O'}, {'a': 'O'}, {'positive': 'O'}, {'predictive': 'O'}, {'value': 'O'}, {'of': 'O'}, {'85%': 'O'}, {'and': 'O'}, {'a': 'O'}, {'striking': 'O'}, {'negative': 'O'}, {'predicative': 'O'}, {'value': 'O'}, {'of': 'O'}, {'96%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'histology': 'O'}, {'results.': 'O'}]"
"Male/female ratio was 2/6, the median age was 64 years (range 37-67 years).","[{'Male/female': 'O'}, {'ratio': 'O'}, {'was': 'O'}, {'2/6,': 'O'}, {'the': 'O'}, {'median': 'O'}, {'age': 'O'}, {'was': 'O'}, {'64': 'O'}, {'years': 'O'}, {'(range': 'O'}, {'37-67': 'O'}, {'years).': 'O'}]"
"Despite failing to demonstrate efficacy in clinical trials, because of the well-established role of B-lymphocytes in the pathogenesis of pSS, rituximab has been the most frequently used to date, but with much less success than in the treatment of patients with rheumatoid arthritis, vasculitis and lupus.","[{'Despite': 'O'}, {'failing': 'O'}, {'to': 'O'}, {'demonstrate': 'O'}, {'efficacy': 'O'}, {'in': 'O'}, {'clinical': 'O'}, {'trials,': 'O'}, {'because': 'O'}, {'of': 'O'}, {'the': 'O'}, {'well-established': 'O'}, {'role': 'O'}, {'of': 'O'}, {'B-lymphocytes': 'O'}, {'in': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'pSS,': 'I-Entity'}, {'rituximab': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'the': 'O'}, {'most': 'O'}, {'frequently': 'O'}, {'used': 'O'}, {'to': 'O'}, {'date,': 'O'}, {'but': 'O'}, {'with': 'O'}, {'much': 'O'}, {'less': 'O'}, {'success': 'O'}, {'than': 'O'}, {'in': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'rheumatoid': 'B-Entity'}]"
"Primary Sjogrens syndrome often includes dry eye manifestations, including a reduction in optical quality from the compromised ocular surface.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'often': 'O'}, {'includes': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'manifestations,': 'O'}, {'including': 'O'}, {'a': 'O'}, {'reduction': 'B-Entity'}, {'in': 'I-Entity'}, {'optical': 'O'}, {'quality': 'O'}, {'from': 'O'}, {'the': 'O'}, {'compromised': 'O'}, {'ocular': 'O'}, {'surface.': 'O'}]"
"As compared with NMOSD-non SS patients, NMOSD-SS patients had worse visual impairment (percentage of patients with visual acuity less than 0.1, 83.9% vs 69.8%, P<0.05), higher positive rate of SSA (92.9% vs 0.0%, P<0.05), higher proportion of dryness of mouth and eye (66.1% vs 5.2%, P<0.05) as well as higher percentage of reduced visual evoked potential (VEP) amplitude (60.7% vs 43.1%, P<0.05).","[{'As': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'NMOSD-non': 'I-Entity'}, {'SS': 'I-Entity'}, {'patients,': 'O'}, {'NMOSD-SS': 'I-Entity'}, {'patients': 'O'}, {'had': 'O'}, {'worse': 'O'}, {'visual': 'B-Entity'}, {'impairment': 'I-Entity'}, {'(percentage': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'visual': 'O'}, {'acuity': 'O'}, {'less': 'O'}, {'than': 'O'}, {'0.1,': 'O'}, {'83.9%': 'O'}, {'vs': 'O'}, {'69.8%,': 'O'}, {'P<0.05),': 'O'}, {'higher': 'O'}, {'positive': 'O'}, {'rate': 'O'}, {'of': 'O'}, {'SSA': 'I-Entity'}, {'(92.9%': 'O'}]"
We report a first case of severe autoimmune hemolytic anemia caused by warm reactive IgM antibodies in primary Sjogrens syndrome.from Sjogrens syndrome: a Caucasian patient and literature review.,"[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'first': 'O'}, {'case': 'O'}, {'of': 'O'}, {'severe': 'O'}, {'autoimmune': 'B-Entity'}, {'hemolytic': 'I-Entity'}, {'anemia': 'I-Entity'}, {'caused': 'O'}, {'by': 'O'}, {'warm': 'O'}, {'reactive': 'O'}, {'IgM': 'O'}, {'antibodies': 'O'}, {'in': 'O'}, {'primary': 'O'}, {'Sjogrens': 'I-Entity'}, {'syndrome.from': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome:': 'I-Entity'}, {'a': 'O'}, {'Caucasian': 'O'}, {'patient': 'O'}, {'and': 'O'}, {'literature': 'O'}, {'review.': 'O'}]"
To investigate the mechanism underlying the changes in the cardiac function in rat models of Sjogren's syndrome (SS) based on Kelch-like ECH-associated protein 1 (Keap1)-Nrf2/ARE signaling pathways.,"[{'To': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'mechanism': 'O'}, {'underlying': 'O'}, {'the': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'the': 'O'}, {'cardiac': 'O'}, {'function': 'O'}, {'in': 'O'}, {'rat': 'O'}, {'models': 'O'}, {'of': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'based': 'O'}, {'on': 'O'}, {'Kelch-like': 'O'}, {'ECH-associated': 'O'}, {'protein': 'O'}, {'1': 'O'}, {'(Keap1)-Nrf2/ARE': 'O'}, {'signaling': 'O'}, {'pathways.': 'O'}]"
Renal involvement in the form of glomerulonephritis in Sjogrens syndrome (SS) is less common and usually a latent sequel in the course of the disease.,"[{'Renal': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {'the': 'O'}, {'form': 'O'}, {'of': 'O'}, {'glomerulonephritis': 'I-Entity'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'less': 'O'}, {'common': 'O'}, {'and': 'O'}, {'usually': 'O'}, {'a': 'O'}, {'latent': 'O'}, {'sequel': 'O'}, {'in': 'O'}, {'the': 'O'}, {'course': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
"Both of 2 cases were treated with steroids, intravenous immunoglobulin, and a diuretic.","[{'Both': 'O'}, {'of': 'O'}, {'2': 'O'}, {'cases': 'O'}, {'were': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'steroids,': 'I-Entity'}, {'intravenous': 'O'}, {'immunoglobulin,': 'O'}, {'and': 'O'}, {'a': 'O'}, {'diuretic.': 'O'}]"
Sjogrens syndrome (SS) is a chronic autoimmune disorder that is characterized by dysfunction and destruction of the exocrine glands.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'autoimmune': 'B-Entity'}, {'disorder': 'I-Entity'}, {'that': 'O'}, {'is': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'dysfunction': 'O'}, {'and': 'O'}, {'destruction': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands.': 'I-Entity'}]"
"Certain diseases, such as hypercoagulation disorders, autoimmune diseases, or drugs have been associated with the pathogenesis of mesenteric inflammatory venoocclusive disease.","[{'Certain': 'O'}, {'diseases,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'hypercoagulation': 'O'}, {'disorders,': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'or': 'O'}, {'drugs': 'O'}, {'have': 'O'}, {'been': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'mesenteric': 'O'}, {'inflammatory': 'B-Entity'}, {'venoocclusive': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"The postoperative reduction in the mean number of episodes of glandular swelling was 87% (95% CI: 77-93) and 75% (95% CI: 47%-88%) in the groups A and B, respectively.","[{'The': 'O'}, {'postoperative': 'O'}, {'reduction': 'O'}, {'in': 'O'}, {'the': 'O'}, {'mean': 'O'}, {'number': 'O'}, {'of': 'O'}, {'episodes': 'O'}, {'of': 'O'}, {'glandular': 'B-Entity'}, {'swelling': 'I-Entity'}, {'was': 'O'}, {'87%': 'O'}, {'(95%': 'O'}, {'CI:': 'O'}, {'77-93)': 'O'}, {'and': 'O'}, {'75%': 'O'}, {'(95%': 'O'}, {'CI:': 'O'}, {'47%-88%)': 'O'}, {'in': 'O'}, {'the': 'O'}, {'groups': 'O'}, {'A': 'O'}, {'and': 'O'}, {'B,': 'O'}, {'respectively.': 'O'}]"
Lung biopsy obtained by wedge resection showed granulomatous inflammation with extensive multinuclear giant cells involving the lung parenchyma and vascular structures.,"[{'Lung': 'O'}, {'biopsy': 'O'}, {'obtained': 'O'}, {'by': 'O'}, {'wedge': 'O'}, {'resection': 'O'}, {'showed': 'O'}, {'granulomatous': 'B-Entity'}, {'inflammation': 'I-Entity'}, {'with': 'O'}, {'extensive': 'O'}, {'multinuclear': 'O'}, {'giant': 'O'}, {'cells': 'O'}, {'involving': 'O'}, {'the': 'O'}, {'lung': 'O'}, {'parenchyma': 'O'}, {'and': 'O'}, {'vascular': 'O'}, {'structures.': 'O'}]"
It can also sometimes indicate health problems and as a result should be brought to the attention of a health care professional.,"[{'It': 'O'}, {'can': 'O'}, {'also': 'O'}, {'sometimes': 'O'}, {'indicate': 'O'}, {'health': 'O'}, {'problems': 'O'}, {'and': 'O'}, {'as': 'O'}, {'a': 'O'}, {'result': 'O'}, {'should': 'O'}, {'be': 'O'}, {'brought': 'O'}, {'to': 'O'}, {'the': 'O'}, {'attention': 'O'}, {'of': 'O'}, {'a': 'O'}, {'health': 'O'}, {'care': 'O'}, {'professional.': 'O'}]"
"Forty-six dry eye patients with SS (SS dry eye), 14 dry eye patients without SS (non-SS dry eye), and 25 controls were included.","[{'Forty-six': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'(SS': 'O'}, {'dry': 'B-Entity'}, {'eye),': 'I-Entity'}, {'14': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'patients': 'O'}, {'without': 'O'}, {'SS': 'I-Entity'}, {'(non-SS': 'O'}, {'dry': 'B-Entity'}, {'eye),': 'I-Entity'}, {'and': 'O'}, {'25': 'O'}, {'controls': 'O'}, {'were': 'O'}, {'included.': 'O'}]"
A total of 247 patients were evaluated; 76% presented with limited-stage disease.,"[{'A': 'O'}, {'total': 'O'}, {'of': 'O'}, {'247': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'evaluated;': 'O'}, {'76%': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'limited-stage': 'O'}, {'disease.': 'O'}]"
"Sjogrens syndrome (SS) is a chronic inflammatory autoimmune disease that can occur as a unique existence (primary Sjogrens syndrome) or merge with other systemic diseases like systemic lupus erythematosus (SLE), rheumatoid arthritis or systemic sclerosis (secondary Sjogrens syndrome).","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'inflammatory': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'can': 'O'}, {'occur': 'O'}, {'as': 'O'}, {'a': 'O'}, {'unique': 'O'}, {'existence': 'O'}, {'(primary': 'O'}, {'Sjogrens': 'I-Entity'}, {'syndrome)': 'I-Entity'}, {'or': 'O'}, {'merge': 'O'}, {'with': 'O'}, {'other': 'O'}, {'systemic': 'O'}, {'diseases': 'O'}, {'like': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE),': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'or': 'O'}]"
"Open-label studies suggest that Rituximab is well tolerated (although infusion-related reactions and serum sickness remain possible), induces a rapid depletion of B cells in the blood and salivary glands, and could improve early active pSS or pSS with active extra glandular involvement.","[{'Open-label': 'O'}, {'studies': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'Rituximab': 'I-Entity'}, {'is': 'O'}, {'well': 'O'}, {'tolerated': 'O'}, {'(although': 'O'}, {'infusion-related': 'O'}, {'reactions': 'O'}, {'and': 'O'}, {'serum': 'B-Entity'}, {'sickness': 'I-Entity'}, {'remain': 'O'}, {'possible),': 'O'}, {'induces': 'O'}, {'a': 'O'}, {'rapid': 'O'}, {'depletion': 'O'}, {'of': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'the': 'O'}, {'blood': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'glands,': 'O'}, {'and': 'O'}, {'could': 'O'}, {'improve': 'O'}, {'early': 'O'}, {'active': 'O'}, {'pSS': 'I-Entity'}, {'or': 'O'}, {'pSS': 'I-Entity'}, {'with': 'O'}, {'active': 'O'}, {'extra': 'O'}, {'glandular': 'O'}]"
"After taking supplements of potassium, phosphate, vitamin D, and sodium bicarbonate for 1¬¨¬®‚Äö√Ñ‚Ä†month, bone pain was alleviated and serological potassium and phosphorus were also back to normal.","[{'After': 'O'}, {'taking': 'O'}, {'supplements': 'O'}, {'of': 'O'}, {'potassium,': 'I-Entity'}, {'phosphate,': 'I-Entity'}, {'vitamin': 'B-Entity'}, {'D,': 'I-Entity'}, {'and': 'O'}, {'sodium': 'B-Entity'}, {'bicarbonate': 'I-Entity'}, {'for': 'O'}, {'1¬¨¬®‚Äö√Ñ‚Ä†month,': 'O'}, {'bone': 'B-Entity'}, {'pain': 'I-Entity'}, {'was': 'O'}, {'alleviated': 'O'}, {'and': 'O'}, {'serological': 'O'}, {'potassium': 'I-Entity'}, {'and': 'O'}, {'phosphorus': 'I-Entity'}, {'were': 'O'}, {'also': 'O'}, {'back': 'O'}, {'to': 'O'}, {'normal.': 'O'}]"
"11 patients were followed for a total of 6months following HDMTX-LR (one was lost to follow up after 1month); and clinical findings were documented at 1month, 3months, and 6months following HDMTX-LR therapy.","[{'11': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'followed': 'O'}, {'for': 'O'}, {'a': 'O'}, {'total': 'O'}, {'of': 'O'}, {'6months': 'O'}, {'following': 'O'}, {'HDMTX-LR': 'I-Entity'}, {'(one': 'O'}, {'was': 'O'}, {'lost': 'O'}, {'to': 'O'}, {'follow': 'O'}, {'up': 'O'}, {'after': 'O'}, {'1month);': 'O'}, {'and': 'O'}, {'clinical': 'O'}, {'findings': 'O'}, {'were': 'O'}, {'documented': 'O'}, {'at': 'O'}, {'1month,': 'O'}, {'3months,': 'O'}, {'and': 'O'}, {'6months': 'O'}, {'following': 'O'}, {'HDMTX-LR': 'I-Entity'}, {'therapy.': 'O'}]"
"This cross-sectional study evaluated renal tubular function of patients with pSS, by detecting proximal tubular injury (through measurements of urinary ‚âà√≠‚Äö√¢¬ß2 microglobulin and albumin), RTA 1 (through an acidification protocol using furosemide and fludrocortisone), and CD (through water deprivation test, WDT).","[{'This': 'O'}, {'cross-sectional': 'O'}, {'study': 'O'}, {'evaluated': 'O'}, {'renal': 'O'}, {'tubular': 'O'}, {'function': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS,': 'I-Entity'}, {'by': 'O'}, {'detecting': 'O'}, {'proximal': 'B-Entity'}, {'tubular': 'B-Entity'}, {'injury': 'I-Entity'}, {'(through': 'O'}, {'measurements': 'O'}, {'of': 'O'}, {'urinary': 'O'}, {'‚âà√≠‚Äö√¢¬ß2': 'O'}, {'microglobulin': 'O'}, {'and': 'O'}, {'albumin),': 'O'}, {'RTA': 'O'}, {'1': 'O'}, {'(through': 'O'}, {'an': 'O'}]"
"Although tendon pain is commonly reported in primary Sjogren syndrome (pSS), the underlying mechanism is unknown.","[{'Although': 'O'}, {'tendon': 'B-Entity'}, {'pain': 'I-Entity'}, {'is': 'O'}, {'commonly': 'O'}, {'reported': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS),': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'mechanism': 'O'}, {'is': 'O'}, {'unknown.': 'O'}]"
"The current study examined levels of the antioxidant enzymes peroxiredoxin 6 (PRDX6), catalase and superoxide dismutase (SOD), as well as PCNA, in NOD.B10.Sn-H2 mice, a model for primary SS, and determined the effect of EGCG on their expression.","[{'The': 'O'}, {'current': 'O'}, {'study': 'O'}, {'examined': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'the': 'O'}, {'antioxidant': 'O'}, {'enzymes': 'O'}, {'peroxiredoxin': 'O'}, {'6': 'O'}, {'(PRDX6),': 'O'}, {'catalase': 'O'}, {'and': 'O'}, {'superoxide': 'I-Entity'}, {'dismutase': 'O'}, {'(SOD),': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'PCNA,': 'O'}, {'in': 'O'}, {'NOD.B10.Sn-H2': 'O'}, {'mice,': 'O'}, {'a': 'O'}, {'model': 'O'}]"
"In this study, we examined whether Ro-peptide immunization produces a Sjogrens-like illness in other strains of mice.","[{'In': 'O'}, {'this': 'O'}, {'study,': 'O'}, {'we': 'O'}, {'examined': 'O'}, {'whether': 'O'}, {'Ro-peptide': 'I-Entity'}, {'immunization': 'O'}, {'produces': 'O'}, {'a': 'O'}, {'Sjogrens-like': 'B-Entity'}, {'illness': 'I-Entity'}, {'in': 'O'}, {'other': 'O'}, {'strains': 'O'}, {'of': 'O'}, {'mice.': 'O'}]"
Mild sicca symptoms were observed in 4/8 cases.,"[{'Mild': 'O'}, {'sicca': 'I-Entity'}, {'symptoms': 'O'}, {'were': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'4/8': 'O'}, {'cases.': 'O'}]"
A history of SjS should raise suspicion of a MALT lymphoma for the differential diagnosis of an anterior mediastinal mass.,"[{'A': 'O'}, {'history': 'O'}, {'of': 'O'}, {'SjS': 'I-Entity'}, {'should': 'O'}, {'raise': 'O'}, {'suspicion': 'O'}, {'of': 'O'}, {'a': 'O'}, {'MALT': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'for': 'O'}, {'the': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'an': 'O'}, {'anterior': 'O'}, {'mediastinal': 'O'}, {'mass.': 'I-Entity'}]"
Alopecia appears to be a significant sign in the course of LE and especially systemic LE.,"[{'Alopecia': 'I-Entity'}, {'appears': 'O'}, {'to': 'O'}, {'be': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'sign': 'O'}, {'in': 'O'}, {'the': 'O'}, {'course': 'O'}, {'of': 'O'}, {'LE': 'I-Entity'}, {'and': 'O'}, {'especially': 'O'}, {'systemic': 'O'}, {'LE.': 'I-Entity'}]"
The condition improved dramatically by stopping LEF and using topical lubricants.,"[{'The': 'O'}, {'condition': 'O'}, {'improved': 'O'}, {'dramatically': 'O'}, {'by': 'O'}, {'stopping': 'O'}, {'LEF': 'I-Entity'}, {'and': 'O'}, {'using': 'O'}, {'topical': 'O'}, {'lubricants.': 'O'}]"
Non-embryogenic adult tissues contain only small numbers of such stem cells and the derivation of such tissues can cause comorbidities.,"[{'Non-embryogenic': 'O'}, {'adult': 'O'}, {'tissues': 'O'}, {'contain': 'O'}, {'only': 'O'}, {'small': 'O'}, {'numbers': 'O'}, {'of': 'O'}, {'such': 'O'}, {'stem': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'the': 'O'}, {'derivation': 'O'}, {'of': 'O'}, {'such': 'O'}, {'tissues': 'O'}, {'can': 'O'}, {'cause': 'O'}, {'comorbidities.': 'O'}]"
"Clinicians should remember to consider MAC infection in patients with acid-fast-positive skin lesions, as the selection of appropriate antibiotic therapy is species specific.sivaramya.kollipara@ttuhsc.edu.Houston, TX, USA.Center, Houston, TX, USA Dermatological Association of Texas, Houston, TX, USA.6.","[{'Clinicians': 'O'}, {'should': 'O'}, {'remember': 'O'}, {'to': 'O'}, {'consider': 'O'}, {'MAC': 'B-Entity'}, {'infection': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'acid-fast-positive': 'O'}, {'skin': 'O'}, {'lesions,': 'O'}, {'as': 'O'}, {'the': 'O'}, {'selection': 'O'}, {'of': 'O'}, {'appropriate': 'O'}, {'antibiotic': 'O'}, {'therapy': 'O'}, {'is': 'O'}, {'species': 'O'}, {'specific.sivaramya.kollipara@ttuhsc.edu.Houston,': 'O'}, {'TX,': 'O'}, {'USA.Center,': 'O'}, {'Houston,': 'O'}, {'TX,': 'O'}, {'USA': 'O'}]"
"Interstitial lung disease is one of the most serious pulmonary complications, and the early diagnosis is essential to initiate a prompt therapy.","[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'is': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'most': 'O'}, {'serious': 'O'}, {'pulmonary': 'O'}, {'complications,': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'early': 'O'}, {'diagnosis': 'O'}, {'is': 'O'}, {'essential': 'O'}, {'to': 'O'}, {'initiate': 'O'}, {'a': 'O'}, {'prompt': 'O'}, {'therapy.': 'O'}]"
"Sjogrens syndrome (SS) is a rare condition characterized by structural damage and secretory dysfunction of the lacrimal and salivary glands that leads to dryness, particularly xerophthalmia (eyes) and xerostomia (mouth).","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'condition': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'structural': 'B-Entity'}, {'damage': 'O'}, {'and': 'O'}, {'secretory': 'O'}, {'dysfunction': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'that': 'O'}, {'leads': 'O'}, {'to': 'O'}, {'dryness,': 'I-Entity'}, {'particularly': 'O'}, {'xerophthalmia': 'I-Entity'}, {'(eyes)': 'O'}, {'and': 'O'}, {'xerostomia': 'I-Entity'}, {'(mouth).': 'O'}]"
"TAFRO syndrome is characterized by a constellation of symptoms: Thrombocytopenia, Anasarca, Fever, Reticulin fibrosis and Organomegaly.","[{'TAFRO': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'a': 'O'}, {'constellation': 'O'}, {'of': 'O'}, {'symptoms:': 'O'}, {'Thrombocytopenia,': 'I-Entity'}, {'Anasarca,': 'I-Entity'}, {'Fever,': 'I-Entity'}, {'Reticulin': 'B-Entity'}, {'fibrosis': 'I-Entity'}, {'and': 'O'}, {'Organomegaly.': 'I-Entity'}]"
"However, cerebellar degeneration and atrophy associated with PSS have been rarely reported.","[{'However,': 'O'}, {'cerebellar': 'B-Entity'}, {'degeneration': 'I-Entity'}, {'and': 'O'}, {'atrophy': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'PSS': 'I-Entity'}, {'have': 'O'}, {'been': 'O'}, {'rarely': 'O'}, {'reported.': 'O'}]"
"The peripheral nervous system is usually involved in the majority of systemic connective tissue diseases, particularly in systemic lupus erythematosus, Sjogrens syndrome, vasculitis and systemic sclerosis.","[{'The': 'O'}, {'peripheral': 'O'}, {'nervous': 'O'}, {'system': 'O'}, {'is': 'O'}, {'usually': 'O'}, {'involved': 'O'}, {'in': 'O'}, {'the': 'O'}, {'majority': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases,': 'I-Entity'}, {'particularly': 'O'}, {'in': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'vasculitis': 'I-Entity'}, {'and': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis.': 'I-Entity'}]"
Decreased parasympathetic activity was observed in 41.6% of pSS patients.,"[{'Decreased': 'O'}, {'parasympathetic': 'O'}, {'activity': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'41.6%': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
"Eight patients had positive (18)F-FDG PET results (intrathoracic (18)F-FDG uptake), including 4 patients with coexisting mucosa-associated lymphoid tissue lymphoma (maximal standardized uptake value [SUVmax] range, 3.1-6.7) and 1 patient with a pleural plasmacytoma (SUVmax, 7.2); the remaining 3 patients had amyloid only (SUVmax range, 2.1-3.2).","[{'Eight': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'positive': 'O'}, {'(18)F-FDG': 'O'}, {'PET': 'O'}, {'results': 'O'}, {'(intrathoracic': 'O'}, {'(18)F-FDG': 'O'}, {'uptake),': 'O'}, {'including': 'O'}, {'4': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'coexisting': 'O'}, {'mucosa-associated': 'O'}, {'lymphoid': 'B-Entity'}, {'tissue': 'I-Entity'}, {'lymphoma': 'I-Entity'}, {'(maximal': 'O'}, {'standardized': 'O'}, {'uptake': 'O'}, {'value': 'O'}, {'[SUVmax]': 'O'}]"
"Investigations revealed interstitial lung disease, inflammatory myopathy and an immunology profile consistent with PL-12 antisynthetase syndrome.","[{'Investigations': 'O'}, {'revealed': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease,': 'I-Entity'}, {'inflammatory': 'B-Entity'}, {'myopathy': 'I-Entity'}, {'and': 'O'}, {'an': 'O'}, {'immunology': 'O'}, {'profile': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'PL-12': 'O'}, {'antisynthetase': 'O'}, {'syndrome.': 'O'}]"
A diagnosis of distal renal tubular acidosis (RTA) was made.,"[{'A': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'distal': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'(RTA)': 'O'}, {'was': 'O'}, {'made.': 'O'}]"
"However, such studies evaluated small numbers of SS patients, often mixed with other inflammatory disorders.","[{'However,': 'O'}, {'such': 'O'}, {'studies': 'O'}, {'evaluated': 'O'}, {'small': 'O'}, {'numbers': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'patients,': 'O'}, {'often': 'O'}, {'mixed': 'O'}, {'with': 'O'}, {'other': 'O'}, {'inflammatory': 'B-Entity'}, {'disorders.': 'I-Entity'}]"
Connective tissue diseases can present with a wide spectrum of neurological symptoms.,"[{'Connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'can': 'O'}, {'present': 'O'}, {'with': 'O'}, {'a': 'O'}, {'wide': 'O'}, {'spectrum': 'O'}, {'of': 'O'}, {'neurological': 'O'}, {'symptoms.': 'O'}]"
Changes in contrast sensitivity in the Sjogrens syndrome group were measured over a 4-hour period after instillation of a variety of artificial tears.,"[{'Changes': 'O'}, {'in': 'O'}, {'contrast': 'O'}, {'sensitivity': 'O'}, {'in': 'O'}, {'the': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'group': 'O'}, {'were': 'O'}, {'measured': 'O'}, {'over': 'O'}, {'a': 'O'}, {'4-hour': 'O'}, {'period': 'O'}, {'after': 'O'}, {'instillation': 'O'}, {'of': 'O'}, {'a': 'O'}, {'variety': 'O'}, {'of': 'O'}, {'artificial': 'O'}, {'tears.': 'O'}]"
"At disease diagnosis, only the articular activity at baseline could predict the long-term outcome of pSS detected at last follow-up visit, being protective in terms of stable or improved disease activity, as measured by ESSDAI [OR 2.9 (1.6-5.4), p = 0.01].","[{'At': 'O'}, {'disease': 'O'}, {'diagnosis,': 'O'}, {'only': 'O'}, {'the': 'O'}, {'articular': 'O'}, {'activity': 'O'}, {'at': 'O'}, {'baseline': 'O'}, {'could': 'O'}, {'predict': 'O'}, {'the': 'O'}, {'long-term': 'O'}, {'outcome': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'detected': 'O'}, {'at': 'O'}, {'last': 'O'}, {'follow-up': 'O'}, {'visit,': 'O'}, {'being': 'O'}, {'protective': 'O'}, {'in': 'O'}, {'terms': 'O'}, {'of': 'O'}, {'stable': 'O'}, {'or': 'O'}, {'improved': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'as': 'O'}, {'measured': 'O'}, {'by': 'O'}, {'ESSDAI': 'O'}, {'[OR': 'O'}, {'2.9': 'O'}, {'(1.6-5.4),': 'O'}]"
MX1 levels have a considerable impact on the assessment of the disease activity in SjS.,"[{'MX1': 'O'}, {'levels': 'O'}, {'have': 'O'}, {'a': 'O'}, {'considerable': 'O'}, {'impact': 'O'}, {'on': 'O'}, {'the': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'SjS.': 'I-Entity'}]"
"Collectively, our results demonstrate dysregulation of MZB cells in TSP1(-/-) mice and highlight their role in the context of SS-related chronic ocular surface disease.USA.","[{'Collectively,': 'O'}, {'our': 'O'}, {'results': 'O'}, {'demonstrate': 'O'}, {'dysregulation': 'O'}, {'of': 'O'}, {'MZB': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'TSP1(-/-)': 'O'}, {'mice': 'O'}, {'and': 'O'}, {'highlight': 'O'}, {'their': 'O'}, {'role': 'O'}, {'in': 'O'}, {'the': 'O'}, {'context': 'O'}, {'of': 'O'}, {'SS-related': 'I-Entity'}, {'chronic': 'O'}, {'ocular': 'B-Entity'}, {'surface': 'I-Entity'}, {'disease.USA.': 'I-Entity'}]"
"The last vaccination in 2010 reduced the risk of influenza by 87%, but previous bacterial infections (bronchitis and pneumonia) increased influenza risk significantly.","[{'The': 'O'}, {'last': 'O'}, {'vaccination': 'O'}, {'in': 'O'}, {'2010': 'O'}, {'reduced': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'influenza': 'I-Entity'}, {'by': 'O'}, {'87%,': 'O'}, {'but': 'O'}, {'previous': 'O'}, {'bacterial': 'B-Entity'}, {'infections': 'I-Entity'}, {'(bronchitis': 'O'}, {'and': 'O'}, {'pneumonia)': 'I-Entity'}, {'increased': 'O'}, {'influenza': 'I-Entity'}, {'risk': 'O'}, {'significantly.': 'O'}]"
"Small fiber neuropathy, which affects the sensory A‚âà√≠¬¨‚Ä¢ and C¬¨¬®‚Äö√Ñ‚Ä†fibers, is now a major diagnostic and therapeutic challenge.","[{'Small': 'O'}, {'fiber': 'O'}, {'neuropathy,': 'I-Entity'}, {'which': 'O'}, {'affects': 'O'}, {'the': 'O'}, {'sensory': 'O'}, {'A‚âà√≠¬¨‚Ä¢': 'O'}, {'and': 'O'}, {'C¬¨¬®‚Äö√Ñ‚Ä†fibers,': 'O'}, {'is': 'O'}, {'now': 'O'}, {'a': 'O'}, {'major': 'O'}, {'diagnostic': 'O'}, {'and': 'O'}, {'therapeutic': 'O'}, {'challenge.': 'O'}]"
Botulinum toxin injection is recognized as an effective treatment option for primary hemifacial spasm.,"[{'Botulinum': 'B-Entity'}, {'toxin': 'I-Entity'}, {'injection': 'O'}, {'is': 'O'}, {'recognized': 'O'}, {'as': 'O'}, {'an': 'O'}, {'effective': 'O'}, {'treatment': 'O'}, {'option': 'O'}, {'for': 'O'}, {'primary': 'B-Entity'}, {'hemifacial': 'I-Entity'}, {'spasm.': 'I-Entity'}]"
Sjogrens syndrome is a frequent autoimmune disease and is associated with a lymphocytic infiltration of the lachrymal and salivary glands and with sicca symptoms.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'frequent': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'lachrymal': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'and': 'O'}, {'with': 'O'}, {'sicca': 'I-Entity'}, {'symptoms.': 'O'}]"
"PATIENTS AND In this study, 24 patients with SS-related dry eyes [12 in AS eye drop therapy and 12 in artificial tear (AT) therapy] and 24 healthy volunteers were recruited.","[{'PATIENTS': 'O'}, {'AND': 'O'}, {'In': 'O'}, {'this': 'O'}, {'study,': 'O'}, {'24': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS-related': 'I-Entity'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'[12': 'O'}, {'in': 'O'}, {'AS': 'O'}, {'eye': 'O'}, {'drop': 'O'}, {'therapy': 'O'}, {'and': 'O'}, {'12': 'O'}, {'in': 'O'}, {'artificial': 'O'}, {'tear': 'O'}, {'(AT)': 'O'}, {'therapy]': 'O'}, {'and': 'O'}, {'24': 'O'}, {'healthy': 'O'}, {'volunteers': 'O'}, {'were': 'O'}, {'recruited.': 'O'}]"
"Sjogren's syndrome (SS) is a systemic autoimmune disease that primarily affects the exocrine glands, resulting in dryness of the eyes and mouth due to lymphocytic infiltration of the salivary and lacrimal glands along with arthritis, kidney, liver, and lung involvement, chronic fatigue, musculoskeletal pain, vasculitis, and so on.","[{""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'primarily': 'O'}, {'affects': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'dryness': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'eyes': 'I-Entity'}, {'and': 'I-Entity'}, {'mouth': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands': 'O'}, {'along': 'O'}, {'with': 'O'}, {'arthritis,': 'I-Entity'}, {'kidney,': 'I-Entity'}]"
This great dependence on clinical judgment frequently leads to delayed diagnosis or misdiagnosis.,"[{'This': 'O'}, {'great': 'O'}, {'dependence': 'O'}, {'on': 'O'}, {'clinical': 'O'}, {'judgment': 'O'}, {'frequently': 'O'}, {'leads': 'O'}, {'to': 'O'}, {'delayed': 'O'}, {'diagnosis': 'O'}, {'or': 'O'}, {'misdiagnosis.': 'O'}]"
"RLS, depression and sicca symptoms contributed to fatigue in the univariate regression analysis only.","[{'RLS,': 'I-Entity'}, {'depression': 'I-Entity'}, {'and': 'O'}, {'sicca': 'B-Entity'}, {'symptoms': 'I-Entity'}, {'contributed': 'O'}, {'to': 'O'}, {'fatigue': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'univariate': 'O'}, {'regression': 'O'}, {'analysis': 'O'}, {'only.': 'O'}]"
"Conversion disorder (CD) is sometimes accompanied by motor and sensory impairments, such as muscle weakness, paralysis, sensory hypersensitivity, and sensory loss.","[{'Conversion': 'B-Entity'}, {'disorder': 'I-Entity'}, {'(CD)': 'O'}, {'is': 'O'}, {'sometimes': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'motor': 'B-Entity'}, {'and': 'I-Entity'}, {'sensory': 'I-Entity'}, {'impairments,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'muscle': 'B-Entity'}, {'weakness,': 'I-Entity'}, {'paralysis,': 'I-Entity'}, {'sensory': 'B-Entity'}, {'hypersensitivity,': 'I-Entity'}, {'and': 'O'}, {'sensory': 'B-Entity'}, {'loss.': 'I-Entity'}]"
"Pooled result demonstrated a significant increase in risk of having cardiovascular disease or cerebrovascular event in pSS patients compared with controls (OR=1.28; 95% CI: 0.11-1.46, p value<0.01, I2=68%).","[{'Pooled': 'O'}, {'result': 'O'}, {'demonstrated': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'having': 'O'}, {'cardiovascular': 'B-Entity'}, {'disease': 'I-Entity'}, {'or': 'O'}, {'cerebrovascular': 'B-Entity'}, {'event': 'I-Entity'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'controls': 'O'}, {'(OR=1.28;': 'O'}, {'95%': 'O'}, {'CI:': 'O'}, {'0.11-1.46,': 'O'}, {'p': 'O'}, {'value<0.01,': 'O'}, {'I2=68%).': 'O'}]"
The available conventional therapies have limited efficacy and there are no biologic therapies licensed for use in SS patients.,"[{'The': 'O'}, {'available': 'O'}, {'conventional': 'O'}, {'therapies': 'O'}, {'have': 'O'}, {'limited': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'there': 'O'}, {'are': 'O'}, {'no': 'O'}, {'biologic': 'O'}, {'therapies': 'O'}, {'licensed': 'O'}, {'for': 'O'}, {'use': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients.': 'O'}]"
The goal of this study is to determine whether any difference in corneal biomechanical properties exists between Sjogrens syndrome dry eye patients and healthy subjects.,"[{'The': 'O'}, {'goal': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'is': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'whether': 'O'}, {'any': 'O'}, {'difference': 'O'}, {'in': 'O'}, {'corneal': 'O'}, {'biomechanical': 'O'}, {'properties': 'O'}, {'exists': 'O'}, {'between': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'healthy': 'O'}, {'subjects.': 'O'}]"
Sicca complaints (sensation of dry mouth and/or eyes) are present in about a quarter of the individuals above the age of 65 years old and are mainly due to medication.,"[{'Sicca': 'O'}, {'complaints': 'O'}, {'(sensation': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'and/or': 'I-Entity'}, {'eyes)': 'I-Entity'}, {'are': 'O'}, {'present': 'O'}, {'in': 'O'}, {'about': 'O'}, {'a': 'O'}, {'quarter': 'O'}, {'of': 'O'}, {'the': 'O'}, {'individuals': 'O'}, {'above': 'O'}, {'the': 'O'}, {'age': 'O'}, {'of': 'O'}, {'65': 'O'}, {'years': 'O'}, {'old': 'O'}, {'and': 'O'}, {'are': 'O'}, {'mainly': 'O'}, {'due': 'O'}, {'to': 'O'}, {'medication.': 'O'}]"
"So although salivary gland swelling is often associated with autoimmune diseases such as Sjogren's syndrome and IgG4-related disease, the awareness and suspicion of a possibility of NHL are essential for rheumatologists.","[{'So': 'O'}, {'although': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'swelling': 'I-Entity'}, {'is': 'O'}, {'often': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'IgG4-related': 'O'}, {'disease,': 'I-Entity'}, {'the': 'O'}, {'awareness': 'O'}, {'and': 'O'}, {'suspicion': 'O'}, {'of': 'O'}, {'a': 'O'}, {'possibility': 'O'}, {'of': 'O'}, {'NHL': 'I-Entity'}, {'are': 'O'}, {'essential': 'O'}, {'for': 'O'}, {'rheumatologists.': 'O'}]"
"Vasculitis involved kidneys (n=13), lungs (n=8), skin (n=6), peripheral nerves (n=5), central nervous system (n=2), small bowel (n=1), muscle (n=1), ear chondritis (n=1) and sinuses (n=1).","[{'Vasculitis': 'I-Entity'}, {'involved': 'O'}, {'kidneys': 'O'}, {'(n=13),': 'O'}, {'lungs': 'O'}, {'(n=8),': 'O'}, {'skin': 'O'}, {'(n=6),': 'O'}, {'peripheral': 'O'}, {'nerves': 'O'}, {'(n=5),': 'O'}, {'central': 'O'}, {'nervous': 'O'}, {'system': 'O'}, {'(n=2),': 'O'}, {'small': 'O'}, {'bowel': 'O'}, {'(n=1),': 'O'}, {'muscle': 'O'}, {'(n=1),': 'O'}, {'ear': 'O'}]"
The objective patients are pSS-C cases who visited our hospital complaining joint pain and/or joint swelling and for whom MSUS was performed.,"[{'The': 'O'}, {'objective': 'O'}, {'patients': 'O'}, {'are': 'O'}, {'pSS-C': 'B-Entity'}, {'cases': 'O'}, {'who': 'O'}, {'visited': 'O'}, {'our': 'O'}, {'hospital': 'O'}, {'complaining': 'O'}, {'joint': 'B-Entity'}, {'pain': 'I-Entity'}, {'and/or': 'O'}, {'joint': 'B-Entity'}, {'swelling': 'I-Entity'}, {'and': 'O'}, {'for': 'O'}, {'whom': 'O'}, {'MSUS': 'O'}, {'was': 'O'}, {'performed.': 'O'}]"
Pooled result demonstrated a significant increase in PWV in patients who have PSS compared with controls (MD‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢1.30¬¨¬®‚Äö√Ñ‚Ä†m/s; 95% CI 0.48-2.12; p value‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.002; I(2)‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢85%).,"[{'Pooled': 'O'}, {'result': 'O'}, {'demonstrated': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'PWV': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'have': 'O'}, {'PSS': 'I-Entity'}, {'compared': 'O'}, {'with': 'O'}, {'controls': 'O'}, {'(MD‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢1.30¬¨¬®‚Äö√Ñ‚Ä†m/s;': 'O'}]"
Microsporidal keratitis can occur in patients with severe ocular surface disease due to SS and OCP.,"[{'Microsporidal': 'B-Entity'}, {'keratitis': 'I-Entity'}, {'can': 'O'}, {'occur': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'severe': 'O'}, {'ocular': 'B-Entity'}, {'surface': 'I-Entity'}, {'disease': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'OCP.': 'I-Entity'}]"
There is evidence that this drug may be effective for treating pSS.,"[{'There': 'O'}, {'is': 'O'}, {'evidence': 'O'}, {'that': 'O'}, {'this': 'O'}, {'drug': 'O'}, {'may': 'O'}, {'be': 'O'}, {'effective': 'O'}, {'for': 'O'}, {'treating': 'O'}, {'pSS.': 'I-Entity'}]"
"The purpose was to characterize the biomarkers associated with Sjogrens syndrome (SS) identified in the serological samples of patients with recalcitrant dry eye disease; additionally, the modalities utilized in the treatment of dry eye disease were evaluated for subsets of patients with and without SS.","[{'The': 'O'}, {'purpose': 'O'}, {'was': 'O'}, {'to': 'O'}, {'characterize': 'O'}, {'the': 'O'}, {'biomarkers': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'identified': 'O'}, {'in': 'O'}, {'the': 'O'}, {'serological': 'O'}, {'samples': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'recalcitrant': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease;': 'I-Entity'}, {'additionally,': 'O'}, {'the': 'O'}, {'modalities': 'O'}, {'utilized': 'O'}, {'in': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease': 'I-Entity'}, {'were': 'O'}, {'evaluated': 'O'}, {'for': 'O'}, {'subsets': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'and': 'O'}]"
"Muscular impairment is a rare systemic manifestation of SS that is rarely described in the literature and classically non-specific, both clinically and histologically.","[{'Muscular': 'B-Entity'}, {'impairment': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'systemic': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'that': 'O'}, {'is': 'O'}, {'rarely': 'O'}, {'described': 'O'}, {'in': 'O'}, {'the': 'O'}, {'literature': 'O'}, {'and': 'O'}, {'classically': 'O'}, {'non-specific,': 'O'}, {'both': 'O'}, {'clinically': 'O'}, {'and': 'O'}, {'histologically.': 'O'}]"
"Meanwhile, outcome parameters to monitor clinical improvement have been developed and a¬¨¬®‚Äö√Ñ‚Ä†large number of therapeutic studies are currently being performed.","[{'Meanwhile,': 'O'}, {'outcome': 'O'}, {'parameters': 'O'}, {'to': 'O'}, {'monitor': 'O'}, {'clinical': 'O'}, {'improvement': 'O'}, {'have': 'O'}, {'been': 'O'}, {'developed': 'O'}, {'and': 'O'}, {'a¬¨¬®‚Äö√Ñ‚Ä†large': 'O'}, {'number': 'O'}, {'of': 'O'}, {'therapeutic': 'O'}, {'studies': 'O'}, {'are': 'O'}, {'currently': 'O'}, {'being': 'O'}, {'performed.': 'O'}]"
This lead to the diagnosis of ganglionopathy associated to Sjogrens syndrome.,"[{'This': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'ganglionopathy': 'I-Entity'}, {'associated': 'O'}, {'to': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"Many factors can impair saliva secretion, such as adverse effects of prescribed medication, auto-immune diseases (for example Sjogrens syndrome) and radiotherapy for head and neck cancers.","[{'Many': 'O'}, {'factors': 'O'}, {'can': 'O'}, {'impair': 'O'}, {'saliva': 'O'}, {'secretion,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'adverse': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'prescribed': 'O'}, {'medication,': 'O'}, {'auto-immune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'(for': 'O'}, {'example': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome)': 'I-Entity'}, {'and': 'O'}, {'radiotherapy': 'O'}, {'for': 'O'}, {'head': 'B-Entity'}, {'and': 'I-Entity'}, {'neck': 'I-Entity'}, {'cancers.': 'I-Entity'}]"
Sjogren syndrome (SS) is a chronic autoimmune disease characterized by lymphocytic inflammation of exocrine glands and a variety of extraglandular sites.,"[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'lymphocytic': 'O'}, {'inflammation': 'I-Entity'}, {'of': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'and': 'O'}, {'a': 'O'}, {'variety': 'O'}, {'of': 'O'}, {'extraglandular': 'O'}, {'sites.': 'O'}]"
"Patients typically show early ataxia, loss of deep tendon reflexes and positive sensory symptoms present both in proximal and distal sites of the body.","[{'Patients': 'O'}, {'typically': 'O'}, {'show': 'O'}, {'early': 'O'}, {'ataxia,': 'I-Entity'}, {'loss': 'B-Entity'}, {'of': 'I-Entity'}, {'deep': 'I-Entity'}, {'tendon': 'I-Entity'}, {'reflexes': 'I-Entity'}, {'and': 'O'}, {'positive': 'O'}, {'sensory': 'O'}, {'symptoms': 'O'}, {'present': 'O'}, {'both': 'O'}, {'in': 'O'}, {'proximal': 'O'}, {'and': 'O'}, {'distal': 'O'}, {'sites': 'O'}, {'of': 'O'}, {'the': 'O'}, {'body.': 'O'}]"
"Tear clearance of patients in advanced-stage disease was delayed significantly, compared with the tear delay in patients in early stage of disease and that of normal individuals (P<0.001).","[{'Tear': 'O'}, {'clearance': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'in': 'O'}, {'advanced-stage': 'O'}, {'disease': 'O'}, {'was': 'O'}, {'delayed': 'O'}, {'significantly,': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'the': 'O'}, {'tear': 'O'}, {'delay': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'in': 'O'}, {'early': 'O'}, {'stage': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'and': 'O'}, {'that': 'O'}, {'of': 'O'}, {'normal': 'O'}, {'individuals': 'O'}, {'(P<0.001).': 'O'}]"
Increased awareness may avoid delay in diagnosis.,"[{'Increased': 'O'}, {'awareness': 'O'}, {'may': 'O'}, {'avoid': 'O'}, {'delay': 'O'}, {'in': 'O'}, {'diagnosis.': 'O'}]"
"Moreover, the fact that the expansion of this cell subset is prevalently observed in patients with inactive disease suggests that these cells may play a role in counteracting inflammatory response.degli Studi di Perugia, Italy.highlight real-world health care burden and lack of treatment options.","[{'Moreover,': 'O'}, {'the': 'O'}, {'fact': 'O'}, {'that': 'O'}, {'the': 'O'}, {'expansion': 'O'}, {'of': 'O'}, {'this': 'O'}, {'cell': 'O'}, {'subset': 'O'}, {'is': 'O'}, {'prevalently': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'inactive': 'O'}, {'disease': 'O'}, {'suggests': 'O'}, {'that': 'O'}, {'these': 'O'}, {'cells': 'O'}, {'may': 'O'}, {'play': 'O'}, {'a': 'O'}, {'role': 'O'}, {'in': 'O'}, {'counteracting': 'O'}, {'inflammatory': 'O'}, {'response.degli': 'O'}, {'Studi': 'O'}, {'di': 'O'}, {'Perugia,': 'O'}, {'Italy.highlight': 'O'}, {'real-world': 'O'}, {'health': 'O'}, {'care': 'O'}, {'burden': 'O'}, {'and': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'treatment': 'O'}, {'options.': 'O'}]"
"The most frequent adverse events were infections, with 24 episodes being described in 19 patients.","[{'The': 'O'}, {'most': 'O'}, {'frequent': 'O'}, {'adverse': 'O'}, {'events': 'O'}, {'were': 'O'}, {'infections,': 'I-Entity'}, {'with': 'O'}, {'24': 'O'}, {'episodes': 'O'}, {'being': 'O'}, {'described': 'O'}, {'in': 'O'}, {'19': 'O'}, {'patients.': 'O'}]"
"Preoperative diagnosis included Stevens-Johnson syndrome (n=7), ocular cicatricial pemphigoid (n=4) and Sjogren's syndrome (n=3).","[{'Preoperative': 'O'}, {'diagnosis': 'O'}, {'included': 'O'}, {'Stevens-Johnson': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(n=7),': 'O'}, {'ocular': 'B-Entity'}, {'cicatricial': 'I-Entity'}, {'pemphigoid': 'I-Entity'}, {'(n=4)': 'O'}, {'and': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(n=3).': 'O'}]"
Examples of oral diseases that affect primarily women are reviewed.,"[{'Examples': 'O'}, {'of': 'O'}, {'oral': 'B-Entity'}, {'diseases': 'I-Entity'}, {'that': 'O'}, {'affect': 'O'}, {'primarily': 'O'}, {'women': 'O'}, {'are': 'O'}, {'reviewed.': 'O'}]"
"Fifty-seven percent of patients were initially treated with local therapy with surgery, radiation, or both; 37 of patients were treated with systemic therapy initially, with 47% of those receiving rituximab; and 6% of patients were observed.","[{'Fifty-seven': 'O'}, {'percent': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'initially': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'local': 'O'}, {'therapy': 'O'}, {'with': 'O'}, {'surgery,': 'O'}, {'radiation,': 'O'}, {'or': 'O'}, {'both;': 'O'}, {'37': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'systemic': 'O'}, {'therapy': 'O'}, {'initially,': 'O'}, {'with': 'O'}, {'47%': 'O'}, {'of': 'O'}, {'those': 'O'}, {'receiving': 'O'}, {'rituximab;': 'I-Entity'}, {'and': 'O'}, {'6%': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'observed.': 'O'}]"
All patients gave written informed consent and the study was performed according to the 1964 Declaration of Helsinki.,"[{'All': 'O'}, {'patients': 'O'}, {'gave': 'O'}, {'written': 'O'}, {'informed': 'O'}, {'consent': 'O'}, {'and': 'O'}, {'the': 'O'}, {'study': 'O'}, {'was': 'O'}, {'performed': 'O'}, {'according': 'O'}, {'to': 'O'}, {'the': 'O'}, {'1964': 'O'}, {'Declaration': 'O'}, {'of': 'O'}, {'Helsinki.': 'O'}]"
Sjogrens syndrome (SS) is an autoimmune disease causing destruction of the exocrine glands secondary to lymphocytic infiltration.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'causing': 'O'}, {'destruction': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'exocrine': 'I-Entity'}, {'glands': 'I-Entity'}, {'secondary': 'O'}, {'to': 'O'}, {'lymphocytic': 'O'}, {'infiltration.': 'O'}]"
The study results also suggest that the improvement is greater when interventional sialendoscopy is combined with a cycle of outpatient steroid ductal irrigations.,"[{'The': 'O'}, {'study': 'O'}, {'results': 'O'}, {'also': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'the': 'O'}, {'improvement': 'O'}, {'is': 'O'}, {'greater': 'O'}, {'when': 'O'}, {'interventional': 'O'}, {'sialendoscopy': 'O'}, {'is': 'O'}, {'combined': 'O'}, {'with': 'O'}, {'a': 'O'}, {'cycle': 'O'}, {'of': 'O'}, {'outpatient': 'O'}, {'steroid': 'I-Entity'}, {'ductal': 'O'}, {'irrigations.': 'O'}]"
"Ro60 peptide immunization in the abdominal area of female Balb/c mice led to impaired SG function, which corresponded with increased Th1 cytokines (IFN-‚âà√≠‚Äö√¢‚Ä¢ and IL-12) systemically and locally in the SG.","[{'Ro60': 'I-Entity'}, {'peptide': 'O'}, {'immunization': 'O'}, {'in': 'O'}, {'the': 'O'}, {'abdominal': 'O'}, {'area': 'O'}, {'of': 'O'}, {'female': 'O'}, {'Balb/c': 'O'}, {'mice': 'O'}, {'led': 'O'}, {'to': 'O'}, {'impaired': 'B-Entity'}, {'SG': 'I-Entity'}, {'function,': 'O'}, {'which': 'O'}, {'corresponded': 'O'}, {'with': 'O'}, {'increased': 'O'}, {'Th1': 'O'}, {'cytokines': 'O'}, {'(IFN-‚âà√≠‚Äö√¢‚Ä¢': 'O'}, {'and': 'O'}, {'IL-12)': 'O'}]"
"Thus, anti-CD20 therapy can be considered an effective treatment option in pSS patients.","[{'Thus,': 'O'}, {'anti-CD20': 'O'}, {'therapy': 'O'}, {'can': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'an': 'O'}, {'effective': 'O'}, {'treatment': 'O'}, {'option': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
"To evaluate the efficacy, tolerability and treatment adherence of Ikervis(¬¨¬®‚àö√ú) (Santen, SAS) (ciclosporine 0.1¬¨¬®‚Äö√Ñ‚Ä†%) for first line therapy or following treatment with Restasis(¬¨¬®‚àö√ú) (Allergan, Inc.) (ciclosporine 0.05¬¨¬®‚Äö√Ñ‚Ä†%) for severe dry eye syndrome.","[{'To': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'efficacy,': 'O'}, {'tolerability': 'O'}, {'and': 'O'}, {'treatment': 'O'}, {'adherence': 'O'}, {'of': 'O'}, {'Ikervis(¬¨¬®‚àö√ú)': 'I-Entity'}, {'(Santen,': 'O'}, {'SAS)': 'O'}, {'(ciclosporine': 'O'}, {'0.1¬¨¬®‚Äö√Ñ‚Ä†%)': 'O'}, {'for': 'O'}, {'first': 'O'}, {'line': 'O'}, {'therapy': 'O'}, {'or': 'O'}, {'following': 'O'}]"
"Patients with PSS and controls had a similar incidence of ischemic stroke occurrence (3.17/1,000 vs. 3.90/1,000 person years).","[{'Patients': 'O'}, {'with': 'O'}, {'PSS': 'I-Entity'}, {'and': 'O'}, {'controls': 'O'}, {'had': 'O'}, {'a': 'O'}, {'similar': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'ischemic': 'B-Entity'}, {'stroke': 'I-Entity'}, {'occurrence': 'O'}, {'(3.17/1,000': 'O'}, {'vs.': 'O'}, {'3.90/1,000': 'O'}, {'person': 'O'}, {'years).': 'O'}]"
"Investigations revealed Sjogren's syndrome as the underlying cause of the metabolic disorders.University of Tunis El Manar, Tunis, Tunisia.manifestation.","[{'Investigations': 'O'}, {'revealed': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'as': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'the': 'O'}, {'metabolic': 'B-Entity'}, {'disorders.University': 'I-Entity'}, {'of': 'O'}, {'Tunis': 'O'}, {'El': 'O'}, {'Manar,': 'O'}, {'Tunis,': 'O'}, {'Tunisia.manifestation.': 'O'}]"
"This case posed treatment challenges due to limited oral access, unpredictable disease progression, and limited data on the success of treatment with endosseous dental implants in these patients.dry eye disease.","[{'This': 'O'}, {'case': 'O'}, {'posed': 'O'}, {'treatment': 'O'}, {'challenges': 'O'}, {'due': 'O'}, {'to': 'O'}, {'limited': 'O'}, {'oral': 'O'}, {'access,': 'O'}, {'unpredictable': 'O'}, {'disease': 'O'}, {'progression,': 'O'}, {'and': 'O'}, {'limited': 'O'}, {'data': 'O'}, {'on': 'O'}, {'the': 'O'}, {'success': 'O'}, {'of': 'O'}, {'treatment': 'O'}, {'with': 'O'}, {'endosseous': 'O'}, {'dental': 'O'}, {'implants': 'O'}, {'in': 'O'}, {'these': 'O'}, {'patients.dry': 'O'}, {'eye': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"The lack of significant difference in subclinical atherosclerosis between elderly primary Sjogren syndrome and control matched patients, indicates that traditional cardiovascular risk factors, immunologic alterations and chronic inflammation do not influence the progression of vascular damage in the carotid circulation of patients with median disease duration of 6.5 years.Rome, Rome, Italy.Rome, Rome, Italy.Rome, Rome, Italy.Rome, Rome, Italy.Rome, Rome, Italy.10.1177/039463201402700422.lymphadenopathy mimicking IgG4-related disease.","[{'The': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'significant': 'O'}, {'difference': 'O'}, {'in': 'O'}, {'subclinical': 'O'}, {'atherosclerosis': 'I-Entity'}, {'between': 'O'}, {'elderly': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'control': 'O'}, {'matched': 'O'}, {'patients,': 'O'}, {'indicates': 'O'}, {'that': 'O'}, {'traditional': 'O'}, {'cardiovascular': 'O'}, {'risk': 'O'}, {'factors,': 'O'}, {'immunologic': 'O'}, {'alterations': 'O'}, {'and': 'O'}, {'chronic': 'O'}, {'inflammation': 'O'}, {'do': 'O'}, {'not': 'O'}, {'influence': 'O'}, {'the': 'O'}, {'progression': 'O'}, {'of': 'O'}, {'vascular': 'B-Entity'}, {'damage': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'carotid': 'O'}, {'circulation': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'median': 'O'}]"
Previous studies demonstrated that aspirin-triggered resolvin D1 (AT-RvD1) prevents chronic inflammation and enhances saliva secretion in a SS-like mouse model when applied before disease onset.,"[{'Previous': 'O'}, {'studies': 'O'}, {'demonstrated': 'O'}, {'that': 'O'}, {'aspirin-triggered': 'I-Entity'}, {'resolvin': 'O'}, {'D1': 'O'}, {'(AT-RvD1)': 'O'}, {'prevents': 'O'}, {'chronic': 'O'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'enhances': 'O'}, {'saliva': 'O'}, {'secretion': 'O'}, {'in': 'O'}, {'a': 'O'}, {'SS-like': 'I-Entity'}, {'mouse': 'O'}, {'model': 'O'}, {'when': 'O'}, {'applied': 'O'}, {'before': 'O'}, {'disease': 'O'}, {'onset.': 'O'}]"
"SS-associated neuropathy need not necessarily be associated with a poor prognosis.India.India.India.India.India.India.India.treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.","[{'SS-associated': 'I-Entity'}, {'neuropathy': 'I-Entity'}, {'need': 'O'}, {'not': 'O'}, {'necessarily': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'poor': 'O'}, {'prognosis.India.India.India.India.India.India.India.treatment': 'O'}, {'of': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'and': 'O'}, {'related': 'O'}, {'diseases.': 'O'}]"
Results obtained demonstrated that the number of IL-15(+) cultured SGEC was significantly higher in cells derived from patients with pSS in comparison with SGEC from healthy subjects; similar results were obtained for IL-15 immunoreactivity by using immunohistochemistry that revealed a strong expression both in acinar and in ductal cells from pSS MSG.,"[{'Results': 'O'}, {'obtained': 'O'}, {'demonstrated': 'O'}, {'that': 'O'}, {'the': 'O'}, {'number': 'O'}, {'of': 'O'}, {'IL-15(+)': 'O'}, {'cultured': 'O'}, {'SGEC': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'cells': 'O'}, {'derived': 'O'}, {'from': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'in': 'O'}, {'comparison': 'O'}, {'with': 'O'}, {'SGEC': 'O'}, {'from': 'O'}, {'healthy': 'O'}, {'subjects;': 'O'}, {'similar': 'O'}, {'results': 'O'}, {'were': 'O'}, {'obtained': 'O'}, {'for': 'O'}, {'IL-15': 'O'}, {'immunoreactivity': 'O'}, {'by': 'O'}, {'using': 'O'}, {'immunohistochemistry': 'O'}, {'that': 'O'}]"
"As therapy varies from cause to cause, knowledge of the different potential diagnoses is crucial.Universit‚Äö√†√∂¬¨√üt M‚Äö√†√∂¬¨‚à´nchen, Ismaningerstr.¬¨¬®‚Äö√Ñ‚Ä†22, 81675, M‚Äö√†√∂¬¨‚à´nchen, Deutschland.","[{'As': 'O'}, {'therapy': 'O'}, {'varies': 'O'}, {'from': 'O'}, {'cause': 'O'}, {'to': 'O'}, {'cause,': 'O'}, {'knowledge': 'O'}, {'of': 'O'}, {'the': 'O'}, {'different': 'O'}, {'potential': 'O'}, {'diagnoses': 'O'}, {'is': 'O'}, {'crucial.Universit‚Äö√†√∂¬¨√üt': 'O'}, {'M‚Äö√†√∂¬¨‚à´nchen,': 'O'}, {'Ismaningerstr.¬¨¬®‚Äö√Ñ‚Ä†22,': 'O'}]"
Patients with a neoplastic disorder or traumatic spinal cord injury can also present with longitudinal spinal lesions.,"[{'Patients': 'O'}, {'with': 'O'}, {'a': 'O'}, {'neoplastic': 'B-Entity'}, {'disorder': 'I-Entity'}, {'or': 'O'}, {'traumatic': 'O'}, {'spinal': 'B-Entity'}, {'cord': 'I-Entity'}, {'injury': 'I-Entity'}, {'can': 'O'}, {'also': 'O'}, {'present': 'O'}, {'with': 'O'}, {'longitudinal': 'O'}, {'spinal': 'B-Entity'}, {'lesions.': 'I-Entity'}]"
"Peripheral neuropathy, interstitial nephritis, and vasculitis were more common in those with vision-threatening ocular findings compared with patients without (P < 0.05 for all).","[{'Peripheral': 'B-Entity'}, {'neuropathy,': 'I-Entity'}, {'interstitial': 'B-Entity'}, {'nephritis,': 'I-Entity'}, {'and': 'O'}, {'vasculitis': 'I-Entity'}, {'were': 'O'}, {'more': 'O'}, {'common': 'O'}, {'in': 'O'}, {'those': 'O'}, {'with': 'O'}, {'vision-threatening': 'O'}, {'ocular': 'O'}, {'findings': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'(P': 'O'}, {'<': 'O'}, {'0.05': 'O'}, {'for': 'O'}, {'all).': 'O'}]"
"Anti-aquaporin-4 antibodies (NMO-IgG) were determined by indirect immunofluorescence (IIF) on mouse cerebellum in 673 samples, as follows: group I (clinically defined Devic's disease, n=47); group II [inflammatory/demyelinating central nervous system (CNS) diseases, n=41]; group III (systemic and organ-specific autoimmune diseases, n=250); group IV (chronic or acute viral diseases, n=35); and group V (randomly selected samples from a general clinical laboratory, n=300).","[{'Anti-aquaporin-4': 'O'}, {'antibodies': 'O'}, {'(NMO-IgG)': 'O'}, {'were': 'O'}, {'determined': 'O'}, {'by': 'O'}, {'indirect': 'O'}, {'immunofluorescence': 'O'}, {'(IIF)': 'O'}, {'on': 'O'}, {'mouse': 'O'}, {'cerebellum': 'O'}, {'in': 'O'}, {'673': 'O'}, {'samples,': 'O'}, {'as': 'O'}, {'follows:': 'O'}, {'group': 'O'}, {'I': 'O'}, {'(clinically': 'O'}, {'defined': 'O'}, {""Devic's"": 'B-Entity'}, {'disease,': 'I-Entity'}, {'n=47);': 'O'}]"
"In our study, we aimed to evaluate left ventricular function in patients with Sjogren syndrome (SS) using tissue Doppler echocardiography (TDE) and myocardial performance index (MPI) in addition to conventional echocardiographic methods.","[{'In': 'O'}, {'our': 'O'}, {'study,': 'O'}, {'we': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'left': 'O'}, {'ventricular': 'O'}, {'function': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'using': 'O'}, {'tissue': 'O'}, {'Doppler': 'O'}, {'echocardiography': 'O'}, {'(TDE)': 'O'}, {'and': 'O'}, {'myocardial': 'O'}, {'performance': 'O'}, {'index': 'O'}, {'(MPI)': 'O'}, {'in': 'O'}, {'addition': 'O'}, {'to': 'O'}, {'conventional': 'O'}, {'echocardiographic': 'O'}, {'methods.': 'O'}]"
"Common cytokines, overlapping antibodies, and similar risk alleles were all potential causes of increased incidence of Sjogren's syndrome in systemic sclerosis.University , Kaohsiung , Taiwan .University Hospital , Kaohsiung , Taiwan .University Hospital , Kaohsiung , Taiwan .Taiwan ., Kaohsiung , Taiwan .University Hospital , Kaohsiung , Taiwan .University Hospital , Kaohsiung , Taiwan .University Hospital , Kaohsiung , Taiwan .University Hospital , Kaohsiung , Taiwan ., Kaohsiung , Taiwan .Changhua Christian Hospital , Changhua , Taiwan .Taiwan , and.Kaohsiung , Kaohsiung , Taiwan.18.keratoconjunctivitis sicca in Sjogren syndrome patients with or without punctal occlusions.","[{'Common': 'O'}, {'cytokines,': 'O'}, {'overlapping': 'O'}, {'antibodies,': 'O'}, {'and': 'O'}, {'similar': 'O'}, {'risk': 'O'}, {'alleles': 'O'}, {'were': 'O'}, {'all': 'O'}, {'potential': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'increased': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'in': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis.University': 'I-Entity'}, {',': 'O'}, {'Kaohsiung': 'O'}, {',': 'O'}, {'Taiwan': 'O'}, {'.University': 'O'}, {'Hospital': 'O'}, {',': 'O'}, {'Kaohsiung': 'O'}, {',': 'O'}, {'Taiwan': 'O'}, {'.University': 'O'}, {'Hospital': 'O'}, {',': 'O'}, {'Kaohsiung': 'O'}, {',': 'O'}]"
"Sjogren syndrome (SjS) is a systemic autoimmune disease that primarily affects the exocrine glands (mainly the salivary and lacrimal glands) and results in the severe dryness of mucosal surfaces, principally in the mouth and eyes.","[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SjS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'primarily': 'O'}, {'affects': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'(mainly': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands)': 'O'}, {'and': 'O'}, {'results': 'O'}, {'in': 'O'}, {'the': 'O'}, {'severe': 'O'}, {'dryness': 'B-Entity'}, {'of': 'O'}, {'mucosal': 'O'}, {'surfaces,': 'O'}, {'principally': 'O'}, {'in': 'O'}, {'the': 'O'}, {'mouth': 'O'}, {'and': 'O'}, {'eyes.': 'O'}]"